

Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelsystem.org.

Overview for Request: cder_mpl1r_wp314, Report 2

Request ID: cder_mpl1r_wp314_nsdp_v01

Request Description: In this report, we characterized dispensing and administration patterns of 23 New Molecular Entities (NMEs) approved from July 1, 2021, to December 31, 2021, stratified by age and sex in the Sentinel Distributed Database (SDD).

Sentinel Routine Querying Module: Cohort Identification and Descriptive Analysis module (CIDA), version 14.2.0.

Data Source: We distributed this request to 13 Sentinel Data Partners on September 3, 2025. We included aggregate results from all 13 Data Partners in this report. The study period included data from January 1, 2021, to April 30, 2025. Report 1 includes NMEs approved from January 1, 2021 to June 30, 2021. Please see Appendix A for a list of available data dates for each Data Partner.

Study Design: We identified individuals initiating any of the 23 NMEs of interest. We described demographic and clinical characteristics for individuals initiating each NME based on history recorded in the six months prior to initiation of treatment with the relevant drug. The analyses characterized dispensing patterns by examining cumulative exposure episode duration, first exposure episode duration, all exposure episode durations, days supplied per dispensing, and lengths of gaps between episodes, overall and stratified by age group and sex. This was a Type 5 analysis in the Query Request Package (QRP) documentation.

Exposures of Interest: Our exposures of interest were NMEs approved between July 1, 2021, to December 31, 2021, administered or dispensed in any care setting. These were defined using Healthcare Common Procedure Coding System (HCPCS) procedure codes and National Drug Codes (NDCs). Please see Appendix B for a list of non-proprietary and proprietary names of medical products and Appendix C for a list of procedure codes used to define exposures in this request. All valid exposure episodes were included.

Cohort Eligibility Criteria: We defined index exposure as the first qualifying administration or dispensing of a given NME to an individual during the study period. We required individuals to be enrolled in health plans with both medical and drug coverage for at least 183 days prior to their index exposure, during which gaps in coverage of up to 45 days were allowed. The following age groups were included: 0-17, 18-24, 25-40, 41-64, 65+ years.

Baseline Characteristics: We described demographic characteristics such as sex, age, and calendar year on the day of each index NME exposure. We also described 33 clinical characteristics based on history recorded in the six months prior to the index exposure. The set of clinical characteristics included 26 chronic conditions and 7 lifestyle-related conditions. Chronic conditions were defined using Centers for Medicare and Medicaid Services' (CMS) Chronic Conditions Data Warehouse¹ (CCW) algorithms and included: acute myocardial infarction, Alzheimer's disease, Non-Alzheimer's Dementia, atrial fibrillation, diabetes, heart failure, hyperlipidemia, hypertension, depression, ischemic heart disease, rheumatoid arthritis/osteoarthritis, stroke/transient ischemic attack (TIA), breast cancer, colorectal cancer, prostate cancer, lung cancer, endometrial cancer, acquired hypothyroidism, anemia, asthma, benign prostatic hyperplasia, chronic kidney disease, chronic obstructive pulmonary disease (COPD) and bronchiectasis, glaucoma, osteoporosis, and liver disease. Lifestyle-related conditions included: obesity, overweight, smoking, alcohol abuse or dependence, drug abuse or dependence, history of cardiac arrest, and history of coronary angioplasty or bypass. International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS) procedure codes, HCPCS procedure codes, Current Procedural Terminology, Fourth Edition (CPT-4) procedure codes, and NDCs were used to define the clinical characteristics. Please see Appendix D for a list of diagnosis and procedure codes and Appendix E for a list of non-proprietary and proprietary names of medical products used to define baseline characteristics in this request.

Please refer to Appendices F, G and H for the specifications of parameters used in this request, baseline characteristics used in this request, and a design diagram.

Overview for Request: cder_mpl1r_wp314, Report 2

Limitations: Algorithms used to define exposures and inclusion criteria are imperfect; thus, it is possible that there may be misclassification. Therefore, data should be interpreted with this limitation in mind.

Notes: Please contact the Sentinel Operations Center (info@sentrinelsystem.org) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel's routine querying modules, please refer to the documentation (<https://dev.sentrinelsystem.org/projects/SETINEL/repos/sentinel-routine-querying-tool-documentation/browse>).

¹Chronic Conditions Data Warehouse. Condition Categories -Chronic Conditions Data Warehouse. <https://www.ccwdata.org/web/guest/condition-categories>

Table of Contents

Glossary (CIDA)	List of Terms to Define the Cohort Identification and Descriptive Analysis (CIDA) Found in this Report
<u>Table 1a</u>	Aggregated Characteristics of finerenone in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Table 1b</u>	Aggregated Characteristics of fexinidazole in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Table 1c</u>	Aggregated Characteristics of belumosudil in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Table 1d</u>	Aggregated Characteristics of odevixibat in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Table 1e</u>	Aggregated Characteristics of anifrolumab-fnia in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Table 1f</u>	Aggregated Characteristics of avalglucosidase alfa-ngpt in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Table 1g</u>	Aggregated Characteristics of belzutifan in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Table 1h</u>	Aggregated Characteristics of difelikefalin in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Table 1i</u>	Aggregated Characteristics of ionapegsomatropin-tcgd in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Table 1j</u>	Aggregated Characteristics of mobocertinib in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Table 1k</u>	Aggregated Characteristics of tisotumab vedotin-tftv in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Table 1l</u>	Aggregated Characteristics of atogepant in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Table 1m</u>	Aggregated Characteristics of maralixibat in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Table 1n</u>	Aggregated Characteristics of avacopan in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Table 1o</u>	Aggregated Characteristics of asciminib in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Table 1p</u>	Aggregated Characteristics of ropeginterferon alfa-2b-njft in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Table 1q</u>	Aggregated Characteristics of vosoritide in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Table 1r</u>	Aggregated Characteristics of maribavir in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Table 1s</u>	Aggregated Characteristics of pafolacianine in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Table 1t</u>	Aggregated Characteristics of tezepelumab-ekko in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Table 1u</u>	Aggregated Characteristics of efgartigimod alfa-fcab in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Table 1v</u>	Aggregated Characteristics of inclisiran in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Table 1w</u>	Aggregated Characteristics of tralokinumab-ldrm in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Table of Contents

<u>Table 2a</u>	Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Table 2b</u>	Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Table 2c</u>	Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex
<u>Table 2d</u>	Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex
<u>Table 2e</u>	Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group
<u>Table 2f</u>	Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group
<u>Table 3a</u>	Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Table 3b</u>	Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Table 3c</u>	Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex
<u>Table 3d</u>	Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex
<u>Table 3e</u>	Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group
<u>Table 3f</u>	Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group
<u>Table 4a</u>	Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Table 4b</u>	Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Table 4c</u>	Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex
<u>Table 4d</u>	Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex
<u>Table 4e</u>	Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group
<u>Table 4f</u>	Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group
<u>Table 5a</u>	Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Table 5b</u>	Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Table 5c</u>	Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex
<u>Table 5d</u>	Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex
<u>Table 5e</u>	Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group
<u>Table 5f</u>	Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

Table of Contents

<u>Table 6a</u>	Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Table 6b</u>	Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Table 6c</u>	Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex
<u>Table 6d</u>	Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex
<u>Table 6e</u>	Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group
<u>Table 6f</u>	Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group
<u>Table 7a</u>	Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Table 7b</u>	Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex
<u>Table 7c</u>	Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group
<u>Table 8a</u>	Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Table 8b</u>	Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex
<u>Table 8c</u>	Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group
<u>Table 9</u>	Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Table 10</u>	Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Figure 1a</u>	Patient Entry into Study by Month for finerenone in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Figure 1b</u>	Patient Entry into Study by Month for fexinidazole in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Figure 1c</u>	Patient Entry into Study by Month for belumosudil in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Figure 1d</u>	Patient Entry into Study by Month for odevixibat in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Figure 1e</u>	Patient Entry into Study by Month for anifrolumab-fnia in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Figure 1f</u>	Patient Entry into Study by Month for avalglucosidase alfa-ngpt in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Figure 1g</u>	Patient Entry into Study by Month for belzutifan in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Figure 1h</u>	Patient Entry into Study by Month for difelikefalin in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Figure 1i</u>	Patient Entry into Study by Month for ionapegsomatropin-tcgd in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Figure 1j</u>	Patient Entry into Study by Month for mobocertinib in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Table of Contents

<u>Figure 1k</u>	Patient Entry into Study by Month for tisotumab vedotin-tftv in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Figure 1l</u>	Patient Entry into Study by Month for atogepant in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Figure 1m</u>	Patient Entry into Study by Month for maralixibat in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Figure 1n</u>	Patient Entry into Study by Month for avacopan in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Figure 1o</u>	Patient Entry into Study by Month for asciminib in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Figure 1p</u>	Patient Entry into Study by Month for ropeginterferon alfa-2b-njft in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Figure 1q</u>	Patient Entry into Study by Month for vosoritide in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Figure 1r</u>	Patient Entry into Study by Month for maribavir in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Figure 1s</u>	Patient Entry into Study by Month for pafolacianine in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Figure 1t</u>	Patient Entry into Study by Month for tezepelumab-ekko in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Figure 1u</u>	Patient Entry into Study by Month for efgartigimod alfa-fcab in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Figure 1v</u>	Patient Entry into Study by Month for inclisiran in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Figure 1w</u>	Patient Entry into Study by Month for tralokinumab-ldrm in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025
<u>Appendix A</u>	Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date
<u>Appendix B</u>	List of Non-proprietary and Proprietary Names of Medical Products Used to Define Exposures in this Request
<u>Appendix C</u>	List of Healthcare Common Procedure Coding System, Level II (HCPCS) and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exposures in this Request
<u>Appendix D</u>	List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request
<u>Appendix E</u>	List of Non-proprietary and Proprietary Names of Medical Products Used to Define Characteristics in this Request
<u>Appendix F</u>	Specifications Used in this Request
<u>Appendix G</u>	Baseline Characteristics Used in this Request
<u>Appendix H</u>	Design Diagram Used to Identify First Valid Index Exposure Meeting Incidence Washout Criteria and All Subsequent Exposure Episodes in this Request

**Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module***

Amount Supplied - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing.

Blackout Period - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Charlson/Elixhauser Combined Comorbidity Score - calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).

Code Days - the minimum number of times the diagnosis must be found during the evaluation period in order to fulfill the algorithm to identify the corresponding patient characteristic.

Cohort Definition (drug/exposure) - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query period; 02: Cohort includes all valid treatment episodes during the query period; 03: Cohort includes all valid treatment episodes during the query period until an event occurs.

Computed Start Marketing Date - represents the first observed dispensing date among all valid users within a GROUP (scenario) within each Data Partner site.

Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.

Eligible Members - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.

Enrollment Gap - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled" sequence.

Episodes - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.

Episode Gap - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.

Event Deduplication - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).

Exposure Episode Length - number of days after exposure initiation that is considered "exposed time."

Exposure Extension Period - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.

Lookback Period - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).

Maximum Episode Duration - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

**Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module***

Member-Years - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure washout period all divided by 365.25.

Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be considered.

Minimum Episode Duration - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Monitoring Period - used to define time periods of interest for both sequential analysis and simple cohort characterization requests.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Caresetting/PDX parameter.

Query Period - period in which the modular program looks for exposures and outcomes of interest.

Switch Evaluation Step Value - value used to differentiate evaluation step. Each switch pattern can support up to 2 evaluation steps (0 = switch pattern evaluation start; 1 = first evaluation; 2 = second evaluation).

Switch Gap Inclusion Indicator - indicator for whether gaps in treatment episodes that are included in a switch episode will be counted as part of the switch episode duration.

Switch Pattern Cohort Inclusion Date - indicates which date to use for inclusion into the switch pattern cohort of interest as well as optionally as the index date of the treatment episode initiating the switch pattern. Valid options are the product approval date, product marketing date, other requester defined date, or computed start marketing date.

Switch Pattern Cohort Inclusion Strategy - indicates how the switch pattern cohort inclusion date will be used: 01: used only as a switch cohort entry date. First treatment episode dispensing date is used as index for computing time to first switch; 02: used as switch cohort entry date and as initial switch step index date for computing time to first switch.

Treatment Episode Truncation Indicator - indicates whether the exposure episode will be truncated at the occurrence of a requester-specified code.

Washout Period (drug/exposure) - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

Washout Period (event/outcome) - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

*all terms may not be used in this report

Table 1a. Aggregated Characteristics of finerenone in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Patient Characteristics	finerenone	
	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	65,377	N/A ²
Demographic Characteristics		
Age (years)	71.1	9.6
Age		
0-17 years	0	0.0%
18-24 years	17	0.0%
25-40 years	725	1.1%
41-64 years	13,040	19.9%
≥ 65 years	51,595	78.9%
Sex		
Female	29,455	45.1%
Male	35,922	54.9%
Race ³		
American Indian or Alaska Native	212	0.3%
Asian	6,128	9.4%
Black or African American	9,895	15.1%
Multi-racial	451	0.7%
Native Hawaiian or Other Pacific Islander	297	0.5%
Unknown	12,723	19.5%
White	35,671	54.6%
Hispanic origin		
Yes	3,894	6.0%
No	44,809	68.5%
Unknown	16,674	25.5%
Year		
2021	0	0.0%
2022	1,412	2.2%
2023	13,513	20.7%
2024	24,757	37.9%
2025	24,521	37.5%
	1,174	1.8%
Health Characteristics		
Acute Myocardial Infarction	710	1.1%
Alzheimer's Disease	741	1.1%
Non-Alzheimer's Dementia	2,398	3.7%
Atrial Fibrillation	7,445	11.4%

Table 1a. Aggregated Characteristics of finerenone in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Health Characteristics	finerenone	
	Number/Mean	Percent/ Standard Deviation ¹
Diabetes Mellitus	57,287	87.6%
Heart Failure	14,566	22.3%
Hyperlipidemia	45,652	69.8%
Hypertension	55,528	84.9%
Depression	10,753	16.4%
Ischemic Heart Disease	21,354	32.7%
Rheumatoid Arthritis/Osteoarthritis	12,621	19.3%
Stroke/TIA ⁴	2,326	3.6%
Breast Cancer	1,267	1.9%
Colorectal Cancer	554	0.8%
Prostate Cancer	1,931	3.0%
Lung Cancer	393	0.6%
Endometrial Cancer	155	0.2%
Acquired Hypothyroidism	10,186	15.6%
Anemia	23,642	36.2%
Asthma	2,793	4.3%
Benign Prostatic Hyperplasia	6,357	9.7%
Chronic Kidney Disease	45,311	69.3%
COPD ⁵ and Bronchiectasis	6,453	9.9%
Glaucoma	9,473	14.5%
Osteoporosis	2,858	4.4%
Obesity: diagnosed or identified by weight management procedures	24,533	37.5%
Obesity: identified by weight management-related dispensings	13,676	20.9%
Overweight	9,051	13.8%
Smoking: diagnosed or identified by smoking cessation procedures	11,710	17.9%
Smoking: identified by smoking-related dispensings	237	0.4%
Alcohol Abuse or Dependence	872	1.3%
Drug Abuse or Dependence	1,679	2.6%
History of Cardiac Arrest	162	0.2%
History of Coronary Angioplasty or Bypass	6,530	10.0%
Liver Disease Based on CCW ⁶ Definition	2,859	4.4%
Liver Disease Extended Definition (CCW + Additional Codes)	2,937	4.5%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	14.2	11.4
Mean number of emergency room encounters	0.3	1.0
Mean number of inpatient hospital encounters	0.1	0.5

Table 1a. Aggregated Characteristics of finerenone in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Health Service Utilization Intensity Metrics	finerenone	
	Number/Mean	Percent/ Standard Deviation ¹
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	4.5	8.1
Mean number of filled prescriptions	29.4	21.0
Mean number of Non-proprietarys dispensed	12.2	5.5
Mean number of unique drug classes dispensed	10.8	4.9

¹Value represents standard deviation if % doesn't follow the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

Table 1b. Aggregated Characteristics of fexinidazole in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Patient Characteristics	fexinidazole	
	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	0	N/A ²
Demographic Characteristics		
Age (years)	N/A	N/A
Age		
0-17 years	N/A	N/A
18-24 years	N/A	N/A
25-40 years	N/A	N/A
41-64 years	N/A	N/A
≥ 65 years	N/A	N/A
Sex		
Female	N/A	N/A
Male	N/A	N/A
Race ³		
American Indian or Alaska Native	N/A	N/A
Asian	N/A	N/A
Black or African American	N/A	N/A
Multi-racial	N/A	N/A
Native Hawaiian or Other Pacific Islander	N/A	N/A
Unknown	N/A	N/A
White	N/A	N/A
Hispanic origin		
Yes	N/A	N/A
No	N/A	N/A
Unknown	N/A	N/A
Year		
2021	N/A	N/A
2021	N/A	N/A
2022	N/A	N/A
2023	N/A	N/A
2024	N/A	N/A
2025	N/A	N/A
Health Characteristics		
Acute Myocardial Infarction	N/A	N/A
Alzheimer's Disease	N/A	N/A
Non-Alzheimer's Dementia	N/A	N/A
Atrial Fibrillation	N/A	N/A

Table 1b. Aggregated Characteristics of fexinidazole in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Health Characteristics	fexinidazole	
	Number/Mean	Percent/ Standard Deviation ¹
Diabetes Mellitus	N/A	N/A
Heart Failure	N/A	N/A
Hyperlipidemia	N/A	N/A
Hypertension	N/A	N/A
Depression	N/A	N/A
Ischemic Heart Disease	N/A	N/A
Rheumatoid Arthritis/Osteoarthritis	N/A	N/A
Stroke/TIA ⁴	N/A	N/A
Breast Cancer	N/A	N/A
Colorectal Cancer	N/A	N/A
Prostate Cancer	N/A	N/A
Lung Cancer	N/A	N/A
Endometrial Cancer	N/A	N/A
Acquired Hypothyroidism	N/A	N/A
Anemia	N/A	N/A
Asthma	N/A	N/A
Benign Prostatic Hyperplasia	N/A	N/A
Chronic Kidney Disease	N/A	N/A
COPD ⁵ and Bronchiectasis	N/A	N/A
Glaucoma	N/A	N/A
Osteoporosis	N/A	N/A
Obesity: diagnosed or identified by weight management procedures	N/A	N/A
Obesity: identified by weight management-related dispensings	N/A	N/A
Overweight	N/A	N/A
Smoking: diagnosed or identified by smoking cessation procedures	N/A	N/A
Smoking: identified by smoking-related dispensings	N/A	N/A
Alcohol Abuse or Dependence	N/A	N/A
Drug Abuse or Dependence	N/A	N/A
History of Cardiac Arrest	N/A	N/A
History of Coronary Angioplasty or Bypass	N/A	N/A
Liver Disease Based on CCW ⁶ Definition	N/A	N/A
Liver Disease Extended Definition (CCW + Additional Codes)	N/A	N/A
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	N/A	N/A
Mean number of emergency room encounters	N/A	N/A
Mean number of inpatient hospital encounters	N/A	N/A

Table 1b. Aggregated Characteristics of fexinidazole in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Health Service Utilization Intensity Metrics	fexinidazole	
	Number/Mean	Percent/ Standard Deviation ¹
Mean number of non-acute institutional encounters	N/A	N/A
Mean number of other ambulatory encounters	N/A	N/A
Mean number of filled prescriptions	N/A	N/A
Mean number of Non-proprietarys dispensed	N/A	N/A
Mean number of unique drug classes dispensed	N/A	N/A

¹Value represents standard deviation if % doesn't follow the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

Table 1c. Aggregated Characteristics of belumosudil in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

belumosudil		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	1,803	N/A ²
Demographic Characteristics		
Age (years)	59.1	13.9
Age		
0-17 years	18	1.0%
18-24 years	37	2.1%
25-40 years	225	12.5%
41-64 years	626	34.7%
≥ 65 years	897	49.8%
Sex		
Female	762	42.3%
Male	1,041	57.7%
Race ³		
American Indian or Alaska Native	*****	*****
Asian	36	2.0%
Black or African American	91	5.0%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	409	22.7%
White	1,248	69.2%
Hispanic origin		
Yes	92	5.1%
No	1,272	70.5%
Unknown	439	24.3%
Year		
2021	0	0.0%
2021	360	20.0%
2022	435	24.1%
2023	444	24.6%
2024	545	30.2%
2025	19	1.1%
Health Characteristics		
Acute Myocardial Infarction	24	1.3%
Alzheimer's Disease	0	0.0%
Non-Alzheimer's Dementia	31	1.7%

Table 1c. Aggregated Characteristics of belumosudil in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Health Characteristics	belumosudil	
	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	194	10.8%
Diabetes Mellitus	449	24.9%
Heart Failure	288	16.0%
Hyperlipidemia	638	35.4%
Hypertension	885	49.1%
Depression	503	27.9%
Ischemic Heart Disease	345	19.1%
Rheumatoid Arthritis/Osteoarthritis	229	12.7%
Stroke/TIA ⁴	54	3.0%
Breast Cancer	49	2.7%
Colorectal Cancer	13	0.7%
Prostate Cancer	40	2.2%
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	261	14.5%
Anemia	1,155	64.1%
Asthma	122	6.8%
Benign Prostatic Hyperplasia	141	7.8%
Chronic Kidney Disease	344	19.1%
COPD ⁵ and Bronchiectasis	365	20.2%
Glaucoma	178	9.9%
Osteoporosis	219	12.1%
Obesity: diagnosed or identified by weight management procedures	234	13.0%
Obesity: identified by weight management-related dispensings	21	1.2%
Overweight	140	7.8%
Smoking: diagnosed or identified by smoking cessation procedures	457	25.3%
Smoking: identified by smoking-related dispensings	17	0.9%
Alcohol Abuse or Dependence	32	1.8%
Drug Abuse or Dependence	83	4.6%
History of Cardiac Arrest	12	0.7%
History of Coronary Angioplasty or Bypass	63	3.5%
Liver Disease Based on CCW ⁶ Definition	207	11.5%
Liver Disease Extended Definition (CCW + Additional Codes)	210	11.6%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	28.1	18.5
Mean number of emergency room encounters	0.6	1.7

Table 1c. Aggregated Characteristics of belumosudil in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Health Service Utilization Intensity Metrics	belumosudil	
	Number/Mean	Percent/ Standard Deviation ¹
Mean number of inpatient hospital encounters	0.7	1.3
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	12.8	21.1
Mean number of filled prescriptions	40.6	23.6
Mean number of Non-proprietarys dispensed	15.7	7.5
Mean number of unique drug classes dispensed	14.5	6.5

¹Value represents standard deviation if % doesn't follow the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶ CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1d. Aggregated Characteristics of odevixibat in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Patient Characteristics	odevixibat	
	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	45	N/A ²
Demographic Characteristics		
Age (years)	18.0	14.7
Age		
0-17 years	29	64.4%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	*****	*****
Sex		
Female	22	48.9%
Male	23	51.1%
Race ³		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	23	51.1%
White	*****	*****
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	22	48.9%
Year		
2021	0	0.0%
2021	17	37.8%
2022	*****	*****
2023	*****	*****
2024	13	28.9%
2025	*****	*****
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease	0	0.0%
Non-Alzheimer's Dementia	0	0.0%

Table 1d. Aggregated Characteristics of odevixibat in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Health Characteristics	odevixibat	
	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	0	0.0%
Diabetes Mellitus	*****	*****
Heart Failure	0	0.0%
Hyperlipidemia	*****	*****
Hypertension	*****	*****
Depression	*****	*****
Ischemic Heart Disease	0	0.0%
Rheumatoid Arthritis/Osteoarthritis	*****	*****
Stroke/TIA ⁴	0	0.0%
Breast Cancer	0	0.0%
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	*****	*****
Anemia	*****	*****
Asthma	*****	*****
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	*****	*****
COPD ⁵ and Bronchiectasis	*****	*****
Glaucoma	0	0.0%
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	*****	*****
Obesity: identified by weight management-related dispensings	*****	*****
Overweight	*****	*****
Smoking: diagnosed or identified by smoking cessation procedures	*****	*****
Smoking: identified by smoking-related dispensings	0	0.0%
Alcohol Abuse or Dependence	0	0.0%
Drug Abuse or Dependence	0	0.0%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	0	0.0%
Liver Disease Based on CCW ⁶ Definition	30	66.7%
Liver Disease Extended Definition (CCW + Additional Codes)	31	68.9%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	13.0	12.5
Mean number of emergency room encounters	0.6	1.1

Table 1d. Aggregated Characteristics of odevixibat in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Health Service Utilization Intensity Metrics	odevixibat	
	Number/Mean	Percent/ Standard Deviation ¹
Mean number of inpatient hospital encounters	0.3	0.7
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	10.7	22.7
Mean number of filled prescriptions	20.4	18.2
Mean number of Non-proprietarys dispensed	6.7	4.8
Mean number of unique drug classes dispensed	6.1	4.2

¹Value represents standard deviation if % doesn't follow the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶ CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a number

Table 1e. Aggregated Characteristics of anifrolumab-fnia in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

anifrolumab-fnia		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	4,578	N/A ²
Demographic Characteristics		
Age (years)	53.8	13.3
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	934	20.4%
41-64 years	2,163	47.2%
≥ 65 years	1,370	29.9%
Sex		
Female	4,228	92.4%
Male	350	7.6%
Race ³		
American Indian or Alaska Native	*****	*****
Asian	68	1.5%
Black or African American	753	16.4%
Multi-racial	93	2.0%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	1,328	29.0%
White	2,319	50.7%
Hispanic origin		
Yes	304	6.6%
No	2,764	60.4%
Unknown	1,510	33.0%
Year		
2021	0	0.0%
2021	82	1.8%
2022	1,185	25.9%
2023	1,504	32.9%
2024	1,727	37.7%
2025	80	1.7%
Health Characteristics		
Acute Myocardial Infarction	22	0.5%
Alzheimer's Disease	13	0.3%
Non-Alzheimer's Dementia	43	0.9%

Table 1e. Aggregated Characteristics of anifrolumab-fnia in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Health Characteristics	anifrolumab-fnia	
	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	168	3.7%
Diabetes Mellitus	625	13.7%
Heart Failure	366	8.0%
Hyperlipidemia	1,080	23.6%
Hypertension	1,764	38.5%
Depression	1,522	33.2%
Ischemic Heart Disease	521	11.4%
Rheumatoid Arthritis/Osteoarthritis	1,886	41.2%
Stroke/TIA ⁴	104	2.3%
Breast Cancer	75	1.6%
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	15	0.3%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	741	16.2%
Anemia	1,426	31.1%
Asthma	455	9.9%
Benign Prostatic Hyperplasia	39	0.9%
Chronic Kidney Disease	727	15.9%
COPD ⁵ and Bronchiectasis	296	6.5%
Glaucoma	279	6.1%
Osteoporosis	546	11.9%
Obesity: diagnosed or identified by weight management procedures	1,317	28.8%
Obesity: identified by weight management-related dispensings	289	6.3%
Overweight	495	10.8%
Smoking: diagnosed or identified by smoking cessation procedures	773	16.9%
Smoking: identified by smoking-related dispensings	24	0.5%
Alcohol Abuse or Dependence	68	1.5%
Drug Abuse or Dependence	307	6.7%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	98	2.1%
Liver Disease Based on CCW ⁶ Definition	260	5.7%
Liver Disease Extended Definition (CCW + Additional Codes)	279	6.1%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	19.6	15.4
Mean number of emergency room encounters	0.6	1.3

Table 1e. Aggregated Characteristics of anifrolumab-fnia in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Health Service Utilization Intensity Metrics	anifrolumab-fnia	
	Number/Mean	Percent/ Standard Deviation ¹
Mean number of inpatient hospital encounters	0.2	0.5
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	5.2	7.8
Mean number of filled prescriptions	29.6	22.2
Mean number of Non-proprietarys dispensed	12.3	6.9
Mean number of unique drug classes dispensed	11.5	6.2

¹Value represents standard deviation if % doesn't follow the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶ CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1f. Aggregated Characteristics of avalglucosidase alfa-ngpt in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

avalglucosidase alfa-ngpt		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	243	N/A ²
Demographic Characteristics		
Age (years)	53.5	16.5
Age		
0-17 years	27	11.1%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	82	33.7%
≥ 65 years	105	43.2%
Sex		
Female	120	49.4%
Male	123	50.6%
Race ³		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	49	20.2%
White	178	73.3%
Hispanic origin		
Yes	*****	*****
No	179	73.7%
Unknown	*****	*****
Year		
2021	0	0.0%
2021	*****	*****
2022	114	46.9%
2023	63	25.9%
2024	50	20.6%
2025	*****	*****
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease	0	0.0%
Non-Alzheimer's Dementia	*****	*****

Table 1f. Aggregated Characteristics of alglucosidase alfa-ngpt in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Health Characteristics	alglucosidase alfa-ngpt	
	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	*****	*****
Diabetes Mellitus	22	9.1%
Heart Failure	25	10.3%
Hyperlipidemia	49	20.2%
Hypertension	74	30.5%
Depression	47	19.3%
Ischemic Heart Disease	24	9.9%
Rheumatoid Arthritis/Osteoarthritis	31	12.8%
Stroke/TIA ⁴	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	0	0.0%
Prostate Cancer	*****	*****
Lung Cancer	0	0.0%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	17	7.0%
Anemia	28	11.5%
Asthma	*****	*****
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	*****	*****
COPD ⁵ and Bronchiectasis	16	6.6%
Glaucoma	*****	*****
Osteoporosis	16	6.6%
Obesity: diagnosed or identified by weight management procedures	29	11.9%
Obesity: identified by weight management-related dispensings	*****	*****
Overweight	17	7.0%
Smoking: diagnosed or identified by smoking cessation procedures	27	11.1%
Smoking: identified by smoking-related dispensings	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	15	6.2%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	*****	*****
Liver Disease Based on CCW ⁶ Definition	*****	*****
Liver Disease Extended Definition (CCW + Additional Codes)	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	21.1	14.7
Mean number of emergency room encounters	0.3	0.8

Table 1f. Aggregated Characteristics of avalglucosidase alfa-ngpt in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Health Service Utilization Intensity Metrics	avalglucosidase alfa-ngpt	
	Number/Mean	Percent/ Standard Deviation ¹
Mean number of inpatient hospital encounters	0.1	0.5
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	6.2	8.4
Mean number of filled prescriptions	12.9	12.1
Mean number of Non-proprietarys dispensed	5.4	4.3
Mean number of unique drug classes dispensed	5.2	4.0

¹Value represents standard deviation if % doesn't follow the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1g. Aggregated Characteristics of belzutifan in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Patient Characteristics	belzutifan	
	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	1,686	N/A ²
Demographic Characteristics		
Age (years)	65.8	12.5
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	100	5.9%
41-64 years	403	23.9%
≥ 65 years	1,147	68.0%
Sex		
Female	515	30.5%
Male	1,171	69.5%
Race ³		
American Indian or Alaska Native	*****	*****
Asian	37	2.2%
Black or African American	78	4.6%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	302	17.9%
White	1,246	73.9%
Hispanic origin		
Yes	63	3.7%
No	1,240	73.5%
Unknown	383	22.7%
Year		
2021	0	0.0%
2021	86	5.1%
2022	157	9.3%
2023	254	15.1%
2024	1,153	68.4%
2025	36	2.1%
Health Characteristics		
Acute Myocardial Infarction	31	1.8%
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	46	2.7%

Table 1g. Aggregated Characteristics of belzutifan in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Health Characteristics	belzutifan	
	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	188	11.2%
Diabetes Mellitus	491	29.1%
Heart Failure	273	16.2%
Hyperlipidemia	707	41.9%
Hypertension	1,111	65.9%
Depression	349	20.7%
Ischemic Heart Disease	439	26.0%
Rheumatoid Arthritis/Osteoarthritis	291	17.3%
Stroke/TIA ⁴	102	6.0%
Breast Cancer	29	1.7%
Colorectal Cancer	27	1.6%
Prostate Cancer	100	5.9%
Lung Cancer	95	5.6%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	683	40.5%
Anemia	828	49.1%
Asthma	77	4.6%
Benign Prostatic Hyperplasia	191	11.3%
Chronic Kidney Disease	687	40.7%
COPD ⁵ and Bronchiectasis	162	9.6%
Glaucoma	130	7.7%
Osteoporosis	50	3.0%
Obesity: diagnosed or identified by weight management procedures	288	17.1%
Obesity: identified by weight management-related dispensings	43	2.6%
Overweight	188	11.2%
Smoking: diagnosed or identified by smoking cessation procedures	542	32.1%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	50	3.0%
Drug Abuse or Dependence	57	3.4%
History of Cardiac Arrest	15	0.9%
History of Coronary Angioplasty or Bypass	133	7.9%
Liver Disease Based on CCW ⁶ Definition	190	11.3%
Liver Disease Extended Definition (CCW + Additional Codes)	202	12.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	25.3	16.4
Mean number of emergency room encounters	0.7	1.2

Table 1g. Aggregated Characteristics of belzutifan in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Health Service Utilization Intensity Metrics	belzutifan	
	Number/Mean	Percent/ Standard Deviation ¹
Mean number of inpatient hospital encounters	0.6	1.0
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	8.8	12.4
Mean number of filled prescriptions	26.3	16.9
Mean number of Non-proprietarys dispensed	11.4	6.0
Mean number of unique drug classes dispensed	10.5	5.3

¹Value represents standard deviation if % doesn't follow the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1h. Aggregated Characteristics of difelikefalin in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

difelikefalin		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	5,528	N/A ²
Demographic Characteristics		
Age (years)	65.8	13.7
Age		
0-17 years	0	0.0%
18-24 years	16	0.3%
25-40 years	303	5.5%
41-64 years	1,990	36.0%
≥ 65 years	3,219	58.2%
Sex		
Female	2,654	48.0%
Male	2,874	52.0%
Race ³		
American Indian or Alaska Native	58	1.0%
Asian	215	3.9%
Black or African American	1,778	32.2%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	724	13.1%
White	2,737	49.5%
Hispanic origin		
Yes	367	6.6%
No	4,503	81.5%
Unknown	658	11.9%
Year		
2021	0	0.0%
2022	0	0.0%
2023	1,203	21.8%
2024	2,787	50.4%
2025	1,503	27.2%
	35	0.6%
Health Characteristics		
Acute Myocardial Infarction	339	6.1%
Alzheimer's Disease	56	1.0%
Non-Alzheimer's Dementia	408	7.4%

Table 1h. Aggregated Characteristics of difelikefalin in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Health Characteristics	difelikefalin	
	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	1,367	24.7%
Diabetes Mellitus	3,651	66.0%
Heart Failure	3,194	57.8%
Hyperlipidemia	3,262	59.0%
Hypertension	4,799	86.8%
Depression	1,675	30.3%
Ischemic Heart Disease	2,622	47.4%
Rheumatoid Arthritis/Osteoarthritis	1,092	19.8%
Stroke/TIA ⁴	448	8.1%
Breast Cancer	111	2.0%
Colorectal Cancer	75	1.4%
Prostate Cancer	135	2.4%
Lung Cancer	55	1.0%
Endometrial Cancer	19	0.3%
Acquired Hypothyroidism	982	17.8%
Anemia	5,281	95.5%
Asthma	391	7.1%
Benign Prostatic Hyperplasia	398	7.2%
Chronic Kidney Disease	5,517	99.8%
COPD ⁵ and Bronchiectasis	1,146	20.7%
Glaucoma	562	10.2%
Osteoporosis	191	3.5%
Obesity: diagnosed or identified by weight management procedures	1,701	30.8%
Obesity: identified by weight management-related dispensings	132	2.4%
Overweight	623	11.3%
Smoking: diagnosed or identified by smoking cessation procedures	2,110	38.2%
Smoking: identified by smoking-related dispensings	20	0.4%
Alcohol Abuse or Dependence	141	2.6%
Drug Abuse or Dependence	343	6.2%
History of Cardiac Arrest	136	2.5%
History of Coronary Angioplasty or Bypass	1,041	18.8%
Liver Disease Based on CCW ⁶ Definition	679	12.3%
Liver Disease Extended Definition (CCW + Additional Codes)	682	12.3%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	82.5	18.0
Mean number of emergency room encounters	1.5	2.5

Table 1h. Aggregated Characteristics of difelikefalin in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Health Service Utilization Intensity Metrics	difelikefalin	
	Number/Mean	Percent/ Standard Deviation ¹
Mean number of inpatient hospital encounters	0.9	1.4
Mean number of non-acute institutional encounters	0.2	0.6
Mean number of other ambulatory encounters	19.9	22.2
Mean number of filled prescriptions	26.7	21.5
Mean number of Non-proprietarys dispensed	11.4	6.0
Mean number of unique drug classes dispensed	10.6	5.3

¹Value represents standard deviation if % doesn't follow the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1i. Aggregated Characteristics of I onapegsomatropin-tcgd in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

I onapegsomatropin-tcgd		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	1,164	N/A ²
Demographic Characteristics		
Age (years)	12.1	3.3
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	0	0.0%
Sex		
Female	283	24.3%
Male	881	75.7%
Race ³		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	27	2.3%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	794	68.2%
White	311	26.7%
Hispanic origin		
Yes	31	2.7%
No	306	26.3%
Unknown	827	71.0%
Year		
2021	0	0.0%
2021	*****	*****
2022	151	13.0%
2023	419	36.0%
2024	565	48.5%
2025	*****	*****
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease	0	0.0%
Non-Alzheimer's Dementia	*****	*****

Table 1i. Aggregated Characteristics of lonapegsomatropin-tcgd in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Health Characteristics	lonapegsomatropin-tcgd	
	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	0	0.0%
Diabetes Mellitus	*****	*****
Heart Failure	*****	*****
Hyperlipidemia	*****	*****
Hypertension	*****	*****
Depression	63	5.4%
Ischemic Heart Disease	0	0.0%
Rheumatoid Arthritis/Osteoarthritis	*****	*****
Stroke/TIA ⁴	*****	*****
Breast Cancer	0	0.0%
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	48	4.1%
Anemia	31	2.7%
Asthma	43	3.7%
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	*****	*****
COPD ⁵ and Bronchiectasis	*****	*****
Glaucoma	*****	*****
Osteoporosis	0	0.0%
Obesity: diagnosed or identified by weight management procedures	34	2.9%
Obesity: identified by weight management-related dispensings	*****	*****
Overweight	13	1.1%
Smoking: diagnosed or identified by smoking cessation procedures	*****	*****
Smoking: identified by smoking-related dispensings	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	0	0.0%
Liver Disease Based on CCW ⁶ Definition	*****	*****
Liver Disease Extended Definition (CCW + Additional Codes)	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	8.6	9.8
Mean number of emergency room encounters	0.1	0.4

Table 1i. Aggregated Characteristics of I onapegsomatropin-tcgd in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Health Service Utilization Intensity Metrics	I onapegsomatropin-tcgd	
	Number/Mean	Percent/ Standard Deviation ¹
Mean number of inpatient hospital encounters	0.0	0.3
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	2.7	11.2
Mean number of filled prescriptions	8.9	13.7
Mean number of Non-proprietarys dispensed	2.9	2.8
Mean number of unique drug classes dispensed	2.8	2.6

¹Value represents standard deviation if % doesn't follow the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1j. Aggregated Characteristics of mobocertinib in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Patient Characteristics	mobocertinib	
	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	157	N/A ²
Demographic Characteristics		
Age (years)	69.9	9.1
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	116	73.9%
Sex		
Female	91	58.0%
Male	66	42.0%
Race ³		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	37	23.6%
White	97	61.8%
Hispanic origin		
Yes	*****	*****
No	117	74.5%
Unknown	*****	*****
Year		
2021	0	0.0%
2021	31	19.7%
2022	79	50.3%
2023	47	29.9%
2024	0	0.0%
2025	0	0.0%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	*****	*****

Table 1j. Aggregated Characteristics of mobocertinib in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Health Characteristics	mobocertinib	
	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	15	9.6%
Diabetes Mellitus	24	15.3%
Heart Failure	23	14.6%
Hyperlipidemia	54	34.4%
Hypertension	83	52.9%
Depression	19	12.1%
Ischemic Heart Disease	32	20.4%
Rheumatoid Arthritis/Osteoarthritis	23	14.6%
Stroke/TIA ⁴	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	155	98.7%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	34	21.7%
Anemia	76	48.4%
Asthma	12	7.6%
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	24	15.3%
COPD ⁵ and Bronchiectasis	24	15.3%
Glaucoma	*****	*****
Osteoporosis	14	8.9%
Obesity: diagnosed or identified by weight management procedures	14	8.9%
Obesity: identified by weight management-related dispensings	*****	*****
Overweight	*****	*****
Smoking: diagnosed or identified by smoking cessation procedures	50	31.8%
Smoking: identified by smoking-related dispensings	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****
Liver Disease Based on CCW ⁶ Definition	11	7.0%
Liver Disease Extended Definition (CCW + Additional Codes)	11	7.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	28.3	13.9
Mean number of emergency room encounters	0.6	1.2

Table 1j. Aggregated Characteristics of mobocertinib in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Health Service Utilization Intensity Metrics	mobocertinib	
	Number/Mean	Percent/ Standard Deviation ¹
Mean number of inpatient hospital encounters	0.6	0.9
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	10.0	10.0
Mean number of filled prescriptions	26.8	23.9
Mean number of Non-proprietarys dispensed	11.8	6.0
Mean number of unique drug classes dispensed	10.7	5.0

¹Value represents standard deviation if % doesn't follow the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1k. Aggregated Characteristics of tisotumab vedotin-tftv in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

tisotumab vedotin-tftv		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	528	N/A ²
Demographic Characteristics		
Age (years)	60.6	12.1
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	49	9.3%
41-64 years	238	45.1%
≥ 65 years	241	45.6%
Sex		
Female	*****	*****
Male	*****	*****
Race ³		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	48	9.1%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	156	29.5%
White	295	55.9%
Hispanic origin		
Yes	33	6.3%
No	318	60.2%
Unknown	177	33.5%
Year		
2021	0	0.0%
2021	*****	*****
2022	134	25.4%
2023	160	30.3%
2024	209	39.6%
2025	*****	*****
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	0	0.0%
Non-Alzheimer's Dementia	*****	*****

Table 1k. Aggregated Characteristics of tisotumab vedotin-tftv in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Health Characteristics	tisotumab vedotin-tftv	
	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	20	3.8%
Diabetes Mellitus	60	11.4%
Heart Failure	29	5.5%
Hyperlipidemia	129	24.4%
Hypertension	227	43.0%
Depression	132	25.0%
Ischemic Heart Disease	49	9.3%
Rheumatoid Arthritis/Osteoarthritis	52	9.8%
Stroke/TIA ⁴	13	2.5%
Breast Cancer	27	5.1%
Colorectal Cancer	13	2.5%
Prostate Cancer	0	0.0%
Lung Cancer	27	5.1%
Endometrial Cancer	47	8.9%
Acquired Hypothyroidism	127	24.1%
Anemia	293	55.5%
Asthma	37	7.0%
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	114	21.6%
COPD ⁵ and Bronchiectasis	39	7.4%
Glaucoma	45	8.5%
Osteoporosis	29	5.5%
Obesity: diagnosed or identified by weight management procedures	87	16.5%
Obesity: identified by weight management-related dispensings	*****	*****
Overweight	42	8.0%
Smoking: diagnosed or identified by smoking cessation procedures	169	32.0%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	42	8.0%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	*****	*****
Liver Disease Based on CCW ⁶ Definition	62	11.7%
Liver Disease Extended Definition (CCW + Additional Codes)	64	12.1%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	28.6	12.7
Mean number of emergency room encounters	1.1	2.0

Table 1k. Aggregated Characteristics of tisotumab vedotin-tftv in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Health Service Utilization Intensity Metrics	tisotumab vedotin-tftv	
	Number/Mean	Percent/ Standard Deviation ¹
Mean number of inpatient hospital encounters	0.7	1.1
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	8.5	10.9
Mean number of filled prescriptions	23.3	15.5
Mean number of Non-proprietarys dispensed	11.5	5.9
Mean number of unique drug classes dispensed	10.5	5.1

¹Value represents standard deviation if % doesn't follow the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1I. Aggregated Characteristics of atogepant in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Patient Characteristics	atogepant	
	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	81,013	N/A ²
Demographic Characteristics		
Age (years)	50.0	13.7
Age		
0-17 years	314	0.4%
18-24 years	4,677	5.8%
25-40 years	18,548	22.9%
41-64 years	41,993	51.8%
≥ 65 years	15,481	19.1%
Sex		
Female	68,841	85.0%
Male	12,172	15.0%
Race ³		
American Indian or Alaska Native	202	0.2%
Asian	949	1.2%
Black or African American	4,579	5.7%
Multi-racial	2,104	2.6%
Native Hawaiian or Other Pacific Islander	75	0.1%
Unknown	25,496	31.5%
White	47,608	58.8%
Hispanic origin		
Yes	3,154	3.9%
No	42,150	52.0%
Unknown	35,709	44.1%
Year		
2021	0	0.0%
2021	1,413	1.7%
2022	15,493	19.1%
2023	23,955	29.6%
2024	36,755	45.4%
2025	3,397	4.2%
Health Characteristics		
Acute Myocardial Infarction	145	0.2%
Alzheimer's Disease	388	0.5%
Non-Alzheimer's Dementia	1,365	1.7%

Table 1I. Aggregated Characteristics of atogepant in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Health Characteristics	atogepant	
	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	1,986	2.5%
Diabetes Mellitus	9,861	12.2%
Heart Failure	3,149	3.9%
Hyperlipidemia	18,894	23.3%
Hypertension	21,284	26.3%
Depression	30,213	37.3%
Ischemic Heart Disease	6,048	7.5%
Rheumatoid Arthritis/Osteoarthritis	16,808	20.7%
Stroke/TIA ⁴	2,397	3.0%
Breast Cancer	1,302	1.6%
Colorectal Cancer	175	0.2%
Prostate Cancer	274	0.3%
Lung Cancer	211	0.3%
Endometrial Cancer	79	0.1%
Acquired Hypothyroidism	9,236	11.4%
Anemia	11,991	14.8%
Asthma	6,115	7.5%
Benign Prostatic Hyperplasia	990	1.2%
Chronic Kidney Disease	3,827	4.7%
COPD ⁵ and Bronchiectasis	4,097	5.1%
Glaucoma	3,734	4.6%
Osteoporosis	2,742	3.4%
Obesity: diagnosed or identified by weight management procedures	21,625	26.7%
Obesity: identified by weight management-related dispensings	6,761	8.3%
Overweight	8,420	10.4%
Smoking: diagnosed or identified by smoking cessation procedures	11,137	13.7%
Smoking: identified by smoking-related dispensings	506	0.6%
Alcohol Abuse or Dependence	1,129	1.4%
Drug Abuse or Dependence	4,032	5.0%
History of Cardiac Arrest	79	0.1%
History of Coronary Angioplasty or Bypass	1,241	1.5%
Liver Disease Based on CCW ⁶ Definition	2,194	2.7%
Liver Disease Extended Definition (CCW + Additional Codes)	2,225	2.7%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	14.7	12.7
Mean number of emergency room encounters	0.5	1.5

Table 1I. Aggregated Characteristics of atogepant in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Health Service Utilization Intensity Metrics	atogepant	
	Number/Mean	Percent/ Standard Deviation ¹
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	3.5	7.2
Mean number of filled prescriptions	28.6	23.4
Mean number of Non-proprietarys dispensed	11.2	6.8
Mean number of unique drug classes dispensed	10.3	6.1

¹Value represents standard deviation if % doesn't follow the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

Table 1m. Aggregated Characteristics of maralixibat in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Patient Characteristics	maralixibat	
	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	71	N/A ²
Demographic Characteristics		
Age (years)	12.3	10.4
Age		
0-17 years	56	78.9%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	0	0.0%
≥ 65 years	*****	*****
Sex		
Female	36	50.7%
Male	35	49.3%
Race ³		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	32	45.1%
White	*****	*****
Hispanic origin		
Yes	*****	*****
No	33	46.5%
Unknown	*****	*****
Year		
2021	0	0.0%
2021	31	43.7%
2022	*****	*****
2023	*****	*****
2024	15	21.1%
2025	*****	*****
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease	0	0.0%
Non-Alzheimer's Dementia	0	0.0%

Table 1m. Aggregated Characteristics of maralixibat in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Health Characteristics	maralixibat	
	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	0	0.0%
Diabetes Mellitus	*****	*****
Heart Failure	*****	*****
Hyperlipidemia	*****	*****
Hypertension	*****	*****
Depression	*****	*****
Ischemic Heart Disease	*****	*****
Rheumatoid Arthritis/Osteoarthritis	*****	*****
Stroke/TIA ⁴	0	0.0%
Breast Cancer	*****	*****
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	*****	*****
Anemia	*****	*****
Asthma	*****	*****
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	19	26.8%
COPD ⁵ and Bronchiectasis	*****	*****
Glaucoma	*****	*****
Osteoporosis	0	0.0%
Obesity: diagnosed or identified by weight management procedures	*****	*****
Obesity: identified by weight management-related dispensings	0	0.0%
Overweight	0	0.0%
Smoking: diagnosed or identified by smoking cessation procedures	0	0.0%
Smoking: identified by smoking-related dispensings	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	0	0.0%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****
Liver Disease Based on CCW ⁶ Definition	18	25.4%
Liver Disease Extended Definition (CCW + Additional Codes)	18	25.4%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	14.7	22.2
Mean number of emergency room encounters	0.3	0.7

Table 1m. Aggregated Characteristics of maralixibat in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Health Service Utilization Intensity Metrics	maralixibat	
	Number/Mean	Percent/ Standard Deviation ¹
Mean number of inpatient hospital encounters	0.1	0.5
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	12.2	28.3
Mean number of filled prescriptions	18.0	15.8
Mean number of Non-proprietarys dispensed	5.9	3.7
Mean number of unique drug classes dispensed	5.4	3.3

¹Value represents standard deviation if % doesn't follow the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶ CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a number

Table 1n. Aggregated Characteristics of avacopan in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Patient Characteristics	avacopan	
	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	970	N/A ²
Demographic Characteristics		
Age (years)	62.3	13.5
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	87	9.0%
41-64 years	357	36.8%
≥ 65 years	506	52.2%
Sex		
Female	541	55.8%
Male	429	44.2%
Race ³		
American Indian or Alaska Native	*****	*****
Asian	30	3.1%
Black or African American	49	5.1%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	304	31.3%
White	564	58.1%
Hispanic origin		
Yes	59	6.1%
No	545	56.2%
Unknown	366	37.7%
Year		
2021	0	0.0%
2021	*****	*****
2022	144	14.8%
2023	296	30.5%
2024	479	49.4%
2025	*****	*****
Health Characteristics		
Acute Myocardial Infarction	32	3.3%
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	30	3.1%

Table 1n. Aggregated Characteristics of avacopan in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Health Characteristics	avacopan	
	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	138	14.2%
Diabetes Mellitus	274	28.2%
Heart Failure	212	21.9%
Hyperlipidemia	457	47.1%
Hypertension	669	69.0%
Depression	180	18.6%
Ischemic Heart Disease	231	23.8%
Rheumatoid Arthritis/Osteoarthritis	228	23.5%
Stroke/TIA ⁴	36	3.7%
Breast Cancer	25	2.6%
Colorectal Cancer	*****	*****
Prostate Cancer	16	1.6%
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	180	18.6%
Anemia	623	64.2%
Asthma	104	10.7%
Benign Prostatic Hyperplasia	87	9.0%
Chronic Kidney Disease	613	63.2%
COPD ⁵ and Bronchiectasis	176	18.1%
Glaucoma	94	9.7%
Osteoporosis	96	9.9%
Obesity: diagnosed or identified by weight management procedures	298	30.7%
Obesity: identified by weight management-related dispensings	57	5.9%
Overweight	130	13.4%
Smoking: diagnosed or identified by smoking cessation procedures	273	28.1%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	11	1.1%
Drug Abuse or Dependence	32	3.3%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	54	5.6%
Liver Disease Based on CCW ⁶ Definition	95	9.8%
Liver Disease Extended Definition (CCW + Additional Codes)	97	10.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	23.0	17.0
Mean number of emergency room encounters	1.0	1.7

Table 1n. Aggregated Characteristics of avacopan in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Health Service Utilization Intensity Metrics	avacopan	
	Number/Mean	Percent/ Standard Deviation ¹
Mean number of inpatient hospital encounters	0.9	1.1
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	10.4	11.9
Mean number of filled prescriptions	25.6	15.8
Mean number of Non-proprietarys dispensed	12.3	5.9
Mean number of unique drug classes dispensed	11.4	5.2

¹Value represents standard deviation if % doesn't follow the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶ CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1o. Aggregated Characteristics of asciminib in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

asciminib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	1,358	N/A ²
Demographic Characteristics		
Age (years)	63.7	14.2
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	441	32.5%
≥ 65 years	754	55.5%
Sex		
Female	687	50.6%
Male	671	49.4%
Race ³		
American Indian or Alaska Native	*****	*****
Asian	40	2.9%
Black or African American	124	9.1%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	290	21.4%
White	883	65.0%
Hispanic origin		
Yes	62	4.6%
No	931	68.6%
Unknown	365	26.9%
Year		
2021	0	0.0%
2021	84	6.2%
2022	277	20.4%
2023	326	24.0%
2024	612	45.1%
2025	59	4.3%
Health Characteristics		
Acute Myocardial Infarction	37	2.7%
Alzheimer's Disease	16	1.2%
Non-Alzheimer's Dementia	52	3.8%

Table 1o. Aggregated Characteristics of asciminib in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Health Characteristics	asciminib	
	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	217	16.0%
Diabetes Mellitus	373	27.5%
Heart Failure	367	27.0%
Hyperlipidemia	586	43.2%
Hypertension	770	56.7%
Depression	365	26.9%
Ischemic Heart Disease	374	27.5%
Rheumatoid Arthritis/Osteoarthritis	258	19.0%
Stroke/TIA ⁴	69	5.1%
Breast Cancer	51	3.8%
Colorectal Cancer	15	1.1%
Prostate Cancer	50	3.7%
Lung Cancer	19	1.4%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	223	16.4%
Anemia	713	52.5%
Asthma	111	8.2%
Benign Prostatic Hyperplasia	94	6.9%
Chronic Kidney Disease	336	24.7%
COPD ⁵ and Bronchiectasis	163	12.0%
Glaucoma	106	7.8%
Osteoporosis	69	5.1%
Obesity: diagnosed or identified by weight management procedures	296	21.8%
Obesity: identified by weight management-related dispensings	59	4.3%
Overweight	157	11.6%
Smoking: diagnosed or identified by smoking cessation procedures	381	28.1%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	33	2.4%
Drug Abuse or Dependence	107	7.9%
History of Cardiac Arrest	13	1.0%
History of Coronary Angioplasty or Bypass	138	10.2%
Liver Disease Based on CCW ⁶ Definition	129	9.5%
Liver Disease Extended Definition (CCW + Additional Codes)	129	9.5%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	21.7	16.0
Mean number of emergency room encounters	0.8	1.8

Table 10. Aggregated Characteristics of asciminib in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Health Service Utilization Intensity Metrics	asciminib	
	Number/Mean	Percent/ Standard Deviation ¹
Mean number of inpatient hospital encounters	0.6	1.2
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	9.2	14.7
Mean number of filled prescriptions	26.2	19.8
Mean number of Non-proprietarys dispensed	11.1	6.9
Mean number of unique drug classes dispensed	10.2	6.1

¹Value represents standard deviation if % doesn't follow the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶ CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1p. Aggregated Characteristics of ropeginterferon alfa-2b-njft in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

ropeginterferon alfa-2b-njft		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	878	N/A ²
Demographic Characteristics		
Age (years)	64.3	10.8
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	250	28.5%
≥ 65 years	555	63.2%
Sex		
Female	474	54.0%
Male	404	46.0%
Race ³		
American Indian or Alaska Native	*****	*****
Asian	16	1.8%
Black or African American	33	3.8%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	195	22.2%
White	618	70.4%
Hispanic origin		
Yes	*****	*****
No	577	65.7%
Unknown	*****	*****
Year		
2021	0	0.0%
2021	*****	*****
2022	227	25.9%
2023	202	23.0%
2024	411	46.8%
2025	*****	*****
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	*****	*****

Table 1p. Aggregated Characteristics of ropeginterferon alfa-2b-njft in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Health Characteristics	ropeginterferon alfa-2b-njft	
	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	72	8.2%
Diabetes Mellitus	111	12.6%
Heart Failure	58	6.6%
Hyperlipidemia	270	30.8%
Hypertension	343	39.1%
Depression	138	15.7%
Ischemic Heart Disease	132	15.0%
Rheumatoid Arthritis/Osteoarthritis	113	12.9%
Stroke/TIA ⁴	28	3.2%
Breast Cancer	32	3.6%
Colorectal Cancer	*****	*****
Prostate Cancer	20	2.3%
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	109	12.4%
Anemia	343	39.1%
Asthma	38	4.3%
Benign Prostatic Hyperplasia	52	5.9%
Chronic Kidney Disease	81	9.2%
COPD ⁵ and Bronchiectasis	37	4.2%
Glaucoma	55	6.3%
Osteoporosis	25	2.8%
Obesity: diagnosed or identified by weight management procedures	132	15.0%
Obesity: identified by weight management-related dispensings	25	2.8%
Overweight	93	10.6%
Smoking: diagnosed or identified by smoking cessation procedures	158	18.0%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	11	1.3%
Drug Abuse or Dependence	18	2.1%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	44	5.0%
Liver Disease Based on CCW ⁶ Definition	60	6.8%
Liver Disease Extended Definition (CCW + Additional Codes)	60	6.8%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	17.6	11.2
Mean number of emergency room encounters	0.3	0.7

Table 1p. Aggregated Characteristics of ropeginterferon alfa-2b-njft in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Health Service Utilization Intensity Metrics	ropeginterferon alfa-2b-njft	
	Number/Mean	Percent/ Standard Deviation ¹
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	4.6	6.9
Mean number of filled prescriptions	15.6	12.1
Mean number of Non-proprietarys dispensed	7.3	4.8
Mean number of unique drug classes dispensed	6.9	4.5

¹Value represents standard deviation if % doesn't follow the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶ CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1q. Aggregated Characteristics of vosoritide in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Patient Characteristics	vosoritide	
	Number/Mean	
Unique patients	94	N/A ²
Demographic Characteristics		
Age (years)	7.6	3.9
Age		
0-17 years	94	100.0%
18-24 years	0	0.0%
25-40 years	0	0.0%
41-64 years	0	0.0%
≥ 65 years	0	0.0%
Sex		
Female	52	55.3%
Male	42	44.7%
Race ³		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	0	0.0%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	51	54.3%
White	29	30.9%
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	60	63.8%
Year		
2021	0	0.0%
2021	0	0.0%
2022	35	37.2%
2023	*****	*****
2024	30	31.9%
2025	*****	*****
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease	0	0.0%
Non-Alzheimer's Dementia	0	0.0%

Table 1q. Aggregated Characteristics of vosoritide in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Health Characteristics	vosoritide	
	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	0	0.0%
Diabetes Mellitus	0	0.0%
Heart Failure	0	0.0%
Hyperlipidemia	0	0.0%
Hypertension	0	0.0%
Depression	0	0.0%
Ischemic Heart Disease	0	0.0%
Rheumatoid Arthritis/Osteoarthritis	0	0.0%
Stroke/TIA ⁴	0	0.0%
Breast Cancer	0	0.0%
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	0	0.0%
Anemia	*****	*****
Asthma	0	0.0%
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	0	0.0%
COPD ⁵ and Bronchiectasis	0	0.0%
Glaucoma	0	0.0%
Osteoporosis	0	0.0%
Obesity: diagnosed or identified by weight management procedures	*****	*****
Obesity: identified by weight management-related dispensings	0	0.0%
Overweight	0	0.0%
Smoking: diagnosed or identified by smoking cessation procedures	0	0.0%
Smoking: identified by smoking-related dispensings	0	0.0%
Alcohol Abuse or Dependence	0	0.0%
Drug Abuse or Dependence	0	0.0%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	0	0.0%
Liver Disease Based on CCW ⁶ Definition	0	0.0%
Liver Disease Extended Definition (CCW + Additional Codes)	0	0.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	8.7	11.1
Mean number of emergency room encounters	0.1	0.5

Table 1q. Aggregated Characteristics of vosoritide in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Health Service Utilization Intensity Metrics	vosoritide	
	Number/Mean	Percent/ Standard Deviation ¹
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	2.1	4.4
Mean number of filled prescriptions	3.2	3.9
Mean number of Non-proprietarys dispensed	1.8	2.0
Mean number of unique drug classes dispensed	1.7	1.9

¹Value represents standard deviation if % doesn't follow the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶ CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a number

Table 1r. Aggregated Characteristics of maribavir in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

maribavir		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	1,030	N/A ²
Demographic Characteristics		
Age (years)	57.3	14.2
Age		
0-17 years	14	1.4%
18-24 years	15	1.5%
25-40 years	133	12.9%
41-64 years	476	46.2%
≥ 65 years	392	38.1%
Sex		
Female	435	42.2%
Male	595	57.8%
Race ³		
American Indian or Alaska Native	*****	*****
Asian	31	3.0%
Black or African American	219	21.3%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	239	23.2%
White	521	50.6%
Hispanic origin		
Yes	65	6.3%
No	683	66.3%
Unknown	282	27.4%
Year		
2021	0	0.0%
2021	16	1.6%
2022	228	22.1%
2023	334	32.4%
2024	432	41.9%
2025	20	1.9%
Health Characteristics		
Acute Myocardial Infarction	27	2.6%
Alzheimer's Disease	0	0.0%
Non-Alzheimer's Dementia	32	3.1%

Table 1r. Aggregated Characteristics of maribavir in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Health Characteristics	maribavir	
	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	149	14.5%
Diabetes Mellitus	500	48.5%
Heart Failure	323	31.4%
Hyperlipidemia	528	51.3%
Hypertension	864	83.9%
Depression	264	25.6%
Ischemic Heart Disease	297	28.8%
Rheumatoid Arthritis/Osteoarthritis	107	10.4%
Stroke/TIA ⁴	59	5.7%
Breast Cancer	21	2.0%
Colorectal Cancer	*****	*****
Prostate Cancer	26	2.5%
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	180	17.5%
Anemia	864	83.9%
Asthma	86	8.3%
Benign Prostatic Hyperplasia	116	11.3%
Chronic Kidney Disease	740	71.8%
COPD ⁵ and Bronchiectasis	143	13.9%
Glaucoma	69	6.7%
Osteoporosis	74	7.2%
Obesity: diagnosed or identified by weight management procedures	287	27.9%
Obesity: identified by weight management-related dispensings	56	5.4%
Overweight	156	15.1%
Smoking: diagnosed or identified by smoking cessation procedures	310	30.1%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	62	6.0%
Drug Abuse or Dependence	34	3.3%
History of Cardiac Arrest	16	1.6%
History of Coronary Angioplasty or Bypass	75	7.3%
Liver Disease Based on CCW ⁶ Definition	250	24.3%
Liver Disease Extended Definition (CCW + Additional Codes)	251	24.4%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	37.3	22.8
Mean number of emergency room encounters	1.0	2.7

Table 1r. Aggregated Characteristics of maribavir in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Health Service Utilization Intensity Metrics	maribavir	
	Number/Mean	Percent/ Standard Deviation ¹
Mean number of inpatient hospital encounters	1.7	1.6
Mean number of non-acute institutional encounters	0.1	0.5
Mean number of other ambulatory encounters	22.9	26.1
Mean number of filled prescriptions	36.2	16.8
Mean number of Non-proprietarys dispensed	15.3	6.4
Mean number of unique drug classes dispensed	14.0	5.6

¹Value represents standard deviation if % doesn't follow the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶ CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1s. Aggregated Characteristics of pafolacianine in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

pafolacianine		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	148	N/A ²
Demographic Characteristics		
Age (years)	70.9	8.2
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	125	84.5%
Sex		
Female	104	70.3%
Male	44	29.7%
Race ³		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	120	81.1%
Hispanic origin		
Yes	*****	*****
No	103	69.6%
Unknown	*****	*****
Year		
2021	0	0.0%
2021	0	0.0%
2022	0	0.0%
2023	*****	*****
2024	128	86.5%
2025	*****	*****
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	*****	*****

Table 1s. Aggregated Characteristics of pafolacianine in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Health Characteristics	pafolacianine	
	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	19	12.8%
Diabetes Mellitus	23	15.5%
Heart Failure	11	7.4%
Hyperlipidemia	80	54.1%
Hypertension	85	57.4%
Depression	39	26.4%
Ischemic Heart Disease	49	33.1%
Rheumatoid Arthritis/Osteoarthritis	30	20.3%
Stroke/TIA ⁴	*****	*****
Breast Cancer	13	8.8%
Colorectal Cancer	11	7.4%
Prostate Cancer	*****	*****
Lung Cancer	60	40.5%
Endometrial Cancer	12	8.1%
Acquired Hypothyroidism	20	13.5%
Anemia	40	27.0%
Asthma	15	10.1%
Benign Prostatic Hyperplasia	13	8.8%
Chronic Kidney Disease	23	15.5%
COPD ⁵ and Bronchiectasis	59	39.9%
Glaucoma	26	17.6%
Osteoporosis	11	7.4%
Obesity: diagnosed or identified by weight management procedures	40	27.0%
Obesity: identified by weight management-related dispensings	*****	*****
Overweight	31	20.9%
Smoking: diagnosed or identified by smoking cessation procedures	91	61.5%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****
Liver Disease Based on CCW ⁶ Definition	*****	*****
Liver Disease Extended Definition (CCW + Additional Codes)	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	20.8	11.1
Mean number of emergency room encounters	0.4	0.9

Table 1s. Aggregated Characteristics of pafolacianine in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Health Service Utilization Intensity Metrics	pafolacianine	
	Number/Mean	Percent/ Standard Deviation ¹
Mean number of inpatient hospital encounters	0.2	0.5
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	4.2	4.6
Mean number of filled prescriptions	18.4	15.1
Mean number of Non-proprietarys dispensed	8.7	4.9
Mean number of unique drug classes dispensed	8.2	4.5

¹Value represents standard deviation if % doesn't follow the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶ CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1t. Aggregated Characteristics of tezepelumab-ekko in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

tezepelumab-ekko		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	17,346	N/A ²
Demographic Characteristics		
Age (years)	64.3	11.9
Age		
0-17 years	103	0.6%
18-24 years	192	1.1%
25-40 years	1,002	5.8%
41-64 years	5,525	31.9%
≥ 65 years	10,524	60.7%
Sex		
Female	11,901	68.6%
Male	5,445	31.4%
Race ³		
American Indian or Alaska Native	51	0.3%
Asian	328	1.9%
Black or African American	1,518	8.8%
Multi-racial	184	1.1%
Native Hawaiian or Other Pacific Islander	22	0.1%
Unknown	3,340	19.3%
White	11,903	68.6%
Hispanic origin		
Yes	452	2.6%
No	12,283	70.8%
Unknown	4,611	26.6%
Year		
2021	0	0.0%
2022	0	0.0%
2023	3,655	21.1%
2024	5,981	34.5%
2025	7,361	42.4%
	349	2.0%
Health Characteristics		
Acute Myocardial Infarction	104	0.6%
Alzheimer's Disease	65	0.4%
Non-Alzheimer's Dementia	257	1.5%

Table 1t. Aggregated Characteristics of tezepelumab-ekko in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Health Characteristics	tezepelumab-ekko	
	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	1,546	8.9%
Diabetes Mellitus	4,042	23.3%
Heart Failure	2,348	13.5%
Hyperlipidemia	6,927	39.9%
Hypertension	8,712	50.2%
Depression	4,627	26.7%
Ischemic Heart Disease	3,712	21.4%
Rheumatoid Arthritis/Osteoarthritis	4,392	25.3%
Stroke/TIA ⁴	310	1.8%
Breast Cancer	495	2.9%
Colorectal Cancer	83	0.5%
Prostate Cancer	337	1.9%
Lung Cancer	187	1.1%
Endometrial Cancer	28	0.2%
Acquired Hypothyroidism	2,663	15.4%
Anemia	3,338	19.2%
Asthma	15,420	88.9%
Benign Prostatic Hyperplasia	786	4.5%
Chronic Kidney Disease	1,749	10.1%
COPD ⁵ and Bronchiectasis	6,648	38.3%
Glaucoma	1,477	8.5%
Osteoporosis	1,381	8.0%
Obesity: diagnosed or identified by weight management procedures	6,552	37.8%
Obesity: identified by weight management-related dispensings	1,221	7.0%
Overweight	1,903	11.0%
Smoking: diagnosed or identified by smoking cessation procedures	4,400	25.4%
Smoking: identified by smoking-related dispensings	117	0.7%
Alcohol Abuse or Dependence	277	1.6%
Drug Abuse or Dependence	762	4.4%
History of Cardiac Arrest	40	0.2%
History of Coronary Angioplasty or Bypass	787	4.5%
Liver Disease Based on CCW ⁶ Definition	688	4.0%
Liver Disease Extended Definition (CCW + Additional Codes)	696	4.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	20.5	13.9
Mean number of emergency room encounters	0.6	1.5

Table 1t. Aggregated Characteristics of tezepelumab-ekko in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Health Service Utilization Intensity Metrics	tezepelumab-ekko	
	Number/Mean	Percent/ Standard Deviation ¹
Mean number of inpatient hospital encounters	0.2	0.7
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	5.1	7.8
Mean number of filled prescriptions	32.3	22.1
Mean number of Non-proprietarys dispensed	13.9	7.0
Mean number of unique drug classes dispensed	12.8	6.2

¹Value represents standard deviation if % doesn't follow the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶ CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

Table 1u. Aggregated Characteristics of efgartigimod alfa-fcab in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

efgartigimod alfa-fcab		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	5,101	N/A ²
Demographic Characteristics		
Age (years)	70.3	11.1
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	168	3.3%
41-64 years	882	17.3%
≥ 65 years	4,026	78.9%
Sex		
Female	2,197	43.1%
Male	2,904	56.9%
Race ³		
American Indian or Alaska Native	*****	*****
Asian	45	0.9%
Black or African American	232	4.5%
Multi-racial	32	0.6%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	632	12.4%
White	4,140	81.2%
Hispanic origin		
Yes	76	1.5%
No	4,011	78.6%
Unknown	1,014	19.9%
Year		
2021	0	0.0%
2021	0	0.0%
2022	1,256	24.6%
2023	1,519	29.8%
2024	2,236	43.8%
2025	90	1.8%
Health Characteristics		
Acute Myocardial Infarction	87	1.7%
Alzheimer's Disease	36	0.7%
Non-Alzheimer's Dementia	146	2.9%

Table 1u. Aggregated Characteristics of efgartigimod alfa-fcab in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Health Characteristics	efgartigimod alfa-fcab	
	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	707	13.9%
Diabetes Mellitus	1,693	33.2%
Heart Failure	839	16.4%
Hyperlipidemia	2,515	49.3%
Hypertension	3,100	60.8%
Depression	1,281	25.1%
Ischemic Heart Disease	1,398	27.4%
Rheumatoid Arthritis/Osteoarthritis	1,285	25.2%
Stroke/TIA ⁴	308	6.0%
Breast Cancer	138	2.7%
Colorectal Cancer	62	1.2%
Prostate Cancer	230	4.5%
Lung Cancer	49	1.0%
Endometrial Cancer	22	0.4%
Acquired Hypothyroidism	982	19.3%
Anemia	1,601	31.4%
Asthma	396	7.8%
Benign Prostatic Hyperplasia	538	10.5%
Chronic Kidney Disease	819	16.1%
COPD ⁵ and Bronchiectasis	548	10.7%
Glaucoma	617	12.1%
Osteoporosis	401	7.9%
Obesity: diagnosed or identified by weight management procedures	1,780	34.9%
Obesity: identified by weight management-related dispensings	268	5.3%
Overweight	688	13.5%
Smoking: diagnosed or identified by smoking cessation procedures	1,122	22.0%
Smoking: identified by smoking-related dispensings	*****	*****
Alcohol Abuse or Dependence	76	1.5%
Drug Abuse or Dependence	184	3.6%
History of Cardiac Arrest	27	0.5%
History of Coronary Angioplasty or Bypass	378	7.4%
Liver Disease Based on CCW ⁶ Definition	287	5.6%
Liver Disease Extended Definition (CCW + Additional Codes)	291	5.7%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	21.1	14.2
Mean number of emergency room encounters	0.6	1.2

Table 1u. Aggregated Characteristics of efgartigimod alfa-fcab in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Health Service Utilization Intensity Metrics	efgartigimod alfa-fcab	
	Number/Mean	Percent/ Standard Deviation ¹
Mean number of inpatient hospital encounters	0.5	0.9
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	8.1	12.0
Mean number of filled prescriptions	25.7	18.7
Mean number of Non-proprietarys dispensed	10.8	5.9
Mean number of unique drug classes dispensed	10.1	5.3

¹Value represents standard deviation if % doesn't follow the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶ CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1v. Aggregated Characteristics of inclisiran in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

inclisiran		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	55,123	N/A ²
Demographic Characteristics		
Age (years)	73.0	6.8
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	3,417	6.2%
≥ 65 years	51,603	93.6%
Sex		
Female	29,711	53.9%
Male	25,412	46.1%
Race ³		
American Indian or Alaska Native	71	0.1%
Asian	817	1.5%
Black or African American	2,428	4.4%
Multi-racial	124	0.2%
Native Hawaiian or Other Pacific Islander	20	0.0%
Unknown	3,936	7.1%
White	47,727	86.6%
Hispanic origin		
Yes	474	0.9%
No	49,312	89.5%
Unknown	5,337	9.7%
Year		
2021	0	0.0%
2022	0	0.0%
2023	6,725	12.2%
2024	18,800	34.1%
2025	29,271	53.1%
	327	0.6%
Health Characteristics		
Acute Myocardial Infarction	1,159	2.1%
Alzheimer's Disease	488	0.9%
Non-Alzheimer's Dementia	1,156	2.1%

Table 1v. Aggregated Characteristics of inclisiran in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Health Characteristics	inclisiran	
	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	7,339	13.3%
Diabetes Mellitus	16,292	29.6%
Heart Failure	9,599	17.4%
Hyperlipidemia	46,695	84.7%
Hypertension	39,333	71.4%
Depression	9,049	16.4%
Ischemic Heart Disease	39,913	72.4%
Rheumatoid Arthritis/Osteoarthritis	14,614	26.5%
Stroke/TIA ⁴	2,625	4.8%
Breast Cancer	1,709	3.1%
Colorectal Cancer	362	0.7%
Prostate Cancer	1,967	3.6%
Lung Cancer	465	0.8%
Endometrial Cancer	118	0.2%
Acquired Hypothyroidism	9,109	16.5%
Anemia	11,115	20.2%
Asthma	2,802	5.1%
Benign Prostatic Hyperplasia	3,940	7.1%
Chronic Kidney Disease	8,562	15.5%
COPD ⁵ and Bronchiectasis	4,806	8.7%
Glaucoma	6,051	11.0%
Osteoporosis	3,836	7.0%
Obesity: diagnosed or identified by weight management procedures	14,375	26.1%
Obesity: identified by weight management-related dispensings	3,306	6.0%
Overweight	7,912	14.4%
Smoking: diagnosed or identified by smoking cessation procedures	12,426	22.5%
Smoking: identified by smoking-related dispensings	126	0.2%
Alcohol Abuse or Dependence	705	1.3%
Drug Abuse or Dependence	1,027	1.9%
History of Cardiac Arrest	237	0.4%
History of Coronary Angioplasty or Bypass	14,593	26.5%
Liver Disease Based on CCW ⁶ Definition	2,313	4.2%
Liver Disease Extended Definition (CCW + Additional Codes)	2,372	4.3%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	16.4	13.0
Mean number of emergency room encounters	0.3	0.7

Table 1v. Aggregated Characteristics of inclisiran in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Health Service Utilization Intensity Metrics	inclisiran	
	Number/Mean	Percent/ Standard Deviation ¹
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	3.5	4.9
Mean number of filled prescriptions	18.2	14.5
Mean number of Non-proprietarys dispensed	8.9	5.1
Mean number of unique drug classes dispensed	8.4	4.6

¹Value represents standard deviation if % doesn't follow the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶ CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1w. Aggregated Characteristics of tralokinumab-Idrm in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

tralokinumab-Idrm		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	4,960	N/A ²
Demographic Characteristics		
Age (years)	52.3	16.7
Age		
0-17 years	99	2.0%
18-24 years	475	9.6%
25-40 years	994	20.0%
41-64 years	1,820	36.7%
≥ 65 years	1,572	31.7%
Sex		
Female	2,773	55.9%
Male	2,187	44.1%
Race ³		
American Indian or Alaska Native	*****	*****
Asian	267	5.4%
Black or African American	406	8.2%
Multi-racial	111	2.2%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	1,847	37.2%
White	2,312	46.6%
Hispanic origin		
Yes	154	3.1%
No	2,401	48.4%
Unknown	2,405	48.5%
Year		
2021	0	0.0%
2022	0	0.0%
2023	992	20.0%
2024	1,735	35.0%
2025	2,088	42.1%
	145	2.9%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	22	0.4%
Non-Alzheimer's Dementia	64	1.3%

Table 1w. Aggregated Characteristics of tralokinumab-Idrm in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Health Characteristics	tralokinumab-Idrm	
	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	219	4.4%
Diabetes Mellitus	651	13.1%
Heart Failure	270	5.4%
Hyperlipidemia	1,076	21.7%
Hypertension	1,355	27.3%
Depression	983	19.8%
Ischemic Heart Disease	472	9.5%
Rheumatoid Arthritis/Osteoarthritis	618	12.5%
Stroke/TIA ⁴	74	1.5%
Breast Cancer	53	1.1%
Colorectal Cancer	13	0.3%
Prostate Cancer	44	0.9%
Lung Cancer	17	0.3%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	375	7.6%
Anemia	575	11.6%
Asthma	373	7.5%
Benign Prostatic Hyperplasia	145	2.9%
Chronic Kidney Disease	318	6.4%
COPD ⁵ and Bronchiectasis	263	5.3%
Glaucoma	277	5.6%
Osteoporosis	135	2.7%
Obesity: diagnosed or identified by weight management procedures	925	18.6%
Obesity: identified by weight management-related dispensings	242	4.9%
Overweight	420	8.5%
Smoking: diagnosed or identified by smoking cessation procedures	677	13.6%
Smoking: identified by smoking-related dispensings	37	0.7%
Alcohol Abuse or Dependence	112	2.3%
Drug Abuse or Dependence	120	2.4%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	109	2.2%
Liver Disease Based on CCW ⁶ Definition	113	2.3%
Liver Disease Extended Definition (CCW + Additional Codes)	113	2.3%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	12.4	11.9
Mean number of emergency room encounters	0.3	1.0

Table 1w. Aggregated Characteristics of tralokinumab-Idrm in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

Health Service Utilization Intensity Metrics	tralokinumab-Idrm	
	Number/Mean	Percent/ Standard Deviation ¹
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	2.7	5.3
Mean number of filled prescriptions	20.5	18.5
Mean number of Non-proprietarys dispensed	9.1	6.1
Mean number of unique drug classes dispensed	8.3	5.4

¹Value represents standard deviation if % doesn't follow the value

²N/A: Not Applicable

³Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

⁴TIA: Transient Ischemic Attack

⁵COPD: Chronic Obstructive Pulmonary Disease

⁶CCW: Chronic Conditions Data Warehouse; <https://www2.ccwdata.org/web/guest/home/>

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 2a. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
<i>finerenone</i>	403,117	297,219	73.7%	11,417	2.8%	94,216	23.4%	265	0.1%
<i>fexinidazole</i>	0	N/A ²	N/A	N/A	N/A	N/A	N/A	N/A	N/A
<i>belumosudil</i>	17,194	17,047	99.1%	73	0.4%	*****	*****	*****	*****
<i>odevixibat</i>	349	*****	*****	*****	*****	*****	*****	0	0.0%
<i>anifrolumab-fnia</i>	43,168	*****	*****	*****	*****	*****	*****	0	0.0%
<i>avalglucosidase alfa-ngpt</i>	8,060	8,060	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>belzutifan</i>	9,089	9,072	99.8%	*****	*****	*****	*****	*****	*****
<i>difelikefalin</i>	339,212	339,212	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>lonapegsomatropin-tcgd</i>	10,999	10,892	99.0%	22	0.2%	85	0.8%	0	0.0%
<i>mobocertinib</i>	686	*****	*****	*****	*****	*****	*****	0	0.0%
<i>tisotumab vedotin-tftv</i>	2,581	2,581	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>atogepant</i>	466,484	418,909	89.8%	5,928	1.3%	41,571	8.9%	76	0.0%
<i>maralixibat</i>	586	586	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>avacopan</i>	6,978	6,960	99.7%	*****	*****	*****	*****	0	0.0%
<i>asciminib</i>	10,934	10,653	97.4%	243	2.2%	*****	*****	*****	*****
<i>ropeginterferon alfa-2b-njft</i>	9,786	9,733	99.5%	35	0.4%	18	0.2%	0	0.0%
<i>vosoritide</i>	1,344	1,310	97.5%	*****	*****	23	1.7%	*****	*****
<i>maribavir</i>	3,718	3,694	99.4%	11	0.3%	13	0.3%	0	0.0%
<i>pafolacianine</i>	149	149	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>tezepelumab-ekko</i>	172,426	171,562	99.5%	*****	*****	588	0.3%	*****	*****
<i>efgartigimod alfa-fcab</i>	75,824	74,391	98.1%	1,360	1.8%	73	0.1%	0	0.0%
<i>inclisiran</i>	137,789	133,397	96.8%	281	0.2%	2,492	1.8%	1,619	1.2%
<i>tralokinumab-ldrm</i>	31,807	31,345	98.5%	*****	*****	257	0.8%	*****	*****

¹For drugs requiring clinical administration and identified by procedure codes (rather than pharmacy claims with NDCs), days supplied are not recorded. A default of 1 day supplied was assigned per administration for summary purposes.

²N/A: Not Applicable

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 2b. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>finerenone</i>	403,117	1	30	30	50	180	43.1	26.2
<i>fexinidazole</i>	0	N/A ²	N/A	N/A	N/A	N/A	N/A	N/A
<i>belumosudil</i>	17,194	1	30	30	30	120	29.4	5.9
<i>odevixibat</i>	349	1	30	30	30	90	28.9	8.9
<i>anifrolumab-fnia</i>	43,168	1	1	1	1	84	2.9	6.9
<i>avalglucosidase alfa-ngpt</i>	8,060	1	1	1	1	28	3.1	6.9
<i>belzutifan</i>	9,089	1	30	30	30	180	28.6	5.8
<i>difelikefalin</i>	339,212	1	1	1	1	1	1.0	0.0
<i>lonapegsomatropin-tcgd</i>	10,999	1	28	28	28	84	27.4	6.7
<i>mobocertinib</i>	686	1	30	30	30	90	29.8	4.9
<i>tisotumab vedotin-tftv</i>	2,581	1	1	1	1	21	1.3	2.5
<i>atogepant</i>	466,484	1	30	30	30	270	34.2	18.0
<i>maralixibat</i>	586	1	30	30	30	30	29.0	4.1
<i>avacopan</i>	6,978	1	30	30	30	90	29.0	5.3
<i>asciminib</i>	10,934	1	30	30	30	140	29.6	7.3
<i>ropégeinterferon alfa-2b-njft</i>	9,786	1	28	28	28	90	26.1	6.5
<i>vosoritide</i>	1,344	1	30	30	30	114	30.6	9.6
<i>maribavir</i>	3,718	1	28	28	28	90	24.8	9.3
<i>pafolacianine</i>	149	1	1	1	1	1	1.0	0.0
<i>tezepelumab-ekko</i>	172,426	1	1	1	28	112	8.6	12.8
<i>efgartigimod alfa-fcab</i>	75,824	1	1	1	1	90	3.6	9.1
<i>inclisiran</i>	137,789	1	1	1	1	270	4.7	21.7
<i>tralokinumab-ldrm</i>	31,807	1	28	28	28	139	26.2	8.3

¹For drugs requiring clinical administration and identified by procedure codes (rather than pharmacy claims with NDCs), days supplied are not recorded. A default of 1 day supplied was assigned per administration for summary purposes.

²N/A: Not Applicable

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
finerenone	403,117	297,219	100.0%	11,417	100.0%	94,216	100.0%	265	100.0%
Female	181,206	135,832	45.7%	4,953	43.4%	40,291	42.8%	130	49.1%
Male	221,911	161,387	54.3%	6,464	56.6%	53,925	57.2%	135	50.9%
fexinidazole	0	N/A²	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Female	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Male	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
belumosudil	17,194	17,047	100.0%	73	100.0%	*****	*****	*****	*****
Female	7,298	7,225	42.4%	*****	*****	*****	*****	*****	*****
Male	9,896	9,822	57.6%	*****	*****	*****	*****	0	0.0%
odevixibat	349	*****	*****	*****	*****	*****	*****	0	NaN
Female	139	*****	*****	*****	*****	*****	*****	0	NaN
Male	210	*****	*****	0	0.0%	0	0.0%	0	NaN
anifrolumab-fnia	43,168	*****	*****	*****	*****	*****	*****	0	NaN
Female	39,866	*****	*****	*****	*****	*****	*****	0	NaN
Male	3,302	*****	*****	0	0.0%	0	0.0%	0	NaN
avalglucosidase alfa-ngpt	8,060	8,060	100.0%	0	NaN	0	NaN	0	NaN
Female	4,387	4,387	54.4%	0	NaN	0	NaN	0	NaN
Male	3,673	3,673	45.6%	0	NaN	0	NaN	0	NaN
belzutifan	9,089	9,072	100.0%	*****	*****	*****	*****	*****	*****
Female	2,980	*****	*****	*****	*****	0	0.0%	0	0.0%
Male	6,109	*****	*****	*****	*****	*****	*****	*****	*****
difelikefalin	339,212	339,212	100.0%	0	NaN	0	NaN	0	NaN
Female	160,497	160,497	47.3%	0	NaN	0	NaN	0	NaN
Male	178,715	178,715	52.7%	0	NaN	0	NaN	0	NaN

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
lonapegsomatropin-tcgd	10,999	10,892	100.0%	22	100.0%	85	100.0%	0	NaN
Female	2,548	*****	*****	*****	*****	22	25.9%	0	NaN
Male	8,451	*****	*****	*****	*****	63	74.1%	0	NaN
mobocertinib	686	*****	*****	*****	*****	*****	*****	0	NaN
Female	420	*****	*****	*****	*****	*****	*****	0	NaN
Male	266	*****	*****	*****	*****	*****	*****	0	NaN
tisotumab vedotin-tftv	2,581	2,581	100.0%	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN
atogepant	466,484	418,909	100.0%	5,928	100.0%	41,571	100.0%	76	100.0%
Female	400,644	359,679	85.9%	5,040	85.0%	35,860	86.3%	65	85.5%
Male	65,840	59,230	14.1%	888	15.0%	5,711	13.7%	11	14.5%
maralixibat	586	586	100.0%	0	NaN	0	NaN	0	NaN
Female	239	239	40.8%	0	NaN	0	NaN	0	NaN
Male	347	347	59.2%	0	NaN	0	NaN	0	NaN
avacopan	6,978	6,960	100.0%	*****	*****	*****	*****	0	NaN
Female	3,722	*****	*****	*****	*****	*****	*****	0	NaN
Male	3,256	*****	*****	*****	*****	*****	*****	0	NaN
asciminib	10,934	10,653	100.0%	243	100.0%	*****	*****	*****	*****
Female	5,728	5,554	52.1%	*****	*****	*****	*****	*****	*****
Male	5,206	5,099	47.9%	*****	*****	*****	*****	*****	*****
ropiegelinterferon alfa-2b-njft	9,786	9,733	100.0%	35	100.0%	18	100.0%	0	NaN
Female	4,973	4,953	50.9%	*****	*****	*****	*****	0	NaN
Male	4,813	4,780	49.1%	*****	*****	*****	*****	0	NaN

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
vosoritide	1,344	1,310	100.0%	*****	*****	23	100.0%	*****	*****
Female	823	*****	*****	*****	*****	*****	*****	0	0.0%
Male	521	*****	*****	*****	*****	*****	*****	*****	*****
maribavir	3,718	3,694	100.0%	11	100.0%	13	100.0%	0	NaN
Female	1,680	*****	*****	*****	*****	*****	*****	0	NaN
Male	2,038	*****	*****	*****	*****	*****	*****	0	NaN
pafolacianine	149	149	100.0%	0	NaN	0	NaN	0	NaN
Female	105	105	70.5%	0	NaN	0	NaN	0	NaN
Male	44	44	29.5%	0	NaN	0	NaN	0	NaN
tezepelumab-ekko	172,426	171,562	100.0%	*****	*****	588	100.0%	*****	*****
Female	118,189	117,611	68.6%	*****	*****	387	65.8%	*****	*****
Male	54,237	53,951	31.4%	*****	*****	201	34.2%	*****	*****
efgartigimod alfa-fcab	75,824	74,391	100.0%	1,360	100.0%	73	100.0%	0	NaN
Female	32,014	31,279	42.0%	711	52.3%	24	32.9%	0	NaN
Male	43,810	43,112	58.0%	649	47.7%	49	67.1%	0	NaN
inclisiran	137,789	133,397	100.0%	281	100.0%	2,492	100.0%	1,619	100.0%
Female	72,902	70,202	52.6%	166	59.1%	1,534	61.6%	1,000	61.8%
Male	64,887	63,195	47.4%	115	40.9%	958	38.4%	619	38.2%
tralokinumab-Idrm	31,807	31,345	100.0%	203	100.0%	*****	*****	*****	*****
Female	17,478	17,242	55.0%	*****	*****	*****	*****	*****	*****
Male	14,329	14,103	45.0%	*****	*****	*****	*****	0	0.0%

¹For drugs requiring clinical administration and identified by procedure codes (rather than pharmacy claims with NDCs), days supplied are not recorded. A default of 1 day supplied was assigned per administration for summary purposes.

²N/A: Not Applicable

NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
finerenone	403,117	1	30	30	50	180	43.1	26.2
Female	181,206	1	30	30	31	180	42.3	25.9
Male	221,911	1	30	30	60	180	43.8	26.5
fexinidazole	0	N/A²	N/A	N/A	N/A	N/A	N/A	N/A
Female	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Male	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
belumosudil	17,194	1	30	30	30	120	29.4	5.9
Female	7,298	1	30	30	30	120	29.5	6.0
Male	9,896	1	30	30	30	90	29.4	5.9
odevixibat	349	1	30	30	30	90	28.9	8.9
Female	139	1	30	30	30	90	30.1	12.0
Male	210	1	30	30	30	30	28.1	5.9
anifrolumab-fnia	43,168	1	1	1	1	84	2.9	6.9
Female	39,866	1	1	1	1	84	2.9	7.0
Male	3,302	1	1	1	1	30	2.3	5.8
avalglucosidase alfa-ngpt	8,060	1	1	1	1	28	3.1	6.9
Female	4,387	1	1	1	1	28	2.9	6.6
Male	3,673	1	1	1	1	28	3.2	7.2
belzutifan	9,089	1	30	30	30	180	28.6	5.8
Female	2,980	1	30	30	30	60	28.7	4.9
Male	6,109	1	30	30	30	180	28.6	6.2
difelikefalin	339,212	1	1	1	1	1	1.0	0.0
Female	160,497	1	1	1	1	1	1.0	0.0
Male	178,715	1	1	1	1	1	1.0	0.0
lonapegsomatropin-tcgd	10,999	1	28	28	28	84	27.4	6.7

Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	2,548	1	28	28	28	84	27.4	7.0
Male	8,451	1	28	28	28	84	27.5	6.6
mobocertinib	686	1	30	30	30	90	29.8	4.9
Female	420	1	30	30	30	90	29.8	4.1
Male	266	2	30	30	30	65	29.8	6.0
tisotumab vedotin-tftv	2,581	1	1	1	1	21	1.3	2.5
Female	*****	1	1	1	1	21	1.3	2.5
Male	*****	1	1	1	1	1	1.0	0.0
atogepant	466,484	1	30	30	30	270	34.2	18.0
Female	400,644	1	30	30	30	270	34.2	18.0
Male	65,840	1	30	30	30	180	34.0	17.9
maralixibat	586	1	30	30	30	30	29.0	4.1
Female	239	1	30	30	30	30	28.7	4.9
Male	347	2	30	30	30	30	29.2	3.5
avacopan	6,978	1	30	30	30	90	29.0	5.3
Female	3,722	1	30	30	30	90	29.1	5.6
Male	3,256	1	30	30	30	90	29.0	4.8
asciminib	10,934	1	30	30	30	140	29.6	7.3
Female	5,728	1	30	30	30	120	29.7	7.5
Male	5,206	1	30	30	30	140	29.4	7.1
ropiegelinterferon alfa-2b-njft	9,786	1	28	28	28	90	26.1	6.5
Female	4,973	1	28	28	28	90	26.3	6.2
Male	4,813	1	28	28	28	84	25.9	6.9
vosoritide	1,344	1	30	30	30	114	30.6	9.6

Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	823	1	30	30	30	90	29.8	6.5
Male	521	1	30	30	30	114	31.7	13.0
maribavir	3,718	1	28	28	28	90	24.8	9.3
Female	1,680	1	28	28	28	84	24.7	8.7
Male	2,038	1	28	28	28	90	24.8	9.7
pafolacianine	149	1	1	1	1	1	1.0	0.0
Female	105	1	1	1	1	1	1.0	0.0
Male	44	1	1	1	1	1	1.0	0.0
tezepelumab-ekko	172,426	1	1	1	28	112	8.6	12.8
Female	118,189	1	1	1	28	112	8.9	12.9
Male	54,237	1	1	1	21	91	8.1	12.6
efgartigimod alfa-fcab	75,824	1	1	1	1	90	3.6	9.1
Female	32,014	1	1	1	1	90	4.0	9.7
Male	43,810	1	1	1	1	90	3.3	8.5
inclisiran	137,789	1	1	1	1	270	4.7	21.7
Female	72,902	1	1	1	1	270	5.3	23.4
Male	64,887	1	1	1	1	270	4.0	19.7
tralokinumab-ldrm	31,807	1	28	28	28	139	26.2	8.3
Female	17,478	1	28	28	28	139	26.1	8.2
Male	14,329	1	28	28	28	90	26.3	8.5

¹For drugs requiring clinical administration and identified by procedure codes (rather than pharmacy claims with NDCs), days supplied are not recorded. A default of 1 day supplied was assigned per administration for summary purposes.

²N/A: Not Applicable

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
finerenone	403,117	297,219	100.0%	11,417	100.0%	94,216	100.0%	265	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	41	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	3,789	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	82,153	63,752	21.4%	1,946	17.0%	16,418	17.4%	37	14.0%
≥ 65 years	317,134	230,479	77.5%	9,386	82.2%	77,041	81.8%	228	86.0%
fexinidazole	0	N/A²	N/A	N/A	N/A	N/A	N/A	N/A	N/A
0-17 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
18-24 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
25-40 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
41-64 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
≥ 65 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
belumosudil	17,194	17,047	100.0%	73	100.0%	*****	*****	*****	*****
0-17 years	176	176	1.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	203	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	2,130	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	5,949	5,926	34.8%	*****	*****	*****	*****	0	0.0%
≥ 65 years	8,736	8,629	50.6%	53	72.6%	*****	*****	*****	*****
odevixibat	349	*****	*****	*****	*****	*****	*****	0	NaN
0-17 years	177	*****	*****	0	0.0%	*****	*****	0	NaN
18-24 years	37	*****	*****	*****	*****	*****	*****	0	NaN
25-40 years	106	*****	*****	0	0.0%	*****	*****	0	NaN
41-64 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
≥ 65 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
anifrolumab-fnia	43,168	*****	*****	*****	*****	*****	*****	0	NaN

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
0-17 years	54	*****	*****	0	0.0%	0	0.0%	0	NaN
18-24 years	914	*****	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	8,279	*****	*****	0	0.0%	*****	*****	0	NaN
41-64 years	20,838	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	13,083	*****	*****	0	0.0%	0	0.0%	0	NaN
avagliucosidase alfa-ngpt	8,060	8,060	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	687	687	8.5%	0	NaN	0	NaN	0	NaN
18-24 years	46	46	0.6%	0	NaN	0	NaN	0	NaN
25-40 years	770	770	9.6%	0	NaN	0	NaN	0	NaN
41-64 years	2,641	2,641	32.8%	0	NaN	0	NaN	0	NaN
≥ 65 years	3,916	3,916	48.6%	0	NaN	0	NaN	0	NaN
beluzutifan	9,089	9,072	100.0%	*****	*****	*****	*****	*****	*****
0-17 years	47	47	0.5%	0	0.0%	0	0.0%	0	0.0%
18-24 years	200	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	1,238	1,238	13.6%	0	0.0%	0	0.0%	0	0.0%
41-64 years	2,872	2,861	31.5%	0	0.0%	*****	*****	*****	*****
≥ 65 years	4,732	*****	*****	*****	*****	0	0.0%	0	0.0%
difelikefalin	339,212	339,212	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	1,330	1,330	0.4%	0	NaN	0	NaN	0	NaN
25-40 years	18,448	18,448	5.4%	0	NaN	0	NaN	0	NaN
41-64 years	123,068	123,068	36.3%	0	NaN	0	NaN	0	NaN
≥ 65 years	196,366	196,366	57.9%	0	NaN	0	NaN	0	NaN
lonapegsomatropin-tcgd	10,999	10,892	100.0%	22	100.0%	85	100.0%	0	NaN
0-17 years	10,965	10,858	99.7%	22	100.0%	85	100.0%	0	NaN

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
41-64 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN
mobocertinib	686	*****	*****	*****	*****	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
41-64 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
≥ 65 years	524	*****	*****	*****	*****	*****	*****	0	NaN
tisotumab vedotin-tftv	2,581	2,581	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	214	214	8.3%	0	NaN	0	NaN	0	NaN
41-64 years	1,234	1,234	47.8%	0	NaN	0	NaN	0	NaN
≥ 65 years	1,133	1,133	43.9%	0	NaN	0	NaN	0	NaN
atogepant	466,484	418,909	100.0%	5,928	100.0%	41,571	100.0%	76	100.0%
0-17 years	1,516	1,331	0.3%	22	0.4%	163	0.4%	0	0.0%
18-24 years	24,617	21,987	5.2%	320	5.4%	*****	*****	*****	*****
25-40 years	105,709	95,715	22.8%	1,242	21.0%	*****	*****	*****	*****
41-64 years	256,554	229,432	54.8%	3,200	54.0%	23,875	57.4%	47	61.8%
≥ 65 years	78,088	70,444	16.8%	1,144	19.3%	6,487	15.6%	13	17.1%
maralixibat	586	586	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	444	444	75.8%	0	NaN	0	NaN	0	NaN
18-24 years	91	91	15.5%	0	NaN	0	NaN	0	NaN

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
avacopan	6,978	6,960	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
18-24 years	146	146	2.1%	0	0.0%	0	0.0%	0	NaN
25-40 years	674	674	9.7%	0	0.0%	0	0.0%	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	3,353	3,339	48.0%	*****	*****	*****	*****	0	NaN
asciminib	10,934	10,653	100.0%	243	100.0%	*****	*****	*****	*****
0-17 years	18	18	0.2%	0	0.0%	0	0.0%	0	0.0%
18-24 years	23	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	1,144	1,131	10.6%	13	5.3%	0	0.0%	0	0.0%
41-64 years	3,541	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	6,208	6,041	56.7%	150	61.7%	*****	*****	*****	*****
ropéinterferon alfa-2b-njft	9,786	9,733	100.0%	35	100.0%	18	100.0%	0	NaN
0-17 years	15	15	0.2%	0	0.0%	0	0.0%	0	NaN
18-24 years	77	77	0.8%	0	0.0%	0	0.0%	0	NaN
25-40 years	935	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	2,694	2,678	27.5%	*****	*****	*****	*****	0	NaN
≥ 65 years	6,065	*****	*****	22	62.9%	*****	*****	0	NaN
vosoritide	1,344	1,310	100.0%	*****	*****	23	100.0%	*****	*****
0-17 years	1,344	1,310	100.0%	*****	*****	23	100.0%	*****	*****
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
41-64 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
maribavir	3,718	3,694	100.0%	11	100.0%	13	100.0%	0	NaN
0-17 years	51	51	1.4%	0	0.0%	0	0.0%	0	NaN
18-24 years	64	64	1.7%	0	0.0%	0	0.0%	0	NaN
25-40 years	613	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	1,806	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	1,184	*****	*****	*****	*****	*****	*****	0	NaN
pafolacianine	149	149	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	126	126	84.6%	0	NaN	0	NaN	0	NaN
tezepelumab-ekko	172,426	171,562	100.0%	273	100.0%	*****	*****	*****	*****
0-17 years	839	825	0.5%	*****	*****	*****	*****	0	0.0%
18-24 years	1,403	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	8,738	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	52,197	51,810	30.2%	132	48.4%	*****	*****	*****	*****
≥ 65 years	109,249	108,876	63.5%	107	39.2%	*****	*****	*****	*****
efgartigimod alfa-fcab	75,824	74,391	100.0%	1,360	100.0%	73	100.0%	0	NaN
0-17 years	32	32	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	342	328	0.4%	14	1.0%	0	0.0%	0	NaN
25-40 years	2,966	2,900	3.9%	*****	*****	*****	*****	0	NaN

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Dispensings ¹	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
41-64 years	13,276	13,030	17.5%	*****	*****	*****	*****	0	NaN
≥ 65 years	59,208	58,101	78.1%	1,047	77.0%	60	82.2%	0	NaN
inclisiran	137,789	133,397	100.0%	281	100.0%	2,492	100.0%	1,619	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
25-40 years	217	205	0.2%	*****	*****	*****	*****	*****	*****
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	130,004	126,382	94.7%	212	75.4%	2,086	83.7%	1,324	81.8%
tralokinumab-Idrm	31,807	31,345	100.0%	203	100.0%	*****	*****	*****	*****
0-17 years	392	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	2,778	2,729	8.7%	23	11.3%	*****	*****	*****	*****
25-40 years	6,443	6,379	20.4%	*****	*****	*****	*****	*****	*****
41-64 years	12,854	*****	*****	57	28.1%	*****	*****	0	0.0%
≥ 65 years	9,340	*****	*****	85	41.9%	*****	*****	0	0.0%

¹For drugs requiring clinical administration and identified by procedure codes (rather than pharmacy claims with NDCs), days supplied are not recorded. A default of 1 day supplied was assigned per administration for summary purposes.

²N/A: Not Applicable

NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
finerenone	403,117	1	30	30	50	180	43.1	26.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	41	3	30	30	30	90	38.7	25.2
25-40 years	3,789	1	30	30	30	90	40.8	24.6
41-64 years	82,153	1	30	30	30	180	40.9	24.9
≥ 65 years	317,134	1	30	30	60	180	43.7	26.5
fexinidazole	0	N/A²	N/A	N/A	N/A	N/A	N/A	N/A
0-17 years	0	N/A	N/A	N/A	N/A	N/A	N/A	N/A
18-24 years	0	N/A	N/A	N/A	N/A	N/A	N/A	N/A
25-40 years	0	N/A	N/A	N/A	N/A	N/A	N/A	N/A
41-64 years	0	N/A	N/A	N/A	N/A	N/A	N/A	N/A
≥ 65 years	0	N/A	N/A	N/A	N/A	N/A	N/A	N/A
belumosudil	17,194	1	30	30	30	120	29.4	5.9
0-17 years	176	1	30	30	30	30	28.9	4.6
18-24 years	203	1	30	30	30	60	28.1	6.6
25-40 years	2,130	1	30	30	30	90	29.4	6.1
41-64 years	5,949	1	30	30	30	90	29.2	5.0
≥ 65 years	8,736	1	30	30	30	120	29.7	6.4
odevixibat	349	1	30	30	30	90	28.9	8.9
0-17 years	177	1	30	30	30	90	28.8	8.9
18-24 years	37	14	30	30	30	90	31.4	10.9
25-40 years	106	1	30	30	30	90	29.2	8.0
41-64 years	*****	8	30	30	30	30	25.8	8.2
≥ 65 years	*****	7	7	30	30	30	22.3	13.3
anifrolumab-fnia	43,168	1	1	1	1	84	2.9	6.9

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
0-17 years	54	1	1	1	1	1	1.0	0.0
18-24 years	914	1	1	1	1	28	1.4	3.3
25-40 years	8,279	1	1	1	1	84	2.7	6.6
41-64 years	20,838	1	1	1	1	84	3.5	8.0
≥ 65 years	13,083	1	1	1	1	30	2.0	5.1
avalglucosidase alfa-ngpt	8,060	1	1	1	1	28	3.1	6.9
0-17 years	687	1	1	1	1	28	1.2	2.5
18-24 years	46	1	1	1	1	28	4.0	8.5
25-40 years	770	1	1	1	1	28	5.3	9.5
41-64 years	2,641	1	1	1	1	28	4.3	8.6
≥ 65 years	3,916	1	1	1	1	28	2.1	5.0
belzutifan	9,089	1	30	30	30	180	28.6	5.8
0-17 years	47	17	30	30	30	30	29.0	3.0
18-24 years	200	1	30	30	30	60	28.5	6.0
25-40 years	1,238	1	30	30	30	30	29.1	3.9
41-64 years	2,872	1	30	30	30	180	28.8	7.2
≥ 65 years	4,732	1	30	30	30	45	28.4	5.2
difelikefalin	339,212	1	1	1	1	1	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	1,330	1	1	1	1	1	1.0	0.0
25-40 years	18,448	1	1	1	1	1	1.0	0.0
41-64 years	123,068	1	1	1	1	1	1.0	0.0
≥ 65 years	196,366	1	1	1	1	1	1.0	0.0
lonapegsomatropin-tcgd	10,999	1	28	28	28	84	27.4	6.7
0-17 years	10,965	1	28	28	28	84	27.4	6.7

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
18-24 years	*****	28	28	28	28	28	28.0	0.0
25-40 years	*****	2	15	28	28	28	21.5	13.0
41-64 years	*****	28	28	28	28	28	28.0	0.0
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
mobocertinib	686	1	30	30	30	90	29.8	4.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	4	30	30	30	30	27.1	8.7
41-64 years	*****	2	30	30	30	30	28.8	4.8
≥ 65 years	524	1	30	30	30	90	30.1	4.8
tisotumab vedotin-tftv	2,581	1	1	1	1	21	1.3	2.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	214	1	1	1	1	21	1.3	2.2
41-64 years	1,234	1	1	1	1	21	1.3	2.4
≥ 65 years	1,133	1	1	1	1	21	1.3	2.6
atogepant	466,484	1	30	30	30	270	34.2	18.0
0-17 years	1,516	1	30	30	30	90	35.2	19.5
18-24 years	24,617	1	30	30	30	180	34.6	18.3
25-40 years	105,709	1	30	30	30	270	33.8	17.4
41-64 years	256,554	1	30	30	30	180	34.5	18.3
≥ 65 years	78,088	1	30	30	30	180	33.6	17.7
maralixibat	586	1	30	30	30	30	29.0	4.1
0-17 years	444	1	30	30	30	30	28.8	4.3
18-24 years	91	4	30	30	30	30	29.5	3.1

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
25-40 years	*****	21	30	30	30	30	29.6	1.7
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	*****	7	30	30	30	30	26.7	8.7
avacopan	6,978	1	30	30	30	90	29.0	5.3
0-17 years	*****	16	28	30	30	30	27.8	4.9
18-24 years	*****	1	30	30	30	30	28.5	5.5
25-40 years	674	1	30	30	30	30	29.1	4.0
41-64 years	2,797	1	30	30	30	90	29.0	5.0
≥ 65 years	3,353	1	30	30	30	90	29.1	5.7
asciminib	10,934	1	30	30	30	140	29.6	7.3
0-17 years	18	19	30	30	30	30	29.2	2.7
18-24 years	23	6	30	30	30	60	28.1	10.1
25-40 years	1,144	1	30	30	30	60	29.2	5.2
41-64 years	3,541	1	30	30	30	120	29.6	7.4
≥ 65 years	6,208	1	30	30	30	140	29.6	7.5
ropiegelinterferon alfa-2b-njft	9,786	1	28	28	28	90	26.1	6.5
0-17 years	15	8	28	28	28	28	26.7	5.2
18-24 years	77	3	28	28	28	30	26.9	4.7
25-40 years	935	1	28	28	28	56	25.1	6.8
41-64 years	2,694	1	28	28	28	90	25.6	7.5
≥ 65 years	6,065	1	28	28	28	84	26.5	6.0
vosoritide	1,344	1	30	30	30	114	30.6	9.6
0-17 years	1,344	1	30	30	30	114	30.6	9.6
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
maribavir	3,718	1	28	28	28	90	24.8	9.3
0-17 years	51	1	28	28	28	28	25.6	6.3
18-24 years	64	1	28	28	28	30	26.3	6.6
25-40 years	613	1	28	28	28	84	25.5	7.9
41-64 years	1,806	1	28	28	28	90	25.8	7.8
≥ 65 years	1,184	1	26	28	28	84	22.7	11.7
pafolacianine	149	1	1	1	1	1	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	NaN
25-40 years	*****	1	1	1	1	1	1.0	NaN
41-64 years	*****	1	1	1	1	1	1.0	0.0
≥ 65 years	126	1	1	1	1	1	1.0	0.0
tezepelumab-ekko	172,426	1	1	1	28	112	8.6	12.8
0-17 years	839	1	1	1	28	84	13.8	14.9
18-24 years	1,403	1	1	3	28	84	14.2	13.7
25-40 years	8,738	1	1	1	28	90	13.7	14.6
41-64 years	52,197	1	1	1	28	112	13.7	14.3
≥ 65 years	109,249	1	1	1	1	91	5.7	10.8
efgartigimod alfa-fcab	75,824	1	1	1	1	90	3.6	9.1
0-17 years	32	1	1	1	1	1	1.0	0.0
18-24 years	342	1	1	1	1	56	3.8	10.3
25-40 years	2,966	1	1	1	1	84	3.1	8.6

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Dispensings ¹	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
41-64 years	13,276	1	1	1	1	70	3.6	9.0
≥ 65 years	59,208	1	1	1	1	90	3.6	9.1
inclisiran	137,789	1	1	1	1	270	4.7	21.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	180	8.1	28.9
41-64 years	7,562	1	1	1	1	270	12.8	37.5
≥ 65 years	130,004	1	1	1	1	182	4.2	20.3
tralokinumab-ldrm	31,807	1	28	28	28	139	26.2	8.3
0-17 years	392	1	14	28	28	46	22.7	9.1
18-24 years	2,778	1	28	28	28	139	26.2	8.8
25-40 years	6,443	1	28	28	28	112	26.0	7.6
41-64 years	12,854	1	28	28	28	84	26.3	7.7
≥ 65 years	9,340	1	28	28	28	90	26.2	9.3

¹For drugs requiring clinical administration and identified by procedure codes (rather than pharmacy claims with NDCs), days supplied are not recorded. A default of 1 day supplied was assigned per administration for summary purposes.

²N/A: Not Applicable

NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 3a. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<i>finerenone</i>	65,377	8,726	13.3%	13,455	20.6%	25,216	38.6%	13,967	21.4%	4,013	6.1%
<i>fexinidazole</i>	0	N/A ¹	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
<i>belumosudil</i>	1,803	255	14.1%	332	18.4%	716	39.7%	346	19.2%	154	8.5%
<i>odevixibat</i>	45	*****	*****	*****	*****	15	33.3%	*****	*****	*****	*****
<i>anifrolumab-fnia</i>	4,578	4,119	90.0%	208	4.5%	177	3.9%	*****	*****	*****	*****
<i>avalglucosidase alfa-ngpt</i>	243	96	39.5%	111	45.7%	*****	*****	*****	*****	11	4.5%
<i>belzutifan</i>	1,686	418	24.8%	499	29.6%	606	35.9%	115	6.8%	48	2.8%
<i>difelikefalin</i>	5,528	2,478	44.8%	1,654	29.9%	1,396	25.3%	0	0.0%	0	0.0%
<i>lonapegsomatropin-tcgd</i>	1,164	108	9.3%	193	16.6%	592	50.9%	227	19.5%	44	3.8%
<i>mobocertinib</i>	157	53	33.8%	48	30.6%	40	25.5%	*****	*****	*****	*****
<i>tisotumab vedotin-tftv</i>	528	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>atogepant</i>	81,013	17,032	21.0%	20,107	24.8%	30,176	37.2%	10,804	13.3%	2,894	3.6%
<i>maralixibat</i>	71	22	31.0%	18	25.4%	17	23.9%	*****	*****	*****	*****
<i>avacopan</i>	970	152	15.7%	211	21.8%	450	46.4%	132	13.6%	25	2.6%
<i>asciminib</i>	1,358	251	18.5%	268	19.7%	538	39.6%	209	15.4%	92	6.8%
<i>ropoginterferon alfa-2b-njft</i>	878	122	13.9%	127	14.5%	377	42.9%	184	21.0%	68	7.7%
<i>vosoritide</i>	94	*****	*****	*****	*****	33	35.1%	27	28.7%	20	21.3%
<i>maribavir</i>	1,030	368	35.7%	364	35.3%	271	26.3%	*****	*****	*****	*****
<i>pafelacianine</i>	148	148	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>tezepelumab-ekko</i>	17,346	11,663	67.2%	1,507	8.7%	2,941	17.0%	1,090	6.3%	145	0.8%
<i>efgartigimod alfa-fcab</i>	5,101	3,404	66.7%	1,043	20.4%	489	9.6%	154	3.0%	11	0.2%
<i>inclisiran</i>	55,123	53,016	96.2%	564	1.0%	1,116	2.0%	358	0.6%	69	0.1%
<i>tralokinumab-ldrm</i>	4,960	1,009	20.3%	1,158	23.3%	2,184	44.0%	538	10.8%	71	1.4%

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

¹N/A: Not Applicable

Table 3b. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>finerenone</i>	65,377	1	83	180	399	1,339	265.9	242.8
<i>fexinidazole</i>	0	N/A ¹	N/A	N/A	N/A	N/A	N/A	N/A
<i>belumosudil</i>	1,803	1	77	180	408	1,199	280.7	272.6
<i>odevixibat</i>	45	1	60	110	320	1,149	224.1	244.3
<i>anifrolumab-fnia</i>	4,578	1	3	7	16	1,010	26.9	81.5
<i>avalglucosidase alfa-ngpt</i>	243	1	15	44	69	1,050	102.0	203.8
<i>belzutifan</i>	1,686	1	33	90	180	1,170	154.3	186.9
<i>difelikefalin</i>	5,528	1	13	34	91	342	61.4	65.0
<i>lonapegsomatropin-tcgd</i>	1,164	1	85	217	359	1,094	259.2	210.7
<i>mobocertinib</i>	157	3	30	60	148	780	130.2	156.7
<i>tisotumab vedotin-tftv</i>	528	1	2	4	6	189	6.4	14.4
<i>atogepant</i>	81,013	1	54	120	270	1,281	197.0	209.1
<i>maralixibat</i>	71	4	30	60	296	1,162	239.2	340.7
<i>avacopan</i>	970	2	60	150	300	1,076	209.0	190.9
<i>asciminib</i>	1,358	1	58	150	330	1,143	238.0	248.7
<i>ropiegelinterferon alfa-2b-njft</i>	878	1	84	204	444	1,119	291.0	267.5
<i>vosoritide</i>	94	15	180	373	660	1,156	437.1	329.1
<i>maribavir</i>	1,030	1	28	56	112	1,087	89.3	110.5
<i>pafolacianine</i>	148	1	1	1	1	2	1.0	0.1
<i>tezepelumab-ekko</i>	17,346	1	5	16	84	1,123	85.8	154.6
<i>efgartigimod alfa-fcab</i>	5,101	1	7	16	44	1,023	53.0	105.4
<i>inclisiran</i>	55,123	1	1	2	4	1,003	11.8	59.6
<i>tralokinumab-ldrm</i>	4,960	1	42	112	225	1,055	167.7	172.8

¹N/A: Not Applicable

Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
finerenone	65,377	8,726	100.0%	13,455	100.0%	25,216	100.0%	13,967	100.0%	4,013	100.0%
Female	29,455	4,020	46.1%	6,145	45.7%	11,428	45.3%	6,156	44.1%	1,706	42.5%
Male	35,922	4,706	53.9%	7,310	54.3%	13,788	54.7%	7,811	55.9%	2,307	57.5%
fexinidazole	0	N/A¹	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Female	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Male	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
belumosudil	1,803	255	100.0%	332	100.0%	716	100.0%	346	100.0%	154	100.0%
Female	762	105	41.2%	145	43.7%	294	41.1%	156	45.1%	62	40.3%
Male	1,041	150	58.8%	187	56.3%	422	58.9%	190	54.9%	92	59.7%
odevixibat	45	*****	*****	*****	*****	15	100.0%	*****	*****	*****	*****
Female	22	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
Male	23	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
anifrolumab-fnia	4,578	4,119	100.0%	208	100.0%	177	100.0%	*****	*****	*****	*****
Female	4,228	3,790	92.0%	*****	*****	*****	*****	*****	*****	*****	*****
Male	350	329	8.0%	*****	*****	*****	*****	*****	*****	0	0.0%
avalglucosidase alfa-ngpt	243	96	100.0%	111	100.0%	18	100.0%	*****	*****	*****	*****
Female	120	40	41.7%	61	55.0%	*****	*****	*****	*****	*****	*****
Male	123	56	58.3%	50	45.0%	*****	*****	*****	*****	*****	*****
beluzutifan	1,686	418	100.0%	499	100.0%	606	100.0%	115	100.0%	48	100.0%
Female	515	124	29.7%	154	30.9%	178	29.4%	40	34.8%	19	39.6%
Male	1,171	294	70.3%	345	69.1%	428	70.6%	75	65.2%	29	60.4%

Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
difelikefalin	5,528	2,478	100.0%	1,654	100.0%	1,396	100.0%	0	NaN	0	NaN
Female	2,654	1,206	48.7%	786	47.5%	662	47.4%	0	NaN	0	NaN
Male	2,874	1,272	51.3%	868	52.5%	734	52.6%	0	NaN	0	NaN
lonapegsomatropin-tcgd	1,164	108	100.0%	193	100.0%	592	100.0%	227	100.0%	44	100.0%
Female	283	36	33.3%	51	26.4%	132	22.3%	53	23.3%	11	25.0%
Male	881	72	66.7%	142	73.6%	460	77.7%	174	76.7%	33	75.0%
mobocertinib	157	53	100.0%	48	100.0%	40	100.0%	*****	*****	*****	*****
Female	91	32	60.4%	25	52.1%	*****	*****	*****	*****	*****	*****
Male	66	21	39.6%	23	47.9%	*****	*****	*****	*****	0	0.0%
tisotumab vedotin-tftv	528	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Female	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
atogepant	81,013	17,032	100.0%	20,107	100.0%	30,176	100.0%	10,804	100.0%	2,894	100.0%
Female	68,841	14,111	82.8%	17,024	84.7%	25,845	85.6%	9,358	86.6%	2,503	86.5%
Male	12,172	2,921	17.2%	3,083	15.3%	4,331	14.4%	1,446	13.4%	391	13.5%
maralixibat	71	22	100.0%	18	100.0%	17	100.0%	*****	*****	*****	*****
Female	36	11	50.0%	*****	*****	*****	*****	0	0.0%	*****	*****
Male	35	11	50.0%	*****	*****	*****	*****	*****	*****	*****	*****
avacopan	970	152	100.0%	211	100.0%	450	100.0%	132	100.0%	25	100.0%
Female	541	90	59.2%	114	54.0%	257	57.1%	*****	*****	*****	*****
Male	429	62	40.8%	97	46.0%	193	42.9%	*****	*****	*****	*****

Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
asciminib	1,358	251	100.0%	268	100.0%	538	100.0%	209	100.0%	92	100.0%
Female	687	119	47.4%	128	47.8%	273	50.7%	118	56.5%	49	53.3%
Male	671	132	52.6%	140	52.2%	265	49.3%	91	43.5%	43	46.7%
ropginterferon alfa-2b-njft	878	122	100.0%	127	100.0%	377	100.0%	184	100.0%	68	100.0%
Female	474	75	61.5%	65	51.2%	212	56.2%	90	48.9%	32	47.1%
Male	404	47	38.5%	62	48.8%	165	43.8%	94	51.1%	36	52.9%
vosoritide	94	*****	*****	*****	*****	33	100.0%	27	100.0%	20	100.0%
Female	52	*****	*****	*****	*****	15	45.5%	*****	*****	*****	*****
Male	42	*****	*****	*****	*****	18	54.5%	*****	*****	*****	*****
maribavir	1,030	368	100.0%	364	100.0%	271	100.0%	*****	*****	*****	*****
Female	435	153	41.6%	151	41.5%	115	42.4%	*****	*****	*****	*****
Male	595	215	58.4%	213	58.5%	156	57.6%	*****	*****	*****	*****
pafolacianine	148	148	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	104	104	70.3%	0	NaN	0	NaN	0	NaN	0	NaN
Male	44	44	29.7%	0	NaN	0	NaN	0	NaN	0	NaN
tezepelumab-ekko	17,346	11,663	100.0%	1,507	100.0%	2,941	100.0%	1,090	100.0%	145	100.0%
Female	11,901	7,907	67.8%	1,053	69.9%	2,082	70.8%	749	68.7%	110	75.9%
Male	5,445	3,756	32.2%	454	30.1%	859	29.2%	341	31.3%	35	24.1%
efgartigimod alfa-fcab	5,101	3,404	100.0%	1,043	100.0%	489	100.0%	154	100.0%	11	100.0%
Female	2,197	1,424	41.8%	450	43.1%	244	49.9%	*****	*****	*****	*****
Male	2,904	1,980	58.2%	593	56.9%	245	50.1%	*****	*****	*****	*****
inclisiran	55,123	53,016	100.0%	564	100.0%	1,116	100.0%	358	100.0%	69	100.0%

Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Female	29,711	28,406	53.6%	364	64.5%	680	60.9%	215	60.1%	46	66.7%
Male	25,412	24,610	46.4%	200	35.5%	436	39.1%	143	39.9%	23	33.3%
tralokinumab-ldrm	4,960	1,009	100.0%	1,158	100.0%	2,184	100.0%	538	100.0%	71	100.0%
Female	2,773	549	54.4%	679	58.6%	1,214	55.6%	294	54.6%	37	52.1%
Male	2,187	460	45.6%	479	41.4%	970	44.4%	244	45.4%	34	47.9%

¹N/A: Not Applicable

NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
finerenone	65,377	1	83	180	399	1,339	265.9	242.8
Female	29,455	1	79	180	390	1,339	260.3	239.3
Male	35,922	1	86	180	410	1,318	270.5	245.5
fexinidazole	0	N/A¹	N/A	N/A	N/A	N/A	N/A	N/A
Female	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Male	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
belumosudil	1,803	1	77	180	408	1,199	280.7	272.6
Female	762	1	73	192	419	1,199	282.1	273.4
Male	1,041	2	80	180	394	1,199	279.6	272.2
odevixibat	45	1	60	110	320	1,149	224.1	244.3
Female	22	1	69	109	282	618	190.3	169.5
Male	23	1	30	110	382	1,149	256.5	299.4
anifrolumab-fnia	4,578	1	3	7	16	1,010	26.9	81.5
Female	4,228	1	3	7	16	1,010	27.3	82.4
Male	350	1	3	8	15	553	21.8	70.4
avalglucosidase alfa-ngpt	243	1	15	44	69	1,050	102.0	203.8
Female	120	1	19	48	71	1,050	107.2	205.0
Male	123	1	11	35	68	1,024	96.9	203.2
belzutifan	1,686	1	33	90	180	1,170	154.3	186.9
Female	515	1	42	90	182	1,069	165.8	203.0
Male	1,171	1	30	90	180	1,170	149.2	179.2
difelikefalin	5,528	1	13	34	91	342	61.4	65.0
Female	2,654	1	13	34	90	342	60.5	64.5
Male	2,874	1	14	34	92	338	62.2	65.6
lonapegsomatropin-tcgd	1,164	1	85	217	359	1,094	259.2	210.7

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	283	2	75	196	338	877	246.4	209.6
Male	881	1	97	224	359	1,094	263.4	211.0
mobocertinib	157	3	30	60	148	780	130.2	156.7
Female	91	9	30	60	150	780	137.6	170.9
Male	66	3	30	60	120	540	120.0	135.4
tisotumab vedotin-tftv	528	1	2	4	6	189	6.4	14.4
Female	*****	1	2	4	6	189	6.5	14.4
Male	*****	1	1	1	1	1	1.0	0.0
atogepant	81,013	1	54	120	270	1,281	197.0	209.1
Female	68,841	1	57	120	270	1,281	199.3	210.1
Male	12,172	1	37	95	242	1,163	184.0	203.3
maralixibat	71	4	30	60	296	1,162	239.2	340.7
Female	36	4	30	56	195	1,162	190.6	309.2
Male	35	15	24	90	410	1,156	289.2	368.2
avacopan	970	2	60	150	300	1,076	209.0	190.9
Female	541	2	60	150	300	960	200.1	176.3
Male	429	3	60	150	307	1,076	220.1	207.5
asciminib	1,358	1	58	150	330	1,143	238.0	248.7
Female	687	1	60	153	356	1,143	247.6	251.0
Male	671	1	49	129	312	1,138	228.0	246.2
ropeginterferon alfa-2b-njft	878	1	84	204	444	1,119	291.0	267.5
Female	474	1	81	196	386	1,083	275.8	258.2
Male	404	2	84	224	474	1,119	308.8	277.2
vosoritide	94	15	180	373	660	1,156	437.1	329.1

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	52	30	242	390	720	1,075	472.3	315.8
Male	42	15	132	314	482	1,156	393.5	343.6
maribavir	1,030	1	28	56	112	1,087	89.3	110.5
Female	435	1	28	56	112	1,031	95.3	115.4
Male	595	1	28	56	112	1,087	84.9	106.7
pafolacianine	148	1	1	1	1	2	1.0	0.1
Female	104	1	1	1	1	2	1.0	0.1
Male	44	1	1	1	1	1	1.0	0.0
tezepelumab-ekko	17,346	1	5	16	84	1,123	85.8	154.6
Female	11,901	1	5	17	87	1,123	88.0	157.3
Male	5,445	1	5	16	73	1,038	80.8	148.3
efgartigimod alfa-fcab	5,101	1	7	16	44	1,023	53.0	105.4
Female	2,197	1	7	19	52	1,023	58.0	111.4
Male	2,904	1	7	16	40	959	49.3	100.4
inclisiran	55,123	1	1	2	4	1,003	11.8	59.6
Female	29,711	1	1	2	3	1,003	13.1	64.2
Male	25,412	1	2	2	4	909	10.3	53.8
tralokinumab-ldrm	4,960	1	42	112	225	1,055	167.7	172.8
Female	2,773	1	42	112	217	1,024	164.2	170.0
Male	2,187	1	42	112	238	1,055	172.0	176.2

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

¹N/A: Not Applicable

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
finerenone	65,377	8,726	100.0%	13,455	100.0%	25,216	100.0%	13,967	100.0%	4,013	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	17	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	725	*****	*****	*****	*****	*****	*****	121	0.9%	17	0.4%
41-64 years	13,040	1,687	19.3%	2,698	20.1%	5,252	20.8%	2,724	19.5%	679	16.9%
≥ 65 years	51,595	6,899	79.1%	10,602	78.8%	19,655	77.9%	11,122	79.6%	3,317	82.7%
fexinidazole	0	N/A ¹	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
0-17 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
18-24 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
25-40 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
41-64 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
≥ 65 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
belumosudil	1,803	255	100.0%	332	100.0%	716	100.0%	346	100.0%	154	100.0%
0-17 years	18	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	37	*****	*****	*****	*****	13	1.8%	*****	*****	0	0.0%
25-40 years	225	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	626	92	36.1%	115	34.6%	242	33.8%	126	36.4%	51	33.1%
≥ 65 years	897	115	45.1%	157	47.3%	377	52.7%	167	48.3%	81	52.6%

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
odevixibat	45	*****	*****	*****	*****	15	100.0%	*****	*****	*****	*****
0-17 years	29	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	0	0.0%	*****	*****	0	0.0%
25-40 years	*****	*****	*****	0	0.0%	*****	*****	*****	*****	*****	*****
41-64 years	*****	0	0.0%	0	0.0%	*****	*****	*****	*****	0	0.0%
≥ 65 years	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%
anifrolumab-fnia	4,578	4,119	100.0%	208	100.0%	177	100.0%	*****	*****	*****	*****
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	934	844	20.5%	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	2,163	1,897	46.1%	104	50.0%	112	63.3%	*****	*****	*****	*****
≥ 65 years	1,370	1,273	30.9%	53	25.5%	32	18.1%	*****	*****	*****	*****
avalglucosidase alfa-ngpt	243	96	100.0%	111	100.0%	18	100.0%	*****	*****	*****	*****
0-17 years	27	15	15.6%	12	10.8%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	82	32	33.3%	33	29.7%	*****	*****	*****	*****	*****	*****
≥ 65 years	105	37	38.5%	55	49.5%	*****	*****	*****	*****	*****	*****

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
belzutifan	1,686	418	100.0%	499	100.0%	606	100.0%	115	100.0%	48	100.0%
0-17 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	100	*****	*****	12	2.4%	37	6.1%	*****	*****	*****	*****
41-64 years	403	87	20.8%	99	19.8%	147	24.3%	46	40.0%	24	50.0%
≥ 65 years	1,147	315	75.4%	378	75.8%	408	67.3%	*****	*****	*****	*****
difelikefalin	5,528	2,478	100.0%	1,654	100.0%	1,396	100.0%	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	16	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
25-40 years	303	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	1,990	895	36.1%	599	36.2%	496	35.5%	0	NaN	0	NaN
≥ 65 years	3,219	1,431	57.7%	970	58.6%	818	58.6%	0	NaN	0	NaN
lonapegsomatropin-tcgd	1,164	108	100.0%	193	100.0%	592	100.0%	227	100.0%	44	100.0%
0-17 years	1,157	*****	*****	*****	*****	*****	*****	*****	*****	44	100.0%
18-24 years	*****	*****	*****	0	0.0%	*****	*****	*****	*****	0	0.0%
25-40 years	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%
41-64 years	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
mobocertinib	157	53	100.0%	48	100.0%	40	100.0%	****	****	****	****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	****	****	****	****	****	****	****	0	0.0%	0	0.0%
41-64 years	****	****	****	****	****	****	****	****	****	0	0.0%
≥ 65 years	116	41	77.4%	31	64.6%	****	****	****	****	****	****
tisotumab vedotin-tftv	528	****	****	****	****	****	****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	49	****	****	****	****	0	0.0%	0	NaN	0	NaN
41-64 years	238	****	****	****	****	****	****	0	NaN	0	NaN
≥ 65 years	241	****	****	****	****	****	****	0	NaN	0	NaN
atogepant	81,013	17,032	100.0%	20,107	100.0%	30,176	100.0%	10,804	100.0%	2,894	100.0%
0-17 years	314	66	0.4%	85	0.4%	123	0.4%	****	****	****	****
18-24 years	4,677	1,028	6.0%	1,199	6.0%	1,752	5.8%	****	****	****	****
25-40 years	18,548	3,809	22.4%	4,740	23.6%	6,965	23.1%	2,474	22.9%	560	19.4%
41-64 years	41,993	7,931	46.6%	10,106	50.3%	16,073	53.3%	6,083	56.3%	1,800	62.2%
≥ 65 years	15,481	4,198	24.6%	3,977	19.8%	5,263	17.4%	1,622	15.0%	421	14.5%

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	
maralixibat	71	22	100.0%	18	100.0%	17	100.0%	****	****	****	
0-17 years	56	****	****	****	****	****	****	****	****	****	
18-24 years	****	****	****	****	****	****	****	0	0.0%	****	
25-40 years	****	****	****	****	****	****	****	0	0.0%	****	
41-64 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	
≥ 65 years	****	****	****	0	0.0%	****	****	0	0.0%	0	
avacopan	970	152	100.0%	211	100.0%	450	100.0%	132	100.0%	25	100.0%
0-17 years	****	****	****	****	****	****	****	0	0.0%	0	0.0%
18-24 years	****	****	****	****	****	****	****	****	****	0	0.0%
25-40 years	87	****	****	****	****	****	****	14	10.6%	****	****
41-64 years	357	****	****	81	38.4%	172	38.2%	****	****	****	****
≥ 65 years	506	100	65.8%	108	51.2%	223	49.6%	****	****	****	****
asciminib	1,358	251	100.0%	268	100.0%	538	100.0%	209	100.0%	92	100.0%
0-17 years	****	0	0.0%	****	****	****	****	0	0.0%	0	0.0%
18-24 years	****	****	****	****	****	****	****	0	0.0%	0	0.0%
25-40 years	****	****	****	****	****	****	****	14	6.7%	14	15.2%
41-64 years	441	78	31.1%	95	35.4%	173	32.2%	65	31.1%	30	32.6%
≥ 65 years	754	132	52.6%	141	52.6%	303	56.3%	130	62.2%	48	52.2%

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
ropginterferon alfa-2b-njft	878	122	100.0%	127	100.0%	377	100.0%	184	100.0%	68	100.0%
0-17 years	*****	0	0.0%	0	0.0%	0	0.0%	*****	*****	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	*****	*****	*****	*****	*****	25	6.6%	17	9.2%	*****	*****
41-64 years	250	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	555	78	63.9%	79	62.2%	245	65.0%	113	61.4%	40	58.8%
vosoritide	94	*****	*****	*****	*****	33	100.0%	27	100.0%	*****	*****
0-17 years	94	*****	*****	*****	*****	33	100.0%	27	100.0%	*****	*****
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
41-64 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
maribavir	1,030	368	100.0%	364	100.0%	271	100.0%	*****	*****	*****	*****
0-17 years	14	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	15	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	133	*****	*****	55	15.1%	*****	*****	*****	*****	0	0.0%
41-64 years	476	143	38.9%	180	49.5%	138	50.9%	*****	*****	*****	*****
≥ 65 years	392	195	53.0%	118	32.4%	*****	*****	*****	*****	*****	*****

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
pafolacianine	148	148	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	125	125	84.5%	0	NaN	0	NaN	0	NaN	0	NaN
tezepelumab-ekko	17,346	11,663	100.0%	1,507	100.0%	2,941	100.0%	1,090	100.0%	145	100.0%
0-17 years	103	51	0.4%	13	0.9%	*****	*****	*****	*****	*****	*****
18-24 years	192	96	0.8%	25	1.7%	59	2.0%	*****	*****	*****	*****
25-40 years	1,002	520	4.5%	119	7.9%	*****	*****	76	7.0%	*****	*****
41-64 years	5,525	2,775	23.8%	635	42.1%	1,465	49.8%	583	53.5%	67	46.2%
≥ 65 years	10,524	8,221	70.5%	715	47.4%	1,109	37.7%	414	38.0%	65	44.8%
efgartigimod alfa-fcab	5,101	3,404	100.0%	1,043	100.0%	489	100.0%	154	100.0%	11	100.0%
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	0	0.0%	*****	*****	0	0.0%
25-40 years	168	105	3.1%	*****	*****	17	3.5%	*****	*****	0	0.0%
41-64 years	882	597	17.5%	176	16.9%	81	16.6%	*****	*****	*****	*****
≥ 65 years	4,026	2,685	78.9%	820	78.6%	391	80.0%	*****	*****	*****	*****

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	
inclisiran	55,123	53,016	100.0%	564	100.0%	1,116	100.0%	358	100.0%	69	100.0%
0-17 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	3,417	3,042	5.7%	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	51,603	49,877	94.1%	451	80.0%	926	83.0%	*****	*****	*****	*****
tralokinumab-Idrm	4,960	1,009	100.0%	1,158	100.0%	2,184	100.0%	538	100.0%	71	100.0%
0-17 years	99	27	2.7%	30	2.6%	42	1.9%	0	0.0%	0	0.0%
18-24 years	475	99	9.8%	112	9.7%	213	9.8%	*****	*****	*****	*****
25-40 years	994	166	16.5%	238	20.6%	478	21.9%	*****	*****	*****	*****
41-64 years	1,820	308	30.5%	406	35.1%	842	38.6%	231	42.9%	33	46.5%
≥ 65 years	1,572	409	40.5%	372	32.1%	609	27.9%	154	28.6%	28	39.4%

¹N/A: Not Applicable

NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
finerenone	65,377	1	83	180	399	1,339	265.9	242.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	17	18	30	60	150	300	93.3	79.9
25-40 years	725	1	60	150	314	1,171	213.5	199.8
41-64 years	13,040	1	78	180	386	1,289	257.5	233.3
≥ 65 years	51,595	1	85	180	407	1,339	268.9	245.5
fexinidazole	0	N/A¹	N/A	N/A	N/A	N/A	N/A	N/A
0-17 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
18-24 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
25-40 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
41-64 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
≥ 65 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
belumosudil	1,803	1	77	180	408	1,199	280.7	272.6
0-17 years	18	12	90	115	480	1,037	282.4	328.0
18-24 years	37	10	30	93	167	709	154.4	179.5
25-40 years	225	4	60	164	443	1,108	277.9	285.0
41-64 years	626	2	73	188	414	1,199	277.3	264.6
≥ 65 years	897	1	90	195	408	1,199	288.9	276.1
odevixibat	45	1	60	110	320	1,149	224.1	244.3
0-17 years	29	1	40	93	266	854	175.7	203.4
18-24 years	*****	18	60	90	374	618	232.0	257.2
25-40 years	*****	1	185	295	493	1,149	386.9	352.1
41-64 years	*****	288	288	335	382	382	335.0	66.5
≥ 65 years	*****	67	67	67	67	67	67.0	NaN
anifrolumab-fnia	4,578	1	3	7	16	1,010	26.9	81.5

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
0-17 years	*****	7	8	9	20	30	13.5	11.0
18-24 years	*****	1	3	6	12	219	12.1	23.8
25-40 years	934	1	3	7	15	947	23.6	75.1
41-64 years	2,163	1	3	8	18	1,010	33.9	96.4
≥ 65 years	1,370	1	3	7	16	896	19.2	58.9
avalglucosidase alfa-ngpt	243	1	15	44	69	1,050	102.0	203.8
0-17 years	27	1	10	20	48	88	31.6	26.8
18-24 years	*****	3	5	24	57	95	36.8	39.1
25-40 years	*****	2	13	44	76	1,024	169.4	300.3
41-64 years	82	1	16	45	70	1,050	139.9	255.5
≥ 65 years	105	1	17	46	70	1,002	78.1	146.2
belzutifan	1,686	1	33	90	180	1,170	154.3	186.9
0-17 years	*****	17	30	97	169	953	227.2	359.9
18-24 years	*****	23	60	113	220	1,069	190.3	227.0
25-40 years	100	1	109	274	584	1,039	359.8	297.4
41-64 years	403	1	49	120	264	1,170	205.3	240.0
≥ 65 years	1,147	1	30	82	150	948	117.1	124.9
difelikefalin	5,528	1	13	34	91	342	61.4	65.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	16	1	21	43	126	342	83.1	92.7
25-40 years	303	1	12	32	94	293	60.9	66.6
41-64 years	1,990	1	14	34	90	338	61.8	65.2
≥ 65 years	3,219	1	13	34	92	327	61.0	64.7
lonapegsomatropin-tcgd	1,164	1	85	217	359	1,094	259.2	210.7
0-17 years	*****	1	85	218	359	1,094	260.0	211.0

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
18-24 years	*****	28	112	112	112	392	151.2	139.4
25-40 years	*****	86	86	86	86	86	86.0	NaN
41-64 years	*****	84	84	84	84	84	84.0	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
mobocertinib	157	3	30	60	148	780	130.2	156.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	30	30	47	92	120	61.0	42.5
41-64 years	*****	3	30	60	120	570	119.1	140.9
≥ 65 years	116	9	30	60	150	780	136.2	163.7
tisotumab vedotin-tftv	528	1	2	4	6	189	6.4	14.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	49	1	2	3	6	58	5.5	8.8
41-64 years	238	1	2	4	7	189	6.7	15.4
≥ 65 years	241	1	2	3	6	163	6.3	14.3
atogepant	81,013	1	54	120	270	1,281	197.0	209.1
0-17 years	314	1	49	104	240	1,072	170.0	173.2
18-24 years	4,677	1	48	108	248	1,192	182.1	191.9
25-40 years	18,548	1	55	118	270	1,281	192.6	202.7
41-64 years	41,993	1	60	120	299	1,226	210.9	218.1
≥ 65 years	15,481	1	30	90	218	1,262	169.5	193.7
maralixibat	71	4	30	60	296	1,162	239.2	340.7
0-17 years	56	4	24	59	259	1,162	228.7	341.0
18-24 years	*****	17	47	150	600	1,076	335.9	416.2

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
25-40 years	*****	21	53	150	297	780	260.2	309.8
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	*****	30	30	94	157	157	93.5	89.8
avacopan	970	2	60	150	300	1,076	209.0	190.9
0-17 years	*****	26	26	76	120	120	74.0	47.0
18-24 years	*****	30	105	202	360	573	244.4	157.6
25-40 years	87	13	90	162	308	1,076	225.4	199.9
41-64 years	357	2	60	179	320	960	227.0	201.3
≥ 65 years	506	2	60	120	279	1,023	193.0	181.9
asciminib	1,358	1	58	150	330	1,143	238.0	248.7
0-17 years	*****	49	49	146	330	330	175.0	142.7
18-24 years	*****	15	26	105	186	210	107.8	84.8
25-40 years	*****	3	30	121	295	1,103	216.7	249.7
41-64 years	441	1	60	148	334	1,143	237.5	252.5
≥ 65 years	754	1	60	150	345	1,125	243.8	247.4
ropiegelinterferon alfa-2b-njft	878	1	84	204	444	1,119	291.0	267.5
0-17 years	*****	400	400	400	400	400	400.0	NaN
18-24 years	*****	28	96	185	431	618	258.6	223.3
25-40 years	*****	9	106	264	600	1,078	366.2	306.6
41-64 years	250	1	78	181	414	1,119	275.7	261.7
≥ 65 years	555	2	84	211	428	1,078	289.5	265.3
vosoritide	94	15	180	373	660	1,156	437.1	329.1
0-17 years	94	15	180	373	660	1,156	437.1	329.1
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
maribavir	1,030	1	28	56	112	1,087	89.3	110.5
0-17 years	14	1	28	56	139	295	93.4	96.9
18-24 years	15	28	70	84	140	337	111.9	77.8
25-40 years	133	1	56	84	140	476	117.4	104.2
41-64 years	476	1	28	58	112	1,087	97.8	116.1
≥ 65 years	392	1	3	32	84	1,031	68.4	103.8
pafolacianine	148	1	1	1	1	2	1.0	0.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	NaN
25-40 years	*****	1	1	1	1	1	1.0	NaN
41-64 years	*****	1	1	1	1	1	1.0	0.0
≥ 65 years	125	1	1	1	1	2	1.0	0.1
tezepelumab-ekko	17,346	1	5	16	84	1,123	85.8	154.6
0-17 years	103	1	4	40	168	738	111.7	153.6
18-24 years	192	1	6	31	167	791	103.5	139.7
25-40 years	1,002	1	6	28	169	1,017	119.5	171.3
41-64 years	5,525	1	7	30	196	1,044	129.6	180.3
≥ 65 years	10,524	1	5	12	28	1,123	58.9	130.7
efgartigimod alfa-fcab	5,101	1	7	16	44	1,023	53.0	105.4
0-17 years	*****	9	9	11	12	12	10.7	1.5
18-24 years	*****	3	8	18	35	494	58.8	124.0
25-40 years	168	1	7	19	52	610	54.6	103.8

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
41-64 years	882	1	6	16	43	1,023	53.7	111.5
≥ 65 years	4,026	1	8	16	44	959	52.8	104.0
inclisiran	55,123	1	1	2	4	1,003	11.8	59.6
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	2	2	2	1.5	0.6
25-40 years	*****	1	1	2	3	481	17.6	69.6
41-64 years	3,417	1	1	2	3	962	28.3	96.9
≥ 65 years	51,603	1	1	2	4	1,003	10.7	56.1
tralokinumab-ldrm	4,960	1	42	112	225	1,055	167.7	172.8
0-17 years	99	1	28	76	127	280	89.8	71.6
18-24 years	475	1	42	112	210	810	153.4	149.5
25-40 years	994	1	56	112	238	947	168.3	160.5
41-64 years	1,820	1	56	126	254	1,024	185.8	184.2
≥ 65 years	1,572	1	28	92	210	1,055	155.5	175.1

¹N/A: Not Applicable

NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 4a. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	Number of Treatment Episodes by Duration										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>finerenone</i>	178,149	77,349	43.4%	60,183	33.8%	33,208	18.6%	6,145	3.4%	1,264	0.7%
<i>fexinidazole</i>	0	N/A ¹	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
<i>belumosudil</i>	5,836	2,970	50.9%	1,579	27.1%	1,095	18.8%	158	2.7%	34	0.6%
<i>odevixibat</i>	99	45	45.5%	28	28.3%	*****	*****	*****	*****	*****	*****
<i>anifrolumab-fnia</i>	40,955	40,339	98.5%	428	1.0%	*****	*****	*****	*****	0	0.0%
<i>avalglucosidase alfa-ngpt</i>	7,503	7,412	98.8%	45	0.6%	*****	*****	*****	*****	*****	*****
<i>belzutifan</i>	4,108	2,389	58.2%	1,161	28.3%	504	12.3%	*****	*****	*****	*****
<i>difelikefalin</i>	335,643	335,643	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>lonapegsomatropin-tcgd</i>	3,102	1,499	48.3%	718	23.1%	740	23.9%	132	4.3%	13	0.4%
<i>mobocertinib</i>	352	223	63.4%	94	26.7%	*****	*****	*****	*****	0	0.0%
<i>tisotumab vedotin-tftv</i>	2,557	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>atogepant</i>	217,044	120,591	55.6%	60,092	27.7%	31,686	14.6%	4,052	1.9%	623	0.3%
<i>maralixibat</i>	153	79	51.6%	42	27.5%	*****	*****	*****	*****	*****	*****
<i>avacopan</i>	2,643	1,369	51.8%	744	28.1%	482	18.2%	*****	*****	*****	*****
<i>ascimininib</i>	4,008	2,200	54.9%	1,034	25.8%	650	16.2%	92	2.3%	32	0.8%
<i>ropiegelinterferon alfa-2b-njft</i>	3,210	1,736	54.1%	763	23.8%	628	19.6%	71	2.2%	12	0.4%
<i>vosoritide</i>	321	155	48.3%	68	21.2%	71	22.1%	*****	*****	*****	*****
<i>maribavir</i>	1,850	1,098	59.4%	541	29.2%	*****	*****	*****	*****	*****	*****
<i>pafolacianine</i>	149	149	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>tezepelumab-ekko</i>	139,660	130,679	93.6%	5,348	3.8%	3,333	2.4%	280	0.2%	20	0.0%
<i>efgartigimod alfa-fcab</i>	72,976	71,897	98.5%	762	1.0%	292	0.4%	25	0.0%	0	0.0%
<i>inclisiran</i>	136,127	132,660	97.5%	1,830	1.3%	1,527	1.1%	98	0.1%	12	0.0%
<i>tralokinumab-ldrm</i>	13,095	7,644	58.4%	3,128	23.9%	2,117	16.2%	184	1.4%	22	0.2%

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

¹N/A: Not Applicable

Table 4b. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>finerenone</i>	178,149	1	30	60	90	1,318	97.6	125.0
<i>fexinidazole</i>	0	N/A ¹	N/A	N/A	N/A	N/A	N/A	N/A
<i>belumosudil</i>	5,836	1	30	30	90	1,199	86.7	117.0
<i>odevixibat</i>	99	1	30	60	110	1,149	101.9	158.1
<i>anifrolumab-fnia</i>	40,955	1	1	1	1	420	3.0	14.3
<i>avalglucosidase alfa-ngpt</i>	7,503	1	1	1	1	1,018	3.3	26.4
<i>belzutifan</i>	4,108	1	30	30	60	1,085	63.3	81.3
<i>difelikefalin</i>	335,643	1	1	1	1	5	1.0	0.1
<i>lonapegsomatropin-tcgd</i>	3,102	1	28	44	112	1,066	97.3	125.5
<i>mobocertinib</i>	352	3	30	30	60	726	58.1	71.0
<i>tisotumab vedotin-tftv</i>	2,557	1	1	1	1	163	1.3	4.8
<i>atogepant</i>	217,044	1	30	30	90	1,281	73.5	94.9
<i>maralixibat</i>	153	4	30	30	90	1,162	111.0	203.4
<i>avacopan</i>	2,643	1	30	30	90	840	76.7	89.5
<i>asciminib</i>	4,008	1	30	30	90	1,140	80.6	118.3
<i>ropégeinterferon alfa-2b-njft</i>	3,210	1	28	28	84	1,051	79.6	113.1
<i>vosoritide</i>	321	3	30	51	120	1,094	128.0	189.9
<i>maribavir</i>	1,850	1	28	28	56	789	49.7	55.8
<i>pafolacianine</i>	149	1	1	1	1	1	1.0	0.0
<i>tezepelumab-ekko</i>	139,660	1	1	1	1	1,095	10.7	39.3
<i>efgartigimod alfa-fcab</i>	72,976	1	1	1	1	689	3.7	16.0
<i>inclisiran</i>	136,127	1	1	1	1	900	4.8	28.2
<i>tralokinumab-ldrm</i>	13,095	1	28	28	70	1,055	63.5	84.5

¹N/A: Not Applicable

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
finerenone	178,149	77,349	100.0%	60,183	100.0%	33,208	100.0%	6,145	100.0%	1,264	100.0%
Female	80,831	35,935	46.5%	27,046	44.9%	14,665	44.2%	2,663	43.3%	522	41.3%
Male	97,318	41,414	53.5%	33,137	55.1%	18,543	55.8%	3,482	56.7%	742	58.7%
fexinidazole	0	N/A¹	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Female	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Male	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
belumosudil	5,836	2,970	100.0%	1,579	100.0%	1,095	100.0%	158	100.0%	34	100.0%
Female	2,453	1,232	41.5%	675	42.7%	458	41.8%	75	47.5%	13	38.2%
Male	3,383	1,738	58.5%	904	57.3%	637	58.2%	83	52.5%	21	61.8%
odevixibat	99	45	100.0%	28	100.0%	*****	*****	*****	*****	*****	*****
Female	56	28	62.2%	*****	*****	*****	*****	0	0.0%	0	0.0%
Male	43	17	37.8%	*****	*****	*****	*****	*****	*****	*****	*****
anifrolumab-fnia	40,955	40,339	100.0%	428	100.0%	*****	*****	*****	*****	0	NaN
Female	37,778	37,196	92.2%	*****	*****	*****	*****	*****	*****	0	NaN
Male	3,177	3,143	7.8%	*****	*****	*****	*****	0	0.0%	0	NaN
avalglucosidase alfa-ngpt	7,503	7,412	100.0%	45	100.0%	*****	*****	*****	*****	*****	*****
Female	4,102	4,063	54.8%	17	37.8%	*****	*****	*****	*****	*****	*****
Male	3,401	3,349	45.2%	28	62.2%	*****	*****	*****	*****	0	0.0%
belzutifan	4,108	2,389	100.0%	1,161	100.0%	504	100.0%	*****	*****	*****	*****
Female	1,379	815	34.1%	389	33.5%	158	31.3%	*****	*****	*****	*****
Male	2,729	1,574	65.9%	772	66.5%	346	68.7%	*****	*****	*****	*****
difelikefalin	335,643	335,643	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	158,602	158,602	47.3%	0	NaN	0	NaN	0	NaN	0	NaN
Male	177,041	177,041	52.7%	0	NaN	0	NaN	0	NaN	0	NaN

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
lonapegsomatropin-tcgd	3,102	1,499	100.0%	718	100.0%	740	100.0%	132	100.0%	13	100.0%
Female	815	431	28.8%	187	26.0%	164	22.2%	*****	*****	*****	*****
Male	2,287	1,068	71.2%	531	74.0%	576	77.8%	*****	*****	*****	*****
mobocertinib	352	223	100.0%	94	100.0%	*****	*****	*****	*****	0	NaN
Female	212	137	61.4%	*****	*****	*****	*****	*****	*****	0	NaN
Male	140	86	38.6%	*****	*****	*****	*****	0	0.0%	0	NaN
tisotumab vedotin-tftv	2,557	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Female	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
atogepant	217,044	120,591	100.0%	60,092	100.0%	31,686	100.0%	4,052	100.0%	623	100.0%
Female	186,525	103,609	85.9%	51,695	86.0%	27,187	85.8%	3,510	86.6%	524	84.1%
Male	30,519	16,982	14.1%	8,397	14.0%	4,499	14.2%	542	13.4%	99	15.9%
maralixibat	153	79	100.0%	42	100.0%	*****	*****	*****	*****	*****	*****
Female	52	29	36.7%	*****	*****	*****	*****	*****	*****	*****	*****
Male	101	50	63.3%	*****	*****	*****	*****	*****	*****	*****	*****
avacopan	2,643	1,369	100.0%	744	100.0%	482	100.0%	*****	*****	*****	*****
Female	1,462	769	56.2%	412	55.4%	260	53.9%	*****	*****	*****	*****
Male	1,181	600	43.8%	332	44.6%	222	46.1%	*****	*****	*****	*****
asciminib	4,008	2,200	100.0%	1,034	100.0%	650	100.0%	92	100.0%	32	100.0%
Female	2,122	1,174	53.4%	536	51.8%	354	54.5%	39	42.4%	19	59.4%
Male	1,886	1,026	46.6%	498	48.2%	296	45.5%	53	57.6%	13	40.6%
ropginterferon alfa-2b-njft	3,210	1,736	100.0%	763	100.0%	628	100.0%	71	100.0%	12	100.0%
Female	1,583	843	48.6%	369	48.4%	330	52.5%	*****	*****	*****	*****
Male	1,627	893	51.4%	394	51.6%	298	47.5%	*****	*****	*****	*****

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
vosoritide	321	155	100.0%	68	100.0%	71	100.0%	*****	*****	*****	*****
Female	201	99	63.9%	41	60.3%	45	63.4%	*****	*****	*****	*****
Male	120	56	36.1%	27	39.7%	26	36.6%	*****	*****	*****	*****
maribavir	1,850	1,098	100.0%	541	100.0%	*****	*****	*****	*****	*****	*****
Female	828	500	45.5%	227	42.0%	*****	*****	*****	*****	0	0.0%
Male	1,022	598	54.5%	314	58.0%	*****	*****	*****	*****	*****	*****
pafolacianine	149	149	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	105	105	70.5%	0	NaN	0	NaN	0	NaN	0	NaN
Male	44	44	29.5%	0	NaN	0	NaN	0	NaN	0	NaN
tezepelumab-ekko	139,660	130,679	100.0%	5,348	100.0%	3,333	100.0%	280	100.0%	20	100.0%
Female	94,828	88,512	67.7%	3,745	70.0%	2,366	71.0%	*****	*****	*****	*****
Male	44,832	42,167	32.3%	1,603	30.0%	967	29.0%	*****	*****	*****	*****
efgartigimod alfa-fcab	72,976	71,897	100.0%	762	100.0%	292	100.0%	25	100.0%	0	NaN
Female	30,610	30,041	41.8%	411	53.9%	*****	*****	*****	*****	0	NaN
Male	42,366	41,856	58.2%	351	46.1%	*****	*****	*****	*****	0	NaN
inclisiran	136,127	132,660	100.0%	1,830	100.0%	1,527	100.0%	98	100.0%	12	100.0%
Female	71,906	69,751	52.6%	1,128	61.6%	963	63.1%	*****	*****	*****	*****
Male	64,221	62,909	47.4%	702	38.4%	564	36.9%	*****	*****	*****	*****
tralokinumab-ldrm	13,095	7,644	100.0%	3,128	100.0%	2,117	100.0%	184	100.0%	22	100.0%
Female	7,235	4,213	55.1%	1,772	56.6%	1,136	53.7%	*****	*****	*****	*****
Male	5,860	3,431	44.9%	1,356	43.4%	981	46.3%	*****	*****	*****	*****

¹N/A: Not Applicable

NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
finerenone	178,149	1	30	60	90	1,318	97.6	125.0
Female	80,831	1	30	60	90	1,315	94.9	121.7
Male	97,318	1	30	60	90	1,318	99.9	127.6
fexinidazole	0	N/A¹	N/A	N/A	N/A	N/A	N/A	N/A
Female	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Male	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
belumosudil	5,836	1	30	30	90	1,199	86.7	117.0
Female	2,453	1	30	30	90	1,199	87.6	117.0
Male	3,383	1	30	30	90	1,163	86.0	116.9
odevixibat	99	1	30	60	110	1,149	101.9	158.1
Female	56	1	30	38	84	360	74.8	81.0
Male	43	1	30	60	150	1,149	137.2	217.8
anifrolumab-fnia	40,955	1	1	1	1	420	3.0	14.3
Female	37,778	1	1	1	1	420	3.1	14.5
Male	3,177	1	1	1	1	196	2.4	11.5
avalglucosidase alfa-ngpt	7,503	1	1	1	1	1,018	3.3	26.4
Female	4,102	1	1	1	1	1,018	3.1	27.6
Male	3,401	1	1	1	1	722	3.5	25.0
belzutifan	4,108	1	30	30	60	1,085	63.3	81.3
Female	1,379	1	30	30	60	1,000	61.9	82.5
Male	2,729	1	30	30	60	1,085	64.0	80.7
difelikefalin	335,643	1	1	1	1	5	1.0	0.1
Female	158,602	1	1	1	1	3	1.0	0.1
Male	177,041	1	1	1	1	5	1.0	0.1
lonapegsomatropin-tcgd	3,102	1	28	44	112	1,066	97.3	125.5

Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	815	1	28	28	84	875	85.6	115.6
Male	2,287	1	28	56	112	1,066	101.4	128.6
mobocertinib	352	3	30	30	60	726	58.1	71.0
Female	212	9	30	30	60	726	59.1	81.8
Male	140	3	30	30	60	300	56.6	50.7
tisotumab vedotin-tftv	2,557	1	1	1	1	163	1.3	4.8
Female	*****	1	1	1	1	163	1.3	4.8
Male	*****	1	1	1	1	1	1.0	0.0
atogepant	217,044	1	30	30	90	1,281	73.5	94.9
Female	186,525	1	30	30	90	1,281	73.6	94.8
Male	30,519	1	30	30	90	1,158	73.4	95.7
maralixibat	153	4	30	30	90	1,162	111.0	203.4
Female	52	4	30	30	105	1,162	131.9	262.9
Male	101	15	30	32	90	978	100.2	165.2
avacopan	2,643	1	30	30	90	840	76.7	89.5
Female	1,462	1	30	30	90	840	74.0	84.0
Male	1,181	1	30	30	90	790	80.0	95.9
asciminib	4,008	1	30	30	90	1,140	80.6	118.3
Female	2,122	1	30	30	90	1,140	80.2	118.4
Male	1,886	1	30	30	90	1,108	81.1	118.2
ropiegelinterferon alfa-2b-njft	3,210	1	28	28	84	1,051	79.6	113.1
Female	1,583	1	28	28	84	1,049	82.6	114.6
Male	1,627	1	28	28	84	1,051	76.7	111.6
vosoritide	321	3	30	51	120	1,094	128.0	189.9

Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	201	3	30	44	120	990	122.2	177.3
Male	120	3	30	56	150	1,094	137.7	209.9
maribavir	1,850	1	28	28	56	789	49.7	55.8
Female	828	1	28	28	56	532	50.1	56.1
Male	1,022	1	28	28	56	789	49.4	55.6
pafolacianine	149	1	1	1	1	1	1.0	0.0
Female	105	1	1	1	1	1	1.0	0.0
Male	44	1	1	1	1	1	1.0	0.0
tezepelumab-ekko	139,660	1	1	1	1	1,095	10.7	39.3
Female	94,828	1	1	1	1	1,095	11.0	40.3
Male	44,832	1	1	1	1	948	9.8	37.2
efgartigimod alfa-fcab	72,976	1	1	1	1	689	3.7	16.0
Female	30,610	1	1	1	1	638	4.2	16.5
Male	42,366	1	1	1	1	689	3.4	15.6
inclisiran	136,127	1	1	1	1	900	4.8	28.2
Female	71,906	1	1	1	1	817	5.4	30.0
Male	64,221	1	1	1	1	900	4.1	25.9
tralokinumab-ldrm	13,095	1	28	28	70	1,055	63.5	84.5
Female	7,235	1	28	28	70	1,024	63.0	84.0
Male	5,860	1	28	28	78	1,055	64.2	85.1

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

¹N/A: Not Applicable

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
finerenone	178,149	77,349	100.0%	60,183	100.0%	33,208	100.0%	6,145	100.0%	1,264	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	31	15	0.0%	16	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	1,938	972	1.3%	623	1.0%	300	0.9%	*****	*****	*****	*****
41-64 years	36,878	17,009	22.0%	12,199	20.3%	6,317	19.0%	*****	*****	*****	*****
≥ 65 years	139,302	59,353	76.7%	47,345	78.7%	26,591	80.1%	4,949	80.5%	1,064	84.2%
fezinidazole	0	N/A¹	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
0-17 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
18-24 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
25-40 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
41-64 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
≥ 65 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
belumosudil	5,836	2,970	100.0%	1,579	100.0%	1,095	100.0%	158	100.0%	34	100.0%
0-17 years	60	34	1.1%	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	77	39	1.3%	*****	*****	15	1.4%	*****	*****	0	0.0%
25-40 years	876	518	17.4%	213	13.5%	123	11.2%	*****	*****	*****	*****
41-64 years	2,069	1,075	36.2%	543	34.4%	*****	*****	54	34.2%	*****	*****
≥ 65 years	2,754	1,304	43.9%	786	49.8%	563	51.4%	80	50.6%	21	61.8%
odevixibat	99	45	100.0%	28	100.0%	*****	*****	*****	*****	*****	*****
0-17 years	58	29	64.4%	15	53.6%	*****	*****	*****	*****	*****	*****
18-24 years	16	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
41-64 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
≥ 65 years	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
anifrolumab-fnia	40,955	40,339	100.0%	428	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	54	54	0.1%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	905	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	7,903	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	19,362	18,955	47.0%	280	65.4%	*****	*****	*****	*****	0	NaN
≥ 65 years	12,731	12,632	31.3%	65	15.2%	*****	*****	*****	*****	0	NaN
avalglucosidase alfa-ngpt	7,503	7,412	100.0%	45	100.0%	*****	*****	*****	*****	*****	*****
0-17 years	685	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
18-24 years	42	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
25-40 years	680	659	8.9%	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	2,344	2,300	31.0%	18	40.0%	*****	*****	*****	*****	*****	*****
≥ 65 years	3,752	3,729	50.3%	11	24.4%	*****	*****	*****	*****	0	0.0%
belzutifan	4,108	2,389	100.0%	1,161	100.0%	504	100.0%	*****	*****	*****	*****
0-17 years	21	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	90	48	2.0%	29	2.5%	*****	*****	*****	*****	0	0.0%
25-40 years	510	291	12.2%	142	12.2%	*****	*****	*****	*****	*****	*****
41-64 years	1,130	*****	*****	*****	*****	157	31.2%	*****	*****	*****	*****
≥ 65 years	2,357	1,394	58.4%	683	58.8%	*****	*****	*****	*****	0	0.0%
difelikefalin	335,643	335,643	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	1,314	1,314	0.4%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	18,082	18,082	5.4%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	121,503	121,503	36.2%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	194,744	194,744	58.0%	0	NaN	0	NaN	0	NaN	0	NaN

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
lonapegsomatropin-tcgd	3,102	1,499	100.0%	718	100.0%	740	100.0%	132	100.0%	13	100.0%
0-17 years	3,090	*****	*****	*****	*****	*****	*****	132	100.0%	13	100.0%
18-24 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
41-64 years	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
mobocertinib	352	223	100.0%	94	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	283	185	83.0%	74	78.7%	*****	*****	*****	*****	0	NaN
tisotumab vedotin-tftv	2,557	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	212	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	1,223	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
≥ 65 years	1,122	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
atogepant	217,044	120,591	100.0%	60,092	100.0%	31,686	100.0%	4,052	100.0%	623	100.0%
0-17 years	782	435	0.4%	239	0.4%	94	0.3%	*****	*****	*****	*****
18-24 years	12,633	7,249	6.0%	3,570	5.9%	1,617	5.1%	*****	*****	*****	*****
25-40 years	51,105	28,960	24.0%	14,259	23.7%	6,980	22.0%	797	19.7%	109	17.5%
41-64 years	117,018	63,850	52.9%	32,623	54.3%	17,810	56.2%	2,374	58.6%	361	57.9%
≥ 65 years	35,506	20,097	16.7%	9,401	15.6%	5,185	16.4%	691	17.1%	132	21.2%

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
maralixibat	153	79	100.0%	42	100.0%	*****	*****	*****	*****	*****	*****
0-17 years	112	58	73.4%	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	26	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 65 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%
avacopan	2,643	1,369	100.0%	744	100.0%	482	100.0%	*****	*****	*****	*****
0-17 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%
18-24 years	*****	24	1.8%	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	296	184	13.4%	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	1,105	585	42.7%	314	42.2%	189	39.2%	*****	*****	*****	*****
≥ 65 years	1,187	572	41.8%	339	45.6%	*****	*****	*****	*****	0	0.0%
asciminib	4,008	2,200	100.0%	1,034	100.0%	650	100.0%	92	100.0%	32	100.0%
0-17 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	437	234	10.6%	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	1,390	812	36.9%	361	34.9%	173	26.6%	*****	*****	*****	*****
≥ 65 years	2,158	1,137	51.7%	542	52.4%	409	62.9%	52	56.5%	18	56.3%
ropiegelinterferon alfa-2b-njft	3,210	1,736	100.0%	763	100.0%	628	100.0%	71	100.0%	12	100.0%
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	263	135	7.8%	66	8.7%	*****	*****	*****	*****	*****	*****
41-64 years	894	475	27.4%	222	29.1%	180	28.7%	*****	*****	*****	*****
≥ 65 years	2,018	1,111	64.0%	461	60.4%	391	62.3%	*****	*****	*****	*****

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
vosoritide	321	155	100.0%	68	100.0%	71	100.0%	*****	*****	*****	*****
0-17 years	321	155	100.0%	68	100.0%	71	100.0%	*****	*****	*****	*****
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
41-64 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
maribavir	1,850	1,098	100.0%	541	100.0%	*****	*****	*****	*****	*****	*****
0-17 years	29	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	31	15	1.4%	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	325	*****	*****	107	19.8%	*****	*****	0	0.0%	0	0.0%
41-64 years	829	455	41.4%	263	48.6%	*****	*****	*****	*****	*****	*****
≥ 65 years	636	419	38.2%	152	28.1%	*****	*****	*****	*****	0	0.0%
pafolacianine	149	149	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	126	126	84.6%	0	NaN	0	NaN	0	NaN	0	NaN
tezepelumab-ekko	139,660	130,679	100.0%	5,348	100.0%	3,333	100.0%	280	100.0%	20	100.0%
0-17 years	591	510	0.4%	54	1.0%	27	0.8%	0	0.0%	0	0.0%
18-24 years	992	872	0.7%	71	1.3%	*****	*****	*****	*****	0	0.0%
25-40 years	6,081	5,320	4.1%	463	8.7%	272	8.2%	26	9.3%	0	0.0%
41-64 years	35,649	31,194	23.9%	2,588	48.4%	*****	*****	*****	*****	*****	*****
≥ 65 years	96,347	92,783	71.0%	2,172	40.6%	1,289	38.7%	*****	*****	*****	*****

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
efgartigimod alfa-fcab	72,976	71,897	100.0%	762	100.0%	292	100.0%	25	100.0%	0	NaN
0-17 years	32	32	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	324	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
25-40 years	2,863	2,820	3.9%	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	12,722	12,533	17.4%	132	17.3%	*****	*****	*****	*****	0	NaN
≥ 65 years	57,035	*****	*****	593	77.8%	*****	*****	*****	*****	0	NaN
inclisiran	136,127	132,660	100.0%	1,830	100.0%	1,527	100.0%	98	100.0%	12	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	7,271	6,671	5.0%	*****	*****	285	18.7%	12	12.2%	*****	*****
≥ 65 years	128,644	125,785	94.8%	1,525	83.3%	*****	*****	86	87.8%	*****	*****
tralokinumab-Idrm	13,095	7,644	100.0%	3,128	100.0%	2,117	100.0%	184	100.0%	22	100.0%
0-17 years	203	135	1.8%	45	1.4%	23	1.1%	0	0.0%	0	0.0%
18-24 years	1,351	839	11.0%	342	10.9%	159	7.5%	11	6.0%	0	0.0%
25-40 years	2,708	1,584	20.7%	647	20.7%	444	21.0%	*****	*****	*****	*****
41-64 years	4,976	2,855	37.3%	1,155	36.9%	867	41.0%	88	47.8%	11	50.0%
≥ 65 years	3,857	2,231	29.2%	939	30.0%	624	29.5%	*****	*****	*****	*****

¹N/A: Not Applicable

NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
finerenone	178,149	1	30	60	90	1,318	97.6	125.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	31	3	30	58	90	90	51.2	28.7
25-40 years	1,938	1	30	30	90	1,111	79.9	96.2
41-64 years	36,878	1	30	60	90	1,199	91.1	116.6
≥ 65 years	139,302	1	30	60	90	1,318	99.6	127.4
flexnidazole	0	N/A¹	N/A	N/A	N/A	N/A	N/A	N/A
0-17 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
18-24 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
25-40 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
41-64 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
≥ 65 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
belumosudil	5,836	1	30	30	90	1,199	86.7	117.0
0-17 years	60	5	30	30	60	690	84.7	140.8
18-24 years	77	4	30	30	90	559	74.2	87.4
25-40 years	876	1	30	30	60	842	71.4	96.7
41-64 years	2,069	1	30	30	90	1,038	83.9	110.8
≥ 65 years	2,754	1	30	59	90	1,199	94.1	126.6
odevixibat	99	1	30	60	110	1,149	101.9	158.1
0-17 years	58	1	30	32	90	854	87.8	130.5
18-24 years	16	18	30	30	75	360	72.5	89.2
25-40 years	*****	1	30	60	232	1,149	162.9	258.3
41-64 years	*****	30	60	60	232	288	134.0	117.4
≥ 65 years	*****	67	67	67	67	67	67.0	NaN

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
anifrolumab-fnia	40,955	1	1	1	1	420	3.0	14.3
0-17 years	54	1	1	1	1	1	1.0	0.0
18-24 years	905	1	1	1	1	84	1.4	5.0
25-40 years	7,903	1	1	1	1	392	2.8	13.4
41-64 years	19,362	1	1	1	1	408	3.8	16.5
≥ 65 years	12,731	1	1	1	1	420	2.1	11.4
avalglucosidase alfa-ngpt	7,503	1	1	1	1	1,018	3.3	26.4
0-17 years	685	1	1	1	1	32	1.2	2.6
18-24 years	42	1	1	1	1	84	4.4	15.3
25-40 years	680	1	1	1	1	588	6.0	31.1
41-64 years	2,344	1	1	1	1	1,018	4.9	36.8
≥ 65 years	3,752	1	1	1	1	722	2.2	19.1
belzutifan	4,108	1	30	30	60	1,085	63.3	81.3
0-17 years	21	17	30	30	60	570	64.9	118.3
18-24 years	90	2	30	30	60	556	63.4	77.4
25-40 years	510	1	30	30	64	930	70.6	97.4
41-64 years	1,130	1	30	30	71	1,085	73.2	107.3
≥ 65 years	2,357	1	30	30	60	690	57.0	59.2
difelikefalin	335,643	1	1	1	1	5	1.0	0.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	1,314	1	1	1	1	2	1.0	0.1
25-40 years	18,082	1	1	1	1	3	1.0	0.2
41-64 years	121,503	1	1	1	1	4	1.0	0.1
≥ 65 years	194,744	1	1	1	1	5	1.0	0.1

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
lonapegsomatropin-tcgd	3,102	1	28	44	112	1,066	97.3	125.5
0-17 years	3,090	1	28	44	112	1,066	97.4	125.6
18-24 years	*****	28	28	28	112	364	84.0	111.1
25-40 years	*****	28	28	43	58	58	43.0	21.2
41-64 years	*****	84	84	84	84	84	84.0	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
mobocertinib	352	3	30	30	60	726	58.1	71.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	30	30	30	64	90	48.8	27.3
41-64 years	*****	3	30	30	60	570	68.8	84.7
≥ 65 years	283	9	30	30	60	726	55.8	68.1
tisotumab vedotin-tftv	2,557	1	1	1	1	163	1.3	4.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	212	1	1	1	1	58	1.3	3.9
41-64 years	1,223	1	1	1	1	84	1.3	4.2
≥ 65 years	1,122	1	1	1	1	163	1.4	5.5
atogepant	217,044	1	30	30	90	1,281	73.5	94.9
0-17 years	782	1	30	30	90	1,072	68.2	86.9
18-24 years	12,633	1	30	30	90	1,192	67.4	82.7
25-40 years	51,105	1	30	30	90	1,281	69.9	88.2
41-64 years	117,018	1	30	30	90	1,226	75.7	97.4
≥ 65 years	35,506	1	30	30	90	1,148	73.9	99.7

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
maralixibat	153	4	30	30	90	1,162	111.0	203.4
0-17 years	112	4	30	30	75	1,162	114.3	219.1
18-24 years	26	17	30	62	120	746	103.3	143.1
25-40 years	*****	21	30	30	90	720	108.4	198.4
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	*****	30	30	30	127	127	62.3	56.0
avacopan	2,643	1	30	30	90	840	76.7	89.5
0-17 years	*****	16	26	30	30	120	44.4	42.6
18-24 years	*****	1	30	60	68	453	83.1	105.2
25-40 years	296	1	30	30	60	720	66.2	90.6
41-64 years	1,105	1	30	30	90	840	73.3	86.3
≥ 65 years	1,187	1	30	47	90	720	82.3	91.3
asciminib	4,008	1	30	30	90	1,140	80.6	118.3
0-17 years	*****	19	30	30	30	240	52.5	66.7
18-24 years	*****	15	30	30	60	186	49.8	45.5
25-40 years	437	1	30	30	76	929	76.4	106.2
41-64 years	1,390	1	30	30	60	1,140	75.3	119.5
≥ 65 years	2,158	1	30	30	90	1,059	85.2	120.2
ropiegelinterferon alfa-2b-njft	3,210	1	28	28	84	1,051	79.6	113.1
0-17 years	*****	28	28	28	56	84	40.0	19.2
18-24 years	*****	3	28	56	84	308	82.8	76.6
25-40 years	263	1	28	28	84	916	89.1	132.0
41-64 years	894	1	28	28	84	1,051	77.1	105.1
≥ 65 years	2,018	1	28	28	84	1,049	79.6	114.5

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
vosoritide	321	3	30	51	120	1,094	128.0	189.9
0-17 years	321	3	30	51	120	1,094	128.0	189.9
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
maribavir	1,850	1	28	28	56	789	49.7	55.8
0-17 years	29	1	28	28	56	168	45.1	40.3
18-24 years	31	1	28	33	84	140	54.1	35.1
25-40 years	325	1	28	28	56	308	48.0	41.7
41-64 years	829	1	28	28	58	789	56.2	64.8
≥ 65 years	636	1	4	28	56	478	42.2	49.6
pafolacianine	149	1	1	1	1	1	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	NaN
25-40 years	*****	1	1	1	1	1	1.0	NaN
41-64 years	*****	1	1	1	1	1	1.0	0.0
≥ 65 years	126	1	1	1	1	1	1.0	0.0
tezepelumab-ekko	139,660	1	1	1	1	1,095	10.7	39.3
0-17 years	591	1	1	1	28	295	19.5	41.5
18-24 years	992	1	1	1	28	651	20.0	50.2
25-40 years	6,081	1	1	1	28	702	19.7	53.1
41-64 years	35,649	1	1	1	28	1,044	20.1	54.2
≥ 65 years	96,347	1	1	1	1	1,095	6.4	29.7

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
efgartigimod alfa-fcab	72,976	1	1	1	1	689	3.7	16.0
0-17 years	32	1	1	1	1	1	1.0	0.0
18-24 years	324	1	1	1	1	410	4.0	24.8
25-40 years	2,863	1	1	1	1	574	3.2	16.7
41-64 years	12,722	1	1	1	1	560	3.7	15.2
≥ 65 years	57,035	1	1	1	1	689	3.7	16.0
inclisiran	136,127	1	1	1	1	900	4.8	28.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	345	8.5	39.0
41-64 years	7,271	1	1	1	1	810	13.3	48.7
≥ 65 years	128,644	1	1	1	1	900	4.3	26.5
tralokinumab-ldrm	13,095	1	28	28	70	1,055	63.5	84.5
0-17 years	203	1	14	28	56	272	43.8	49.0
18-24 years	1,351	1	28	28	56	642	53.9	62.7
25-40 years	2,708	1	28	28	70	770	61.8	78.1
41-64 years	4,976	1	28	28	84	1,024	68.0	91.8
≥ 65 years	3,857	1	28	28	70	1,055	63.4	86.6

¹N/A: Not Applicable

NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 5a. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<i>finerenone</i>	65,377	26,157	40.0%	21,722	33.2%	13,311	20.4%	3,292	5.0%	895	1.4%
<i>fexinidazole</i>	0	N/A ¹	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
<i>belumosudil</i>	1,803	767	42.5%	471	26.1%	462	25.6%	80	4.4%	23	1.3%
<i>odevixibat</i>	45	18	40.0%	13	28.9%	*****	*****	*****	*****	*****	*****
<i>anifrolumab-fnia</i>	4,578	4,428	96.7%	88	1.9%	62	1.4%	0	0.0%	0	0.0%
<i>avalglucosidase alfa-ngpt</i>	243	231	95.1%	*****	*****	*****	*****	0	0.0%	*****	*****
<i>belzutifan</i>	1,686	910	54.0%	522	31.0%	227	13.5%	*****	*****	*****	*****
<i>difelikefalin</i>	5,528	5,528	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>lonapegsomatropin-tcgd</i>	1,164	457	39.3%	246	21.1%	372	32.0%	*****	*****	*****	*****
<i>mobocertinib</i>	157	107	68.2%	35	22.3%	*****	*****	*****	*****	0	0.0%
<i>tisotumab vedotin-tftv</i>	528	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>atogepant</i>	81,013	43,653	53.9%	21,746	26.8%	13,097	16.2%	2,107	2.6%	410	0.5%
<i>maralixibat</i>	71	36	50.7%	18	25.4%	*****	*****	*****	*****	*****	*****
<i>avacopan</i>	970	425	43.8%	270	27.8%	240	24.7%	35	3.6%	0	0.0%
<i>asciminib</i>	1,358	703	51.8%	330	24.3%	258	19.0%	41	3.0%	26	1.9%
<i>ropoginterferon alfa-2b-njft</i>	878	440	50.1%	195	22.2%	205	23.3%	*****	*****	*****	*****
<i>vosoritide</i>	94	33	35.1%	18	19.1%	24	25.5%	*****	*****	*****	*****
<i>maribavir</i>	1,030	592	57.5%	324	31.5%	*****	*****	*****	*****	*****	*****
<i>pafolacianine</i>	148	148	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>tezepelumab-ekko</i>	17,346	14,762	85.1%	1,322	7.6%	1,118	6.4%	*****	*****	*****	*****
<i>efgartigimod alfa-fcab</i>	5,101	4,850	95.1%	176	3.5%	*****	*****	*****	*****	0	0.0%
<i>inclisiran</i>	55,123	53,194	96.5%	1,190	2.2%	667	1.2%	60	0.1%	12	0.0%
<i>tralokinumab-ldrm</i>	4,960	2,878	58.0%	1,063	21.4%	906	18.3%	102	2.1%	11	0.2%

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

¹N/A: Not Applicable

Table 5b. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>finerenone</i>	65,377	1	30	60	120	1,318	115.7	152.1
<i>fexinidazole</i>	0	N/A ¹	N/A	N/A	N/A	N/A	N/A	N/A
<i>belumosudil</i>	1,803	1	30	60	121	1,199	115.3	152.5
<i>odevixibat</i>	45	1	30	60	120	1,149	133.5	216.8
<i>anifrolumab-fnia</i>	4,578	1	1	1	1	364	5.6	23.4
<i>avalglucosidase alfa-ngpt</i>	243	1	1	1	1	821	9.8	57.0
<i>belzutifan</i>	1,686	1	30	30	78	1,000	68.3	88.8
<i>difelikefalin</i>	5,528	1	1	1	1	3	1.0	0.1
<i>lonapegsomatropin-tcgd</i>	1,164	1	28	56	185	954	130.7	151.4
<i>mobocertinib</i>	157	3	30	30	60	726	57.1	82.0
<i>tisotumab vedotin-tftv</i>	528	1	1	1	1	163	1.8	8.8
<i>atogepant</i>	81,013	1	30	30	90	1,281	81.6	110.8
<i>maralixibat</i>	71	4	30	30	90	1,162	132.5	247.7
<i>avacopan</i>	970	2	30	60	120	720	96.2	109.2
<i>asciminib</i>	1,358	1	30	30	90	1,140	96.9	150.0
<i>ropéginterferon alfa-2b-njft</i>	878	1	28	30	112	1,051	100.2	142.6
<i>vosoritide</i>	94	15	30	90	338	1,094	220.1	280.6
<i>maribavir</i>	1,030	1	27	28	56	789	49.2	58.6
<i>pafolacianine</i>	148	1	1	1	1	1	1.0	0.0
<i>tezepelumab-ekko</i>	17,346	1	1	1	28	1,044	26.1	68.6
<i>efgartigimod alfa-fcab</i>	5,101	1	1	1	1	577	9.4	26.1
<i>inclisiran</i>	55,123	1	1	1	1	900	6.0	32.9
<i>tralokinumab-ldrm</i>	4,960	1	14	28	79	1,055	66.8	97.1

¹N/A: Not Applicable

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
finerenone	65,377	26,157	100.0%	21,722	100.0%	13,311	100.0%	3,292	100.0%	895	100.0%
Female	29,455	12,087	46.2%	9,694	44.6%	5,884	44.2%	1,429	43.4%	361	40.3%
Male	35,922	14,070	53.8%	12,028	55.4%	7,427	55.8%	1,863	56.6%	534	59.7%
feixinidazole	0	N/A ¹	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Female	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Male	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
belumosudil	1,803	767	100.0%	471	100.0%	462	100.0%	80	100.0%	23	100.0%
Female	762	331	43.2%	203	43.1%	183	39.6%	*****	*****	*****	*****
Male	1,041	436	56.8%	268	56.9%	279	60.4%	*****	*****	*****	*****
odevixibat	45	18	100.0%	13	100.0%	*****	*****	*****	*****	*****	*****
Female	22	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
Male	23	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
anifrolumab-fnia	4,578	4,428	100.0%	88	100.0%	62	100.0%	0	NaN	0	NaN
Female	4,228	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	350	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
avalglucosidase alfa-ngpt	243	231	100.0%	*****	*****	*****	*****	0	NaN	*****	*****
Female	120	*****	*****	*****	*****	*****	*****	0	NaN	*****	*****
Male	123	*****	*****	*****	*****	*****	*****	0	NaN	0	0.0%
belzutifan	1,686	910	100.0%	522	100.0%	227	100.0%	*****	*****	*****	*****
Female	515	283	31.1%	158	30.3%	61	26.9%	*****	*****	*****	*****
Male	1,171	627	68.9%	364	69.7%	166	73.1%	*****	*****	*****	*****
difelikefalin	5,528	5,528	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	2,654	2,654	48.0%	0	NaN	0	NaN	0	NaN	0	NaN
Male	2,874	2,874	52.0%	0	NaN	0	NaN	0	NaN	0	NaN
lonapegsomatropin-tcgd	1,164	457	100.0%	246	100.0%	372	100.0%	*****	*****	*****	*****

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Female	283	133	29.1%	56	22.8%	74	19.9%	*****	*****	*****	*****
Male	881	324	70.9%	190	77.2%	298	80.1%	*****	*****	*****	*****
mobocertinib	157	107	100.0%	35	100.0%	*****	*****	*****	*****	0	NaN
Female	91	67	62.6%	*****	*****	*****	*****	*****	*****	0	NaN
Male	66	40	37.4%	*****	*****	*****	*****	0	0.0%	0	NaN
tisotumab vedotin-tftv	528	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Female	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
atogepant	81,013	43,653	100.0%	21,746	100.0%	13,097	100.0%	2,107	100.0%	410	100.0%
Female	68,841	36,989	84.7%	18,527	85.2%	11,171	85.3%	1,808	85.8%	346	84.4%
Male	12,172	6,664	15.3%	3,219	14.8%	1,926	14.7%	299	14.2%	64	15.6%
maralixibat	71	36	100.0%	18	100.0%	*****	*****	*****	*****	*****	*****
Female	36	19	52.8%	*****	*****	*****	*****	0	0.0%	*****	*****
Male	35	17	47.2%	*****	*****	*****	*****	*****	*****	*****	*****
avacopan	970	425	100.0%	270	100.0%	240	100.0%	35	100.0%	0	NaN
Female	541	240	56.5%	148	54.8%	136	56.7%	17	48.6%	0	NaN
Male	429	185	43.5%	122	45.2%	104	43.3%	18	51.4%	0	NaN
asciminib	1,358	703	100.0%	330	100.0%	258	100.0%	41	100.0%	26	100.0%
Female	687	363	51.6%	160	48.5%	135	52.3%	15	36.6%	14	53.8%
Male	671	340	48.4%	170	51.5%	123	47.7%	26	63.4%	12	46.2%
ropiegelinterferon alfa-2b-njft	878	440	100.0%	195	100.0%	205	100.0%	*****	*****	*****	*****
Female	474	238	54.1%	95	48.7%	122	59.5%	*****	*****	*****	*****
Male	404	202	45.9%	100	51.3%	83	40.5%	*****	*****	*****	*****
vosoritide	94	33	100.0%	18	100.0%	24	100.0%	*****	*****	*****	*****

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Female	52	17	51.5%	*****	*****	13	54.2%	*****	*****	*****	*****
Male	42	16	48.5%	*****	*****	11	45.8%	*****	*****	*****	*****
maribavir	1,030	592	100.0%	324	100.0%	*****	*****	*****	*****	*****	*****
Female	435	258	43.6%	127	39.2%	*****	*****	*****	*****	0	0.0%
Male	595	334	56.4%	197	60.8%	*****	*****	*****	*****	*****	*****
pafolacianine	148	148	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	104	104	70.3%	0	NaN	0	NaN	0	NaN	0	NaN
Male	44	44	29.7%	0	NaN	0	NaN	0	NaN	0	NaN
tezepelumab-ekko	17,346	14,762	100.0%	1,322	100.0%	1,118	100.0%	*****	*****	*****	*****
Female	11,901	10,059	68.1%	950	71.9%	799	71.5%	*****	*****	*****	*****
Male	5,445	4,703	31.9%	372	28.1%	319	28.5%	*****	*****	*****	*****
efgartigimod alfa-fcab	5,101	4,850	100.0%	176	100.0%	*****	*****	*****	*****	0	NaN
Female	2,197	2,052	42.3%	108	61.4%	*****	*****	*****	*****	0	NaN
Male	2,904	2,798	57.7%	68	38.6%	*****	*****	*****	*****	0	NaN
inclisiran	55,123	53,194	100.0%	1,190	100.0%	667	100.0%	60	100.0%	12	100.0%
Female	29,711	28,504	53.6%	753	63.3%	413	61.9%	*****	*****	*****	*****
Male	25,412	24,690	46.4%	437	36.7%	254	38.1%	*****	*****	*****	*****
tralokinumab-ldrm	4,960	2,878	100.0%	1,063	100.0%	906	100.0%	102	100.0%	11	100.0%
Female	2,773	1,585	55.1%	621	58.4%	502	55.4%	*****	*****	*****	*****
Male	2,187	1,293	44.9%	442	41.6%	404	44.6%	*****	*****	*****	*****

¹N/A: Not Applicable

NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
finerenone	65,377	1	30	60	120	1,318	115.7	152.1
Female	29,455	1	30	60	112	1,315	112.3	147.9
Male	35,922	1	30	60	120	1,318	118.5	155.4
fexinidazole	0	N/A¹	N/A	N/A	N/A	N/A	N/A	N/A
Female	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Male	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
belumosudil	1,803	1	30	60	121	1,199	115.3	152.5
Female	762	1	30	60	120	1,199	113.8	152.0
Male	1,041	2	30	60	122	1,163	116.4	153.0
odevixibat	45	1	30	60	120	1,149	133.5	216.8
Female	22	1	30	60	113	360	91.4	94.5
Male	23	1	30	60	180	1,149	173.8	286.3
anifrolumab-fnia	4,578	1	1	1	1	364	5.6	23.4
Female	4,228	1	1	1	1	364	5.7	23.8
Male	350	1	1	1	1	196	4.3	18.5
avalglucosidase alfa-ngpt	243	1	1	1	1	821	9.8	57.0
Female	120	1	1	1	1	821	13.9	79.0
Male	123	1	1	1	1	140	5.9	18.0
belzutifan	1,686	1	30	30	78	1,000	68.3	88.8
Female	515	1	30	30	61	1,000	72.0	110.6
Male	1,171	1	30	30	85	791	66.7	77.3
difelikefalin	5,528	1	1	1	1	3	1.0	0.1
Female	2,654	1	1	1	1	3	1.0	0.1
Male	2,874	1	1	1	1	3	1.0	0.1
lonapegsomatropin-tcgd	1,164	1	28	56	185	954	130.7	151.4

Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	283	1	28	49	140	875	113.6	143.2
Male	881	1	28	59	196	954	136.2	153.6
mobocertinib	157	3	30	30	60	726	57.1	82.0
Female	91	9	30	30	60	726	59.7	100.1
Male	66	3	30	30	60	300	53.4	47.1
tisotumab vedotin-tftv	528	1	1	1	1	163	1.8	8.8
Female	*****	1	1	1	1	163	1.8	8.8
Male	*****	1	1	1	1	1	1.0	0.0
atogepant	81,013	1	30	30	90	1,281	81.6	110.8
Female	68,841	1	30	30	90	1,281	81.8	110.8
Male	12,172	1	30	30	90	1,158	80.3	111.1
maralixibat	71	4	30	30	90	1,162	132.5	247.7
Female	36	4	30	30	75	1,162	143.3	296.0
Male	35	15	24	32	150	978	121.5	189.5
avacopan	970	2	30	60	120	720	96.2	109.2
Female	541	2	30	60	120	720	94.2	105.4
Male	429	3	30	60	120	720	98.8	113.9
asciminib	1,358	1	30	30	90	1,140	96.9	150.0
Female	687	1	30	30	90	1,140	94.4	149.4
Male	671	1	30	30	90	1,107	99.4	150.7
ropiegelinterferon alfa-2b-njft	878	1	28	30	112	1,051	100.2	142.6
Female	474	1	28	30	113	1,049	103.5	146.8
Male	404	1	28	33	91	1,051	96.2	137.6
vosoritide	94	15	30	90	338	1,094	220.1	280.6

Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	52	30	30	80	269	990	201.5	257.6
Male	42	15	30	90	354	1,094	243.1	308.3
maribavir	1,030	1	27	28	56	789	49.2	58.6
Female	435	1	20	28	56	448	48.8	57.4
Male	595	1	28	28	56	789	49.5	59.6
pafolacianine	148	1	1	1	1	1	1.0	0.0
Female	104	1	1	1	1	1	1.0	0.0
Male	44	1	1	1	1	1	1.0	0.0
tezepelumab-ekko	17,346	1	1	1	28	1,044	26.1	68.6
Female	11,901	1	1	1	28	1,044	26.9	69.2
Male	5,445	1	1	1	28	948	24.6	67.2
efgartigimod alfa-fcab	5,101	1	1	1	1	577	9.4	26.1
Female	2,197	1	1	1	1	525	10.9	28.8
Male	2,904	1	1	1	1	577	8.2	23.7
inclisiran	55,123	1	1	1	1	900	6.0	32.9
Female	29,711	1	1	1	1	817	6.7	34.6
Male	25,412	1	1	1	1	900	5.2	30.8
tralokinumab-ldrm	4,960	1	14	28	79	1,055	66.8	97.1
Female	2,773	1	14	28	79	1,024	67.0	98.1
Male	2,187	1	14	28	77	1,055	66.5	95.8

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

¹N/A: Not Applicable

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Number of Patients by First Treatment Episode Duration										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
finerenone	65,377	26,157	100.0%	21,722	100.0%	13,311	100.0%	3,292	100.0%	895	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	17	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
25-40 years	725	344	1.3%	*****	*****	145	1.1%	21	0.6%	*****	*****
41-64 years	13,040	*****	*****	4,282	19.7%	2,589	19.5%	625	19.0%	*****	*****
≥ 65 years	51,595	20,410	78.0%	17,220	79.3%	10,577	79.5%	2,646	80.4%	742	82.9%
fezinidazole	0	N/A¹	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
0-17 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
18-24 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
25-40 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
41-64 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
≥ 65 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
belumosudil	1,803	767	100.0%	471	100.0%	462	100.0%	80	100.0%	23	100.0%
0-17 years	18	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	37	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	225	122	15.9%	51	10.8%	*****	*****	*****	*****	*****	*****
41-64 years	626	272	35.5%	171	36.3%	155	33.5%	*****	*****	*****	*****
≥ 65 years	897	345	45.0%	236	50.1%	256	55.4%	*****	*****	*****	*****
odevixibat	45	18	100.0%	13	100.0%	*****	*****	*****	*****	*****	*****
0-17 years	29	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
41-64 years	*****	0	0.0%	*****	*****	*****	*****	0	0.0%	0	0.0%
≥ 65 years	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Number of Patients by First Treatment Episode Duration										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
anifrolumab-fnia	4,578	4,428	100.0%	88	100.0%	62	100.0%	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
25-40 years	934	905	20.4%	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	2,163	2,068	46.7%	56	63.6%	39	62.9%	0	NaN	0	NaN
≥ 65 years	1,370	1,345	30.4%	*****	*****	*****	*****	0	NaN	0	NaN
avalglucosidase alfa-ngpt	243	231	100.0%	*****	*****	*****	*****	0	NaN	*****	*****
0-17 years	27	27	11.7%	0	0.0%	0	0.0%	0	NaN	0	0.0%
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	0.0%
25-40 years	*****	*****	*****	0	0.0%	*****	*****	0	NaN	0	0.0%
41-64 years	82	*****	*****	*****	*****	*****	*****	0	NaN	*****	*****
≥ 65 years	105	*****	*****	*****	*****	*****	*****	0	NaN	0	0.0%
belzutifan	1,686	910	100.0%	522	100.0%	227	100.0%	*****	*****	*****	*****
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	14	2.7%	*****	*****	0	0.0%	0	0.0%
25-40 years	100	57	6.3%	22	4.2%	*****	*****	*****	*****	*****	*****
41-64 years	403	204	22.4%	121	23.2%	64	28.2%	*****	*****	*****	*****
≥ 65 years	1,147	633	69.6%	365	69.9%	*****	*****	*****	*****	0	0.0%
difelikefalin	5,528	5,528	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	16	16	0.3%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	303	303	5.5%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	1,990	1,990	36.0%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	3,219	3,219	58.2%	0	NaN	0	NaN	0	NaN	0	NaN

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Number of Patients by First Treatment Episode Duration										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
lonapegsomatropin-tcgd	1,164	457	100.0%	246	100.0%	*****	*****	79	100.0%	*****	*****
0-17 years	1,157	453	99.1%	*****	*****	*****	*****	79	100.0%	*****	*****
18-24 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
41-64 years	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
mobocertinib	157	107	100.0%	35	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
41-64 years	*****	*****	*****	12	34.3%	*****	*****	*****	*****	0	NaN
≥ 65 years	116	85	79.4%	*****	*****	*****	*****	*****	*****	0	NaN
tisotumab vedotin-tftv	528	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	49	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	238	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
≥ 65 years	241	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
atogepant	81,013	43,653	100.0%	21,746	100.0%	13,097	100.0%	2,107	100.0%	410	100.0%
0-17 years	314	176	0.4%	90	0.4%	*****	*****	*****	*****	*****	*****
18-24 years	4,677	2,675	6.1%	1,256	5.8%	*****	*****	*****	*****	*****	*****
25-40 years	18,548	10,114	23.2%	5,088	23.4%	2,866	21.9%	405	19.2%	75	18.3%
41-64 years	41,993	22,054	50.5%	11,294	51.9%	7,199	55.0%	1,211	57.5%	235	57.3%

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Number of Patients by First Treatment Episode Duration										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
≥ 65 years	15,481	8,634	19.8%	4,018	18.5%	2,339	17.9%	407	19.3%	83	20.2%
maralixibat	71	36	100.0%	18	100.0%	*****	*****	*****	*****	*****	*****
0-17 years	56	25	69.4%	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
41-64 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 65 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
avacopan	970	425	100.0%	270	100.0%	240	100.0%	35	100.0%	0	NaN
0-17 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	NaN
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
25-40 years	87	*****	*****	*****	*****	15	6.3%	*****	*****	0	NaN
41-64 years	357	165	38.8%	98	36.3%	*****	*****	*****	*****	0	NaN
≥ 65 years	506	209	49.2%	141	52.2%	141	58.8%	15	42.9%	0	NaN
asciminib	1,358	703	100.0%	330	100.0%	258	100.0%	41	100.0%	26	100.0%
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	441	240	34.1%	112	33.9%	62	24.0%	*****	*****	*****	*****
≥ 65 years	754	371	52.8%	179	54.2%	171	66.3%	20	48.8%	13	50.0%
ropiegelinterferon alfa-2b-njft	878	440	100.0%	195	100.0%	205	100.0%	*****	*****	*****	*****
0-17 years	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	14	6.8%	*****	*****	0	0.0%

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Number of Patients by First Treatment Episode Duration											
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days			
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Percent of Total Patients
41-64 years	250	115	26.1%	56	28.7%	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	555	285	64.8%	123	63.1%	119	58.0%	*****	*****	*****	*****	*****
vosoritide	94	33	100.0%	18	100.0%	24	100.0%	*****	*****	*****	*****	*****
0-17 years	94	33	100.0%	18	100.0%	24	100.0%	*****	*****	*****	*****	*****
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0.0%
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0.0%
41-64 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0.0%
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0.0%
maribavir	1,030	592	100.0%	324	100.0%	*****	*****	*****	*****	*****	*****	*****
0-17 years	14	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0.0%
18-24 years	15	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0.0%
25-40 years	133	64	10.8%	*****	*****	*****	*****	0	0.0%	0	0.0%	0.0%
41-64 years	476	254	42.9%	162	50.0%	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	392	257	43.4%	101	31.2%	*****	*****	*****	*****	*****	0	0.0%
pafolacianine	148	148	100.0%	0	NaN	0	NaN	0	NaN	0	NaN	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN	NaN
≥ 65 years	125	125	84.5%	0	NaN	0	NaN	0	NaN	0	NaN	NaN
tezepelumab-ekko	17,346	14,762	100.0%	1,322	100.0%	1,118	100.0%	*****	*****	*****	*****	*****
0-17 years	103	88	0.6%	*****	*****	*****	*****	0	0.0%	0	0.0%	0.0%
18-24 years	192	150	1.0%	*****	*****	*****	*****	*****	*****	0	0.0%	0.0%

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Number of Patients by First Treatment Episode Duration										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
25-40 years	1,002	776	5.3%	118	8.9%	95	8.5%	13	9.7%	0	0.0%
41-64 years	5,525	4,255	28.8%	644	48.7%	546	48.8%	*****	*****	*****	*****
≥ 65 years	10,524	9,493	64.3%	532	40.2%	451	40.3%	*****	*****	*****	*****
efgartigimod alfa-fcab	5,101	4,850	100.0%	176	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	22	22	0.5%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	882	841	17.3%	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	4,026	3,824	78.8%	140	79.5%	*****	*****	*****	*****	0	NaN
inclisiran	55,123	53,194	100.0%	1,190	100.0%	667	100.0%	60	100.0%	12	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	3,417	3,075	5.8%	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	51,603	50,020	94.0%	982	82.5%	538	80.7%	*****	*****	*****	*****
tralokinumab-Idrm	4,960	2,878	100.0%	1,063	100.0%	906	100.0%	*****	*****	*****	*****
0-17 years	99	69	2.4%	16	1.5%	14	1.5%	0	0.0%	0	0.0%
18-24 years	475	287	10.0%	113	10.6%	*****	*****	*****	*****	0	0.0%
25-40 years	994	558	19.4%	223	21.0%	*****	*****	20	19.6%	*****	*****
41-64 years	1,820	1,007	35.0%	380	35.7%	383	42.3%	*****	*****	*****	*****
≥ 65 years	1,572	957	33.3%	331	31.1%	250	27.6%	*****	*****	*****	*****

¹N/A: Not Applicable

NaN: Not a number

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Number of Patients by First Treatment Episode Duration									
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
finerenone	65,377	1	30	60	120	1,318	115.7	152.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	17	18	30	30	60	90	46.1	23.2
25-40 years	725	1	30	48	90	758	91.0	106.5
41-64 years	13,040	1	30	60	104	1,155	110.7	145.1
≥ 65 years	51,595	1	30	60	120	1,318	117.4	154.3
fexinidazole	0	N/A¹	N/A	N/A	N/A	N/A	N/A	N/A
0-17 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
18-24 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
25-40 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
41-64 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
≥ 65 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
belumosudil	1,803	1	30	60	121	1,199	115.3	152.5
0-17 years	18	12	30	30	90	690	146.4	235.3
18-24 years	37	4	30	38	93	390	75.4	80.5
25-40 years	225	4	30	30	90	842	91.6	136.4
41-64 years	626	2	30	60	120	1,038	106.4	138.2
≥ 65 years	897	1	30	60	150	1,199	128.5	164.5
odevixibat	45	1	30	60	120	1,149	133.5	216.8
0-17 years	29	1	30	60	113	854	114.3	172.2
18-24 years	*****	18	30	30	60	360	99.6	146.4
25-40 years	*****	1	30	60	225	1,149	222.5	385.2
41-64 years	*****	60	60	174	288	288	174.0	161.2
≥ 65 years	*****	67	67	67	67	67	67.0	NaN

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
anifrolumab-fnia	4,578	1	1	1	1	364	5.6	23.4
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	84	2.3	8.8
25-40 years	934	1	1	1	1	336	5.6	23.6
41-64 years	2,163	1	1	1	1	364	6.9	25.2
≥ 65 years	1,370	1	1	1	1	364	3.9	20.9
avalglucosidase alfa-ngpt	243	1	1	1	1	821	9.8	57.0
0-17 years	27	1	1	1	1	28	3.0	7.2
18-24 years	*****	1	1	1	1	57	12.2	25.0
25-40 years	*****	1	1	1	1	112	9.5	23.7
41-64 years	82	1	1	1	1	821	18.1	94.9
≥ 65 years	105	1	1	1	1	123	5.1	17.1
belzutifan	1,686	1	30	30	78	1,000	68.3	88.8
0-17 years	*****	17	30	30	30	30	27.8	5.3
18-24 years	*****	23	30	60	90	180	68.2	40.3
25-40 years	100	1	30	30	90	930	106.4	174.5
41-64 years	403	1	30	30	90	1,000	82.5	119.2
≥ 65 years	1,147	1	30	30	60	690	60.3	60.7
difelikefalin	5,528	1	1	1	1	3	1.0	0.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	16	1	1	1	1	2	1.1	0.3
25-40 years	303	1	1	1	1	2	1.0	0.1
41-64 years	1,990	1	1	1	1	3	1.0	0.1
≥ 65 years	3,219	1	1	1	1	3	1.0	0.1

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
lonapegsomatropin-tcgd	1,164	1	28	56	185	954	130.7	151.4
0-17 years	*****	1	28	56	188	954	131.1	151.7
18-24 years	*****	28	28	28	112	112	61.6	46.0
25-40 years	*****	28	28	28	28	28	28.0	NaN
41-64 years	*****	84	84	84	84	84	84.0	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
mobocertinib	157	3	30	30	60	726	57.1	82.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	30	30	47	77	90	53.5	29.1
41-64 years	*****	3	30	30	60	570	65.9	93.8
≥ 65 years	116	9	30	30	60	726	54.4	79.4
tisotumab vedotin-tftv	528	1	1	1	1	163	1.8	8.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	49	1	1	1	1	58	2.2	8.1
41-64 years	238	1	1	1	1	84	1.5	5.7
≥ 65 years	241	1	1	1	1	163	2.1	11.1
atogepant	81,013	1	30	30	90	1,281	81.6	110.8
0-17 years	314	1	30	30	71	1,072	67.5	90.0
18-24 years	4,677	1	30	30	90	1,192	72.0	95.3
25-40 years	18,548	1	30	30	90	1,281	77.5	103.8
41-64 years	41,993	1	30	30	90	1,226	85.0	114.7
≥ 65 years	15,481	1	30	30	90	1,148	80.1	112.6

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
maralixibat	71	4	30	30	90	1,162	132.5	247.7
0-17 years	56	4	24	37	155	1,162	154.9	274.2
18-24 years	*****	17	30	45	92	180	66.4	56.4
25-40 years	*****	21	30	30	30	30	28.2	4.0
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	*****	30	30	30	30	30	30.0	0.0
avacopan	970	2	30	60	120	720	96.2	109.2
0-17 years	*****	26	26	30	120	120	58.7	53.2
18-24 years	*****	15	30	60	90	450	115.7	130.2
25-40 years	87	13	30	30	90	720	92.3	123.7
41-64 years	357	2	30	49	120	663	92.1	108.3
≥ 65 years	506	2	30	60	120	720	99.4	106.9
asciminib	1,358	1	30	30	90	1,140	96.9	150.0
0-17 years	*****	30	30	30	60	60	40.0	17.3
18-24 years	*****	15	26	30	90	186	62.8	65.9
25-40 years	*****	3	30	30	90	929	90.7	147.4
41-64 years	441	1	30	30	90	1,140	97.5	165.9
≥ 65 years	754	1	30	40	112	1,059	98.2	141.4
ropiegelinterferon alfa-2b-njft	878	1	28	30	112	1,051	100.2	142.6
0-17 years	*****	56	56	56	56	56	56.0	NaN
18-24 years	*****	28	28	42	70	140	56.0	39.6
25-40 years	*****	1	28	28	88	655	83.5	120.6
41-64 years	250	1	28	56	152	1,051	106.4	133.3
≥ 65 years	555	1	28	28	112	1,049	100.0	149.8

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
vosoritide	94	15	30	90	338	1,094	220.1	280.6
0-17 years	94	15	30	90	338	1,094	220.1	280.6
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
maribavir	1,030	1	27	28	56	789	49.2	58.6
0-17 years	14	1	28	28	56	168	48.4	48.0
18-24 years	15	1	28	28	84	140	56.5	39.8
25-40 years	133	1	28	37	56	308	53.1	45.7
41-64 years	476	1	28	28	60	789	54.8	66.2
≥ 65 years	392	1	1	28	56	478	40.9	52.6
pafolacianine	148	1	1	1	1	1	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	NaN
25-40 years	*****	1	1	1	1	1	1.0	NaN
41-64 years	*****	1	1	1	1	1	1.0	0.0
≥ 65 years	125	1	1	1	1	1	1.0	0.0
tezepelumab-ekko	17,346	1	1	1	28	1,044	26.1	68.6
0-17 years	103	1	1	1	28	280	22.7	44.1
18-24 years	192	1	1	1	28	588	38.8	77.3
25-40 years	1,002	1	1	1	28	637	39.2	81.9
41-64 years	5,525	1	1	1	28	1,044	40.0	84.9
≥ 65 years	10,524	1	1	1	1	978	17.4	54.9

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
efgartigimod alfa-fcab	5,101	1	1	1	1	577	9.4	26.1
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	28	5.3	9.6
25-40 years	168	1	1	1	1	370	9.6	35.0
41-64 years	882	1	1	1	1	186	8.4	19.1
≥ 65 years	4,026	1	1	1	1	577	9.6	27.0
inclisiran	55,123	1	1	1	1	900	6.0	32.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	345	10.6	48.4
41-64 years	3,417	1	1	1	1	810	15.2	52.0
≥ 65 years	51,603	1	1	1	1	900	5.4	31.1
tralokinumab-ldrm	4,960	1	14	28	79	1,055	66.8	97.1
0-17 years	99	1	14	28	42	272	45.1	57.6
18-24 years	475	1	14	28	58	642	58.0	79.1
25-40 years	994	1	14	28	84	770	69.2	94.8
41-64 years	1,820	1	14	28	84	1,024	74.3	105.9
≥ 65 years	1,572	1	14	28	70	1,055	60.6	94.1

¹N/A: Not Applicable

NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 6a. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>finerenone</i>	112,772	51,192	45.4%	38,461	34.1%	19,897	17.6%	2,853	2.5%	369	0.3%
<i>fexinidazole</i>	0	N/A ¹	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
<i>belumosudil</i>	4,033	2,203	54.6%	1,108	27.5%	633	15.7%	78	1.9%	11	0.3%
<i>odevixibat</i>	54	27	50.0%	15	27.8%	12	22.2%	0	0.0%	0	0.0%
<i>anifrolumab-fnia</i>	36,377	35,911	98.7%	340	0.9%	*****	*****	*****	*****	0	0.0%
<i>avalglucosidase alfa-ngpt</i>	7,260	7,181	98.9%	38	0.5%	*****	*****	*****	*****	*****	*****
<i>belzutifan</i>	2,422	1,479	61.1%	639	26.4%	277	11.4%	*****	*****	*****	*****
<i>difelikefalin</i>	330,115	330,115	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>lonapegsomatropin-tcgd</i>	1,938	1,042	53.8%	472	24.4%	368	19.0%	*****	*****	*****	*****
<i>mobocertinib</i>	195	116	59.5%	59	30.3%	*****	*****	*****	*****	0	0.0%
<i>tisotumab vedotin-tftv</i>	2,029	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>atogepant</i>	136,031	76,938	56.6%	38,346	28.2%	18,589	13.7%	1,945	1.4%	213	0.2%
<i>maralixibat</i>	82	43	52.4%	24	29.3%	*****	*****	*****	*****	*****	*****
<i>avacopan</i>	1,673	944	56.4%	474	28.3%	242	14.5%	*****	*****	*****	*****
<i>asciminib</i>	2,650	1,497	56.5%	704	26.6%	392	14.8%	*****	*****	*****	*****
<i>ropoginterferon alfa-2b-njft</i>	2,332	1,296	55.6%	568	24.4%	423	18.1%	*****	*****	*****	*****
<i>vosoritide</i>	227	122	53.7%	50	22.0%	*****	*****	*****	*****	*****	*****
<i>maribavir</i>	820	506	61.7%	217	26.5%	*****	*****	*****	*****	0	0.0%
<i>pafolacianine</i>	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>tezepelumab-ekko</i>	122,314	115,917	94.8%	4,026	3.3%	2,215	1.8%	*****	*****	*****	*****
<i>efgartigimod alfa-fcab</i>	67,875	67,047	98.8%	586	0.9%	222	0.3%	20	0.0%	0	0.0%
<i>inclisiran</i>	81,004	79,466	98.1%	640	0.8%	860	1.1%	38	0.0%	0	0.0%
<i>tralokinumab-ldrm</i>	8,135	4,766	58.6%	2,065	25.4%	1,211	14.9%	82	1.0%	11	0.1%

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

¹N/A: Not Applicable

Table 6b. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>finerenone</i>	112,772	1	30	60	90	1,263	87.1	104.8
<i>fexinidazole</i>	0	N/A ¹	N/A	N/A	N/A	N/A	N/A	N/A
<i>belumosudil</i>	4,033	1	30	30	90	1,024	73.9	94.2
<i>odevixibat</i>	54	5	30	31	90	334	75.5	74.9
<i>anifrolumab-fnia</i>	36,377	1	1	1	1	420	2.7	12.6
<i>avalglucosidase alfa-ngpt</i>	7,260	1	1	1	1	1,018	3.1	24.7
<i>belzutifan</i>	2,422	1	30	30	60	1,085	59.8	75.4
<i>difelikefalin</i>	330,115	1	1	1	1	5	1.0	0.1
<i>lonapegsomatropin-tcgd</i>	1,938	1	28	28	84	1,066	77.2	101.9
<i>mobocertinib</i>	195	17	30	30	60	570	58.9	61.0
<i>tisotumab vedotin-tftv</i>	2,029	1	1	1	1	84	1.2	3.0
<i>atogepant</i>	136,031	1	30	30	90	1,225	68.8	83.7
<i>maralixibat</i>	82	22	30	30	90	886	92.4	154.3
<i>avacopan</i>	1,673	1	30	30	60	840	65.4	73.5
<i>asciminib</i>	2,650	1	30	30	64	1,108	72.3	97.2
<i>ropoginterferon alfa-2b-njft</i>	2,332	1	28	28	84	1,036	71.8	98.7
<i>vosoritide</i>	227	3	30	30	90	780	89.8	117.1
<i>maribavir</i>	820	1	28	28	56	532	50.3	52.1
<i>pafolacianine</i>	*****	1	1	1	1	1	1.0	NaN
<i>tezepelumab-ekko</i>	122,314	1	1	1	1	1,095	8.5	32.5
<i>efgartigimod alfa-fcab</i>	67,875	1	1	1	1	689	3.3	14.8
<i>inclisiran</i>	81,004	1	1	1	1	687	3.9	24.4
<i>tralokinumab-ldrm</i>	8,135	1	28	28	65	976	61.5	75.7

¹N/A: Not Applicable

NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
finerenone	112,772	51,192	100.0%	38,461	100.0%	19,897	100.0%	2,853	100.0%	369	100.0%
Female	51,376	23,848	46.6%	17,352	45.1%	8,781	44.1%	1,234	43.3%	161	43.6%
Male	61,396	27,344	53.4%	21,109	54.9%	11,116	55.9%	1,619	56.7%	208	56.4%
fexinidazole	0	N/A¹	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Female	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Male	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
belumosudil	4,033	2,203	100.0%	1,108	100.0%	633	100.0%	*****	*****	*****	*****
Female	1,691	901	40.9%	472	42.6%	275	43.4%	*****	*****	*****	*****
Male	2,342	1,302	59.1%	636	57.4%	358	56.6%	*****	*****	*****	*****
odevixibat	54	27	100.0%	15	100.0%	12	100.0%	0	NaN	0	NaN
Female	34	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	20	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
anifrolumab-fnia	36,377	35,911	100.0%	340	100.0%	*****	*****	*****	*****	0	NaN
Female	33,550	33,111	92.2%	*****	*****	*****	*****	*****	*****	0	NaN
Male	2,827	2,800	7.8%	*****	*****	*****	*****	0	0.0%	0	NaN
avalglucosidase alfa-ngpt	7,260	7,181	100.0%	38	100.0%	*****	*****	*****	*****	*****	*****
Female	3,982	3,949	55.0%	15	39.5%	*****	*****	*****	*****	*****	*****
Male	3,278	3,232	45.0%	23	60.5%	*****	*****	*****	*****	0	0.0%
belzutifan	2,422	1,479	100.0%	639	100.0%	277	100.0%	*****	*****	*****	*****
Female	864	532	36.0%	231	36.2%	*****	*****	*****	*****	0	0.0%
Male	1,558	947	64.0%	408	63.8%	*****	*****	*****	*****	*****	*****

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
difelikefalin	330,115	330,115	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	155,948	155,948	47.2%	0	NaN	0	NaN	0	NaN	0	NaN
Male	174,167	174,167	52.8%	0	NaN	0	NaN	0	NaN	0	NaN
lonapegsomatropin-tcgd	1,938	1,042	100.0%	472	100.0%	368	100.0%	*****	*****	*****	*****
Female	532	298	28.6%	131	27.8%	*****	*****	*****	*****	0	0.0%
Male	1,406	744	71.4%	341	72.2%	*****	*****	*****	*****	*****	*****
mobocertinib	195	116	100.0%	59	100.0%	*****	*****	*****	*****	0	NaN
Female	121	70	60.3%	*****	*****	*****	*****	*****	*****	0	NaN
Male	74	46	39.7%	*****	*****	*****	*****	0	0.0%	0	NaN
tisotumab vedotin-tftv	2,029	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	2,029	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
atogepant	136,031	76,938	100.0%	38,346	100.0%	18,589	100.0%	1,945	100.0%	213	100.0%
Female	117,684	66,620	86.6%	33,168	86.5%	16,016	86.2%	1,702	87.5%	178	83.6%
Male	18,347	10,318	13.4%	5,178	13.5%	2,573	13.8%	243	12.5%	35	16.4%
maralixibat	82	43	100.0%	24	100.0%	*****	*****	*****	*****	*****	*****
Female	16	*****	*****	0	0.0%	*****	*****	*****	*****	0	0.0%
Male	66	*****	*****	24	100.0%	*****	*****	*****	*****	*****	*****
avacopan	1,673	944	100.0%	474	100.0%	242	100.0%	*****	*****	*****	*****
Female	921	529	56.0%	264	55.7%	*****	*****	*****	*****	*****	*****
Male	752	415	44.0%	210	44.3%	*****	*****	*****	*****	*****	*****

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
asciminib	2,650	1,497	100.0%	704	100.0%	392	100.0%	*****	*****	*****	*****
Female	1,435	811	54.2%	376	53.4%	219	55.9%	*****	*****	*****	*****
Male	1,215	686	45.8%	328	46.6%	173	44.1%	*****	*****	*****	*****
ropginterferon alfa-2b-njft	2,332	1,296	100.0%	568	100.0%	423	100.0%	*****	*****	*****	*****
Female	1,109	605	46.7%	274	48.2%	208	49.2%	*****	*****	*****	*****
Male	1,223	691	53.3%	294	51.8%	215	50.8%	*****	*****	*****	*****
vosoritide	227	122	100.0%	50	100.0%	*****	*****	*****	*****	*****	*****
Female	149	82	67.2%	29	58.0%	*****	*****	*****	*****	*****	*****
Male	78	40	32.8%	21	42.0%	*****	*****	*****	*****	0	0.0%
maribavir	820	506	100.0%	217	100.0%	*****	*****	*****	*****	0	NaN
Female	393	242	47.8%	*****	*****	*****	*****	*****	*****	0	NaN
Male	427	264	52.2%	*****	*****	*****	*****	0	0.0%	0	NaN
pafolacianine	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Male	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
tezepelumab-ekko	122,314	115,917	100.0%	4,026	100.0%	2,215	100.0%	*****	*****	*****	*****
Female	82,927	78,453	67.7%	2,795	69.4%	1,567	70.7%	*****	*****	*****	*****
Male	39,387	37,464	32.3%	1,231	30.6%	648	29.3%	*****	*****	*****	*****
efgartigimod alfa-fcab	67,875	67,047	100.0%	586	100.0%	222	100.0%	20	100.0%	0	NaN
Female	28,413	27,989	41.7%	303	51.7%	*****	*****	*****	*****	0	NaN
Male	39,462	39,058	58.3%	283	48.3%	*****	*****	*****	*****	0	NaN

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
inclisiran	81,004	79,466	100.0%	640	100.0%	860	100.0%	38	100.0%	0	NaN
Female	42,195	41,247	51.9%	375	58.6%	550	64.0%	23	60.5%	0	NaN
Male	38,809	38,219	48.1%	265	41.4%	310	36.0%	15	39.5%	0	NaN
tralokinumab-ldrm	8,135	4,766	100.0%	2,065	100.0%	1,211	100.0%	*****	*****	*****	*****
Female	4,462	2,628	55.1%	1,151	55.7%	634	52.4%	*****	*****	*****	*****
Male	3,673	2,138	44.9%	914	44.3%	577	47.6%	*****	*****	*****	*****

¹N/A: Not Applicable

NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
finerenone	112,772	1	30	60	90	1,263	87.1	104.8
Female	51,376	1	30	58	90	1,202	84.9	102.4
Male	61,396	1	30	60	90	1,263	89.0	106.7
fexinidazole	0	N/A¹	N/A	N/A	N/A	N/A	N/A	N/A
Female	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Male	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
belumosudil	4,033	1	30	30	90	1,024	73.9	94.2
Female	1,691	1	30	30	90	1,024	75.9	95.0
Male	2,342	1	30	30	84	975	72.5	93.5
odevixibat	54	5	30	31	90	334	75.5	74.9
Female	34	5	30	30	60	334	64.0	70.3
Male	20	10	30	75	121	260	95.1	80.1
anifrolumab-fnia	36,377	1	1	1	1	420	2.7	12.6
Female	33,550	1	1	1	1	420	2.7	12.8
Male	2,827	1	1	1	1	196	2.2	10.3
avalglucosidase alfa-ngpt	7,260	1	1	1	1	1,018	3.1	24.7
Female	3,982	1	1	1	1	1,018	2.8	24.3
Male	3,278	1	1	1	1	722	3.4	25.2
belzutifan	2,422	1	30	30	60	1,085	59.8	75.4
Female	864	1	30	30	60	725	55.9	59.1
Male	1,558	1	30	30	60	1,085	62.0	83.1
difelikefalin	330,115	1	1	1	1	5	1.0	0.1
Female	155,948	1	1	1	1	3	1.0	0.1
Male	174,167	1	1	1	1	5	1.0	0.1
lonapegsomatropin-tcgd	1,938	1	28	28	84	1,066	77.2	101.9

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	532	1	28	28	83	700	70.6	94.6
Male	1,406	1	28	28	84	1,066	79.7	104.4
mobocertinib	195	17	30	30	60	570	58.9	61.0
Female	121	17	30	30	60	570	58.6	65.2
Male	74	17	30	30	60	277	59.4	53.8
tisotumab vedotin-tftv	2,029	1	1	1	1	84	1.2	3.0
Female	2,029	1	1	1	1	84	1.2	3.0
Male	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
atogepant	136,031	1	30	30	90	1,225	68.8	83.7
Female	117,684	1	30	30	90	1,225	68.8	83.7
Male	18,347	1	30	30	90	1,071	68.8	83.6
maralixibat	82	22	30	30	90	886	92.4	154.3
Female	16	23	30	30	139	720	106.4	171.9
Male	66	22	30	40	90	886	88.9	151.0
avacopan	1,673	1	30	30	60	840	65.4	73.5
Female	921	1	30	30	60	840	62.2	65.5
Male	752	1	30	30	64	790	69.2	82.1
asciminib	2,650	1	30	30	64	1,108	72.3	97.2
Female	1,435	1	30	30	66	995	73.4	99.6
Male	1,215	1	30	30	61	1,108	71.0	94.2
ropiegelinterferon alfa-2b-njft	2,332	1	28	28	84	1,036	71.8	98.7
Female	1,109	1	28	28	84	910	73.6	96.3
Male	1,223	1	28	28	84	1,036	70.2	100.9
vosoritide	227	3	30	30	90	780	89.8	117.1
Female	149	3	30	30	97	780	94.5	128.9

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Male	78	3	30	30	90	480	81.0	90.4
maribavir	820	1	28	28	56	532	50.3	52.1
Female	393	1	28	28	56	532	51.5	54.7
Male	427	1	28	28	56	364	49.3	49.6
pafolacianine	*****	1	1	1	1	1	1.0	NaN
Female	*****	1	1	1	1	1	1.0	NaN
Male	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
tezepelumab-ekko	122,314	1	1	1	1	1,095	8.5	32.5
Female	82,927	1	1	1	1	1,095	8.8	33.6
Male	39,387	1	1	1	1	895	7.8	30.3
efgartigimod alfa-fcab	67,875	1	1	1	1	689	3.3	14.8
Female	28,413	1	1	1	1	638	3.6	15.0
Male	39,462	1	1	1	1	689	3.0	14.7
inclisiran	81,004	1	1	1	1	687	3.9	24.4
Female	42,195	1	1	1	1	637	4.5	26.4
Male	38,809	1	1	1	1	687	3.3	22.1
tralokinumab-ldrm	8,135	1	28	28	65	976	61.5	75.7
Female	4,462	1	28	28	57	976	60.5	73.8
Male	3,673	1	28	28	80	882	62.8	78.0

¹N/A: Not Applicable

NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)										
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
finerenone	112,772	51,192	100.0%	38,461	100.0%	19,897	100.0%	2,853	100.0%	369	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	14	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
25-40 years	1,213	*****	*****	*****	*****	155	0.8%	18	0.6%	*****	*****
41-64 years	23,838	*****	*****	*****	*****	3,728	18.7%	532	18.6%	*****	*****
≥ 65 years	87,707	38,943	76.1%	30,125	78.3%	16,014	80.5%	2,303	80.7%	322	87.3%
fexinidazole	0	N/A¹	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
0-17 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
18-24 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
25-40 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
41-64 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
≥ 65 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
belumosudil	4,033	2,203	100.0%	1,108	100.0%	633	100.0%	*****	*****	*****	*****
0-17 years	42	24	1.1%	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	40	21	1.0%	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	651	396	18.0%	162	14.6%	82	13.0%	11	14.1%	0	0.0%
41-64 years	1,443	803	36.5%	372	33.6%	232	36.7%	*****	*****	*****	*****
≥ 65 years	1,857	959	43.5%	550	49.6%	307	48.5%	*****	*****	*****	*****
odevixibat	54	27	100.0%	15	100.0%	12	100.0%	0	NaN	0	NaN
0-17 years	29	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
18-24 years	11	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
anifrolumab-fnia	36,377	35,911	100.0%	*****	*****	122	100.0%	*****	*****	0	NaN
0-17 years	50	50	0.1%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	798	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	6,969	*****	*****	*****	*****	13	10.7%	*****	*****	0	NaN
41-64 years	17,199	16,887	47.0%	*****	*****	87	71.3%	*****	*****	0	NaN
≥ 65 years	11,361	11,287	31.4%	*****	*****	22	18.0%	*****	*****	0	NaN
avalglucosidase alfa-ngpt	7,260	7,181	100.0%	*****	*****	34	100.0%	*****	*****	*****	*****
0-17 years	658	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
18-24 years	37	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
25-40 years	656	636	8.9%	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	2,262	2,223	31.0%	*****	*****	21	61.8%	*****	*****	*****	*****
≥ 65 years	3,647	3,629	50.5%	*****	*****	*****	*****	*****	*****	0	0.0%
belzutifan	2,422	1,479	100.0%	639	100.0%	277	100.0%	*****	*****	*****	*****
0-17 years	15	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	60	*****	*****	15	2.3%	*****	*****	*****	*****	0	0.0%
25-40 years	410	234	15.8%	120	18.8%	*****	*****	*****	*****	0	0.0%
41-64 years	727	437	29.5%	182	28.5%	93	33.6%	*****	*****	*****	*****
≥ 65 years	1,210	761	51.5%	*****	*****	123	44.4%	*****	*****	0	0.0%
difelikefalin	330,115	330,115	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	1,298	1,298	0.4%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	17,779	17,779	5.4%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	119,513	119,513	36.2%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	191,525	191,525	58.0%	0	NaN	0	NaN	0	NaN	0	NaN

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)										
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
lonapegsomatropin-tcgd	1,938	1,042	100.0%	472	100.0%	*****	*****	53	100.0%	*****	*****
0-17 years	*****	*****	*****	*****	*****	*****	*****	53	100.0%	*****	*****
18-24 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%
25-40 years	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%
41-64 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
mobocertinib	195	116	100.0%	59	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	167	100	86.2%	*****	*****	*****	*****	*****	*****	0	NaN
tisotumab vedotin-tftv	2,029	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	881	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
atogepant	136,031	76,938	100.0%	38,346	100.0%	18,589	100.0%	1,945	100.0%	213	100.0%
0-17 years	468	259	0.3%	149	0.4%	*****	*****	*****	*****	0	0.0%
18-24 years	7,956	4,574	5.9%	2,314	6.0%	*****	*****	96	4.9%	*****	*****
25-40 years	32,557	18,846	24.5%	9,171	23.9%	4,114	22.1%	*****	*****	*****	*****
41-64 years	75,025	41,796	54.3%	21,329	55.6%	10,611	57.1%	1,163	59.8%	126	59.2%
≥ 65 years	20,025	11,463	14.9%	5,383	14.0%	2,846	15.3%	284	14.6%	49	23.0%

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
maralixibat	82	43	100.0%	24	100.0%	*****	*****	*****	*****	*****	*****
0-17 years	56	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 65 years	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	0.0%
avacopan	1,673	944	100.0%	474	100.0%	242	100.0%	*****	*****	*****	*****
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	209	140	14.8%	*****	*****	17	7.0%	*****	*****	0	0.0%
41-64 years	748	420	44.5%	216	45.6%	*****	*****	*****	*****	*****	*****
≥ 65 years	681	363	38.5%	198	41.8%	*****	*****	*****	*****	0	0.0%
asciminib	2,650	1,497	100.0%	704	100.0%	392	100.0%	*****	*****	*****	*****
0-17 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
25-40 years	283	148	9.9%	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	949	572	38.2%	249	35.4%	111	28.3%	*****	*****	*****	*****
≥ 65 years	1,404	766	51.2%	363	51.6%	238	60.7%	*****	*****	*****	*****
ropiegelinterferon alfa-2b-njft	2,332	1,296	100.0%	568	100.0%	423	100.0%	*****	*****	*****	*****
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	199	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	644	360	27.8%	166	29.2%	*****	*****	*****	*****	*****	*****
≥ 65 years	1,463	826	63.7%	338	59.5%	272	64.3%	*****	*****	*****	*****

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
vosoritide	227	122	100.0%	50	100.0%	*****	*****	*****	*****	*****	*****
0-17 years	227	122	100.0%	50	100.0%	*****	*****	*****	*****	*****	*****
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
41-64 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
maribavir	820	506	100.0%	217	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	15	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
18-24 years	16	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	192	126	24.9%	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	353	201	39.7%	101	46.5%	*****	*****	*****	*****	0	NaN
≥ 65 years	244	162	32.0%	*****	*****	*****	*****	0	0.0%	0	NaN
pafolacianine	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
tezepelumab-ekko	122,314	115,917	100.0%	4,026	100.0%	2,215	100.0%	*****	*****	*****	*****
0-17 years	488	422	0.4%	45	1.1%	21	0.9%	0	0.0%	0	0.0%
18-24 years	800	722	0.6%	52	1.3%	*****	*****	*****	*****	0	0.0%
25-40 years	5,079	4,544	3.9%	345	8.6%	*****	*****	*****	*****	0	0.0%
41-64 years	30,124	26,939	23.2%	1,944	48.3%	1,154	52.1%	*****	*****	*****	*****
≥ 65 years	85,823	83,290	71.9%	1,640	40.7%	838	37.8%	*****	*****	*****	*****

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)										
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
efgartigimod alfa-fcab	67,875	67,047	100.0%	586	100.0%	222	100.0%	20	100.0%	0	NaN
0-17 years	29	29	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	302	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
25-40 years	2,695	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	11,840	11,692	17.4%	102	17.4%	*****	*****	*****	*****	0	NaN
≥ 65 years	53,009	52,370	78.1%	453	77.3%	*****	*****	*****	*****	0	NaN
inclisiran	81,004	79,466	100.0%	640	100.0%	860	100.0%	38	100.0%	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	3,854	3,596	4.5%	*****	*****	158	18.4%	*****	*****	0	NaN
≥ 65 years	77,041	75,765	95.3%	543	84.8%	*****	*****	*****	*****	0	NaN
tralokinumab-Idrm	8,135	4,766	100.0%	2,065	100.0%	1,211	100.0%	*****	*****	*****	*****
0-17 years	104	66	1.4%	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	876	552	11.6%	*****	*****	92	7.6%	*****	*****	0	0.0%
25-40 years	1,714	1,026	21.5%	424	20.5%	252	20.8%	12	14.6%	0	0.0%
41-64 years	3,156	1,848	38.8%	775	37.5%	*****	*****	44	53.7%	*****	*****
≥ 65 years	2,285	1,274	26.7%	608	29.4%	374	30.9%	*****	*****	*****	*****

¹N/A: Not Applicable

NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
finerenone	112,772	1	30	60	90	1,263	87.1	104.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	14	3	30	60	90	90	57.4	34.2
25-40 years	1,213	1	30	30	90	1,111	73.2	89.0
41-64 years	23,838	1	30	41	90	1,199	80.3	95.8
≥ 65 years	87,707	1	30	60	90	1,263	89.1	107.2
fexinidazole	0	N/A¹	N/A	N/A	N/A	N/A	N/A	N/A
0-17 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
18-24 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
25-40 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
41-64 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
≥ 65 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
belumosudil	4,033	1	30	30	90	1,024	73.9	94.2
0-17 years	42	5	30	30	60	270	58.3	56.3
18-24 years	40	6	30	30	90	559	73.1	94.3
25-40 years	651	1	30	30	60	645	64.4	77.4
41-64 years	1,443	1	30	30	90	868	74.1	94.9
≥ 65 years	1,857	1	30	30	90	1,024	77.5	99.3
odevixibat	54	5	30	31	90	334	75.5	74.9
0-17 years	29	5	30	30	90	269	61.3	59.6
18-24 years	11	30	30	30	90	198	60.2	53.1
25-40 years	*****	30	31	90	232	334	119.5	106.4
41-64 years	*****	30	30	60	232	232	107.3	109.0
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
anifrolumab-fnia	36,377	1	1	1	1	420	2.7	12.6

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
0-17 years	50	1	1	1	1	1	1.0	0.0
18-24 years	798	1	1	1	1	84	1.3	4.2
25-40 years	6,969	1	1	1	1	392	2.4	11.2
41-64 years	17,199	1	1	1	1	408	3.4	15.0
≥ 65 years	11,361	1	1	1	1	420	1.8	9.6
avalglucosidase alfa-ngpt	7,260	1	1	1	1	1,018	3.1	24.7
0-17 years	658	1	1	1	1	32	1.2	2.2
18-24 years	37	1	1	1	1	84	3.3	13.6
25-40 years	656	1	1	1	1	588	5.8	31.4
41-64 years	2,262	1	1	1	1	1,018	4.4	32.8
≥ 65 years	3,647	1	1	1	1	722	2.1	19.2
belzutifan	2,422	1	30	30	60	1,085	59.8	75.4
0-17 years	15	19	30	30	60	570	79.7	138.4
18-24 years	60	2	30	30	60	556	61.1	90.7
25-40 years	410	1	30	30	60	690	61.8	63.6
41-64 years	727	1	30	30	60	1,085	68.1	99.9
≥ 65 years	1,210	1	30	30	60	660	53.9	57.7
difelikefalin	330,115	1	1	1	1	5	1.0	0.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	1,298	1	1	1	1	2	1.0	0.1
25-40 years	17,779	1	1	1	1	3	1.0	0.2
41-64 years	119,513	1	1	1	1	4	1.0	0.1
≥ 65 years	191,525	1	1	1	1	5	1.0	0.1
lonapegsomatropin-tcgd	1,938	1	28	28	84	1,066	77.2	101.9
0-17 years	*****	1	28	28	84	1,066	77.1	101.8

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
18-24 years	*****	28	28	28	196	364	112.0	168.0
25-40 years	*****	58	58	58	58	58	58.0	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
mobocertinib	195	17	30	30	60	570	58.9	61.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	30	30	30	30	30	30.0	NaN
41-64 years	*****	17	30	30	90	277	72.9	71.8
≥ 65 years	167	17	30	30	60	570	56.8	59.2
tisotumab vedotin-tftv	2,029	1	1	1	1	84	1.2	3.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	163	1	1	1	1	1	1.0	0.0
41-64 years	985	1	1	1	1	84	1.3	3.8
≥ 65 years	881	1	1	1	1	42	1.2	2.1
atogepant	136,031	1	30	30	90	1,225	68.8	83.7
0-17 years	468	1	30	30	90	678	68.8	84.8
18-24 years	7,956	1	30	30	90	1,129	64.7	74.1
25-40 years	32,557	1	30	30	83	1,225	65.6	77.7
41-64 years	75,025	1	30	30	90	1,059	70.5	85.8
≥ 65 years	20,025	1	30	30	87	1,142	69.1	88.1
maralixibat	82	22	30	30	90	886	92.4	154.3
0-17 years	56	22	30	30	60	886	73.8	135.3
18-24 years	*****	30	30	90	150	746	119.8	166.9

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
25-40 years	*****	23	30	60	177	720	165.7	250.9
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	*****	127	127	127	127	127	127.0	NaN
avacopan	1,673	1	30	30	60	840	65.4	73.5
0-17 years	*****	16	16	23	30	30	23.0	9.9
18-24 years	*****	1	30	30	60	453	66.3	87.3
25-40 years	209	1	30	30	60	716	55.4	70.1
41-64 years	748	1	30	30	60	840	64.4	71.9
≥ 65 years	681	1	30	30	86	570	69.6	75.4
asciminib	2,650	1	30	30	64	1,108	72.3	97.2
0-17 years	*****	19	26	30	30	240	57.9	80.4
18-24 years	*****	30	30	30	60	60	38.6	14.6
25-40 years	283	1	30	30	66	483	68.5	74.0
41-64 years	949	1	30	30	60	1,108	65.0	88.4
≥ 65 years	1,404	1	30	30	90	995	78.2	106.5
ropiegelinterferon alfa-2b-njft	2,332	1	28	28	84	1,036	71.8	98.7
0-17 years	*****	28	28	28	36	84	38.2	19.5
18-24 years	*****	3	28	56	114	308	95.4	87.1
25-40 years	199	1	28	37	84	916	90.9	135.8
41-64 years	644	1	28	28	82	945	65.7	89.4
≥ 65 years	1,463	1	28	28	84	1,036	71.9	96.8
vosoritide	227	3	30	30	90	780	89.8	117.1
0-17 years	227	3	30	30	90	780	89.8	117.1
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
maribavir	820	1	28	28	56	532	50.3	52.1
0-17 years	15	12	28	28	56	142	42.0	33.0
18-24 years	16	14	28	45	70	112	51.9	31.2
25-40 years	192	1	28	28	56	280	44.6	38.4
41-64 years	353	1	28	28	56	532	58.0	63.0
≥ 65 years	244	1	28	28	56	308	44.3	44.2
pafolacianine	*****	1	1	1	1	1	1.0	NaN
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	*****	1	1	1	1	1	1.0	NaN
tezepelumab-ekko	122,314	1	1	1	1	1,095	8.5	32.5
0-17 years	488	1	1	1	28	295	18.8	40.9
18-24 years	800	1	1	1	28	651	15.5	39.9
25-40 years	5,079	1	1	1	1	702	15.8	44.4
41-64 years	30,124	1	1	1	1	827	16.4	45.5
≥ 65 years	85,823	1	1	1	1	1,095	5.1	24.6
efgartigimod alfa-fcab	67,875	1	1	1	1	689	3.3	14.8
0-17 years	29	1	1	1	1	1	1.0	0.0
18-24 years	302	1	1	1	1	410	3.9	25.5
25-40 years	2,695	1	1	1	1	574	2.8	14.8
41-64 years	11,840	1	1	1	1	560	3.4	14.8

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	53,009	1	1	1	1	689	3.3	14.8
inclisiran	81,004	1	1	1	1	687	3.9	24.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	180	6.5	27.7
41-64 years	3,854	1	1	1	1	618	11.7	45.5
≥ 65 years	77,041	1	1	1	1	687	3.6	22.8
tralokinumab-ldrm	8,135	1	28	28	65	976	61.5	75.7
0-17 years	104	1	28	28	56	252	42.5	39.3
18-24 years	876	1	28	28	56	420	51.8	51.7
25-40 years	1,714	1	28	28	56	688	57.5	66.2
41-64 years	3,156	1	28	28	78	976	64.3	82.4
≥ 65 years	2,285	1	28	28	84	856	65.3	81.1

¹N/A: Not Applicable

NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 7a. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>finerenone</i>	112,772	1	3	8	23	1,114	24.8	53.3
<i>fexinidazole</i>	0	N/A ¹	N/A	N/A	N/A	N/A	N/A	N/A
<i>belumosudil</i>	4,033	1	2	5	14	961	21.8	64.5
<i>odevixibat</i>	54	1	3	7	17	313	18.5	45.6
<i>anifrolumab-fnia</i>	36,377	1	27	27	31	811	32.7	27.6
<i>avalglucosidase alfa-ngpt</i>	7,260	1	13	13	13	573	14.2	10.2
<i>belzutifan</i>	2,422	1	3	6	15	646	14.8	31.2
<i>difelikefalin</i>	330,115	1	1	1	2	688	2.1	8.2
<i>lonapegsomatropin-tcgd</i>	1,938	1	2	6	14	752	15.0	38.9
<i>mobocertinib</i>	195	1	4	9	25	293	19.1	30.6
<i>tisotumab vedotin-tftv</i>	2,029	1	20	20	23	525	24.6	17.5
<i>atogepant</i>	136,031	1	3	7	19	1,119	22.9	55.9
<i>maralixibat</i>	82	1	4	7	17	213	17.6	31.6
<i>avacopan</i>	1,673	1	3	6	12	616	13.7	33.4
<i>asciminib</i>	2,650	1	3	8	23	802	21.2	46.5
<i>ropoginterferon alfa-2b-njft</i>	2,332	1	3	7	14	706	16.3	37.0
<i>vosoritide</i>	227	1	3	5	10	220	9.5	18.3
<i>maribavir</i>	820	1	3	7	23	734	27.6	66.5
<i>pafolacianine</i>	*****	337	337	337	337	337	337.0	NaN
<i>tezepelumab-ekko</i>	122,314	1	27	27	29	744	29.4	23.3
<i>efgartigimod alfa-fcab</i>	67,875	1	6	6	14	848	15.6	26.3
<i>inclisiran</i>	81,004	1	91	181	185	843	147.6	59.1
<i>tralokinumab-ldrm</i>	8,135	1	3	8	18	795	19.1	41.5

¹N/A: Not Applicable

NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
finerenone	112,772	1	3	8	23	1,114	24.8	53.3
Female	51,376	1	3	8	23	1,055	24.6	53.0
Male	61,396	1	3	8	23	1,114	25.0	53.7
fexinidazole	0	N/A¹	N/A	N/A	N/A	N/A	N/A	N/A
Female	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Male	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
belumosudil	4,033	1	2	5	14	961	21.8	64.5
Female	1,691	1	3	5	14	961	23.4	72.9
Male	2,342	1	2	5	14	920	20.6	57.7
odevixibat	54	1	3	7	17	313	18.5	45.6
Female	34	1	3	6	12	68	9.4	12.0
Male	20	1	2	16	24	313	34.0	71.7
anifrolumab-fnia	36,377	1	27	27	31	811	32.7	27.6
Female	33,550	1	27	27	31	779	32.8	27.9
Male	2,827	1	27	27	31	811	32.0	23.3
avalglucosidase alfa-ngpt	7,260	1	13	13	13	573	14.2	10.2
Female	3,982	1	13	13	13	573	14.3	11.7
Male	3,278	1	13	13	13	243	14.1	8.0
belzutifan	2,422	1	3	6	15	646	14.8	31.2
Female	864	1	3	6	16	343	16.1	33.9
Male	1,558	1	2	6	15	646	14.0	29.6
difelikefalin	330,115	1	1	1	2	688	2.1	8.2
Female	155,948	1	1	1	2	688	2.1	7.9
Male	174,167	1	1	1	2	657	2.1	8.4
lonapegsomatropin-tcgd	1,938	1	2	6	14	752	15.0	38.9
Female	532	1	3	7	17	587	17.0	39.6

Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Male	1,406	1	2	5	13	752	14.3	38.6
mobocertinib	195	1	4	9	25	293	19.1	30.6
Female	121	1	4	9	25	293	19.6	33.3
Male	74	1	3	10	22	159	18.4	25.9
tisotumab vedotin-tftv	2,029	1	20	20	23	525	24.6	17.5
Female	2,029	1	20	20	23	525	24.6	17.5
Male	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
atogepant	136,031	1	3	7	19	1,119	22.9	55.9
Female	117,684	1	3	7	19	1,119	23.0	56.1
Male	18,347	1	3	7	19	1,027	22.5	54.8
maralixibat	82	1	4	7	17	213	17.6	31.6
Female	16	1	4	9	49	213	38.4	61.8
Male	66	1	4	7	14	80	12.5	15.2
avacopan	1,673	1	3	6	12	616	13.7	33.4
Female	921	1	3	5	12	563	13.3	33.0
Male	752	1	3	6	12	616	14.1	33.9
asciminib	2,650	1	3	8	23	802	21.2	46.5
Female	1,435	1	3	8	25	802	23.2	51.3
Male	1,215	1	3	7	20	579	18.7	40.0
ropiegelinterferon alfa-2b-njft	2,332	1	3	7	14	706	16.3	37.0
Female	1,109	1	3	6	14	514	17.6	40.1
Male	1,223	1	3	7	14	706	15.1	34.0
vosoritide	227	1	3	5	10	220	9.5	18.3
Female	149	1	3	5	10	220	9.8	21.0
Male	78	1	3	5	9	67	9.1	11.8
maribavir	820	1	3	7	23	734	27.6	66.5

Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	393	1	3	7	21	561	27.1	64.8
Male	427	1	3	7	24	734	28.1	68.2
pafolacianine	*****	337	337	337	337	337	337.0	NaN
Female	*****	337	337	337	337	337	337.0	NaN
Male	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
tezepelumab-ekko	122,314	1	27	27	29	744	29.4	23.3
Female	82,927	1	27	27	30	744	29.5	23.7
Male	39,387	1	27	27	29	725	29.3	22.3
efgartigimod alfa-fcab	67,875	1	6	6	14	848	15.6	26.3
Female	28,413	1	6	6	15	772	15.8	26.9
Male	39,462	1	6	6	13	848	15.4	25.8
inclisiran	81,004	1	91	181	185	843	147.6	59.1
Female	42,195	1	91	180	185	821	146.7	60.3
Male	38,809	1	91	181	184	843	148.6	57.8
tralokinumab-Idrm	8,135	1	3	8	18	795	19.1	41.5
Female	4,462	1	3	8	18	622	18.8	40.5
Male	3,673	1	3	8	17	795	19.4	42.7

¹N/A: Not Applicable

NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
finerenone	112,772	1	3	8	23	1,114	24.8	53.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	14	2	2	7	51	273	35.3	71.7
25-40 years	1,213	1	4	10	26	543	25.1	46.9
41-64 years	23,838	1	3	8	23	1,106	24.8	51.4
≥ 65 years	87,707	1	3	8	23	1,114	24.8	53.9
fexinidazole	0	N/A¹	N/A	N/A	N/A	N/A	N/A	N/A
0-17 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
18-24 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
25-40 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
41-64 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
≥ 65 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
belumosudil	4,033	1	2	5	14	961	21.8	64.5
0-17 years	42	1	3	6	10	124	10.2	19.7
18-24 years	40	1	3	9	20	537	32.3	89.1
25-40 years	651	1	3	7	19	492	22.3	51.2
41-64 years	1,443	1	2	5	14	920	21.0	64.0
≥ 65 years	1,857	1	2	5	13	961	22.2	69.0
odevixibat	54	1	3	7	17	313	18.5	45.6
0-17 years	29	1	4	8	18	131	15.5	24.5
18-24 years	11	1	5	11	20	68	16.4	18.4
25-40 years	*****	2	2	4	9	313	33.4	92.9
41-64 years	*****	1	1	1	2	2	1.3	0.6
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
anifrolumab-fnia	36,377	1	27	27	31	811	32.7	27.6

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
0-17 years	50	23	27	27	29	55	28.2	4.8
18-24 years	798	1	27	27	31	323	31.9	20.3
25-40 years	6,969	1	27	27	32	779	33.2	31.1
41-64 years	17,199	1	27	27	32	748	32.9	28.8
≥ 65 years	11,361	1	27	27	31	811	32.3	23.8
avalglucosidase alfa-ngpt	7,260	1	13	13	13	573	14.2	10.2
0-17 years	658	1	13	13	13	73	13.7	5.4
18-24 years	37	6	13	14	27	48	20.3	10.3
25-40 years	656	1	13	13	13	167	15.0	11.0
41-64 years	2,262	1	13	13	13	573	14.7	13.6
≥ 65 years	3,647	1	13	13	13	243	13.7	8.0
belzutifan	2,422	1	3	6	15	646	14.8	31.2
0-17 years	15	1	1	3	6	32	6.3	8.9
18-24 years	60	1	4	7	20	62	14.0	15.4
25-40 years	410	1	3	6	17	308	15.5	29.2
41-64 years	727	1	3	6	13	646	15.3	37.7
≥ 65 years	1,210	1	2	6	15	431	14.3	28.1
difelikefalin	330,115	1	1	1	2	688	2.1	8.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	1,298	1	1	1	2	123	2.1	5.5
25-40 years	17,779	1	1	1	2	528	2.2	8.5
41-64 years	119,513	1	1	1	2	688	2.1	7.8
≥ 65 years	191,525	1	1	1	2	657	2.1	8.4
lonapegsomatropin-tcgd	1,938	1	2	6	14	752	15.0	38.9
0-17 years	*****	1	2	6	14	752	15.0	38.9

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
18-24 years	*****	2	3	5	9	12	5.8	4.3
25-40 years	*****	46	46	46	46	46	46.0	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
mobocertinib	195	1	4	9	25	293	19.1	30.6
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	NaN
41-64 years	*****	1	4	10	26	51	15.7	15.4
≥ 65 years	167	1	4	9	25	293	19.8	32.5
tisotumab vedotin-tftv	2,029	1	20	20	23	525	24.6	17.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	163	12	20	20	27	104	24.9	9.7
41-64 years	985	1	20	20	23	525	24.7	19.9
≥ 65 years	881	1	20	20	22	271	24.5	15.8
atogepant	136,031	1	3	7	19	1,119	22.9	55.9
0-17 years	468	1	3	7	20	549	23.4	52.9
18-24 years	7,956	1	3	7	20	851	22.5	50.9
25-40 years	32,557	1	3	7	18	911	21.8	53.3
41-64 years	75,025	1	3	7	19	1,119	22.7	55.4
≥ 65 years	20,025	1	3	7	21	1,080	25.6	63.6
maralixibat	82	1	4	7	17	213	17.6	31.6
0-17 years	56	1	5	7	16	213	15.7	29.9
18-24 years	*****	1	5	9	29	156	25.7	39.4

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
25-40 years	*****	1	2	4	5	67	12.4	24.1
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	*****	12	12	12	12	12	12.0	NaN
avacopan	1,673	1	3	6	12	616	13.7	33.4
0-17 years	*****	6	6	58	109	109	57.5	72.8
18-24 years	*****	2	2	5	8	214	20.1	44.9
25-40 years	209	1	3	6	12	193	12.8	22.1
41-64 years	748	1	3	6	12	304	13.0	26.6
≥ 65 years	681	1	3	6	12	616	14.3	41.2
asciminib	2,650	1	3	8	23	802	21.2	46.5
0-17 years	*****	1	1	4	21	33	10.1	12.3
18-24 years	*****	7	11	54	90	147	58.0	49.4
25-40 years	283	1	3	8	19	579	25.5	63.6
41-64 years	949	1	3	8	24	802	23.4	53.4
≥ 65 years	1,404	1	3	7	23	527	18.7	36.2
ropginterferon alfa-2b-njft	2,332	1	3	7	14	706	16.3	37.0
0-17 years	*****	3	6	11	16	50	14.6	14.5
18-24 years	*****	1	1	3	6	35	7.6	10.8
25-40 years	199	1	3	7	13	206	11.5	18.7
41-64 years	644	1	3	7	14	706	15.6	42.1
≥ 65 years	1,463	1	3	7	15	384	17.4	36.8
vosoritide	227	1	3	5	10	220	9.5	18.3
0-17 years	227	1	3	5	10	220	9.5	18.3
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
maribavir	820	1	3	7	23	734	27.6	66.5
0-17 years	15	2	3	5	13	39	9.9	9.8
18-24 years	16	1	5	12	28	119	25.0	33.4
25-40 years	192	1	3	7	15	414	18.1	41.8
41-64 years	353	1	3	7	23	734	29.7	76.9
≥ 65 years	244	1	3	11	28	583	33.4	69.1
pafolacianine	*****	337	337	337	337	337	337.0	NaN
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	*****	337	337	337	337	337	337.0	NaN
tezepelumab-ekko	122,314	1	27	27	29	744	29.4	23.3
0-17 years	488	1	11	27	31	399	27.6	35.0
18-24 years	800	1	19	27	32	526	29.3	31.8
25-40 years	5,079	1	20	27	30	744	29.0	33.0
41-64 years	30,124	1	21	27	30	677	28.1	27.5
≥ 65 years	85,823	1	27	27	29	725	29.9	20.6
efgartigimod alfa-fcab	67,875	1	6	6	14	848	15.6	26.3
0-17 years	29	4	6	6	9	224	20.1	42.3
18-24 years	302	1	6	6	19	168	16.5	21.0
25-40 years	2,695	1	6	6	13	759	14.5	31.4
41-64 years	11,840	1	6	6	16	577	15.7	24.6

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	53,009	1	6	6	14	848	15.6	26.4
inclisiran	81,004	1	91	181	185	843	147.6	59.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	83	83	126	169	169	126.0	60.8
25-40 years	*****	2	91	119	184	379	146.0	70.2
41-64 years	3,854	1	90	134	184	693	141.0	67.8
≥ 65 years	77,041	1	91	181	185	843	147.9	58.6
tralokinumab-ldrm	8,135	1	3	8	18	795	19.1	41.5
0-17 years	104	1	4	10	21	301	23.4	42.4
18-24 years	876	1	4	9	20	622	19.9	39.9
25-40 years	1,714	1	4	9	20	609	19.8	38.5
41-64 years	3,156	1	3	7	17	795	19.0	42.5
≥ 65 years	2,285	1	3	7	16	525	18.2	43.0

¹N/A: Not Applicable

NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 8a. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>finerenone</i>	37,705	1	3	9	29	1,114	32.3	68.8
<i>fexinidazole</i>	0	N/A ¹	N/A	N/A	N/A	N/A	N/A	N/A
<i>belumosudil</i>	1,100	1	2	5	16	920	29.2	82.9
<i>odevixibat</i>	21	1	3	5	23	131	16.1	27.8
<i>anifrolumab-fnia</i>	3,978	1	27	27	32	635	34.0	33.7
<i>avalglucosidase alfa-ngpt</i>	229	1	13	13	13	141	15.0	11.3
<i>belzutifan</i>	864	1	3	7	18	646	17.3	38.9
<i>difelikefalin</i>	5,259	1	1	1	2	423	3.0	14.1
<i>lonapegsomatropin-tcgd</i>	638	1	3	6	14	752	17.3	52.8
<i>mobocertinib</i>	75	1	6	14	37	293	26.9	39.2
<i>tisotumab vedotin-tftv</i>	436	1	20	20	23	525	26.0	27.8
<i>atogepant</i>	44,600	1	3	8	23	1,119	28.5	70.1
<i>maralixibat</i>	25	1	4	7	23	213	24.1	44.8
<i>avacopan</i>	534	1	3	6	12	616	15.8	46.5
<i>asciminib</i>	791	1	3	7	22	802	22.1	54.9
<i>ropéginterferon alfa-2b-njft</i>	591	1	3	7	15	338	17.8	38.5
<i>vosoritide</i>	58	1	2	5	9	220	11.5	29.9
<i>maribavir</i>	436	1	4	8	25	583	28.0	62.2
<i>pafolacianine</i>	*****	337	337	337	337	337	337.0	NaN
<i>tezepelumab-ekko</i>	14,180	1	26	27	30	724	30.3	35.3
<i>efgartigimod alfa-fcab</i>	4,689	1	6	6	7	581	12.9	26.2
<i>inclisiran</i>	39,689	1	90	91	98	843	106.6	49.2
<i>tralokinumab-ldrm</i>	2,870	1	3	8	18	622	20.0	44.3

¹N/A: Not Applicable

NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
finerenone	37,705	1	3	9	29	1,114	32.3	68.8
Female	16,994	1	3	9	28	1,055	32.1	69.3
Male	20,711	1	3	9	29	1,114	32.4	68.5
fexinidazole	0	N/A¹	N/A	N/A	N/A	N/A	N/A	N/A
Female	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Male	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
belumosudil	1,100	1	2	5	16	920	29.2	82.9
Female	481	1	3	6	17	718	29.6	80.5
Male	619	1	2	5	16	920	28.9	84.8
odevixibat	21	1	3	5	23	131	16.1	27.8
Female	*****	1	2	5	11	24	7.5	7.0
Male	*****	1	4	20	25	131	25.6	38.4
anifrolumab-fnia	3,978	1	27	27	32	635	34.0	33.7
Female	3,684	1	27	27	32	635	34.0	34.3
Male	294	1	27	27	31	371	33.2	26.2
avalglucosidase alfa-ngpt	229	1	13	13	13	141	15.0	11.3
Female	112	3	13	13	14	67	15.6	9.3
Male	117	1	13	13	13	141	14.4	12.9
belzutifan	864	1	3	7	18	646	17.3	38.9
Female	280	1	3	8	21	343	19.6	38.3
Male	584	1	3	7	18	646	16.3	39.1
difelikefalin	5,259	1	1	1	2	423	3.0	14.1
Female	2,521	1	1	1	2	391	2.9	11.2
Male	2,738	1	1	1	2	423	3.1	16.3
lonapegsomatropin-tcgd	638	1	3	6	14	752	17.3	52.8
Female	161	1	3	6	17	587	22.3	62.5
Male	477	1	2	6	13	752	15.6	49.0

Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
mobocertinib	75	1	6	14	37	293	26.9	39.2
Female	46	1	6	17	34	293	30.0	47.2
Male	29	1	4	12	37	66	21.9	20.8
tisotumab vedotin-tftv	436	1	20	20	23	525	26.0	27.8
Female	436	1	20	20	23	525	26.0	27.8
Male	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
atogepant	44,600	1	3	8	23	1,119	28.5	70.1
Female	38,355	1	3	8	23	1,119	28.5	70.5
Male	6,245	1	3	8	23	946	28.5	67.3
maralixibat	25	1	4	7	23	213	24.1	44.8
Female	*****	1	2	5	12	213	31.7	66.7
Male	*****	1	5	8	29	80	19.0	22.5
avacopan	534	1	3	6	12	616	15.8	46.5
Female	294	1	3	6	12	563	14.7	44.8
Male	240	1	3	6	12	616	17.2	48.5
asciminib	791	1	3	7	22	802	22.1	54.9
Female	419	1	3	8	24	802	25.5	63.4
Male	372	1	3	6	19	579	18.4	43.2
ropiegelinterferon alfa-2b-njft	591	1	3	7	15	338	17.8	38.5
Female	301	1	3	6	14	338	20.3	46.0
Male	290	1	3	7	15	274	15.2	28.7
vosoritide	58	1	2	5	9	220	11.5	29.9
Female	36	1	2	4	6	220	12.0	36.6
Male	22	1	2	7	12	57	10.5	13.7
maribavir	436	1	4	8	25	583	28.0	62.2
Female	190	1	3	8	21	531	26.1	59.9
Male	246	1	4	9	28	583	29.5	64.0

Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
pafolacianine	*****	337	337	337	337	337	337.0	NaN
Female	*****	337	337	337	337	337	337.0	NaN
Male	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
tezepelumab-ekko	14,180	1	26	27	30	724	30.3	35.3
Female	9,717	1	25	27	30	685	30.1	34.6
Male	4,463	1	26	27	30	724	30.7	36.8
efgartigimod alfa-fcab	4,689	1	6	6	7	581	12.9	26.2
Female	1,988	1	6	6	8	581	14.1	30.9
Male	2,701	1	6	6	7	471	12.0	22.0
inclisiran	39,689	1	90	91	98	843	106.6	49.2
Female	21,004	1	90	91	98	821	106.1	50.0
Male	18,685	1	90	91	98	843	107.1	48.2
tralokinumab-Idrm	2,870	1	3	8	18	622	20.0	44.3
Female	1,601	1	3	8	18	622	19.4	43.4
Male	1,269	1	3	8	18	503	20.7	45.5

¹N/A: Not Applicable

NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
finerenone	37,705	1	3	9	29	1,114	32.3	68.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	2	4	10	57	273	52.1	92.3
25-40 years	*****	1	3	11	31	543	29.8	60.0
41-64 years	7,728	1	3	9	29	1,106	31.1	64.6
≥ 65 years	29,551	1	3	9	29	1,114	32.6	70.0
feixinidazole	0	N/A¹	N/A	N/A	N/A	N/A	N/A	N/A
0-17 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
18-24 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
25-40 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
41-64 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
≥ 65 years	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
belumosudil	1,100	1	2	5	16	920	29.2	82.9
0-17 years	13	1	2	3	9	124	14.1	33.2
18-24 years	19	2	4	9	39	207	29.3	48.4
25-40 years	151	1	3	6	16	492	29.2	76.2
41-64 years	386	1	2	5	19	920	33.1	98.6
≥ 65 years	531	1	2	5	14	702	26.7	73.7
odevixibat	21	1	3	5	23	131	16.1	27.8
0-17 years	*****	1	2	10	25	131	22.7	37.3
18-24 years	*****	5	8	13	20	24	13.8	8.0
25-40 years	*****	2	3	4	5	17	6.2	6.1
41-64 years	*****	2	2	2	2	2	2.0	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
anifrolumab-fnia	3,978	1	27	27	32	635	34.0	33.7

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
0-17 years	*****	26	27	27	29	30	27.5	1.7
18-24 years	*****	4	27	27	34	170	32.7	20.2
25-40 years	815	1	27	27	33	327	34.0	26.5
41-64 years	1,882	1	27	27	32	635	35.8	42.5
≥ 65 years	1,182	1	27	27	30	518	31.2	20.7
avalglucosidase alfa-ngpt	229	1	13	13	13	141	15.0	11.3
0-17 years	26	5	13	13	13	20	12.8	2.9
18-24 years	*****	12	13	14	24	33	18.0	10.0
25-40 years	*****	2	13	13	16	40	14.3	7.3
41-64 years	76	1	13	13	13	141	16.0	15.8
≥ 65 years	99	1	13	13	13	67	14.9	9.3
belzutifan	864	1	3	7	18	646	17.3	38.9
0-17 years	*****	1	1	2	3	4	2.0	1.4
18-24 years	*****	1	2	9	19	28	10.9	8.8
25-40 years	79	1	2	5	18	219	16.5	33.9
41-64 years	217	1	3	7	17	646	19.1	51.0
≥ 65 years	549	1	3	7	19	431	17.1	34.4
difelikefalin	5,259	1	1	1	2	423	3.0	14.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	15	1	1	2	2	27	3.5	6.5
25-40 years	286	1	1	2	2	107	3.1	9.9
41-64 years	1,881	1	1	1	2	423	2.8	11.5
≥ 65 years	3,077	1	1	1	2	412	3.1	15.8
lonapegsomatropin-tcgd	638	1	3	6	14	752	17.3	52.8
0-17 years	*****	1	3	6	14	752	17.3	52.9

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
18-24 years	*****	4	4	5	5	5	4.5	0.7
25-40 years	*****	46	46	46	46	46	46.0	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
mobocertinib	75	1	6	14	37	293	26.9	39.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	NaN
41-64 years	*****	1	6	15	34	51	20.6	18.2
≥ 65 years	60	1	6	16	38	293	28.8	42.8
tisotumab vedotin-tftv	436	1	20	20	23	525	26.0	27.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	40	12	20	20	27	42	23.5	6.4
41-64 years	204	3	20	20	23	525	26.7	37.5
≥ 65 years	192	1	20	20	23	143	25.9	15.8
atogepant	44,600	1	3	8	23	1,119	28.5	70.1
0-17 years	178	1	3	8	24	549	25.8	55.2
18-24 years	2,641	1	3	8	24	749	25.7	57.7
25-40 years	10,403	1	3	8	22	911	26.8	65.4
41-64 years	23,913	1	3	8	22	1,119	28.0	69.1
≥ 65 years	7,465	1	3	8	26	1,080	33.6	82.5
maralixibat	25	1	4	7	23	213	24.1	44.8
0-17 years	*****	1	3	7	29	213	26.4	53.8
18-24 years	*****	1	5	7	23	80	23.2	32.8

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
25-40 years	*****	2	3	5	36	67	19.5	31.7
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	*****	12	12	12	12	12	12.0	NaN
avacopan	534	1	3	6	12	616	15.8	46.5
0-17 years	*****	6	6	6	6	6	6.0	NaN
18-24 years	*****	2	3	4	5	214	33.2	70.9
25-40 years	64	1	3	5	11	108	10.1	17.0
41-64 years	219	1	3	7	14	231	13.9	24.0
≥ 65 years	238	1	3	6	12	616	18.2	63.1
asciminib	791	1	3	7	22	802	22.1	54.9
0-17 years	*****	1	1	4	8	8	4.3	3.5
18-24 years	*****	7	7	11	90	90	36.0	46.8
25-40 years	*****	1	3	8	21	579	34.6	90.0
41-64 years	262	1	3	9	24	802	24.3	64.3
≥ 65 years	435	1	2	5	20	397	18.3	36.2
ropiegelinterferon alfa-2b-njft	591	1	3	7	15	338	17.8	38.5
0-17 years	*****	21	21	21	21	21	21.0	NaN
18-24 years	*****	1	2	5	31	35	11.9	14.6
25-40 years	*****	1	3	5	13	53	10.0	12.4
41-64 years	170	1	3	7	14	338	17.5	39.0
≥ 65 years	368	1	3	7	15	337	19.0	40.7
vosoritide	58	1	2	5	9	220	11.5	29.9
0-17 years	58	1	2	5	9	220	11.5	29.9
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
maribavir	436	1	4	8	25	583	28.0	62.2
0-17 years	*****	3	4	8	16	39	12.0	12.2
18-24 years	*****	2	5	12	34	119	30.2	38.5
25-40 years	73	1	3	7	12	110	13.5	18.9
41-64 years	211	1	3	8	24	583	30.0	69.6
≥ 65 years	135	1	4	12	32	583	33.6	67.1
pafolacianine	*****	337	337	337	337	337	337.0	NaN
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	*****	337	337	337	337	337	337.0	NaN
tezepelumab-ekko	14,180	1	26	27	30	724	30.3	35.3
0-17 years	84	1	7	26	34	310	29.0	38.0
18-24 years	145	1	8	27	33	450	30.6	47.6
25-40 years	753	1	10	27	32	540	29.4	37.8
41-64 years	4,276	1	9	27	30	552	28.9	35.2
≥ 65 years	8,922	1	27	27	29	724	31.0	34.8
efgartigimod alfa-fcab	4,689	1	6	6	7	581	12.9	26.2
0-17 years	*****	5	5	6	9	9	6.7	2.1
18-24 years	*****	1	6	6	8	72	13.1	17.5
25-40 years	156	1	6	6	7	72	9.9	10.7
41-64 years	805	1	6	6	8	284	14.5	26.6

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	3,703	1	6	6	7	581	12.7	26.6
inclisiran	39,689	1	90	91	98	843	106.6	49.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	83	83	126	169	169	126.0	60.8
25-40 years	*****	2	90	93	103	321	109.8	52.3
41-64 years	2,107	1	90	91	103	693	108.3	59.4
≥ 65 years	37,519	1	90	91	98	843	106.5	48.5
tralokinumab-ldrm	2,870	1	3	8	18	622	20.0	44.3
0-17 years	53	1	5	10	30	301	28.4	49.0
18-24 years	300	1	4	9	18	622	19.7	48.9
25-40 years	603	1	3	8	18	396	19.9	40.1
41-64 years	1,057	1	3	8	18	551	20.3	44.6
≥ 65 years	857	1	3	8	16	503	19.2	45.0

¹N/A: Not Applicable

NaN: Not a number

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 9. Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025^{1,2}

	Censoring Reason								
	Total Number of Episodes	End of Exposure Episode ³		Occurrence of User-Defined Censoring Criteria ⁴		Disenrollment ⁵		End of Data ⁶	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>finerenone</i>	178,149	177,264	99.5%	0	0.0%	36,013	20.2%	26,642	15.0%
<i>fexinidazole</i>	0	N/A ⁷	N/A	N/A	N/A	N/A	N/A	N/A	N/A
<i>belumosudil</i>	5,836	5,732	98.2%	0	0.0%	899	15.4%	674	11.5%
<i>odevixibat</i>	99	99	100.0%	0	0.0%	33	33.3%	25	25.3%
<i>anifrolumab-fnia</i>	40,955	40,951	100.0%	0	0.0%	245	0.6%	194	0.5%
<i>avalglucosidase alfa-ngpt</i>	7,503	7,502	100.0%	0	0.0%	43	0.6%	43	0.6%
<i>belzutifan</i>	4,108	4,011	97.6%	0	0.0%	709	17.3%	571	13.9%
<i>difelikefalin</i>	335,643	335,643	100.0%	0	0.0%	437	0.1%	302	0.1%
<i>lonapegsomatropin-tcgd</i>	3,102	3,102	100.0%	0	0.0%	808	26.0%	556	17.9%
<i>mobocertinib</i>	352	339	96.3%	0	0.0%	*****	*****	*****	*****
<i>tisotumab vedotin-tftv</i>	2,557	2,556	100.0%	0	0.0%	*****	*****	*****	*****
<i>atogepant</i>	217,044	216,884	99.9%	0	0.0%	38,809	17.9%	24,518	11.3%
<i>maralixibat</i>	153	153	100.0%	0	0.0%	48	31.4%	40	26.1%
<i>avacopan</i>	2,643	2,630	99.5%	0	0.0%	489	18.5%	354	13.4%
<i>asciminib</i>	4,008	3,963	98.9%	0	0.0%	850	21.2%	636	15.9%
<i>ropeginterferon alfa-2b-njft</i>	3,210	3,203	99.8%	0	0.0%	545	17.0%	415	12.9%
<i>vosoritide</i>	321	321	100.0%	0	0.0%	73	22.7%	42	13.1%
<i>maribavir</i>	1,850	1,820	98.4%	0	0.0%	182	9.8%	111	6.0%
<i>pafolacianine</i>	149	149	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>tezepelumab-ekko</i>	139,660	139,625	100.0%	0	0.0%	3,903	2.8%	2,816	2.0%
<i>efgartigimod alfa-fcab</i>	72,976	72,962	100.0%	0	0.0%	726	1.0%	640	0.9%
<i>inclisiran</i>	136,127	136,102	100.0%	0	0.0%	1,324	1.0%	1,109	0.8%

Table 9. Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025^{1,2}

	Censoring Reason								
	End of Exposure Episode ³		Occurrence of User-Defined Censoring Criteria ⁴		Disenrollment ⁵		End of Data ⁶		
Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	
tralokinumab-ldrm	13,095	13,075	99.8%	0	0.0%	1,826	13.9%	1,125	8.6%

¹An episode may be censored due to more than one reason if they occur on the same date. Therefore, the sum of the reasons for censoring may be greater than the total number of episodes.

²All reasons for censoring may not be displayed to prevent publication of small cells.

³Represents episodes censored due to end of the exposure episode. In as-treated analyses, exposure episodes are defined using days supplied as recorded in outpatient pharmacy dispensing records, and episodes end after days supplied are exhausted or a pre-determined maximum episode duration is met. In point exposure analyses, exposure episodes end when a pre-determined maximum episode duration is met.

⁴Represents episodes censored due to occurrence of additional user-defined criteria using drug, procedure, diagnosis, and/or laboratory codes.

⁵Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

⁶Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

⁷N/A: Not Applicable

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	finerenone		fexinidazole		belumosudil		odevixibat	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	266,924,925	N/A ¹	266,924,925	N/A	266,924,925	N/A	266,924,925	N/A
Had required coverage type (medical and/or drug coverage)	199,756,524	67,168,401	199,756,524	67,168,401	199,756,524	67,168,401	199,756,524	67,168,401
Enrolled during specified age range	199,750,838	5,686	199,750,838	5,686	199,750,838	5,686	199,750,838	5,686
Had requestable medical charts	199,750,838	0	199,750,838	0	199,750,838	0	199,750,838	0
Met demographic requirements (sex, race, and Hispanic origin)	199,665,165	85,673	199,665,165	85,673	199,665,165	85,673	199,665,165	85,673
Members with a valid index event								
Had any cohort-defining claim during the query period	*****	*****	0	199,665,165	2,042	199,663,123	*****	*****
Claim recorded during specified age range	76,175	*****	0	0	2,042	0	*****	0
Episode defining index claim recorded during the query period	76,175	0	0	0	2,042	0	*****	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	65,377	10,798	0	0	1,803	239	45	*****
Met inclusion and exclusion criteria	65,377	0	0	0	1,803	0	45	0
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	65,377	0	0	0	1,803	0	45	0
Final cohort								
Number of members	65,377	N/A	0	N/A	1,803	N/A	45	N/A

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	anifrolumab-fnia		avalglucosidase alfa-ngpt		belzutifan		difelikefalin	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	266,924,925	N/A	266,924,925	N/A	266,924,925	N/A	266,924,925	N/A
Had required coverage type (medical and/or drug coverage)	199,756,524	67,168,401	199,756,524	67,168,401	199,756,524	67,168,401	199,756,524	67,168,401
Enrolled during specified age range	199,750,838	5,686	199,750,838	5,686	199,750,838	5,686	199,750,838	5,686
Had requestable medical charts	199,750,838	0	199,750,838	0	199,750,838	0	199,750,838	0
Met demographic requirements (sex, race, and Hispanic origin)	199,665,165	85,673	199,665,165	85,673	199,665,165	85,673	199,665,165	85,673
Members with a valid index event								
Had any cohort-defining claim during the query period	5,061	199,660,104	262	199,664,903	1,904	199,663,261	6,238	199,658,927
Claim recorded during specified age range	5,061	0	262	0	1,904	0	6,238	0
Episode defining index claim recorded during the query period	5,061	0	262	0	1,904	0	6,238	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	4,578	483	243	19	1,686	218	5,528	710
Met inclusion and exclusion criteria	4,578	0	243	0	1,686	0	5,528	0
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	4,578	0	243	0	1,686	0	5,528	0
Final cohort								
Number of members	4,578	N/A	243	N/A	1,686	N/A	5,528	N/A

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	lonapegsomatropin-tcgd		mobocertinib		tisotumab vedotin-tftv		atogepant	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	266,924,925	N/A	266,924,925	N/A	266,924,925	N/A	266,924,925	N/A
Had required coverage type (medical and/or drug coverage)	199,756,524	67,168,401	199,756,524	67,168,401	199,756,524	67,168,401	199,756,524	67,168,401
Enrolled during specified age range	199,750,838	5,686	199,750,838	5,686	199,750,838	5,686	199,750,838	5,686
Had requestable medical charts	199,750,838	0	199,750,838	0	199,750,838	0	199,750,838	0
Met demographic requirements (sex, race, and Hispanic origin)	199,665,165	85,673	199,665,165	85,673	199,665,165	85,673	199,665,165	85,673
Members with a valid index event								
Had any cohort-defining claim during the query period	1,327	199,663,838	178	199,664,987	621	199,664,544	96,735	199,568,430
Claim recorded during specified age range	1,327	0	178	0	621	0	96,735	0
Episode defining index claim recorded during the query period	1,327	0	178	0	621	0	96,735	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	1,164	163	157	21	528	93	81,013	15,722
Met inclusion and exclusion criteria	1,164	0	157	0	528	0	81,013	0
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	1,164	0	157	0	528	0	81,013	0
Final cohort								
Number of members	1,164	N/A	157	N/A	528	N/A	81,013	N/A

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	maralixibat		avacopan		asciminib		ropginterferon alfa-2b-njft	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	266,924,925	N/A	266,924,925	N/A	266,924,925	N/A	266,924,925	N/A
Had required coverage type (medical and/or drug coverage)	199,756,524	67,168,401	199,756,524	67,168,401	199,756,524	67,168,401	199,756,524	67,168,401
Enrolled during specified age range	199,750,838	5,686	199,750,838	5,686	199,750,838	5,686	199,750,838	5,686
Had requestable medical charts	199,750,838	0	199,750,838	0	199,750,838	0	199,750,838	0
Met demographic requirements (sex, race, and Hispanic origin)	199,665,165	85,673	199,665,165	85,673	199,665,165	85,673	199,665,165	85,673
Members with a valid index event								
Had any cohort-defining claim during the query period	85	199,665,080	1,131	199,664,034	1,581	199,663,584	993	199,664,172
Claim recorded during specified age range	85	0	1,131	0	1,581	0	993	0
Episode defining index claim recorded during the query period	85	0	1,131	0	1,581	0	993	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	71	14	970	161	1,358	223	878	115
Met inclusion and exclusion criteria	71	0	970	0	1,358	0	878	0
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	71	0	970	0	1,358	0	878	0
Final cohort								
Number of members	71	N/A	970	N/A	1,358	N/A	878	N/A

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	vosoritide		maribavir		pafolacianine		tezepelumab-ekko	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	266,924,925	N/A	266,924,925	N/A	266,924,925	N/A	266,924,925	N/A
Had required coverage type (medical and/or drug coverage)	199,756,524	67,168,401	199,756,524	67,168,401	199,756,524	67,168,401	199,756,524	67,168,401
Enrolled during specified age range	199,750,838	5,686	199,750,838	5,686	199,750,838	5,686	199,750,838	5,686
Had requestable medical charts	199,750,838	0	199,750,838	0	199,750,838	0	199,750,838	0
Met demographic requirements (sex, race, and Hispanic origin)	199,665,165	85,673	199,665,165	85,673	199,665,165	85,673	199,665,165	85,673
Members with a valid index event								
Had any cohort-defining claim during the query period	120	199,665,045	1,161	199,664,004	162	199,665,003	19,145	199,646,020
Claim recorded during specified age range	120	0	1,161	0	162	0	19,145	0
Episode defining index claim recorded during the query period	120	0	1,161	0	162	0	19,145	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	94	26	1,030	131	148	14	17,346	1,799
Met inclusion and exclusion criteria	94	0	1,030	0	148	0	17,346	0
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	94	0	1,030	0	148	0	17,346	0
Final cohort								
Number of members	94	N/A	1,030	N/A	148	N/A	17,346	N/A


Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

	efgartigimod alfa-fcab		inclisiran		tralokinumab-Idrm	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements						
Enrolled at any point during the query period	266,924,925	N/A	266,924,925	N/A	266,924,925	N/A
Had required coverage type (medical and/or drug coverage)	199,756,524	67,168,401	199,756,524	67,168,401	199,756,524	67,168,401
Enrolled during specified age range	199,750,838	5,686	199,750,838	5,686	199,750,838	5,686
Had requestable medical charts	199,750,838	0	199,750,838	0	199,750,838	0
Met demographic requirements (sex, race, and Hispanic origin)	199,665,165	85,673	199,665,165	85,673	199,665,165	85,673
Members with a valid index event						
Had any cohort-defining claim during the query period	5,457	199,659,708	57,219	199,607,946	5,703	199,659,462
Claim recorded during specified age range	5,457	0	57,219	0	5,703	0
Episode defining index claim recorded during the query period	5,457	0	57,219	0	5,703	0
Members with required pre-index history						
Had sufficient pre-index continuous enrollment	5,101	356	55,123	2,096	4,960	743
Met inclusion and exclusion criteria	5,101	0	55,123	0	4,960	0
Members with required post-index follow-up						
Had sufficient post-index continuous enrollment	5,101	0	55,123	0	4,960	0
Final cohort						
Number of members	5,101	N/A	55,123	N/A	4,960	N/A

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

¹N/A: Not Applicable


Figure 1a. Patient Entry into Study by Month for finerenone in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025



*The FDA approval date for this drug was on July 9, 2021, as listed on the FDA website:

<https://web.archive.org/web/20240430031329/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021>

Figure 1b. Patient Entry into Study by Month for fexinidazole¹ in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025



*The FDA approval date for this drug was on July 16, 2021, as listed on the FDA website:

<https://web.archive.org/web/20240430031329/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021>

¹There was no use during the query period.

Figure 1c. Patient Entry into Study by Month for belumosudil in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

*The FDA approval date for this drug was on July 16, 2021, as listed on the FDA website:

<https://web.archive.org/web/20240430031329/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021>

*****Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1d. Patient Entry into Study by Month for odevixibat in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

*The FDA approval date for this drug was on July 20, 2021, as listed on the FDA website:

<https://web.archive.org/web/20240430031329/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021>

*****Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1e. Patient Entry into Study by Month for anifrolumab-fnia in the Sentinel Distributed Database from January 1, 2021 to April 30,2025

*The FDA approval date for this drug was on July 30, 2021, as listed on the FDA website:

<https://web.archive.org/web/20240430031329/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021>

*****Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1f. Patient Entry into Study by Month for avalglucosidase alfa-ngpt in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

*The FDA approval date for this drug was on August 6, 2021, as listed on the FDA website:

<https://web.archive.org/web/20240430031329/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021>

****Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.


Figure 1g. Patient Entry into Study by Month for belzutifan in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

*The FDA approval date for this drug was on August 13, 2021, as listed on the FDA website:

<https://web.archive.org/web/20240430031329/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021>

*****Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1h. Patient Entry into Study by Month for difelikefalin in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025



*The FDA approval date for this drug was on August 23, 2021, as listed on the FDA website:

<https://web.archive.org/web/20240430031329/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021>

Figure 1i. Patient Entry into Study by Month for I onapegsomatropin-tcgd in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

*The FDA approval date for this drug was on August 25, 2021, as listed on the FDA website:

<https://web.archive.org/web/20240430031329/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021>

*****Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1j. Patient Entry into Study by Month for mobocertinib in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

*The FDA approval date for this drug was on September 15, 2021, as listed on the FDA website:

<https://web.archive.org/web/20240430031329/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021>

*****Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.


Figure 1k. Patient Entry into Study by Month for tisotumab vedotin-tftv in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

*The FDA approval date for this drug was on September 20, 2021, as listed on the FDA website:

<https://web.archive.org/web/20240430031329/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021>

*****Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1l. Patient Entry into Study by Month for atogepant in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025



*The FDA approval date for this drug was on September 28, 2021, as listed on the FDA website:

<https://web.archive.org/web/20240430031329/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021>

Figure 1m. Patient Entry into Study by Month for maralixibat in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

*The FDA approval date for this drug was on September 29, 2021, as listed on the FDA website:

<https://web.archive.org/web/20240430031329/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021>

*****Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.


Figure 1n. Patient Entry into Study by Month for avacopan in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

*The FDA approval date for this drug was on October 7, 2021, as listed on the FDA website:

<https://web.archive.org/web/20240430031329/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021>

*****Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1o. Patient Entry into Study by Month for asciminib in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025



*The FDA approval date for this drug was on October 29, 2021, as listed on the FDA website:
<https://web.archive.org/web/20240430031329/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021>

Figure 1p. Patient Entry into Study by Month for ropeginterferon alfa-2b-njft in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

*The FDA approval date for this drug was on November 12, 2021, as listed on the FDA website:

<https://web.archive.org/web/20240430031329/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021>

*****Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1q. Patient Entry into Study by Month for vosoritide in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

*The FDA approval date for this drug was on November 19, 2021, as listed on the FDA website:

<https://web.archive.org/web/20240430031329/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021>

*****Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Figure 1r. Patient Entry into Study by Month for maribavir in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

*The FDA approval date for this drug was on November 23, 2021, as listed on the FDA website:

<https://web.archive.org/web/20240430031329/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021>

*****Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.


Figure 1s. Patient Entry into Study by Month for pafolacianine in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025

*The FDA approval date for this drug was on November 29, 2021, as listed on the FDA website:

<https://web.archive.org/web/20240430031329/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021>

*****Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.


Figure 1t. Patient Entry into Study by Month for tezepelumab-ekko in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025



*The FDA approval date for this drug was on December 17, 2021, as listed on the FDA website:


<https://web.archive.org/web/20240430031329/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021>

Figure 1u. Patient Entry into Study by Month for efgartigimod alfa-fcab in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025



*The FDA approval date for this drug was on December 17, 2021, as listed on the FDA website:
<https://web.archive.org/web/20240430031329/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021>

Figure 1v. Patient Entry into Study by Month for inclisiran in the Sentinel Distributed Database from January 1, 2021 to April 30, 2025



*The FDA approval date for this drug was on December 22, 2021, as listed on the FDA website:

<https://web.archive.org/web/20240430031329/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021>

Figure 1w. Patient Entry into Study by Month for tralokinumab-Idrm in the Sentinel Distributed Database from January 1, 2021 to April 30,2025

*The FDA approval date for this drug was on December 27, 2021, as listed on the FDA website:

<https://web.archive.org/web/20240430031329/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021>

*****Data are not presented due to a small sample size or to ensure a small data point cannot be recalculated through the data presented.

Appendix A. Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date

Masked DP ID	DP Start Date	DP End Date ¹
DP01	01/01/2000	01/31/2024
DP02	01/01/2000	01/31/2024
DP03	01/01/2008	12/31/2024
DP04	01/01/2006	01/31/2025
DP05	01/01/2005	07/31/2022
DP06	01/01/2000	04/30/2025
DP07	01/01/2004	03/31/2024
DP08	01/01/2000	04/30/2024
DP09	01/01/2007	10/31/2024
DP10	01/01/2000	04/30/2024
DP11	01/01/2014	12/31/2021
DP12	01/01/2008	03/31/2025
DP13	01/01/2010	12/31/2024

¹End Date represents the earliest of: (1) query end date, or (2) last day of the most recent month for which all of a Data Partner's data tables (enrollment, dispensing, etc.) have at least 80% of the record count relative to the prior month.

Appendix B. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposures in this Request

Non-Proprietary Name	Proprietary Name
finerenone	
finerenone	Kerendia
fexinidazole	
fexinidazole	Fexinidazole
belumosudil	
BELUMOSUDIL	Rezurock
belumosudil mesylate	Rezurock
odevixibat	
odevixibat	Bylvay
anifrolumab-fnia	
anifrolumab-fnia	Saphnelo
avalglucosidase alfa-ngpt	
avalglucosidase alfa-ngpt	Nexviazyme
belzutifan	
belzutifan	Welireg
difelikefalin	
difelikefalin acetate	Korsuva
lonapegsomatropin-tcgd	
lonapegsomatropin-tcgd	Skytrofa
mobocertinib	
mobocertinib succinate	Exkivity
tisotumab vedotin-tftv	
tisotumab vedotin-tftv	Tivdak
atogepant	
atogepant	Quipta
maralixibat	
maralixibat chloride	Livmarli
avacopan	
avacopan	Tavneos
asciminib	
asciminib hydrochloride	Scemblix
ropginterferon alfa-2b-njft	
ropginterferon alfa-2b-njft	Besremi
vosoritide	
vosoritide	Voxzogo
maribavir	
maribavir	Livtency
pafolacianine	

Appendix B. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposures in this Request

Non-Proprietary Name	Proprietary Name
pafolacianine sodium	Cytalux
tezepelumab-ekko	
tezepelumab-ekko	Tezspire
efgartigimod alfa-fcab	
efgartigimod alfa and hyaluronidase (human recombinant)	VYVGART Hytrulo
efgartigimod alfa-fcab	Vyvgart
inclisiran	
inclisiran sodium	Leqvio
tralokinumab-ldrm	
tralokinumab-ldrm	Adbry

Appendix C. List of Healthcare Common Procedure Coding System, Level II (HCPCS) and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exposures in this Request

Code	Description	Code Category	Code Type
anifrolumab-fnia			
C9086	Injection, anifrolumab-fnia, 1 mg	Procedure	HCPCS
J0491	Injection, anifrolumab-fnia, 1 mg	Procedure	HCPCS
avalglucosidase alfa-ngpt			
C9085	Injection, avalglucosidase alfa-ngpt, 4 mg	Procedure	HCPCS
J0219	Injection, avalglucosidase alfa-ngpt, 4 mg	Procedure	HCPCS
difelikefalin			
J0879	Injection, difelikefalin, 0.1 mcg, (for ESRD on dialysis)	Procedure	HCPCS
tisotumab vedotin-tftv			
J9273	Injection, tisotumab vedotin-tftv, 1 mg	Procedure	HCPCS
maribavir			
XW0DX38	Introduction of Maribavir Anti-infective into Mouth and Pharynx, External Approach, New Technology Group 8	Procedure	ICD-10-PCS
XW0G738	Introduction of Maribavir Anti-infective into Upper GI, Via Natural or Artificial Opening, New Technology Group 8	Procedure	ICD-10-PCS
XW0H738	Introduction of Maribavir Anti-infective into Lower GI, Via Natural or Artificial Opening, New Technology Group 8	Procedure	ICD-10-PCS
pafolacianine			
8EOUOEN	Fluorescence Guided Procedure of Female Reproductive System using Pafolacianine, Open Approach	Procedure	ICD-10-PCS
8EOU3EN	Fluorescence Guided Procedure of Female Reproductive System using Pafolacianine, Percutaneous Approach	Procedure	ICD-10-PCS
8EOU4EN	Fluorescence Guided Procedure of Female Reproductive System using Pafolacianine, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
8EOU7EN	Fluorescence Guided Procedure of Female Reproductive System using Pafolacianine, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
8EOU8EN	Fluorescence Guided Procedure of Female Reproductive System using Pafolacianine, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
8EOWOEN	Fluorescence Guided Procedure of Trunk Region using Pafolacianine, Open Approach	Procedure	ICD-10-PCS
8EOW3EN	Fluorescence Guided Procedure of Trunk Region using Pafolacianine, Percutaneous Approach	Procedure	ICD-10-PCS
8EOW4EN	Fluorescence Guided Procedure of Trunk Region using Pafolacianine, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
8EOW7EN	Fluorescence Guided Procedure of Trunk Region using Pafolacianine, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
8EOW8EN	Fluorescence Guided Procedure of Trunk Region using Pafolacianine, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
A9603	Injection, pafolacianine, 0.1 mg	Procedure	HCPCS
tezepelumab-ekko			
J2356	Injection, tezepelumab-ekko, 1 mg	Procedure	HCPCS
efgartigimod alfa-fcab			
J9332	Injection, efgartigimod alfa-fcab, 2 mg	Procedure	HCPCS
J9334	Injection, efgartigimod alfa, 2 mg and hyaluronidase-qvfc	Procedure	HCPCS
inclisiran			

Appendix C. List of Healthcare Common Procedure Coding System, Level II (HCPCS) and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exposures in this Request

Code	Description	Code Category	Code Type
J1306	Injection, inclisiran, 1 mg	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
Acquired Hypothyroidism			
E00.0	Congenital iodine-deficiency syndrome, neurological type	Diagnosis	ICD-10-CM
E00.1	Congenital iodine-deficiency syndrome, myxedematous type	Diagnosis	ICD-10-CM
E00.2	Congenital iodine-deficiency syndrome, mixed type	Diagnosis	ICD-10-CM
E00.9	Congenital iodine-deficiency syndrome, unspecified	Diagnosis	ICD-10-CM
E01.8	Other iodine-deficiency related thyroid disorders and allied conditions	Diagnosis	ICD-10-CM
E02	Subclinical iodine-deficiency hypothyroidism	Diagnosis	ICD-10-CM
E03.0	Congenital hypothyroidism with diffuse goiter	Diagnosis	ICD-10-CM
E03.1	Congenital hypothyroidism without goiter	Diagnosis	ICD-10-CM
E03.2	Hypothyroidism due to medicaments and other exogenous substances	Diagnosis	ICD-10-CM
E03.3	Postinfectious hypothyroidism	Diagnosis	ICD-10-CM
E03.4	Atrophy of thyroid (acquired)	Diagnosis	ICD-10-CM
E03.8	Other specified hypothyroidism	Diagnosis	ICD-10-CM
E03.9	Hypothyroidism, unspecified	Diagnosis	ICD-10-CM
E89.0	Postprocedural hypothyroidism	Diagnosis	ICD-10-CM
Alcohol Abuse			
F10.10	Alcohol abuse, uncomplicated	Diagnosis	ICD-10-CM
F10.11	Alcohol abuse, in remission	Diagnosis	ICD-10-CM
F10.120	Alcohol abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.121	Alcohol abuse with intoxication delirium	Diagnosis	ICD-10-CM
F10.129	Alcohol abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.130	Alcohol abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.131	Alcohol abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F10.132	Alcohol abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.139	Alcohol abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.14	Alcohol abuse with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.150	Alcohol abuse with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.151	Alcohol abuse with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.159	Alcohol abuse with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.180	Alcohol abuse with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.181	Alcohol abuse with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.182	Alcohol abuse with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.188	Alcohol abuse with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.19	Alcohol abuse with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.20	Alcohol dependence, uncomplicated	Diagnosis	ICD-10-CM
F10.21	Alcohol dependence, in remission	Diagnosis	ICD-10-CM
F10.220	Alcohol dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.221	Alcohol dependence with intoxication delirium	Diagnosis	ICD-10-CM
F10.229	Alcohol dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.230	Alcohol dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.231	Alcohol dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F10.232	Alcohol dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.239	Alcohol dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.24	Alcohol dependence with alcohol-induced mood disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
F10.250	Alcohol dependence with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.251	Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.259	Alcohol dependence with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.26	Alcohol dependence with alcohol-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F10.27	Alcohol dependence with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.280	Alcohol dependence with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.281	Alcohol dependence with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.282	Alcohol dependence with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.288	Alcohol dependence with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.29	Alcohol dependence with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.920	Alcohol use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.921	Alcohol use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F10.929	Alcohol use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.930	Alcohol use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.931	Alcohol use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F10.932	Alcohol use, unspecified with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.939	Alcohol use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.94	Alcohol use, unspecified with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.950	Alcohol use, unspecified with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.951	Alcohol use, unspecified with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.959	Alcohol use, unspecified with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.96	Alcohol use, unspecified with alcohol-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F10.97	Alcohol use, unspecified with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.980	Alcohol use, unspecified with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.981	Alcohol use, unspecified with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.982	Alcohol use, unspecified with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.988	Alcohol use, unspecified with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.99	Alcohol use, unspecified with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
G62.1	Alcoholic polyneuropathy	Diagnosis	ICD-10-CM
HZ2ZZZZ	Detoxification Services for Substance Abuse Treatment	Procedure	ICD-10-PCS
HZ30ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ31ZZZ	Individual Counseling for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ32ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ33ZZZ	Individual Counseling for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ34ZZZ	Individual Counseling for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ35ZZZ	Individual Counseling for Substance Abuse Treatment, Vocational	Procedure	ICD-10-PCS
HZ36ZZZ	Individual Counseling for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
	Individual Counseling for Substance Abuse Treatment, Motivational		
HZ37ZZZ	Enhancement	Procedure	ICD-10-PCS
HZ38ZZZ	Individual Counseling for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ39ZZZ	Individual Counseling for Substance Abuse Treatment, Continuing Care	Procedure	ICD-10-PCS
HZ3BZZZ	Individual Counseling for Substance Abuse Treatment, Spiritual	Procedure	ICD-10-PCS
HZ40ZZZ	Group Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ93ZZZ	Pharmacotherapy for Substance Abuse Treatment, Antabuse	Procedure	ICD-10-PCS
HZ96ZZZ	Pharmacotherapy for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
I42.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
K29.20	Alcoholic gastritis without bleeding	Diagnosis	ICD-10-CM
K29.21	Alcoholic gastritis with bleeding	Diagnosis	ICD-10-CM
K70.0	Alcoholic fatty liver	Diagnosis	ICD-10-CM
K70.10	Alcoholic hepatitis without ascites	Diagnosis	ICD-10-CM
K70.11	Alcoholic hepatitis with ascites	Diagnosis	ICD-10-CM
K70.2	Alcoholic fibrosis and sclerosis of liver	Diagnosis	ICD-10-CM
K70.30	Alcoholic cirrhosis of liver without ascites	Diagnosis	ICD-10-CM
K70.31	Alcoholic cirrhosis of liver with ascites	Diagnosis	ICD-10-CM
K70.40	Alcoholic hepatic failure without coma	Diagnosis	ICD-10-CM
K70.41	Alcoholic hepatic failure with coma	Diagnosis	ICD-10-CM
K70.9	Alcoholic liver disease, unspecified	Diagnosis	ICD-10-CM
R78.0	Finding of alcohol in blood	Diagnosis	ICD-10-CM
T51.0X1A	Toxic effect of ethanol, accidental (unintentional), initial encounter	Procedure	ICD-10-PCS
T51.0X2A	Toxic effect of ethanol, intentional self-harm, initial encounter	Procedure	ICD-10-PCS
T51.0X3A	Toxic effect of ethanol, assault, initial encounter	Procedure	ICD-10-PCS
T51.0X4A	Toxic effect of ethanol, undetermined, initial encounter	Procedure	ICD-10-PCS
Z65.8	Other specified problems related to psychosocial circumstances	Diagnosis	ICD-10-CM
Z71.41	Alcohol abuse counseling and surveillance of alcoholic	Diagnosis	ICD-10-CM
Alzheimers			
G30.0	Alzheimer's disease with early onset	Diagnosis	ICD-10-CM
G30.1	Alzheimer's disease with late onset	Diagnosis	ICD-10-CM
G30.8	Other Alzheimer's disease	Diagnosis	ICD-10-CM
G30.9	Alzheimer's disease, unspecified	Diagnosis	ICD-10-CM
Acute Myocardial Infraction			
I21.01	ST elevation (STEMI) myocardial infarction involving left main coronary artery	Diagnosis	ICD-10-CM
I21.02	ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery	Diagnosis	ICD-10-CM
I21.09	ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall	Diagnosis	ICD-10-CM
I21.11	ST elevation (STEMI) myocardial infarction involving right coronary artery	Diagnosis	ICD-10-CM
I21.19	ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall	Diagnosis	ICD-10-CM
I21.21	ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I21.29	ST elevation (STEMI) myocardial infarction involving other sites	Diagnosis	ICD-10-CM
I21.3	ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I21.4	Non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I21.9	Acute myocardial infarction, unspecified	Diagnosis	ICD-10-CM
I21.A1	Myocardial infarction type 2	Diagnosis	ICD-10-CM
I21.A9	Other myocardial infarction type	Diagnosis	ICD-10-CM
I21.B	Myocardial infarction with coronary microvascular dysfunction	Diagnosis	ICD-10-CM
I22.0	Subsequent ST elevation (STEMI) myocardial infarction of anterior wall	Diagnosis	ICD-10-CM
I22.1	Subsequent ST elevation (STEMI) myocardial infarction of inferior wall	Diagnosis	ICD-10-CM
I22.2	Subsequent non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I22.8	Subsequent ST elevation (STEMI) myocardial infarction of other sites	Diagnosis	ICD-10-CM
I22.9	Subsequent ST elevation (STEMI) myocardial infarction of unspecified site Hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.0	Atrial septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.1	Ventricular septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.2	Rupture of cardiac wall without hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.3	Rupture of chordae tendineae as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.4	Rupture of papillary muscle as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.5	Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.6	Postinfarction angina	Diagnosis	ICD-10-CM
I23.7	Other current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
Anemia			
C94.6	Myelodysplastic disease, not elsewhere classified	Diagnosis	ICD-10-CM
D46.0	Refractory anemia without ring sideroblasts, so stated	Diagnosis	ICD-10-CM
D46.1	Refractory anemia with ring sideroblasts	Diagnosis	ICD-10-CM
D46.20	Refractory anemia with excess of blasts, unspecified	Diagnosis	ICD-10-CM
D46.21	Refractory anemia with excess of blasts 1	Diagnosis	ICD-10-CM
D46.22	Refractory anemia with excess of blasts 2	Diagnosis	ICD-10-CM
D46.4	Refractory anemia, unspecified	Diagnosis	ICD-10-CM
D46.9	Myelodysplastic syndrome, unspecified	Diagnosis	ICD-10-CM
D46.A	Refractory cytopenia with multilineage dysplasia	Diagnosis	ICD-10-CM
D46.B	Refractory cytopenia with multilineage dysplasia and ring sideroblasts	Diagnosis	ICD-10-CM
D46.C	Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality	Diagnosis	ICD-10-CM
D46.Z	Other myelodysplastic syndromes	Diagnosis	ICD-10-CM
D47.4	Osteomyelofibrosis	Diagnosis	ICD-10-CM
D50.0	Iron deficiency anemia secondary to blood loss (chronic)	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
D50.1	Sideropenic dysphagia	Diagnosis	ICD-10-CM
D50.8	Other iron deficiency anemias	Diagnosis	ICD-10-CM
D50.9	Iron deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D51.0	Vitamin B12 deficiency anemia due to intrinsic factor deficiency	Diagnosis	ICD-10-CM
	Vitamin B12 deficiency anemia due to selective vitamin B12 malabsorption		
D51.1	with proteinuria	Diagnosis	ICD-10-CM
D51.2	Transcobalamin II deficiency	Diagnosis	ICD-10-CM
D51.3	Other dietary vitamin B12 deficiency anemia	Diagnosis	ICD-10-CM
D51.8	Other vitamin B12 deficiency anemias	Diagnosis	ICD-10-CM
D51.9	Vitamin B12 deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D52.0	Dietary folate deficiency anemia	Diagnosis	ICD-10-CM
D52.1	Drug-induced folate deficiency anemia	Diagnosis	ICD-10-CM
D52.8	Other folate deficiency anemias	Diagnosis	ICD-10-CM
D52.9	Folate deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D53.0	Protein deficiency anemia	Diagnosis	ICD-10-CM
D53.1	Other megaloblastic anemias, not elsewhere classified	Diagnosis	ICD-10-CM
D53.2	Scorbutic anemia	Diagnosis	ICD-10-CM
D53.8	Other specified nutritional anemias	Diagnosis	ICD-10-CM
D53.9	Nutritional anemia, unspecified	Diagnosis	ICD-10-CM
D55.0	Anemia due to glucose-6-phosphate dehydrogenase [G6PD] deficiency	Diagnosis	ICD-10-CM
D55.1	Anemia due to other disorders of glutathione metabolism	Diagnosis	ICD-10-CM
D55.2	Anemia due to disorders of glycolytic enzymes	Diagnosis	ICD-10-CM
D55.21	Anemia due to pyruvate kinase deficiency	Diagnosis	ICD-10-CM
D55.29	Anemia due to other disorders of glycolytic enzymes	Diagnosis	ICD-10-CM
D55.3	Anemia due to disorders of nucleotide metabolism	Diagnosis	ICD-10-CM
D55.8	Other anemias due to enzyme disorders	Diagnosis	ICD-10-CM
D55.9	Anemia due to enzyme disorder, unspecified	Diagnosis	ICD-10-CM
D56.0	Alpha thalassemia	Diagnosis	ICD-10-CM
D56.1	Beta thalassemia	Diagnosis	ICD-10-CM
D56.2	Delta-beta thalassemia	Diagnosis	ICD-10-CM
D56.3	Thalassemia minor	Diagnosis	ICD-10-CM
D56.4	Hereditary persistence of fetal hemoglobin [HPFH]	Diagnosis	ICD-10-CM
D56.5	Hemoglobin E-beta thalassemia	Diagnosis	ICD-10-CM
D56.8	Other thalassemias	Diagnosis	ICD-10-CM
D56.9	Thalassemia, unspecified	Diagnosis	ICD-10-CM
D57.00	Hb-SS disease with crisis, unspecified	Diagnosis	ICD-10-CM
D57.01	Hb-SS disease with acute chest syndrome	Diagnosis	ICD-10-CM
D57.02	Hb-SS disease with splenic sequestration	Diagnosis	ICD-10-CM
D57.03	Hb-SS disease with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.04	Hb-SS disease with dactylitis	Diagnosis	ICD-10-CM
D57.09	Hb-SS disease with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.1	Sickle-cell disease without crisis	Diagnosis	ICD-10-CM
D57.20	Sickle-cell/Hb-C disease without crisis	Diagnosis	ICD-10-CM
D57.211	Sickle-cell/Hb-C disease with acute chest syndrome	Diagnosis	ICD-10-CM
D57.212	Sickle-cell/Hb-C disease with splenic sequestration	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPGS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
D57.213	Sickle-cell/Hb-C disease with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.214	Sickle-cell/Hb-C disease with dactylitis	Diagnosis	ICD-10-CM
D57.218	Sickle-cell/Hb-C disease with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.219	Sickle-cell/Hb-C disease with crisis, unspecified	Diagnosis	ICD-10-CM
D57.3	Sickle-cell trait	Diagnosis	ICD-10-CM
D57.40	Sickle-cell thalassemia without crisis	Diagnosis	ICD-10-CM
D57.411	Sickle-cell thalassemia, unspecified, with acute chest syndrome	Diagnosis	ICD-10-CM
D57.412	Sickle-cell thalassemia, unspecified, with splenic sequestration	Diagnosis	ICD-10-CM
D57.413	Sickle-cell thalassemia, unspecified, with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.414	Sickle-cell thalassemia, unspecified, with dactylitis	Diagnosis	ICD-10-CM
	Sickle-cell thalassemia, unspecified, with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.418	Sickle-cell thalassemia, unspecified, with crisis	Diagnosis	ICD-10-CM
D57.42	Sickle-cell thalassemia beta zero without crisis	Diagnosis	ICD-10-CM
D57.431	Sickle-cell thalassemia beta zero with acute chest syndrome	Diagnosis	ICD-10-CM
D57.432	Sickle-cell thalassemia beta zero with splenic sequestration	Diagnosis	ICD-10-CM
D57.433	Sickle-cell thalassemia beta zero with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.434	Sickle-cell thalassemia beta zero with dactylitis	Diagnosis	ICD-10-CM
	Sickle-cell thalassemia beta zero with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.439	Sickle-cell thalassemia beta zero with crisis, unspecified	Diagnosis	ICD-10-CM
D57.44	Sickle-cell thalassemia beta plus without crisis	Diagnosis	ICD-10-CM
D57.451	Sickle-cell thalassemia beta plus with acute chest syndrome	Diagnosis	ICD-10-CM
D57.452	Sickle-cell thalassemia beta plus with splenic sequestration	Diagnosis	ICD-10-CM
D57.453	Sickle-cell thalassemia beta plus with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.454	Sickle-cell thalassemia beta plus with dactylitis	Diagnosis	ICD-10-CM
	Sickle-cell thalassemia beta plus with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.459	Sickle-cell thalassemia beta plus with crisis, unspecified	Diagnosis	ICD-10-CM
D57.80	Other sickle-cell disorders without crisis	Diagnosis	ICD-10-CM
D57.811	Other sickle-cell disorders with acute chest syndrome	Diagnosis	ICD-10-CM
D57.812	Other sickle-cell disorders with splenic sequestration	Diagnosis	ICD-10-CM
D57.813	Other sickle-cell disorders with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.814	Other sickle-cell disorders with dactylitis	Diagnosis	ICD-10-CM
D57.818	Other sickle-cell disorders with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.819	Other sickle-cell disorders with crisis, unspecified	Diagnosis	ICD-10-CM
D58.0	Hereditary spherocytosis	Diagnosis	ICD-10-CM
D58.1	Hereditary elliptocytosis	Diagnosis	ICD-10-CM
D58.2	Other hemoglobinopathies	Diagnosis	ICD-10-CM
D58.8	Other specified hereditary hemolytic anemias	Diagnosis	ICD-10-CM
D58.9	Hereditary hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D59.0	Drug-induced autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.1	Other autoimmune hemolytic anemias	Diagnosis	ICD-10-CM
D59.10	Autoimmune hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D59.11	Warm autoimmune hemolytic anemia	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
D59.12	Cold autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.13	Mixed type autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.19	Other autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.2	Drug-induced nonautoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.3	Hemolytic-uremic syndrome	Diagnosis	ICD-10-CM
D59.30	Hemolytic-uremic syndrome, unspecified	Diagnosis	ICD-10-CM
D59.31	Infection-associated hemolytic-uremic syndrome	Diagnosis	ICD-10-CM
D59.32	Hereditary hemolytic-uremic syndrome	Diagnosis	ICD-10-CM
D59.39	Other hemolytic-uremic syndrome	Diagnosis	ICD-10-CM
D59.4	Other nonautoimmune hemolytic anemias	Diagnosis	ICD-10-CM
D59.5	Paroxysmal nocturnal hemoglobinuria [Marchiafava-Micheli]	Diagnosis	ICD-10-CM
D59.6	Hemoglobinuria due to hemolysis from other external causes	Diagnosis	ICD-10-CM
D59.8	Other acquired hemolytic anemias	Diagnosis	ICD-10-CM
D59.9	Acquired hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D60.0	Chronic acquired pure red cell aplasia	Diagnosis	ICD-10-CM
D60.1	Transient acquired pure red cell aplasia	Diagnosis	ICD-10-CM
D60.8	Other acquired pure red cell aplasias	Diagnosis	ICD-10-CM
D60.9	Acquired pure red cell aplasia, unspecified	Diagnosis	ICD-10-CM
D61.01	Constitutional (pure) red blood cell aplasia	Diagnosis	ICD-10-CM
D61.02	Shwachman-Diamond syndrome	Diagnosis	ICD-10-CM
D61.09	Other constitutional aplastic anemia	Diagnosis	ICD-10-CM
D61.1	Drug-induced aplastic anemia	Diagnosis	ICD-10-CM
D61.2	Aplastic anemia due to other external agents	Diagnosis	ICD-10-CM
D61.3	Idiopathic aplastic anemia	Diagnosis	ICD-10-CM
D61.810	Antineoplastic chemotherapy induced pancytopenia	Diagnosis	ICD-10-CM
D61.811	Other drug-induced pancytopenia	Diagnosis	ICD-10-CM
D61.818	Other pancytopenia	Diagnosis	ICD-10-CM
D61.82	Myelophthisis	Diagnosis	ICD-10-CM
D61.89	Other specified aplastic anemias and other bone marrow failure syndromes	Diagnosis	ICD-10-CM
D61.9	Aplastic anemia, unspecified	Diagnosis	ICD-10-CM
D63.0	Anemia in neoplastic disease	Diagnosis	ICD-10-CM
D63.1	Anemia in chronic kidney disease	Diagnosis	ICD-10-CM
D63.8	Anemia in other chronic diseases classified elsewhere	Diagnosis	ICD-10-CM
D64.0	Hereditary sideroblastic anemia	Diagnosis	ICD-10-CM
D64.1	Secondary sideroblastic anemia due to disease	Diagnosis	ICD-10-CM
D64.2	Secondary sideroblastic anemia due to drugs and toxins	Diagnosis	ICD-10-CM
D64.3	Other sideroblastic anemias	Diagnosis	ICD-10-CM
D64.4	Congenital dyserythropoietic anemia	Diagnosis	ICD-10-CM
D64.81	Anemia due to antineoplastic chemotherapy	Diagnosis	ICD-10-CM
D64.89	Other specified anemias	Diagnosis	ICD-10-CM
D64.9	Anemia, unspecified	Diagnosis	ICD-10-CM
D75.81	Myelofibrosis	Diagnosis	ICD-10-CM
Asthma			
J45.20	Mild intermittent asthma, uncomplicated	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
J45.21	Mild intermittent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.22	Mild intermittent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.30	Mild persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.31	Mild persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.32	Mild persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.40	Moderate persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.41	Moderate persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.42	Moderate persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.50	Severe persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.51	Severe persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.52	Severe persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.901	Unspecified asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.902	Unspecified asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.909	Unspecified asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.990	Exercise induced bronchospasm	Diagnosis	ICD-10-CM
J45.991	Cough variant asthma	Diagnosis	ICD-10-CM
J45.998	Other asthma	Diagnosis	ICD-10-CM
Atrial Fibrillation			
I48.0	Paroxysmal atrial fibrillation	Diagnosis	ICD-10-CM
I48.1	Persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.11	Longstanding persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.19	Other persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.2	Chronic atrial fibrillation	Diagnosis	ICD-10-CM
I48.20	Chronic atrial fibrillation, unspecified	Diagnosis	ICD-10-CM
I48.21	Permanent atrial fibrillation	Diagnosis	ICD-10-CM
I48.3	Typical atrial flutter	Diagnosis	ICD-10-CM
I48.4	Atypical atrial flutter	Diagnosis	ICD-10-CM
I48.91	Unspecified atrial fibrillation	Diagnosis	ICD-10-CM
Benign Prostatic Hyperplasia			
N40.0	Benign prostatic hyperplasia without lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.1	Benign prostatic hyperplasia with lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.2	Nodular prostate without lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.3	Nodular prostate with lower urinary tract symptoms	Diagnosis	ICD-10-CM
Breast Cancer			
C50.011	Malignant neoplasm of nipple and areola, right female breast	Diagnosis	ICD-10-CM
C50.012	Malignant neoplasm of nipple and areola, left female breast	Diagnosis	ICD-10-CM
C50.019	Malignant neoplasm of nipple and areola, unspecified female breast	Diagnosis	ICD-10-CM
C50.021	Malignant neoplasm of nipple and areola, right male breast	Diagnosis	ICD-10-CM
C50.022	Malignant neoplasm of nipple and areola, left male breast	Diagnosis	ICD-10-CM
C50.029	Malignant neoplasm of nipple and areola, unspecified male breast	Diagnosis	ICD-10-CM
C50.111	Malignant neoplasm of central portion of right female breast	Diagnosis	ICD-10-CM
C50.112	Malignant neoplasm of central portion of left female breast	Diagnosis	ICD-10-CM
C50.119	Malignant neoplasm of central portion of unspecified female breast	Diagnosis	ICD-10-CM
C50.121	Malignant neoplasm of central portion of right male breast	Diagnosis	ICD-10-CM
C50.122	Malignant neoplasm of central portion of left male breast	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPGS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
C50.129	Malignant neoplasm of central portion of unspecified male breast	Diagnosis	ICD-10-CM
C50.211	Malignant neoplasm of upper-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.212	Malignant neoplasm of upper-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.219	Malignant neoplasm of upper-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.221	Malignant neoplasm of upper-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.222	Malignant neoplasm of upper-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.229	Malignant neoplasm of upper-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.311	Malignant neoplasm of lower-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.312	Malignant neoplasm of lower-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.319	Malignant neoplasm of lower-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.321	Malignant neoplasm of lower-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.322	Malignant neoplasm of lower-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.329	Malignant neoplasm of lower-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.411	Malignant neoplasm of upper-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.412	Malignant neoplasm of upper-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.419	Malignant neoplasm of upper-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.421	Malignant neoplasm of upper-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.422	Malignant neoplasm of upper-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.429	Malignant neoplasm of upper-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.511	Malignant neoplasm of lower-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.512	Malignant neoplasm of lower-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.519	Malignant neoplasm of lower-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.521	Malignant neoplasm of lower-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.522	Malignant neoplasm of lower-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.529	Malignant neoplasm of lower-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.611	Malignant neoplasm of axillary tail of right female breast	Diagnosis	ICD-10-CM
C50.612	Malignant neoplasm of axillary tail of left female breast	Diagnosis	ICD-10-CM
C50.619	Malignant neoplasm of axillary tail of unspecified female breast	Diagnosis	ICD-10-CM
C50.621	Malignant neoplasm of axillary tail of right male breast	Diagnosis	ICD-10-CM
C50.622	Malignant neoplasm of axillary tail of left male breast	Diagnosis	ICD-10-CM
C50.629	Malignant neoplasm of axillary tail of unspecified male breast	Diagnosis	ICD-10-CM
C50.811	Malignant neoplasm of overlapping sites of right female breast	Diagnosis	ICD-10-CM
C50.812	Malignant neoplasm of overlapping sites of left female breast	Diagnosis	ICD-10-CM
C50.819	Malignant neoplasm of overlapping sites of unspecified female breast	Diagnosis	ICD-10-CM
C50.821	Malignant neoplasm of overlapping sites of right male breast	Diagnosis	ICD-10-CM
C50.822	Malignant neoplasm of overlapping sites of left male breast	Diagnosis	ICD-10-CM
C50.829	Malignant neoplasm of overlapping sites of unspecified male breast	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
C50.911	Malignant neoplasm of unspecified site of right female breast	Diagnosis	ICD-10-CM
C50.912	Malignant neoplasm of unspecified site of left female breast	Diagnosis	ICD-10-CM
C50.919	Malignant neoplasm of unspecified site of unspecified female breast	Diagnosis	ICD-10-CM
C50.921	Malignant neoplasm of unspecified site of right male breast	Diagnosis	ICD-10-CM
C50.922	Malignant neoplasm of unspecified site of left male breast	Diagnosis	ICD-10-CM
C50.929	Malignant neoplasm of unspecified site of unspecified male breast	Diagnosis	ICD-10-CM
D05.00	Lobular carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.01	Lobular carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.02	Lobular carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.10	Intraductal carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.11	Intraductal carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.12	Intraductal carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.80	Other specified type of carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.81	Other specified type of carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.82	Other specified type of carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.90	Unspecified type of carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.91	Unspecified type of carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.92	Unspecified type of carcinoma in situ of left breast	Diagnosis	ICD-10-CM
Z17.0	Estrogen receptor positive status [ER+]	Diagnosis	ICD-10-CM
Z17.1	Estrogen receptor negative status [ER-]	Diagnosis	ICD-10-CM
Z19.1	Hormone sensitive malignancy status	Diagnosis	ICD-10-CM
Z19.2	Hormone resistant malignancy status	Diagnosis	ICD-10-CM
Z85.3	Personal history of malignant neoplasm of breast	Diagnosis	ICD-10-CM
Z86.000	Personal history of in-situ neoplasm of breast	Diagnosis	ICD-10-CM
Cardiac Arrest			
I46.2	Cardiac arrest due to underlying cardiac condition	Diagnosis	ICD-10-CM
I46.8	Cardiac arrest due to other underlying condition	Diagnosis	ICD-10-CM
I46.9	Cardiac arrest, cause unspecified	Diagnosis	ICD-10-CM
I97.120	Postprocedural cardiac arrest following cardiac surgery	Diagnosis	ICD-10-CM
I97.121	Postprocedural cardiac arrest following other surgery	Diagnosis	ICD-10-CM
I97.710	Intraoperative cardiac arrest during cardiac surgery	Diagnosis	ICD-10-CM
I97.711	Intraoperative cardiac arrest during other surgery	Diagnosis	ICD-10-CM
Z86.74	Personal history of sudden cardiac arrest	Diagnosis	ICD-10-CM
Chronic Kidney Disease			
A18.11	Tuberculosis of kidney and ureter	Diagnosis	ICD-10-CM
A52.75	Syphilis of kidney and ureter	Diagnosis	ICD-10-CM
B52.0	Plasmodium malariae malaria with nephropathy	Diagnosis	ICD-10-CM
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with other diabetic kidney complication	Diagnosis	ICD-10-CM
E08.29	Drug or chemical induced diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E09.21		Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E09.22	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E09.29	Drug or chemical induced diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
I12.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease	Diagnosis	ICD-10-CM
I12.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
K76.7	Hepatorenal syndrome	Diagnosis	ICD-10-CM
M10.30	Gout due to renal impairment, unspecified site	Diagnosis	ICD-10-CM
M10.311	Gout due to renal impairment, right shoulder	Diagnosis	ICD-10-CM
M10.312	Gout due to renal impairment, left shoulder	Diagnosis	ICD-10-CM
M10.319	Gout due to renal impairment, unspecified shoulder	Diagnosis	ICD-10-CM
M10.321	Gout due to renal impairment, right elbow	Diagnosis	ICD-10-CM
M10.322	Gout due to renal impairment, left elbow	Diagnosis	ICD-10-CM
M10.329	Gout due to renal impairment, unspecified elbow	Diagnosis	ICD-10-CM
M10.331	Gout due to renal impairment, right wrist	Diagnosis	ICD-10-CM
M10.332	Gout due to renal impairment, left wrist	Diagnosis	ICD-10-CM
M10.339	Gout due to renal impairment, unspecified wrist	Diagnosis	ICD-10-CM
M10.341	Gout due to renal impairment, right hand	Diagnosis	ICD-10-CM
M10.342	Gout due to renal impairment, left hand	Diagnosis	ICD-10-CM
M10.349	Gout due to renal impairment, unspecified hand	Diagnosis	ICD-10-CM
M10.351	Gout due to renal impairment, right hip	Diagnosis	ICD-10-CM
M10.352	Gout due to renal impairment, left hip	Diagnosis	ICD-10-CM
M10.359	Gout due to renal impairment, unspecified hip	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPGS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M10.361	Gout due to renal impairment, right knee	Diagnosis	ICD-10-CM
M10.362	Gout due to renal impairment, left knee	Diagnosis	ICD-10-CM
M10.369	Gout due to renal impairment, unspecified knee	Diagnosis	ICD-10-CM
M10.371	Gout due to renal impairment, right ankle and foot	Diagnosis	ICD-10-CM
M10.372	Gout due to renal impairment, left ankle and foot	Diagnosis	ICD-10-CM
M10.379	Gout due to renal impairment, unspecified ankle and foot	Diagnosis	ICD-10-CM
M10.38	Gout due to renal impairment, vertebrae	Diagnosis	ICD-10-CM
M10.39	Gout due to renal impairment, multiple sites	Diagnosis	ICD-10-CM
M32.14	Glomerular disease in systemic lupus erythematosus	Diagnosis	ICD-10-CM
M32.15	Tubulo-interstitial nephropathy in systemic lupus erythematosus	Diagnosis	ICD-10-CM
M35.04	Sjogren syndrome with tubulo-interstitial nephropathy	Diagnosis	ICD-10-CM
M35.0A	Sjogren syndrome with glomerular disease	Diagnosis	ICD-10-CM
N01.0	Rapidly progressive nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N01.1	Rapidly progressive nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N01.2	Rapidly progressive nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N01.3	Rapidly progressive nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N01.4	Rapidly progressive nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N01.5	Rapidly progressive nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N01.6	Rapidly progressive nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N01.7	Rapidly progressive nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N01.8	Rapidly progressive nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N01.9	Rapidly progressive nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N01.A	Rapidly progressive nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N02.0	Recurrent and persistent hematuria with minor glomerular abnormality	Diagnosis	ICD-10-CM
N02.1	Recurrent and persistent hematuria with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N02.2	Recurrent and persistent hematuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N02.3	Recurrent and persistent hematuria with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.4	Recurrent and persistent hematuria with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.5	Recurrent and persistent hematuria with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N02.6	Recurrent and persistent hematuria with dense deposit disease	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
N02.7	Recurrent and persistent hematuria with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N02.8	Recurrent and persistent hematuria with other morphologic changes	Diagnosis	ICD-10-CM
N02.9	Recurrent and persistent hematuria with unspecified morphologic changes	Diagnosis	ICD-10-CM
N02.A	Recurrent and persistent hematuria with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N02.B1	Recurrent and persistent immunoglobulin A nephropathy with glomerular lesion	Diagnosis	ICD-10-CM
N02.B2	Recurrent and persistent immunoglobulin A nephropathy with focal and segmental glomerular lesion	Diagnosis	ICD-10-CM
N02.B3	Recurrent and persistent immunoglobulin A nephropathy with diffuse membranoproliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.B4	Recurrent and persistent immunoglobulin A nephropathy with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N02.B5	Recurrent and persistent immunoglobulin A nephropathy with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.B6	Recurrent and persistent immunoglobulin A nephropathy with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N02.B9	Other recurrent and persistent immunoglobulin A nephropathy	Diagnosis	ICD-10-CM
N03.0	Chronic nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N03.1	Chronic nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N03.2	Chronic nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N03.3	Chronic nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N03.4	Chronic nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N03.5	Chronic nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N03.6	Chronic nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N03.7	Chronic nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N03.8	Chronic nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N03.9	Chronic nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N03.A	Chronic nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N04.0	Nephrotic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N04.1	Nephrotic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N04.2	Nephrotic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N04.20	Nephrotic syndrome with diffuse membranous glomerulonephritis, unspecified	Diagnosis	ICD-10-CM
N04.21	Primary membranous nephropathy with nephrotic syndrome	Diagnosis	ICD-10-CM
N04.22	Secondary membranous nephropathy with nephrotic syndrome	Diagnosis	ICD-10-CM
N04.29	Other nephrotic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
N04.3	Nephrotic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
	Nephrotic syndrome with diffuse endocapillary proliferative glomerulonephritis		
N04.4	glomerulonephritis	Diagnosis	ICD-10-CM
N04.5	Nephrotic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N04.6	Nephrotic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N04.7	Nephrotic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N04.8	Nephrotic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N04.9	Nephrotic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N04.A	Nephrotic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N05.0	Unspecified nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N05.1	Unspecified nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
	Unspecified nephritic syndrome with diffuse membranous		
N05.2	glomerulonephritis	Diagnosis	ICD-10-CM
	Unspecified nephritic syndrome with diffuse mesangial proliferative		
N05.3	glomerulonephritis	Diagnosis	ICD-10-CM
	Unspecified nephritic syndrome with diffuse endocapillary proliferative		
N05.4	glomerulonephritis	Diagnosis	ICD-10-CM
	Unspecified nephritic syndrome with diffuse mesangiocapillary		
N05.5	glomerulonephritis	Diagnosis	ICD-10-CM
N05.6	Unspecified nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N05.7	Unspecified nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N05.8	Unspecified nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N05.9	Unspecified nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N05.A	Unspecified nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N06.0	Isolated proteinuria with minor glomerular abnormality	Diagnosis	ICD-10-CM
N06.1	Isolated proteinuria with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N06.2	Isolated proteinuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
	Isolated proteinuria with diffuse membranous glomerulonephritis,		
N06.20	unspecified	Diagnosis	ICD-10-CM
N06.21	Primary membranous nephropathy with isolated proteinuria	Diagnosis	ICD-10-CM
N06.22	Secondary membranous nephropathy with isolated proteinuria	Diagnosis	ICD-10-CM
N06.29	Other isolated proteinuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N06.3	Isolated proteinuria with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
	Isolated proteinuria with diffuse endocapillary proliferative		
N06.4	glomerulonephritis	Diagnosis	ICD-10-CM
N06.5	Isolated proteinuria with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N06.6	Isolated proteinuria with dense deposit disease	Diagnosis	ICD-10-CM
N06.7	Isolated proteinuria with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N06.8	Isolated proteinuria with other morphologic lesion	Diagnosis	ICD-10-CM
N06.9	Isolated proteinuria with unspecified morphologic lesion	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPGS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
N06.A	Isolated proteinuria with C3 glomerulonephritis	Diagnosis	ICD-10-CM
	Hereditary nephropathy, not elsewhere classified with minor glomerular abnormality	Diagnosis	ICD-10-CM
N07.0	Hereditary nephropathy, not elsewhere classified with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N07.1	Hereditary nephropathy, not elsewhere classified with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N07.2	Hereditary nephropathy, not elsewhere classified with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N07.3	Hereditary nephropathy, not elsewhere classified with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N07.4	Hereditary nephropathy, not elsewhere classified with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N07.5	Hereditary nephropathy, not elsewhere classified with dense deposit disease	Diagnosis	ICD-10-CM
N07.6	Hereditary nephropathy, not elsewhere classified with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N07.7	Hereditary nephropathy, not elsewhere classified with other morphologic lesions	Diagnosis	ICD-10-CM
N07.8	Hereditary nephropathy, not elsewhere classified with unspecified morphologic lesions	Diagnosis	ICD-10-CM
N07.9	Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N07.A	Glomerular disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
N08	Analgesic nephropathy	Diagnosis	ICD-10-CM
N14.0	Nephropathy induced by other drugs, medicaments and biological substances	Diagnosis	ICD-10-CM
N14.1	Contrast-induced nephropathy	Diagnosis	ICD-10-CM
N14.11	Nephropathy induced by other drugs, medicaments and biological substances	Diagnosis	ICD-10-CM
N14.19	Nephropathy induced by unspecified drug, medicament or biological substance	Diagnosis	ICD-10-CM
N14.2	Nephropathy induced by heavy metals	Diagnosis	ICD-10-CM
N14.3	Toxic nephropathy, not elsewhere classified	Diagnosis	ICD-10-CM
N14.4	Balkan nephropathy	Diagnosis	ICD-10-CM
N15.0	Other specified renal tubulo-interstitial diseases	Diagnosis	ICD-10-CM
N15.8	Renal tubulo-interstitial disease, unspecified	Diagnosis	ICD-10-CM
N15.9	Renal tubulo-interstitial disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
N16	Chronic kidney disease, stage 1	Diagnosis	ICD-10-CM
N18.1	Chronic kidney disease, stage 2 (mild)	Diagnosis	ICD-10-CM
N18.2	Chronic kidney disease, stage 3 (moderate)	Diagnosis	ICD-10-CM
N18.3	Chronic kidney disease, stage 3 unspecified	Diagnosis	ICD-10-CM
N18.30	Chronic kidney disease, stage 3a	Diagnosis	ICD-10-CM
N18.31	Chronic kidney disease, stage 3b	Diagnosis	ICD-10-CM
N18.32	Chronic kidney disease, stage 4 (severe)	Diagnosis	ICD-10-CM
N18.4		Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
N18.5	Chronic kidney disease, stage 5	Diagnosis	ICD-10-CM
N18.6	End stage renal disease	Diagnosis	ICD-10-CM
N18.9	Chronic kidney disease, unspecified	Diagnosis	ICD-10-CM
N25.1	Nephrogenic diabetes insipidus	Diagnosis	ICD-10-CM
N25.89	Other disorders resulting from impaired renal tubular function	Diagnosis	ICD-10-CM
N25.9	Disorder resulting from impaired renal tubular function, unspecified	Diagnosis	ICD-10-CM
N26.1	Atrophy of kidney (terminal)	Diagnosis	ICD-10-CM
N26.9	Renal sclerosis, unspecified	Diagnosis	ICD-10-CM
N99.0	Postprocedural (acute) (chronic) kidney failure	Diagnosis	ICD-10-CM
Q61.02	Congenital multiple renal cysts	Diagnosis	ICD-10-CM
Q61.11	Cystic dilatation of collecting ducts	Diagnosis	ICD-10-CM
Q61.19	Other polycystic kidney, infantile type	Diagnosis	ICD-10-CM
Q61.2	Polycystic kidney, adult type	Diagnosis	ICD-10-CM
Q61.3	Polycystic kidney, unspecified	Diagnosis	ICD-10-CM
Q61.4	Renal dysplasia	Diagnosis	ICD-10-CM
Q61.5	Medullary cystic kidney	Diagnosis	ICD-10-CM
Q61.8	Other cystic kidney diseases	Diagnosis	ICD-10-CM
Colorectal Cancer			
C18.0	Malignant neoplasm of cecum	Diagnosis	ICD-10-CM
C18.1	Malignant neoplasm of appendix	Diagnosis	ICD-10-CM
C18.2	Malignant neoplasm of ascending colon	Diagnosis	ICD-10-CM
C18.3	Malignant neoplasm of hepatic flexure	Diagnosis	ICD-10-CM
C18.4	Malignant neoplasm of transverse colon	Diagnosis	ICD-10-CM
C18.5	Malignant neoplasm of splenic flexure	Diagnosis	ICD-10-CM
C18.6	Malignant neoplasm of descending colon	Diagnosis	ICD-10-CM
C18.7	Malignant neoplasm of sigmoid colon	Diagnosis	ICD-10-CM
C18.8	Malignant neoplasm of overlapping sites of colon	Diagnosis	ICD-10-CM
C18.9	Malignant neoplasm of colon, unspecified	Diagnosis	ICD-10-CM
C19	Malignant neoplasm of rectosigmoid junction	Diagnosis	ICD-10-CM
C20	Malignant neoplasm of rectum	Diagnosis	ICD-10-CM
C49.A4	Gastrointestinal stromal tumor of large intestine	Diagnosis	ICD-10-CM
C49.A5	Gastrointestinal stromal tumor of rectum	Diagnosis	ICD-10-CM
D01.0	Carcinoma in situ of colon	Diagnosis	ICD-10-CM
D01.1	Carcinoma in situ of rectosigmoid junction	Diagnosis	ICD-10-CM
D01.2	Carcinoma in situ of rectum	Diagnosis	ICD-10-CM
Z85.030	Personal history of malignant carcinoid tumor of large intestine	Diagnosis	ICD-10-CM
Z85.038	Personal history of other malignant neoplasm of large intestine	Diagnosis	ICD-10-CM
Z85.040	Personal history of malignant carcinoid tumor of rectum	Diagnosis	ICD-10-CM
Z85.048	Personal history of other malignant neoplasm of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-10-CM
Chronic Obstructive Pulmonary Disease			
J40	Bronchitis, not specified as acute or chronic	Diagnosis	ICD-10-CM
J41.0	Simple chronic bronchitis	Diagnosis	ICD-10-CM
J41.1	Mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM
J41.8	Mixed simple and mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
J42	Unspecified chronic bronchitis	Diagnosis	ICD-10-CM
J43.0	Unilateral pulmonary emphysema [MacLeod's syndrome]	Diagnosis	ICD-10-CM
J43.1	Panlobular emphysema	Diagnosis	ICD-10-CM
J43.2	Centrilobular emphysema	Diagnosis	ICD-10-CM
J43.9	Emphysema, unspecified	Diagnosis	ICD-10-CM
	Chronic obstructive pulmonary disease with (acute) lower respiratory infection		
J44.0	Chronic obstructive pulmonary disease with (acute) lower respiratory infection	Diagnosis	ICD-10-CM
J44.1	Chronic obstructive pulmonary disease with (acute) exacerbation	Diagnosis	ICD-10-CM
J44.81	Bronchiolitis obliterans and bronchiolitis obliterans syndrome	Diagnosis	ICD-10-CM
J44.89	Other specified chronic obstructive pulmonary disease	Diagnosis	ICD-10-CM
J44.9	Chronic obstructive pulmonary disease, unspecified	Diagnosis	ICD-10-CM
J47.0	Bronchiectasis with acute lower respiratory infection	Diagnosis	ICD-10-CM
J47.1	Bronchiectasis with (acute) exacerbation	Diagnosis	ICD-10-CM
J47.9	Bronchiectasis, uncomplicated	Diagnosis	ICD-10-CM
J98.2	Interstitial emphysema	Diagnosis	ICD-10-CM
J98.3	Compensatory emphysema	Diagnosis	ICD-10-CM

Coronary Angioplasty Bypass

00566	Anesthesia for direct coronary artery bypass grafting; without pump oxygenator	Procedure	CPT-4
00567	Anesthesia for direct coronary artery bypass grafting; with pump oxygenator	Procedure	CPT-4
02104Z3	Bypass Coronary Artery, One Artery from Coronary Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114Z3	Bypass Coronary Artery, Two Arteries from Coronary Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124Z3	Bypass Coronary Artery, Three Arteries from Coronary Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134Z3	Bypass Coronary Artery, Four or More Arteries from Coronary Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0270346	Dilation of Coronary Artery, One Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
027034Z	Dilation of Coronary Artery, One Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0270356	Dilation of Coronary Artery, One Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027035Z	Dilation of Coronary Artery, One Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0270366	Dilation of Coronary Artery, One Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027036Z	Dilation of Coronary Artery, One Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0270376	Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027037Z	Dilation of Coronary Artery, One Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
02703D6	Dilation of Coronary Artery, One Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02703DZ	Dilation of Coronary Artery, One Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02703E6	Dilation of Coronary Artery, One Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703EZ	Dilation of Coronary Artery, One Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703F6	Dilation of Coronary Artery, One Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703FZ	Dilation of Coronary Artery, One Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703G6	Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703GZ	Dilation of Coronary Artery, One Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703T6	Dilation of Coronary Artery, One Artery, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02703TZ	Dilation of Coronary Artery, One Artery with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02703Z6	Dilation of Coronary Artery, One Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
02703ZZ	Dilation of Coronary Artery, One Artery, Percutaneous Approach	Procedure	ICD-10-PCS
0270446	Dilation of Coronary Artery, One Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027044Z	Dilation of Coronary Artery, One Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0270456	Dilation of Coronary Artery, One Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027045Z	Dilation of Coronary Artery, One Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0270466	Dilation of Coronary Artery, One Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027046Z	Dilation of Coronary Artery, One Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0270476	Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027047Z	Dilation of Coronary Artery, One Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704D6	Dilation of Coronary Artery, One Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704DZ	Dilation of Coronary Artery, One Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704E6	Dilation of Coronary Artery, One Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
02704EZ	Dilation of Coronary Artery, One Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704F6	Dilation of Coronary Artery, One Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704FZ	Dilation of Coronary Artery, One Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704G6	Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704GZ	Dilation of Coronary Artery, One Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704T6	Dilation of Coronary Artery, One Artery, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704TZ	Dilation of Coronary Artery, One Artery with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704Z6	Dilation of Coronary Artery, One Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704ZZ	Dilation of Coronary Artery, One Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0271346	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
027134Z	Dilation of Coronary Artery, Two Arteries with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0271356	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027135Z	Dilation of Coronary Artery, Two Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0271366	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027136Z	Dilation of Coronary Artery, Two Arteries with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0271376	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027137Z	Dilation of Coronary Artery, Two Arteries with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713D6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02713DZ	Dilation of Coronary Artery, Two Arteries with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02713E6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713EZ	Dilation of Coronary Artery, Two Arteries with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713F6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
02713FZ	Dilation of Coronary Artery, Two Arteries with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713G6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713GZ	Dilation of Coronary Artery, Two Arteries with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713T6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02713TZ	Dilation of Coronary Artery, Two Arteries with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02713Z6	Dilation of Coronary Artery, Two Arteries, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
02713ZZ	Dilation of Coronary Artery, Two Arteries, Percutaneous Approach	Procedure	ICD-10-PCS
0271446	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027144Z	Dilation of Coronary Artery, Two Arteries with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0271456	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027145Z	Dilation of Coronary Artery, Two Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0271466	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027146Z	Dilation of Coronary Artery, Two Arteries with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0271476	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027147Z	Dilation of Coronary Artery, Two Arteries with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714D6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714DZ	Dilation of Coronary Artery, Two Arteries with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714E6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714EZ	Dilation of Coronary Artery, Two Arteries with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714F6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714FZ	Dilation of Coronary Artery, Two Arteries with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714G6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
02714GZ	Dilation of Coronary Artery, Two Arteries with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714T6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714TZ	Dilation of Coronary Artery, Two Arteries with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714Z6	Dilation of Coronary Artery, Two Arteries, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714ZZ	Dilation of Coronary Artery, Two Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0272346	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
027234Z	Dilation of Coronary Artery, Three Arteries with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0272356	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027235Z	Dilation of Coronary Artery, Three Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0272366	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027236Z	Dilation of Coronary Artery, Three Arteries with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0272376	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027237Z	Dilation of Coronary Artery, Three Arteries with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723D6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02723DZ	Dilation of Coronary Artery, Three Arteries with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02723E6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723EZ	Dilation of Coronary Artery, Three Arteries with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723F6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723FZ	Dilation of Coronary Artery, Three Arteries with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723G6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723GZ	Dilation of Coronary Artery, Three Arteries with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723T6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPGS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
02723TZ	Dilation of Coronary Artery, Three Arteries with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02723Z6	Dilation of Coronary Artery, Three Arteries, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
02723ZZ	Dilation of Coronary Artery, Three Arteries, Percutaneous Approach	Procedure	ICD-10-PCS
0272446	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027244Z	Dilation of Coronary Artery, Three Arteries with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0272456	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027245Z	Dilation of Coronary Artery, Three Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0272466	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027246Z	Dilation of Coronary Artery, Three Arteries with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0272476	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027247Z	Dilation of Coronary Artery, Three Arteries with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724D6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724DZ	Dilation of Coronary Artery, Three Arteries with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724E6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724EZ	Dilation of Coronary Artery, Three Arteries with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724F6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724FZ	Dilation of Coronary Artery, Three Arteries with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724G6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724GZ	Dilation of Coronary Artery, Three Arteries with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724T6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724TZ	Dilation of Coronary Artery, Three Arteries with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724Z6	Dilation of Coronary Artery, Three Arteries, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
02724ZZ	Dilation of Coronary Artery, Three Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0273346	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
027334Z	Dilation of Coronary Artery, Four or More Arteries with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0273356	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027335Z	Dilation of Coronary Artery, Four or More Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0273366	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027336Z	Dilation of Coronary Artery, Four or More Arteries with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0273376	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027337Z	Dilation of Coronary Artery, Four or More Arteries with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733D6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02733DZ	Dilation of Coronary Artery, Four or More Arteries with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02733E6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733EZ	Dilation of Coronary Artery, Four or More Arteries with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733F6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733FZ	Dilation of Coronary Artery, Four or More Arteries with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733G6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733GZ	Dilation of Coronary Artery, Four or More Arteries with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733T6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02733TZ	Dilation of Coronary Artery, Four or More Arteries with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02733Z6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
02733ZZ	Dilation of Coronary Artery, Four or More Arteries, Percutaneous Approach	Procedure	ICD-10-PCS
0273446	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
027344Z	Dilation of Coronary Artery, Four or More Arteries with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0273456	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027345Z	Dilation of Coronary Artery, Four or More Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0273466	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027346Z	Dilation of Coronary Artery, Four or More Arteries with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0273476	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027347Z	Dilation of Coronary Artery, Four or More Arteries with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734D6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734DZ	Dilation of Coronary Artery, Four or More Arteries with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734E6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734EZ	Dilation of Coronary Artery, Four or More Arteries with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734F6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734FZ	Dilation of Coronary Artery, Four or More Arteries with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734G6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734GZ	Dilation of Coronary Artery, Four or More Arteries with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734T6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734TZ	Dilation of Coronary Artery, Four or More Arteries with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734Z6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734ZZ	Dilation of Coronary Artery, Four or More Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0644T	Transcatheter removal or debulking of intracardiac mass (eg, vegetations, thrombus) via suction (eg, vacuum, aspiration) device, percutaneous approach, with intraoperative reinfusion of aspirated blood, including imaging guidance, when performed	Procedure	CPT-3

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
33508	Endoscopy, surgical, including video-assisted harvest of vein(s) for coronary artery bypass procedure (List separately in addition to code for primary procedure)	Procedure	CPT-4
33509	Harvest of upper extremity artery, 1 segment, for coronary artery bypass procedure, endoscopic	Procedure	CPT-4
33510	Coronary artery bypass, vein only; single coronary venous graft	Procedure	CPT-4
33511	Coronary artery bypass, vein only; 2 coronary venous grafts	Procedure	CPT-4
33512	Coronary artery bypass, vein only; 3 coronary venous grafts	Procedure	CPT-4
33513	Coronary artery bypass, vein only; 4 coronary venous grafts	Procedure	CPT-4
33514	Coronary artery bypass, vein only; 5 coronary venous grafts	Procedure	CPT-4
33516	Coronary artery bypass, vein only; 6 or more coronary venous grafts	Procedure	CPT-4
33517	Coronary artery bypass, using venous graft(s) and arterial graft(s); single vein graft (List separately in addition to code for primary procedure)	Procedure	CPT-4
33518	Coronary artery bypass, using venous graft(s) and arterial graft(s); 2 venous grafts (List separately in addition to code for primary procedure)	Procedure	CPT-4
33519	Coronary artery bypass, using venous graft(s) and arterial graft(s); 3 venous grafts (List separately in addition to code for primary procedure)	Procedure	CPT-4
33520	Coronary Artery Bypass, Nonautogenous Graft (eg, Synthetic Or Cadaver); Single Graft	Procedure	CPT-4
33521	Coronary artery bypass, using venous graft(s) and arterial graft(s); 4 venous grafts (List separately in addition to code for primary procedure)	Procedure	CPT-4
33522	Coronary artery bypass, using venous graft(s) and arterial graft(s); 5 venous grafts (List separately in addition to code for primary procedure)	Procedure	CPT-4
33523	Coronary artery bypass, using venous graft(s) and arterial graft(s); 6 or more venous grafts (List separately in addition to code for primary procedure)	Procedure	CPT-4
33525	Coronary Artery Bypass, Nonautogenous Graft (eg, Synthetic Or Cadaver); Two Coronary Grafts	Procedure	CPT-4
33528	Coronary Artery Bypass, Nonautogenous Graft (eg, Synthetic Or Cadaver); Three Or More Coronary Grafts	Procedure	CPT-4
33530	Reoperation, coronary artery bypass procedure or valve procedure, more than 1 month after original operation (List separately in addition to code for primary procedure)	Procedure	CPT-4
33533	Coronary artery bypass, using arterial graft(s); single arterial graft	Procedure	CPT-4
33534	Coronary artery bypass, using arterial graft(s); 2 coronary arterial grafts	Procedure	CPT-4
33535	Coronary artery bypass, using arterial graft(s); 3 coronary arterial grafts	Procedure	CPT-4
33536	Coronary artery bypass, using arterial graft(s); 4 or more coronary arterial grafts	Procedure	CPT-4
33572	Coronary endarterectomy, open, any method, of left anterior descending, circumflex, or right coronary artery performed in conjunction with coronary artery bypass graft procedure, each vessel (List separately in addition to primary procedure)	Procedure	CPT-4
35500	Harvest of upper extremity vein, 1 segment, for lower extremity or coronary artery bypass procedure (List separately in addition to code for primary procedure)	Procedure	CPT-4

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
35600	Harvest of upper extremity artery, 1 segment, for coronary artery bypass procedure, open	Procedure	CPT-4
4110F	Internal mammary artery graft performed for primary, isolated coronary artery bypass graft procedure (CABG)	Procedure	CPT-2
92920	Percutaneous transluminal coronary angioplasty; single major coronary artery or branch	Procedure	CPT-4
92921	Percutaneous transluminal coronary angioplasty; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)	Procedure	CPT-4
92924	Percutaneous transluminal coronary atherectomy, with coronary angioplasty when performed; single major coronary artery or branch	Procedure	CPT-4
92925	Percutaneous transluminal coronary atherectomy, with coronary angioplasty when performed; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)	Procedure	CPT-4
92928	Percutaneous transcatheter placement of intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch	Procedure	CPT-4
92929	Percutaneous transcatheter placement of intracoronary stent(s), with coronary angioplasty when performed; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)	Procedure	CPT-4
92933	Percutaneous transluminal coronary atherectomy, with intracoronary stent, with coronary angioplasty when performed; single major coronary artery or branch	Procedure	CPT-4
92934	Percutaneous transluminal coronary atherectomy, with intracoronary stent, with coronary angioplasty when performed; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)	Procedure	CPT-4
92937	Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of intracoronary stent, atherectomy and angioplasty, including distal protection when performed; single	Procedure	CPT-4
92938	Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of intracoronary stent, atherectomy and angioplasty, including distal protection when performed; each ad	Procedure	CPT-4
92941	Percutaneous transluminal revascularization of acute total/subtotal occlusion during acute myocardial infarction, coronary artery or coronary artery bypass graft, any combination of intracoronary stent, atherectomy and angioplasty, including aspirati	Procedure	CPT-4
92943	Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of intracoronary stent, atherectomy and angioplasty; single vessel	Procedure	CPT-4

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
92944	Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of intracoronary stent, atherectomy and angioplasty; each additional coronary artery, co	Procedure	CPT-4
C9600	Percutaneous transcatheter placement of drug eluting intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch	Procedure	HCPCS
C9601	Percutaneous transcatheter placement of drug-eluting intracoronary stent(s), with coronary angioplasty when performed; each additional branch of a major coronary artery (list separately in addition to code for primary procedure)	Procedure	HCPCS
C9602	Percutaneous transluminal coronary atherectomy, with drug eluting intracoronary stent, with coronary angioplasty when performed; single major coronary artery or branch	Procedure	HCPCS
C9603	Percutaneous transluminal coronary atherectomy, with drug-eluting intracoronary stent, with coronary angioplasty when performed; each additional branch of a major coronary artery (list separately in addition to code for primary procedure)	Procedure	HCPCS
C9604	Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of drug-eluting intracoronary stent, atherectomy and angioplasty, including distal protection when perfo	Procedure	HCPCS
C9605	Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of drug-eluting intracoronary stent, atherectomy and angioplasty, including distal protection when perfo	Procedure	HCPCS
C9606	Percutaneous transluminal revascularization of acute total/subtotal occlusion during acute myocardial infarction, coronary artery or coronary artery bypass graft, any combination of drug-eluting intracoronary stent, atherectomy and angioplasty, inclu	Procedure	HCPCS
C9607	Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of drug-eluting intracoronary stent, atherectomy and angioplasty; single vessel	Procedure	HCPCS
C9608	Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of drug-eluting intracoronary stent, atherectomy and angioplasty; each additional corona	Procedure	HCPCS
S2205	Minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using arterial graft(s), single coronary arterial graft	Procedure	HCPCS
S2206	Minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using arterial graft(s), two coronary arterial grafts	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
S2207	Minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using venous graft only, single coronary venous graft	Procedure	HCPCS
S2208	Minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using single arterial and venous graft(s), single venous graft	Procedure	HCPCS
S2209	Minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using two arterial grafts and single venous graft	Procedure	HCPCS
T82.2	Mechanical complication of coronary artery bypass graft and biological heart valve graft	Diagnosis	ICD-10-CM
T82.21	Mechanical complication of coronary artery bypass graft	Diagnosis	ICD-10-CM
T82.211	Breakdown (mechanical) of coronary artery bypass graft	Diagnosis	ICD-10-CM
T82.211A	Breakdown (mechanical) of coronary artery bypass graft, initial encounter	Diagnosis	ICD-10-CM
T82.211D	Breakdown (mechanical) of coronary artery bypass graft, subsequent encounter	Diagnosis	ICD-10-CM
T82.211S	Breakdown (mechanical) of coronary artery bypass graft, sequela	Diagnosis	ICD-10-CM
T82.212	Displacement of coronary artery bypass graft	Diagnosis	ICD-10-CM
T82.212A	Displacement of coronary artery bypass graft, initial encounter	Diagnosis	ICD-10-CM
T82.212D	Displacement of coronary artery bypass graft, subsequent encounter	Diagnosis	ICD-10-CM
T82.212S	Displacement of coronary artery bypass graft, sequela	Diagnosis	ICD-10-CM
T82.213	Leakage of coronary artery bypass graft	Diagnosis	ICD-10-CM
T82.213A	Leakage of coronary artery bypass graft, initial encounter	Diagnosis	ICD-10-CM
T82.213D	Leakage of coronary artery bypass graft, subsequent encounter	Diagnosis	ICD-10-CM
T82.213S	Leakage of coronary artery bypass graft, sequela	Diagnosis	ICD-10-CM
T82.218	Other mechanical complication of coronary artery bypass graft	Diagnosis	ICD-10-CM
T82.218A	Other mechanical complication of coronary artery bypass graft, initial encounter	Diagnosis	ICD-10-CM
T82.218D	Other mechanical complication of coronary artery bypass graft, subsequent encounter	Diagnosis	ICD-10-CM
T82.218S	Other mechanical complication of coronary artery bypass graft, sequela	Diagnosis	ICD-10-CM
Z95.1	Presence of aortocoronary bypass graft	Diagnosis	ICD-10-CM
Z95.5	Presence of coronary angioplasty implant and graft	Diagnosis	ICD-10-CM
Z98.61	Coronary angioplasty status	Diagnosis	ICD-10-CM
Dementia			
F01.50	Vascular dementia, unspecified severity, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F01.51	Vascular dementia, unspecified severity, with behavioral disturbance	Diagnosis	ICD-10-CM
F01.511	Vascular dementia, unspecified severity, with agitation	Diagnosis	ICD-10-CM
F01.518	Vascular dementia, unspecified severity, with other behavioral disturbance	Diagnosis	ICD-10-CM
F01.52	Vascular dementia, unspecified severity, with psychotic disturbance	Diagnosis	ICD-10-CM
F01.53	Vascular dementia, unspecified severity, with mood disturbance	Diagnosis	ICD-10-CM
F01.54	Vascular dementia, unspecified severity, with anxiety	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPGS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
F01.A0	Vascular dementia, mild, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F01.A11	Vascular dementia, mild, with agitation	Diagnosis	ICD-10-CM
F01.A18	Vascular dementia, mild, with other behavioral disturbance	Diagnosis	ICD-10-CM
F01.A2	Vascular dementia, mild, with psychotic disturbance	Diagnosis	ICD-10-CM
F01.A3	Vascular dementia, mild, with mood disturbance	Diagnosis	ICD-10-CM
F01.A4	Vascular dementia, mild, with anxiety	Diagnosis	ICD-10-CM
F01.B0	Vascular dementia, moderate, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F01.B11	Vascular dementia, moderate, with agitation	Diagnosis	ICD-10-CM
F01.B18	Vascular dementia, moderate, with other behavioral disturbance	Diagnosis	ICD-10-CM
F01.B2	Vascular dementia, moderate, with psychotic disturbance	Diagnosis	ICD-10-CM
F01.B3	Vascular dementia, moderate, with mood disturbance	Diagnosis	ICD-10-CM
F01.B4	Vascular dementia, moderate, with anxiety	Diagnosis	ICD-10-CM
F01.C0	Vascular dementia, severe, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F01.C11	Vascular dementia, severe, with agitation	Diagnosis	ICD-10-CM
F01.C18	Vascular dementia, severe, with other behavioral disturbance	Diagnosis	ICD-10-CM
F01.C2	Vascular dementia, severe, with psychotic disturbance	Diagnosis	ICD-10-CM
F01.C3	Vascular dementia, severe, with mood disturbance	Diagnosis	ICD-10-CM
F01.C4	Vascular dementia, severe, with anxiety	Diagnosis	ICD-10-CM
F02.80	Dementia in other diseases classified elsewhere, unspecified severity, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F02.81	Dementia in other diseases classified elsewhere, unspecified severity, with behavioral disturbance	Diagnosis	ICD-10-CM
F02.811	Dementia in other diseases classified elsewhere, unspecified severity, with agitation	Diagnosis	ICD-10-CM
F02.818	Dementia in other diseases classified elsewhere, unspecified severity, with other behavioral disturbance	Diagnosis	ICD-10-CM
F02.82	Dementia in other diseases classified elsewhere, unspecified severity, with psychotic disturbance	Diagnosis	ICD-10-CM
F02.83	Dementia in other diseases classified elsewhere, unspecified severity, with mood disturbance	Diagnosis	ICD-10-CM
F02.84	Dementia in other diseases classified elsewhere, unspecified severity, with anxiety	Diagnosis	ICD-10-CM
F02.A0	Dementia in other diseases classified elsewhere, mild, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F02.A11	Dementia in other diseases classified elsewhere, mild, with agitation	Diagnosis	ICD-10-CM
F02.A18	Dementia in other diseases classified elsewhere, mild, with other behavioral disturbance	Diagnosis	ICD-10-CM
F02.A2	Dementia in other diseases classified elsewhere, mild, with psychotic disturbance	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
F02.A3	Dementia in other diseases classified elsewhere, mild, with mood disturbance	Diagnosis	ICD-10-CM
F02.A4	Dementia in other diseases classified elsewhere, mild, with anxiety	Diagnosis	ICD-10-CM
	Dementia in other diseases classified elsewhere, moderate, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety		
F02.B0	Dementia in other diseases classified elsewhere, moderate, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F02.B11	Dementia in other diseases classified elsewhere, moderate, with agitation	Diagnosis	ICD-10-CM
	Dementia in other diseases classified elsewhere, moderate, with other behavioral disturbance		
F02.B18	Dementia in other diseases classified elsewhere, moderate, with other behavioral disturbance	Diagnosis	ICD-10-CM
	Dementia in other diseases classified elsewhere, moderate, with psychotic disturbance		
F02.B2	Dementia in other diseases classified elsewhere, moderate, with psychotic disturbance	Diagnosis	ICD-10-CM
	Dementia in other diseases classified elsewhere, moderate, with mood disturbance		
F02.B3	Dementia in other diseases classified elsewhere, moderate, with mood disturbance	Diagnosis	ICD-10-CM
F02.B4	Dementia in other diseases classified elsewhere, moderate, with anxiety	Diagnosis	ICD-10-CM
	Dementia in other diseases classified elsewhere, severe, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety		
F02.C0	Dementia in other diseases classified elsewhere, severe, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F02.C11	Dementia in other diseases classified elsewhere, severe, with agitation	Diagnosis	ICD-10-CM
	Dementia in other diseases classified elsewhere, severe, with other behavioral disturbance		
F02.C18	Dementia in other diseases classified elsewhere, severe, with other behavioral disturbance	Diagnosis	ICD-10-CM
	Dementia in other diseases classified elsewhere, severe, with psychotic disturbance		
F02.C2	Dementia in other diseases classified elsewhere, severe, with psychotic disturbance	Diagnosis	ICD-10-CM
	Dementia in other diseases classified elsewhere, severe, with mood disturbance		
F02.C3	Dementia in other diseases classified elsewhere, severe, with mood disturbance	Diagnosis	ICD-10-CM
F02.C4	Dementia in other diseases classified elsewhere, severe, with anxiety	Diagnosis	ICD-10-CM
	Unspecified dementia, unspecified severity, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety		
F03.90	Unspecified dementia, unspecified severity, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F03.91	Unspecified dementia, unspecified severity, with behavioral disturbance	Diagnosis	ICD-10-CM
F03.911	Unspecified dementia, unspecified severity, with agitation	Diagnosis	ICD-10-CM
	Unspecified dementia, unspecified severity, with other behavioral disturbance		
F03.918	Unspecified dementia, unspecified severity, with other behavioral disturbance	Diagnosis	ICD-10-CM
F03.92	Unspecified dementia, unspecified severity, with psychotic disturbance	Diagnosis	ICD-10-CM
F03.93	Unspecified dementia, unspecified severity, with mood disturbance	Diagnosis	ICD-10-CM
F03.94	Unspecified dementia, unspecified severity, with anxiety	Diagnosis	ICD-10-CM
	Unspecified dementia, mild, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety		
F03.A0	Unspecified dementia, mild, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F03.A11	Unspecified dementia, mild, with agitation	Diagnosis	ICD-10-CM
F03.A18	Unspecified dementia, mild, with other behavioral disturbance	Diagnosis	ICD-10-CM
F03.A2	Unspecified dementia, mild, with psychotic disturbance	Diagnosis	ICD-10-CM
F03.A3	Unspecified dementia, mild, with mood disturbance	Diagnosis	ICD-10-CM
F03.A4	Unspecified dementia, mild, with anxiety	Diagnosis	ICD-10-CM
	Unspecified dementia, moderate, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety		
F03.B0	Unspecified dementia, moderate, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F03.B11	Unspecified dementia, moderate, with agitation	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
F03.B18	Unspecified dementia, moderate, with other behavioral disturbance	Diagnosis	ICD-10-CM
F03.B2	Unspecified dementia, moderate, with psychotic disturbance	Diagnosis	ICD-10-CM
F03.B3	Unspecified dementia, moderate, with mood disturbance	Diagnosis	ICD-10-CM
F03.B4	Unspecified dementia, moderate, with anxiety	Diagnosis	ICD-10-CM
	Unspecified dementia, severe, without behavioral disturbance, psychotic		
F03.C0	disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F03.C11	Unspecified dementia, severe, with agitation	Diagnosis	ICD-10-CM
F03.C18	Unspecified dementia, severe, with other behavioral disturbance	Diagnosis	ICD-10-CM
F03.C2	Unspecified dementia, severe, with psychotic disturbance	Diagnosis	ICD-10-CM
F03.C3	Unspecified dementia, severe, with mood disturbance	Diagnosis	ICD-10-CM
F03.C4	Unspecified dementia, severe, with anxiety	Diagnosis	ICD-10-CM
F05	Delirium due to known physiological condition	Diagnosis	ICD-10-CM
	Systemic atrophy primarily affecting central nervous system in other		
G13.8	diseases classified elsewhere	Diagnosis	ICD-10-CM
G31.01	Pick's disease	Diagnosis	ICD-10-CM
G31.09	Other frontotemporal neurocognitive disorder	Diagnosis	ICD-10-CM
G31.1	Senile degeneration of brain, not elsewhere classified	Diagnosis	ICD-10-CM
G31.2	Degeneration of nervous system due to alcohol	Diagnosis	ICD-10-CM
G31.83	Neurocognitive disorder with Lewy bodies	Diagnosis	ICD-10-CM
G94	Other disorders of brain in diseases classified elsewhere	Diagnosis	ICD-10-CM
R41.81	Age-related cognitive decline	Diagnosis	ICD-10-CM

Depression

F06.31	Mood disorder due to known physiological condition with depressive features	Diagnosis	ICD-10-CM
F06.32	Mood disorder due to known physiological condition with major depressive-like episode	Diagnosis	ICD-10-CM
F31.0	Bipolar disorder, current episode hypomanic	Diagnosis	ICD-10-CM
F31.10	Bipolar disorder, current episode manic without psychotic features, unspecified	Diagnosis	ICD-10-CM
F31.11	Bipolar disorder, current episode manic without psychotic features, mild	Diagnosis	ICD-10-CM
F31.12	Bipolar disorder, current episode manic without psychotic features, moderate	Diagnosis	ICD-10-CM
F31.13	Bipolar disorder, current episode manic without psychotic features, severe	Diagnosis	ICD-10-CM
F31.2	Bipolar disorder, current episode manic severe with psychotic features	Diagnosis	ICD-10-CM
F31.30	Bipolar disorder, current episode depressed, mild or moderate severity, unspecified	Diagnosis	ICD-10-CM
F31.31	Bipolar disorder, current episode depressed, mild	Diagnosis	ICD-10-CM
F31.32	Bipolar disorder, current episode depressed, moderate	Diagnosis	ICD-10-CM
F31.4	Bipolar disorder, current episode depressed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.5	Bipolar disorder, current episode depressed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.60	Bipolar disorder, current episode mixed, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPGS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
F31.61	Bipolar disorder, current episode mixed, mild	Diagnosis	ICD-10-CM
F31.62	Bipolar disorder, current episode mixed, moderate	Diagnosis	ICD-10-CM
F31.63	Bipolar disorder, current episode mixed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.64	Bipolar disorder, current episode mixed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.71	Bipolar disorder, in partial remission, most recent episode hypomanic	Diagnosis	ICD-10-CM
F31.73	Bipolar disorder, in partial remission, most recent episode manic	Diagnosis	ICD-10-CM
F31.75	Bipolar disorder, in partial remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.76	Bipolar disorder, in full remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.77	Bipolar disorder, in partial remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.78	Bipolar disorder, in full remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.81	Bipolar II disorder	Diagnosis	ICD-10-CM
F31.89	Other bipolar disorder	Diagnosis	ICD-10-CM
F31.9	Bipolar disorder, unspecified	Diagnosis	ICD-10-CM
F32.0	Major depressive disorder, single episode, mild	Diagnosis	ICD-10-CM
F32.1	Major depressive disorder, single episode, moderate	Diagnosis	ICD-10-CM
F32.2	Major depressive disorder, single episode, severe without psychotic features	Diagnosis	ICD-10-CM
F32.3	Major depressive disorder, single episode, severe with psychotic features	Diagnosis	ICD-10-CM
F32.4	Major depressive disorder, single episode, in partial remission	Diagnosis	ICD-10-CM
F32.5	Major depressive disorder, single episode, in full remission	Diagnosis	ICD-10-CM
F32.8	Other depressive episodes	Diagnosis	ICD-10-CM
F32.89	Other specified depressive episodes	Diagnosis	ICD-10-CM
F32.9	Major depressive disorder, single episode, unspecified	Diagnosis	ICD-10-CM
F32.A	Depression, unspecified	Diagnosis	ICD-10-CM
F33.0	Major depressive disorder, recurrent, mild	Diagnosis	ICD-10-CM
F33.1	Major depressive disorder, recurrent, moderate	Diagnosis	ICD-10-CM
F33.2	Major depressive disorder, recurrent severe without psychotic features	Diagnosis	ICD-10-CM
F33.3	Major depressive disorder, recurrent, severe with psychotic symptoms	Diagnosis	ICD-10-CM
F33.40	Major depressive disorder, recurrent, in remission, unspecified	Diagnosis	ICD-10-CM
F33.41	Major depressive disorder, recurrent, in partial remission	Diagnosis	ICD-10-CM
F33.42	Major depressive disorder, recurrent, in full remission	Diagnosis	ICD-10-CM
F33.8	Other recurrent depressive disorders	Diagnosis	ICD-10-CM
F33.9	Major depressive disorder, recurrent, unspecified	Diagnosis	ICD-10-CM
F34.0	Cyclothymic disorder	Diagnosis	ICD-10-CM
F34.1	Dysthymic disorder	Diagnosis	ICD-10-CM
F43.21	Adjustment disorder with depressed mood	Diagnosis	ICD-10-CM
F43.23	Adjustment disorder with mixed anxiety and depressed mood	Diagnosis	ICD-10-CM
Diabetes			
E08.00	Diabetes mellitus due to underlying condition with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E08.01	Diabetes mellitus due to underlying condition with hyperosmolarity with coma	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPGS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E08.10	Diabetes mellitus due to underlying condition with ketoacidosis without coma	Diagnosis	ICD-10-CM
E08.11	Diabetes mellitus due to underlying condition with ketoacidosis with coma	Diagnosis	ICD-10-CM
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E08.29	Diabetes mellitus due to underlying condition with other diabetic kidney complication	Diagnosis	ICD-10-CM
E08.311	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.319	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.321	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3211	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3212	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3213	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3219	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.329	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3291	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3292	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3293	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3299	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.331	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3311	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3312	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3313	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPGS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E08.3319	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.339	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3391	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3392	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3393	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3399	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.341	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3411	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3412	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3413	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3419	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.349	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3491	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3492	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3493	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3499	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.351	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3511	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3512	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3513	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E08.3519	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.3521	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E08.3522	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E08.3523	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3529	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E08.3531	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E08.3532	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E08.3533	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3539	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E08.3541	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E08.3542	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E08.3543	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E08.3549	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E08.3551	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E08.3552	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E08.3553	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPGS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E08.3559	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E08.359	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3591	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3592	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3593	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3599	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.36	Diabetes mellitus due to underlying condition with diabetic cataract	Diagnosis	ICD-10-CM
E08.37X1	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E08.37X2	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E08.37X3	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E08.37X9	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E08.39	Diabetes mellitus due to underlying condition with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E08.40	Diabetes mellitus due to underlying condition with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E08.41	Diabetes mellitus due to underlying condition with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E08.42	Diabetes mellitus due to underlying condition with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E08.43	Diabetes mellitus due to underlying condition with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E08.44	Diabetes mellitus due to underlying condition with diabetic amyotrophy	Diagnosis	ICD-10-CM
E08.49	Diabetes mellitus due to underlying condition with other diabetic neurological complication	Diagnosis	ICD-10-CM
E08.51	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E08.52	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E08.59	Diabetes mellitus due to underlying condition with other circulatory complications	Diagnosis	ICD-10-CM
E08.610	Diabetes mellitus due to underlying condition with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E08.618	Diabetes mellitus due to underlying condition with other diabetic arthropathy	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPGS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E08.620	Diabetes mellitus due to underlying condition with diabetic dermatitis	Diagnosis	ICD-10-CM
E08.621	Diabetes mellitus due to underlying condition with foot ulcer	Diagnosis	ICD-10-CM
E08.622	Diabetes mellitus due to underlying condition with other skin ulcer	Diagnosis	ICD-10-CM
E08.628	Diabetes mellitus due to underlying condition with other skin complications	Diagnosis	ICD-10-CM
E08.630	Diabetes mellitus due to underlying condition with periodontal disease	Diagnosis	ICD-10-CM
E08.638	Diabetes mellitus due to underlying condition with other oral complications	Diagnosis	ICD-10-CM
E08.641	Diabetes mellitus due to underlying condition with hypoglycemia with coma	Diagnosis	ICD-10-CM
	Diabetes mellitus due to underlying condition with hypoglycemia without coma	Diagnosis	ICD-10-CM
E08.649			
E08.65	Diabetes mellitus due to underlying condition with hyperglycemia	Diagnosis	ICD-10-CM
	Diabetes mellitus due to underlying condition with other specified complication	Diagnosis	ICD-10-CM
E08.69			
E08.8	Diabetes mellitus due to underlying condition with unspecified complications	Diagnosis	ICD-10-CM
E08.9	Diabetes mellitus due to underlying condition without complications	Diagnosis	ICD-10-CM
	Drug or chemical induced diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E09.00			
E09.01	Drug or chemical induced diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E09.10	Drug or chemical induced diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E09.11	Drug or chemical induced diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E09.21	Drug or chemical induced diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E09.22			
E09.29	Drug or chemical induced diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.311			
E09.319	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.321			
E09.3211	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3212			
E09.3213	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.3219			

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E09.329	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3291	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3292	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3293	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3299	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.331	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3311	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3312	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3313	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3319	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.339	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3391	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3392	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3393	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3399	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.341	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3411	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3412	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3413	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3419	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.349	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E09.3491	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3492	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3493	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3499	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.351	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3511	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3512	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3513	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3519	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.3521	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E09.3522	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E09.3523	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E09.3529	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E09.3531	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E09.3532	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E09.3533	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E09.3539	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E09.3541	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E09.3542	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E09.3543	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E09.3549	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E09.3551	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E09.3552	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E09.3553	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E09.3559	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E09.359	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3591	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3592	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3593	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3599	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.36	Drug or chemical induced diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E09.37X1	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E09.37X2	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E09.37X3	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E09.37X9	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E09.39	Drug or chemical induced diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E09.40	Drug or chemical induced diabetes mellitus with neurological complications with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E09.41	Drug or chemical induced diabetes mellitus with neurological complications with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E09.42	Drug or chemical induced diabetes mellitus with neurological complications with diabetic polyneuropathy	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPGS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E09.43	Drug or chemical induced diabetes mellitus with neurological complications with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E09.44	Drug or chemical induced diabetes mellitus with neurological complications with diabetic amyotrophy	Diagnosis	ICD-10-CM
E09.49	Drug or chemical induced diabetes mellitus with neurological complications with other diabetic neurological complication	Diagnosis	ICD-10-CM
E09.51	Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E09.52	Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E09.59	Drug or chemical induced diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E09.610	Drug or chemical induced diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E09.618	Drug or chemical induced diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E09.620	Drug or chemical induced diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E09.621	Drug or chemical induced diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E09.622	Drug or chemical induced diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E09.628	Drug or chemical induced diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E09.630	Drug or chemical induced diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E09.638	Drug or chemical induced diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E09.641	Drug or chemical induced diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E09.649	Drug or chemical induced diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E09.65	Drug or chemical induced diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E09.69	Drug or chemical induced diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E09.8	Drug or chemical induced diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E09.9	Drug or chemical induced diabetes mellitus without complications	Diagnosis	ICD-10-CM
E10.10	Type 1 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E10.11	Type 1 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E10.311	Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.319	Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.321	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E10.3211	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3212	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3219	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.329	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3291	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3292	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3293	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3299	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.331	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3311	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3312	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3319	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.339	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3391	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3392	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3393	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3399	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.341	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3411	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3412	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3419	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.349	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3491	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3492	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3493	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3499	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.351	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3511	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3512	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3513	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3519	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.3521	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3522	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E10.3523	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3529	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E10.3531	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3532	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E10.3533	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3539	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E10.3541	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E10.3542	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E10.3543	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E10.3549	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E10.3551	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E10.3552	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E10.3553	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E10.3559	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E10.359	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3591	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3592	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3593	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3599	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.36	Type 1 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E10.37X1	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E10.37X2	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E10.37X3	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E10.37X9	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E10.39	Type 1 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E10.40	Type 1 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E10.41	Type 1 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E10.42	Type 1 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E10.43	Type 1 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E10.44	Type 1 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E10.49	Type 1 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E10.51	Type 1 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPSC), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E10.52	Type 1 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E10.59	Type 1 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E10.610	Type 1 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E10.618	Type 1 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E10.620	Type 1 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E10.621	Type 1 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E10.622	Type 1 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E10.628	Type 1 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E10.630	Type 1 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E10.638	Type 1 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E10.641	Type 1 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E10.649	Type 1 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E10.65	Type 1 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E10.69	Type 1 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E10.8	Type 1 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E10.9	Type 1 diabetes mellitus without complications	Diagnosis	ICD-10-CM
	Type 2 diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)		
E11.00	Type 2 diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E11.01	Type 2 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E11.10	Type 2 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E11.11	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
	Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema		
E11.311	Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.319	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.321	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3211	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3212	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.3219	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.329	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3291	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3292			

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E11.3293	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3299	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.331	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3311	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3312	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3319	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.339	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3391	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3392	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3393	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3399	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.341	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3411	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3412	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3413	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3419	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.349	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3491	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3492	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3493	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3499	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPGS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E11.351	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3511	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3512	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3519	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.3521	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3522	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3523	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3529	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.3531	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3532	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3533	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3539	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.3541	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E11.3542	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E11.3543	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E11.3549	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E11.3551	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E11.3552	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E11.3553	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E11.3559	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E11.359	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3591	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3592	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3593	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3599	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.36	Type 2 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E11.37X1	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E11.37X2	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E11.37X3	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E11.37X9	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E11.39	Type 2 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E11.40	Type 2 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E11.41	Type 2 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E11.42	Type 2 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E11.43	Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E11.44	Type 2 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E11.49	Type 2 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E11.51	Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E11.52	Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E11.59	Type 2 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E11.610	Type 2 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E11.618	Type 2 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E11.620	Type 2 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E11.621	Type 2 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E11.622	Type 2 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E11.628	Type 2 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E11.630	Type 2 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E11.638	Type 2 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E11.641	Type 2 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E11.649	Type 2 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E11.65	Type 2 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E11.69	Type 2 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPSC), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E11.8	Type 2 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E11.9	Type 2 diabetes mellitus without complications	Diagnosis	ICD-10-CM
	Other specified diabetes mellitus with hyperosmolarity without nonketotic		
E13.00	hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E13.01	Other specified diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E13.10	Other specified diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E13.11	Other specified diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
	Other specified diabetes mellitus with unspecified diabetic retinopathy with		
E13.311	macular edema	Diagnosis	ICD-10-CM
	Other specified diabetes mellitus with unspecified diabetic retinopathy		
E13.319	without macular edema	Diagnosis	ICD-10-CM
	Other specified diabetes mellitus with mild nonproliferative diabetic		
E13.321	retinopathy with macular edema	Diagnosis	ICD-10-CM
	Other specified diabetes mellitus with mild nonproliferative diabetic		
E13.3211	retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
	Other specified diabetes mellitus with mild nonproliferative diabetic		
E13.3212	retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
	Other specified diabetes mellitus with mild nonproliferative diabetic		
E13.3213	retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
	Other specified diabetes mellitus with mild nonproliferative diabetic		
E13.3219	retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
	Other specified diabetes mellitus with mild nonproliferative diabetic		
E13.329	retinopathy without macular edema	Diagnosis	ICD-10-CM
	Other specified diabetes mellitus with mild nonproliferative diabetic		
E13.3291	retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
	Other specified diabetes mellitus with mild nonproliferative diabetic		
E13.3292	retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
	Other specified diabetes mellitus with mild nonproliferative diabetic		
E13.3293	retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
	Other specified diabetes mellitus with mild nonproliferative diabetic		
E13.3299	retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
	Other specified diabetes mellitus with moderate nonproliferative diabetic		
E13.331	retinopathy with macular edema	Diagnosis	ICD-10-CM
	Other specified diabetes mellitus with moderate nonproliferative diabetic		
E13.3311	retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
	Other specified diabetes mellitus with moderate nonproliferative diabetic		
E13.3312	retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
	Other specified diabetes mellitus with moderate nonproliferative diabetic		
E13.3313	retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
	Other specified diabetes mellitus with moderate nonproliferative diabetic		
E13.3319	retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E13.339	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3391	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3392	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3393	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3399	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.341	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3411	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3412	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3413	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3419	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.349	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3491	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3492	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3493	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3499	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.351	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3511	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3512	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3513	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3519	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.3521	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3522	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E13.3523	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3529	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.3531	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3532	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3533	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3539	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.3541	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E13.3542	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E13.3543	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E13.3549	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E13.3551	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E13.3552	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E13.3553	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E13.3559	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E13.359	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3591	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3592	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3593	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3599	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.36	Other specified diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
E13.39	Other specified diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E13.40	Other specified diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E13.41	Other specified diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E13.42	Other specified diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E13.43	Other specified diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E13.44	Other specified diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E13.49	Other specified diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E13.51	Other specified diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E13.52	Other specified diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E13.59	Other specified diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E13.610	Other specified diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E13.618	Other specified diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E13.620	Other specified diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E13.621	Other specified diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E13.622	Other specified diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E13.628	Other specified diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E13.630	Other specified diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E13.638	Other specified diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E13.641	Other specified diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E13.649	Other specified diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E13.65	Other specified diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E13.69	Other specified diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E13.8	Other specified diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E13.9	Other specified diabetes mellitus without complications	Diagnosis	ICD-10-CM

Drug Abuse

F11.10	Opioid abuse, uncomplicated	Diagnosis	ICD-10-CM
F11.11	Opioid abuse, in remission	Diagnosis	ICD-10-CM
F11.120	Opioid abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.121	Opioid abuse with intoxication delirium	Diagnosis	ICD-10-CM
F11.122	Opioid abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.129	Opioid abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.13	Opioid abuse with withdrawal	Diagnosis	ICD-10-CM
F11.14	Opioid abuse with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.150	Opioid abuse with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.151	Opioid abuse with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.159	Opioid abuse with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.181	Opioid abuse with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.182	Opioid abuse with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.188	Opioid abuse with other opioid-induced disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
F11.19	Opioid abuse with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.20	Opioid dependence, uncomplicated	Diagnosis	ICD-10-CM
F11.220	Opioid dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.221	Opioid dependence with intoxication delirium	Diagnosis	ICD-10-CM
F11.222	Opioid dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.229	Opioid dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.23	Opioid dependence with withdrawal	Diagnosis	ICD-10-CM
F11.24	Opioid dependence with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.250	Opioid dependence with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
	Opioid dependence with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.251	Opioid dependence with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.281	Opioid dependence with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.282	Opioid dependence with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.288	Opioid dependence with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.29	Opioid dependence with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.90	Opioid use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F11.920	Opioid use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.921	Opioid use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F11.922	Opioid use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.929	Opioid use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.93	Opioid use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F11.94	Opioid use, unspecified with opioid-induced mood disorder	Diagnosis	ICD-10-CM
	Opioid use, unspecified with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.950	Opioid use, unspecified with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.951		Diagnosis	ICD-10-CM
F11.959	Opioid use, unspecified with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.981	Opioid use, unspecified with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.982	Opioid use, unspecified with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.988	Opioid use, unspecified with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.99	Opioid use, unspecified with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F12.10	Cannabis abuse, uncomplicated	Diagnosis	ICD-10-CM
F12.11	Cannabis abuse, in remission	Diagnosis	ICD-10-CM
F12.120	Cannabis abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.121	Cannabis abuse with intoxication delirium	Diagnosis	ICD-10-CM
F12.122	Cannabis abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.129	Cannabis abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.13	Cannabis abuse with withdrawal	Diagnosis	ICD-10-CM
F12.150	Cannabis abuse with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.151	Cannabis abuse with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.159	Cannabis abuse with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.180	Cannabis abuse with cannabis-induced anxiety disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPGS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
F12.188	Cannabis abuse with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.19	Cannabis abuse with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.20	Cannabis dependence, uncomplicated	Diagnosis	ICD-10-CM
F12.220	Cannabis dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.221	Cannabis dependence with intoxication delirium	Diagnosis	ICD-10-CM
F12.222	Cannabis dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.229	Cannabis dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.250	Cannabis dependence with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.251	Cannabis dependence with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.259	Cannabis dependence with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.280	Cannabis dependence with cannabis-induced anxiety disorder	Diagnosis	ICD-10-CM
F12.288	Cannabis dependence with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.29	Cannabis dependence with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.90	Cannabis use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F12.920	Cannabis use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.921	Cannabis use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F12.922	Cannabis use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.929	Cannabis use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.950	Cannabis use, unspecified with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.951	Cannabis use, unspecified with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.959	Cannabis use, unspecified with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.980	Cannabis use, unspecified with anxiety disorder	Diagnosis	ICD-10-CM
F12.988	Cannabis use, unspecified with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.99	Cannabis use, unspecified with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F13.10	Sedative, hypnotic or anxiolytic abuse, uncomplicated	Diagnosis	ICD-10-CM
F13.11	Sedative, hypnotic or anxiolytic abuse, in remission	Diagnosis	ICD-10-CM
F13.120	Sedative, hypnotic or anxiolytic abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.121	Sedative, hypnotic or anxiolytic abuse with intoxication delirium	Diagnosis	ICD-10-CM
F13.129	Sedative, hypnotic or anxiolytic abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.130	Sedative, hypnotic or anxiolytic abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.131	Sedative, hypnotic or anxiolytic abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F13.132	Sedative, hypnotic or anxiolytic abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F13.139	Sedative, hypnotic or anxiolytic abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.14	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.150	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.151	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.159	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.180	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPGS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
F13.181	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.182	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.188	Sedative, hypnotic or anxiolytic abuse with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.19	Sedative, hypnotic or anxiolytic abuse with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.20	Sedative, hypnotic or anxiolytic dependence, uncomplicated	Diagnosis	ICD-10-CM
F13.220	Sedative, hypnotic or anxiolytic dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.221	Sedative, hypnotic or anxiolytic dependence with intoxication delirium	Diagnosis	ICD-10-CM
F13.229	Sedative, hypnotic or anxiolytic dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.230	Sedative, hypnotic or anxiolytic dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.231	Sedative, hypnotic or anxiolytic dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F13.232	Sedative, hypnotic or anxiolytic dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F13.239	Sedative, hypnotic or anxiolytic dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.24	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.250	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.251	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.259	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.26	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F13.27	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting dementia	Diagnosis	ICD-10-CM
F13.280	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.281	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.282	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.288	Sedative, hypnotic or anxiolytic dependence with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.29	Sedative, hypnotic or anxiolytic dependence with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.90	Sedative, hypnotic, or anxiolytic use, unspecified, uncomplicated	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
F13.920	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.921	Sedative, hypnotic or anxiolytic use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F13.929	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.930	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.931	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F13.932	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal with perceptual disturbances	Diagnosis	ICD-10-CM
F13.939	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.94	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.950	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.951	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.959	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.96	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F13.97	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting dementia	Diagnosis	ICD-10-CM
F13.980	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.981	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.982	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.988	Sedative, hypnotic or anxiolytic use, unspecified with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.99	Sedative, hypnotic or anxiolytic use, unspecified with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F14.10	Cocaine abuse, uncomplicated	Diagnosis	ICD-10-CM
F14.11	Cocaine abuse, in remission	Diagnosis	ICD-10-CM
F14.120	Cocaine abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.121	Cocaine abuse with intoxication with delirium	Diagnosis	ICD-10-CM
F14.122	Cocaine abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.129	Cocaine abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.13	Cocaine abuse, unspecified with withdrawal	Diagnosis	ICD-10-CM
F14.14	Cocaine abuse with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.150	Cocaine abuse with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
F14.151	Cocaine abuse with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.159	Cocaine abuse with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.180	Cocaine abuse with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.181	Cocaine abuse with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.182	Cocaine abuse with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.188	Cocaine abuse with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.19	Cocaine abuse with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.20	Cocaine dependence, uncomplicated	Diagnosis	ICD-10-CM
F14.220	Cocaine dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.221	Cocaine dependence with intoxication delirium	Diagnosis	ICD-10-CM
F14.222	Cocaine dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.229	Cocaine dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.23	Cocaine dependence with withdrawal	Diagnosis	ICD-10-CM
F14.24	Cocaine dependence with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.250	Cocaine dependence with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.251	Cocaine dependence with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.259	Cocaine dependence with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.280	Cocaine dependence with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.281	Cocaine dependence with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.282	Cocaine dependence with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.288	Cocaine dependence with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.29	Cocaine dependence with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.90	Cocaine use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F14.920	Cocaine use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.921	Cocaine use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F14.922	Cocaine use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.929	Cocaine use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.93	Cocaine use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F14.94	Cocaine use, unspecified with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.950	Cocaine use, unspecified with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.951	Cocaine use, unspecified with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.959	Cocaine use, unspecified with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.980	Cocaine use, unspecified with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.981	Cocaine use, unspecified with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.982	Cocaine use, unspecified with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.988	Cocaine use, unspecified with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.99	Cocaine use, unspecified with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F15.10	Other stimulant abuse, uncomplicated	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
F15.11	Other stimulant abuse, in remission	Diagnosis	ICD-10-CM
F15.120	Other stimulant abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.121	Other stimulant abuse with intoxication delirium	Diagnosis	ICD-10-CM
F15.122	Other stimulant abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.129	Other stimulant abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.13	Other stimulant abuse with withdrawal	Diagnosis	ICD-10-CM
F15.14	Other stimulant abuse with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
	Other stimulant abuse with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
	Other stimulant abuse with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.159	Other stimulant abuse with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.180	Other stimulant abuse with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.181	Other stimulant abuse with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.182	Other stimulant abuse with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.188	Other stimulant abuse with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.19	Other stimulant abuse with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.20	Other stimulant dependence, uncomplicated	Diagnosis	ICD-10-CM
F15.220	Other stimulant dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.221	Other stimulant dependence with intoxication delirium	Diagnosis	ICD-10-CM
	Other stimulant dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.229	Other stimulant dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.23	Other stimulant dependence with withdrawal	Diagnosis	ICD-10-CM
F15.24	Other stimulant dependence with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
	Other stimulant dependence with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
	Other stimulant dependence with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.259	Other stimulant dependence with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.280	Other stimulant dependence with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.281	Other stimulant dependence with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.282	Other stimulant dependence with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.288	Other stimulant dependence with other stimulant-induced disorder	Diagnosis	ICD-10-CM
	Other stimulant dependence with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.90	Other stimulant use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F15.920	Other stimulant use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.921	Other stimulant use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
	Other stimulant use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.929	Other stimulant use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.93	Other stimulant use, unspecified with withdrawal	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPGS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
F15.94	Other stimulant use, unspecified with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
	Other stimulant use, unspecified with stimulant-induced psychotic disorder		
F15.950	with delusions	Diagnosis	ICD-10-CM
	Other stimulant use, unspecified with stimulant-induced psychotic disorder		
F15.951	with hallucinations	Diagnosis	ICD-10-CM
	Other stimulant use, unspecified with stimulant-induced psychotic disorder,		
F15.959	unspecified	Diagnosis	ICD-10-CM
	Other stimulant use, unspecified with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.981	Other stimulant use, unspecified with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.982	Other stimulant use, unspecified with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.988	Other stimulant use, unspecified with other stimulant-induced disorder	Diagnosis	ICD-10-CM
	Other stimulant use, unspecified with unspecified stimulant-induced		
F15.99	disorder	Diagnosis	ICD-10-CM
F16.10	Hallucinogen abuse, uncomplicated	Diagnosis	ICD-10-CM
F16.11	Hallucinogen abuse, in remission	Diagnosis	ICD-10-CM
F16.120	Hallucinogen abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.121	Hallucinogen abuse with intoxication with delirium	Diagnosis	ICD-10-CM
F16.122	Hallucinogen abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F16.129	Hallucinogen abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.14	Hallucinogen abuse with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
	Hallucinogen abuse with hallucinogen-induced psychotic disorder with		
F16.150	delusions	Diagnosis	ICD-10-CM
	Hallucinogen abuse with hallucinogen-induced psychotic disorder with		
F16.151	hallucinations	Diagnosis	ICD-10-CM
	Hallucinogen abuse with hallucinogen-induced psychotic disorder,		
F16.159	unspecified	Diagnosis	ICD-10-CM
F16.180	Hallucinogen abuse with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
	Hallucinogen abuse with hallucinogen persisting perception disorder		
F16.183	(flashbacks)	Diagnosis	ICD-10-CM
F16.188	Hallucinogen abuse with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.19	Hallucinogen abuse with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.20	Hallucinogen dependence, uncomplicated	Diagnosis	ICD-10-CM
F16.220	Hallucinogen dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.221	Hallucinogen dependence with intoxication with delirium	Diagnosis	ICD-10-CM
F16.229	Hallucinogen dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.24	Hallucinogen dependence with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
	Hallucinogen dependence with hallucinogen-induced psychotic disorder with		
F16.250	delusions	Diagnosis	ICD-10-CM
	Hallucinogen dependence with hallucinogen-induced psychotic disorder with		
F16.251	hallucinations	Diagnosis	ICD-10-CM
	Hallucinogen dependence with hallucinogen-induced psychotic disorder,		
F16.259	unspecified	Diagnosis	ICD-10-CM
F16.280	Hallucinogen dependence with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPGS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
	Hallucinogen dependence with hallucinogen persisting perception disorder		
F16.283	(flashbacks)	Diagnosis	ICD-10-CM
F16.288	Hallucinogen dependence with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.29	Hallucinogen dependence with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.90	Hallucinogen use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F16.920	Hallucinogen use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.921	Hallucinogen use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F16.929	Hallucinogen use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.94	Hallucinogen use, unspecified with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder		
F16.950	with delusions	Diagnosis	ICD-10-CM
	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder		
F16.951	with hallucinations	Diagnosis	ICD-10-CM
	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder, unspecified		
F16.959		Diagnosis	ICD-10-CM
F16.980	Hallucinogen use, unspecified with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
	Hallucinogen use, unspecified with hallucinogen persisting perception disorder (flashbacks)		
F16.983		Diagnosis	ICD-10-CM
F16.988	Hallucinogen use, unspecified with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
	Hallucinogen use, unspecified with unspecified hallucinogen-induced disorder		
F16.99		Diagnosis	ICD-10-CM
F18.10	Inhalant abuse, uncomplicated	Diagnosis	ICD-10-CM
F18.11	Inhalant abuse, in remission	Diagnosis	ICD-10-CM
F18.120	Inhalant abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.121	Inhalant abuse with intoxication delirium	Diagnosis	ICD-10-CM
F18.129	Inhalant abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.14	Inhalant abuse with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.150	Inhalant abuse with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.151	Inhalant abuse with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.159	Inhalant abuse with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.17	Inhalant abuse with inhalant-induced dementia	Diagnosis	ICD-10-CM
F18.180	Inhalant abuse with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.188	Inhalant abuse with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.19	Inhalant abuse with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.20	Inhalant dependence, uncomplicated	Diagnosis	ICD-10-CM
F18.220	Inhalant dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.221	Inhalant dependence with intoxication delirium	Diagnosis	ICD-10-CM
F18.229	Inhalant dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.24	Inhalant dependence with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
	Inhalant dependence with inhalant-induced psychotic disorder with delusions		
F18.250		Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPGS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
F18.251	Inhalant dependence with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.259	Inhalant dependence with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.27	Inhalant dependence with inhalant-induced dementia	Diagnosis	ICD-10-CM
F18.280	Inhalant dependence with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.288	Inhalant dependence with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.29	Inhalant dependence with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.90	Inhalant use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F18.920	Inhalant use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.921	Inhalant use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F18.929	Inhalant use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.94	Inhalant use, unspecified with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.950	Inhalant use, unspecified with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.951	Inhalant use, unspecified with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.959	Inhalant use, unspecified with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.97	Inhalant use, unspecified with inhalant-induced persisting dementia	Diagnosis	ICD-10-CM
F18.980	Inhalant use, unspecified with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.988	Inhalant use, unspecified with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.99	Inhalant use, unspecified with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F19.10	Other psychoactive substance abuse, uncomplicated	Diagnosis	ICD-10-CM
F19.11	Other psychoactive substance abuse, in remission	Diagnosis	ICD-10-CM
F19.120	Other psychoactive substance abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.121	Other psychoactive substance abuse with intoxication delirium	Diagnosis	ICD-10-CM
F19.122	Other psychoactive substance abuse with intoxication with perceptual disturbances	Diagnosis	ICD-10-CM
F19.129	Other psychoactive substance abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.130	Other psychoactive substance abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.131	Other psychoactive substance abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F19.132	Other psychoactive substance abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.139	Other psychoactive substance abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.14	Other psychoactive substance abuse with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.150	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.151	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.159	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.16	Other psychoactive substance abuse with psychoactive substance-induced persisting amnestic disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
F19.17	Other psychoactive substance abuse with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.180	Other psychoactive substance abuse with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.181	Other psychoactive substance abuse with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.182	Other psychoactive substance abuse with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.188	Other psychoactive substance abuse with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.19	Other psychoactive substance abuse with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.20	Other psychoactive substance dependence, uncomplicated	Diagnosis	ICD-10-CM
F19.21	Other psychoactive substance dependence, in remission	Diagnosis	ICD-10-CM
F19.220	Other psychoactive substance dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.221	Other psychoactive substance dependence with intoxication delirium	Diagnosis	ICD-10-CM
F19.222	Other psychoactive substance dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F19.229	Other psychoactive substance dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.230	Other psychoactive substance dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.231	Other psychoactive substance dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F19.232	Other psychoactive substance dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.239	Other psychoactive substance dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.24	Other psychoactive substance dependence with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.250	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.251	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.259	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.26	Other psychoactive substance dependence with psychoactive substance-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F19.27	Other psychoactive substance dependence with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.280	Other psychoactive substance dependence with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.281	Other psychoactive substance dependence with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.282	Other psychoactive substance dependence with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
F19.288	Other psychoactive substance dependence with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.29	Other psychoactive substance dependence with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.90	Other psychoactive substance use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F19.920	Other psychoactive substance use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.921	Other psychoactive substance use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F19.922	Other psychoactive substance use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F19.929	Other psychoactive substance use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.930	Other psychoactive substance use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.931	Other psychoactive substance use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F19.932	Other psychoactive substance use, unspecified with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.939	Other psychoactive substance use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.94	Other psychoactive substance use, unspecified with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.950	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.951	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.959	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.96	Other psychoactive substance use, unspecified with psychoactive substance-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F19.97	Other psychoactive substance use, unspecified with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.980	Other psychoactive substance use, unspecified with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.981	Other psychoactive substance use, unspecified with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.982	Other psychoactive substance use, unspecified with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.988	Other psychoactive substance use, unspecified with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.99	Other psychoactive substance use, unspecified with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
H2ZZZZ	Detoxification Services for Substance Abuse Treatment	Procedure	ICD-10-PCS
HZ30ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
HZ31ZZZ	Individual Counseling for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ32ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ33ZZZ	Individual Counseling for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ34ZZZ	Individual Counseling for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ35ZZZ	Individual Counseling for Substance Abuse Treatment, Vocational	Procedure	ICD-10-PCS
HZ36ZZZ	Individual Counseling for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
	Individual Counseling for Substance Abuse Treatment, Motivational		
HZ37ZZZ	Enhancement	Procedure	ICD-10-PCS
HZ38ZZZ	Individual Counseling for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ39ZZZ	Individual Counseling for Substance Abuse Treatment, Continuing Care	Procedure	ICD-10-PCS
HZ3BZZZ	Individual Counseling for Substance Abuse Treatment, Spiritual	Procedure	ICD-10-PCS
HZ40ZZZ	Group Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ41ZZZ	Group Counseling for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ42ZZZ	Group Counseling for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ43ZZZ	Group Counseling for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ44ZZZ	Group Counseling for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ45ZZZ	Group Counseling for Substance Abuse Treatment, Vocational	Procedure	ICD-10-PCS
HZ46ZZZ	Group Counseling for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
	Group Counseling for Substance Abuse Treatment, Motivational		
HZ47ZZZ	Enhancement	Procedure	ICD-10-PCS
HZ48ZZZ	Group Counseling for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ49ZZZ	Group Counseling for Substance Abuse Treatment, Continuing Care	Procedure	ICD-10-PCS
HZ4BZZZ	Group Counseling for Substance Abuse Treatment, Spiritual	Procedure	ICD-10-PCS
HZ50ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ51ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
	Individual Psychotherapy for Substance Abuse Treatment, Cognitive-Behavioral		
HZ52ZZZ	Individual Psychotherapy for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ54ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ55ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Interactive	Procedure	ICD-10-PCS
HZ56ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
	Individual Psychotherapy for Substance Abuse Treatment, Motivational		
HZ57ZZZ	Enhancement	Procedure	ICD-10-PCS
HZ58ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ59ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Supportive	Procedure	ICD-10-PCS
HZ5BZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychoanalysis	Procedure	ICD-10-PCS
HZ5CZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychodynamic	Procedure	ICD-10-PCS
	Individual Psychotherapy for Substance Abuse Treatment,		
HZ5DZZZ	Psychophysiological	Procedure	ICD-10-PCS
HZ63ZZZ	Family Counseling for Substance Abuse Treatment	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
HZ83ZZZ	Medication Management for Substance Abuse Treatment, Antabuse	Procedure	ICD-10-PCS
HZ86ZZZ	Medication Management for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
	Medication Management for Substance Abuse Treatment, Psychiatric		
HZ88ZZZ	Medication	Procedure	ICD-10-PCS
	Medication Management for Substance Abuse Treatment, Other		
HZ89ZZZ	Replacement Medication	Procedure	ICD-10-PCS
HZ93ZZZ	Pharmacotherapy for Substance Abuse Treatment, Antabuse	Procedure	ICD-10-PCS
HZ96ZZZ	Pharmacotherapy for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
HZ98ZZZ	Pharmacotherapy for Substance Abuse Treatment, Psychiatric Medication	Procedure	ICD-10-PCS
	Pharmacotherapy for Substance Abuse Treatment, Other Replacement		
HZ99ZZZ	Medication	Procedure	ICD-10-PCS
	Maternal care for (suspected) damage to fetus by drugs, not applicable or unspecified		
O35.5XX0	Maternal care for (suspected) damage to fetus by drugs, fetus 1	Diagnosis	ICD-10-CM
O35.5XX1	Maternal care for (suspected) damage to fetus by drugs, fetus 2	Diagnosis	ICD-10-CM
O35.5XX2	Maternal care for (suspected) damage to fetus by drugs, fetus 3	Diagnosis	ICD-10-CM
O35.5XX3	Maternal care for (suspected) damage to fetus by drugs, fetus 4	Diagnosis	ICD-10-CM
O35.5XX4	Maternal care for (suspected) damage to fetus by drugs, fetus 5	Diagnosis	ICD-10-CM
O35.5XX5	Maternal care for (suspected) damage to fetus by drugs, other fetus	Diagnosis	ICD-10-CM
O35.5XX9			
T40.0X1A	Poisoning by opium, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.0X2A	Poisoning by opium, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.0X3A	Poisoning by opium, assault, initial encounter	Diagnosis	ICD-10-CM
T40.0X4A	Poisoning by opium, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.0X5A	Adverse effect of opium, initial encounter	Diagnosis	ICD-10-CM
T40.0X5S	Adverse effect of opium, sequela	Diagnosis	ICD-10-CM
T40.1X1A	Poisoning by heroin, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.1X2A	Poisoning by heroin, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.1X3A	Poisoning by heroin, assault, initial encounter	Diagnosis	ICD-10-CM
T40.1X4A	Poisoning by heroin, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.2X1A	Poisoning by other opioids, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.2X2A	Poisoning by other opioids, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.2X3A	Poisoning by other opioids, assault, initial encounter	Diagnosis	ICD-10-CM
T40.2X4A	Poisoning by other opioids, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.3X1A	Poisoning by methadone, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.3X2A	Poisoning by methadone, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.3X3A	Poisoning by methadone, assault, initial encounter	Diagnosis	ICD-10-CM
T40.3X4A	Poisoning by methadone, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.3X5A	Adverse effect of methadone, initial encounter	Diagnosis	ICD-10-CM
T40.3X5S	Adverse effect of methadone, sequela	Diagnosis	ICD-10-CM
T40.411A	Poisoning by fentanyl or fentanyl analogs, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
	Poisoning by fentanyl or fentanyl analogs, intentional self-harm, initial		
T40.412A	encounter	Diagnosis	ICD-10-CM
T40.413A	Poisoning by fentanyl or fentanyl analogs, assault, initial encounter	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
T40.414A	Poisoning by fentanyl or fentanyl analogs, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.415A	Adverse effect of fentanyl or fentanyl analogs, initial encounter	Diagnosis	ICD-10-CM
T40.421A	Poisoning by tramadol, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.422A	Poisoning by tramadol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.423A	Poisoning by tramadol, assault, initial encounter	Diagnosis	ICD-10-CM
T40.424A	Poisoning by tramadol, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.425A	Adverse effect of tramadol, initial encounter	Diagnosis	ICD-10-CM
	Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter		
T40.491A		Diagnosis	ICD-10-CM
	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter		
T40.492A		Diagnosis	ICD-10-CM
T40.493A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.494A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.495A	Adverse effect of other synthetic narcotics, initial encounter	Diagnosis	ICD-10-CM
	Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter		
T40.4X1A		Diagnosis	ICD-10-CM
	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter		
T40.4X2A		Diagnosis	ICD-10-CM
T40.4X3A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.4X4A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
	Poisoning by unspecified narcotics, accidental (unintentional), initial encounter		
T40.601A		Diagnosis	ICD-10-CM
	Poisoning by unspecified narcotics, intentional self-harm, initial encounter		
T40.602A		Diagnosis	ICD-10-CM
T40.603A	Poisoning by unspecified narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.604A	Poisoning by unspecified narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
	Poisoning by other narcotics, accidental (unintentional), initial encounter		
T40.691A		Diagnosis	ICD-10-CM
T40.692A	Poisoning by other narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.693A	Poisoning by other narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.694A	Poisoning by other narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.711A	Poisoning by cannabis, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
	Poisoning by synthetic cannabinoids, accidental (unintentional), initial encounter		
T40.721A		Diagnosis	ICD-10-CM
	Poisoning by cannabis (derivatives), accidental (unintentional), initial encounter		
T40.7X1A		Diagnosis	ICD-10-CM
	Poisoning by lysergide [LSD], accidental (unintentional), initial encounter		
T40.8X1A	Poisoning by unspecified psychodysleptics [hallucinogens], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.901A	Poisoning by other psychodysleptics [hallucinogens], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
	Poisoning by other psychodysleptics [hallucinogens], accidental (unintentional), initial encounter		
T40.991A		Diagnosis	ICD-10-CM
Z71.51	Drug abuse counseling and surveillance of drug abuser	Diagnosis	ICD-10-CM

Endometrial Cancer

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
C54.0	Malignant neoplasm of isthmus uteri	Diagnosis	ICD-10-CM
C54.1	Malignant neoplasm of endometrium	Diagnosis	ICD-10-CM
C54.2	Malignant neoplasm of myometrium	Diagnosis	ICD-10-CM
C54.3	Malignant neoplasm of fundus uteri	Diagnosis	ICD-10-CM
C54.8	Malignant neoplasm of overlapping sites of corpus uteri	Diagnosis	ICD-10-CM
C54.9	Malignant neoplasm of corpus uteri, unspecified	Diagnosis	ICD-10-CM
D07.0	Carcinoma in situ of endometrium	Diagnosis	ICD-10-CM
Z85.42	Personal history of malignant neoplasm of other parts of uterus	Diagnosis	ICD-10-CM
Glaucoma			
H40.011	Open angle with borderline findings, low risk, right eye	Diagnosis	ICD-10-CM
H40.012	Open angle with borderline findings, low risk, left eye	Diagnosis	ICD-10-CM
H40.013	Open angle with borderline findings, low risk, bilateral	Diagnosis	ICD-10-CM
H40.019	Open angle with borderline findings, low risk, unspecified eye	Diagnosis	ICD-10-CM
H40.021	Open angle with borderline findings, high risk, right eye	Diagnosis	ICD-10-CM
H40.022	Open angle with borderline findings, high risk, left eye	Diagnosis	ICD-10-CM
H40.023	Open angle with borderline findings, high risk, bilateral	Diagnosis	ICD-10-CM
H40.029	Open angle with borderline findings, high risk, unspecified eye	Diagnosis	ICD-10-CM
H40.041	Steroid responder, right eye	Diagnosis	ICD-10-CM
H40.042	Steroid responder, left eye	Diagnosis	ICD-10-CM
H40.043	Steroid responder, bilateral	Diagnosis	ICD-10-CM
H40.049	Steroid responder, unspecified eye	Diagnosis	ICD-10-CM
H40.051	Ocular hypertension, right eye	Diagnosis	ICD-10-CM
H40.052	Ocular hypertension, left eye	Diagnosis	ICD-10-CM
H40.053	Ocular hypertension, bilateral	Diagnosis	ICD-10-CM
H40.059	Ocular hypertension, unspecified eye	Diagnosis	ICD-10-CM
H40.10X0	Unspecified open-angle glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.10X1	Unspecified open-angle glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.10X2	Unspecified open-angle glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.10X3	Unspecified open-angle glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.10X4	Unspecified open-angle glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.1110	Primary open-angle glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1111	Primary open-angle glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1112	Primary open-angle glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1113	Primary open-angle glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1114	Primary open-angle glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1120	Primary open-angle glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1121	Primary open-angle glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1122	Primary open-angle glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1123	Primary open-angle glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1124	Primary open-angle glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1130	Primary open-angle glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1131	Primary open-angle glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1132	Primary open-angle glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1133	Primary open-angle glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1134	Primary open-angle glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPGS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
H40.1190	Primary open-angle glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1191	Primary open-angle glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1192	Primary open-angle glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1193	Primary open-angle glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1194	Primary open-angle glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.11X0	Primary open-angle glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.11X1	Primary open-angle glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.11X2	Primary open-angle glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.11X3	Primary open-angle glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.11X4	Primary open-angle glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.1210	Low-tension glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1211	Low-tension glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1212	Low-tension glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1213	Low-tension glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1214	Low-tension glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1220	Low-tension glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1221	Low-tension glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1222	Low-tension glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1223	Low-tension glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1224	Low-tension glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1230	Low-tension glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1231	Low-tension glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1232	Low-tension glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1233	Low-tension glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1234	Low-tension glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1290	Low-tension glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1291	Low-tension glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1292	Low-tension glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1293	Low-tension glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1294	Low-tension glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1310	Pigmentary glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1311	Pigmentary glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1312	Pigmentary glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1313	Pigmentary glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1314	Pigmentary glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1320	Pigmentary glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1321	Pigmentary glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1322	Pigmentary glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1323	Pigmentary glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1324	Pigmentary glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1330	Pigmentary glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1331	Pigmentary glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1332	Pigmentary glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1333	Pigmentary glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1334	Pigmentary glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPGS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
H40.1390	Pigmentary glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1391	Pigmentary glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1392	Pigmentary glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1393	Pigmentary glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1394	Pigmentary glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
	Capsular glaucoma with pseudoexfoliation of lens, right eye, stage		
H40.1410	unspecified	Diagnosis	ICD-10-CM
H40.1411	Capsular glaucoma with pseudoexfoliation of lens, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1412	Capsular glaucoma with pseudoexfoliation of lens, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1413	Capsular glaucoma with pseudoexfoliation of lens, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1414	Capsular glaucoma with pseudoexfoliation of lens, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1420	Capsular glaucoma with pseudoexfoliation of lens, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1421	Capsular glaucoma with pseudoexfoliation of lens, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1422	Capsular glaucoma with pseudoexfoliation of lens, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1423	Capsular glaucoma with pseudoexfoliation of lens, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1424	Capsular glaucoma with pseudoexfoliation of lens, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1430	Capsular glaucoma with pseudoexfoliation of lens, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1431	Capsular glaucoma with pseudoexfoliation of lens, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1432	Capsular glaucoma with pseudoexfoliation of lens, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1433	Capsular glaucoma with pseudoexfoliation of lens, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1434	Capsular glaucoma with pseudoexfoliation of lens, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1490	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1491	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1492	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1493	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1494	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.151	Residual stage of open-angle glaucoma, right eye	Diagnosis	ICD-10-CM
H40.152	Residual stage of open-angle glaucoma, left eye	Diagnosis	ICD-10-CM
H40.153	Residual stage of open-angle glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.159	Residual stage of open-angle glaucoma, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
H40.20X0	Unspecified primary angle-closure glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.20X1	Unspecified primary angle-closure glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.20X2	Unspecified primary angle-closure glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.20X3	Unspecified primary angle-closure glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.20X4	Unspecified primary angle-closure glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.211	Acute angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.212	Acute angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.213	Acute angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.219	Acute angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.2210	Chronic angle-closure glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2211	Chronic angle-closure glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.2212	Chronic angle-closure glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.2213	Chronic angle-closure glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.2214	Chronic angle-closure glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.2220	Chronic angle-closure glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2221	Chronic angle-closure glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.2222	Chronic angle-closure glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.2223	Chronic angle-closure glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.2224	Chronic angle-closure glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.2230	Chronic angle-closure glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.2231	Chronic angle-closure glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.2232	Chronic angle-closure glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.2233	Chronic angle-closure glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.2234	Chronic angle-closure glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.2290	Chronic angle-closure glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2291	Chronic angle-closure glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.2292	Chronic angle-closure glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.2293	Chronic angle-closure glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.2294	Chronic angle-closure glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.231	Intermittent angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.232	Intermittent angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.233	Intermittent angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.239	Intermittent angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.241	Residual stage of angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.242	Residual stage of angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.243	Residual stage of angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.249	Residual stage of angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.30X0	Glaucoma secondary to eye trauma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.30X1	Glaucoma secondary to eye trauma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.30X2	Glaucoma secondary to eye trauma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.30X3	Glaucoma secondary to eye trauma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.30X4	Glaucoma secondary to eye trauma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.31X0	Glaucoma secondary to eye trauma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.31X1	Glaucoma secondary to eye trauma, right eye, mild stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
H40.31X2	Glaucoma secondary to eye trauma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.31X3	Glaucoma secondary to eye trauma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.31X4	Glaucoma secondary to eye trauma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.32X0	Glaucoma secondary to eye trauma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.32X1	Glaucoma secondary to eye trauma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.32X2	Glaucoma secondary to eye trauma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.32X3	Glaucoma secondary to eye trauma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.32X4	Glaucoma secondary to eye trauma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.33X0	Glaucoma secondary to eye trauma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.33X1	Glaucoma secondary to eye trauma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.33X2	Glaucoma secondary to eye trauma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.33X3	Glaucoma secondary to eye trauma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.33X4	Glaucoma secondary to eye trauma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.40X0	Glaucoma secondary to eye inflammation, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.40X1	Glaucoma secondary to eye inflammation, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.40X2	Glaucoma secondary to eye inflammation, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.40X3	Glaucoma secondary to eye inflammation, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.40X4	Glaucoma secondary to eye inflammation, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.41X0	Glaucoma secondary to eye inflammation, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.41X1	Glaucoma secondary to eye inflammation, right eye, mild stage	Diagnosis	ICD-10-CM
H40.41X2	Glaucoma secondary to eye inflammation, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.41X3	Glaucoma secondary to eye inflammation, right eye, severe stage	Diagnosis	ICD-10-CM
H40.41X4	Glaucoma secondary to eye inflammation, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.42X0	Glaucoma secondary to eye inflammation, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.42X1	Glaucoma secondary to eye inflammation, left eye, mild stage	Diagnosis	ICD-10-CM
H40.42X2	Glaucoma secondary to eye inflammation, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.42X3	Glaucoma secondary to eye inflammation, left eye, severe stage	Diagnosis	ICD-10-CM
H40.42X4	Glaucoma secondary to eye inflammation, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.43X0	Glaucoma secondary to eye inflammation, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.43X1	Glaucoma secondary to eye inflammation, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.43X2	Glaucoma secondary to eye inflammation, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.43X3	Glaucoma secondary to eye inflammation, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.43X4	Glaucoma secondary to eye inflammation, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.45X0	Glaucoma secondary to other eye disorders, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.45X1	Glaucoma secondary to other eye disorders, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.45X2	Glaucoma secondary to other eye disorders, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.45X3	Glaucoma secondary to other eye disorders, unspecified eye, severe stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
	Glaucoma secondary to other eye disorders, unspecified eye, indeterminate stage		
H40.50X4	Glaucoma secondary to other eye disorders, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.51X0	Glaucoma secondary to other eye disorders, right eye, mild stage	Diagnosis	ICD-10-CM
H40.51X1	Glaucoma secondary to other eye disorders, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.51X2	Glaucoma secondary to other eye disorders, right eye, severe stage	Diagnosis	ICD-10-CM
H40.51X3	Glaucoma secondary to other eye disorders, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.51X4	Glaucoma secondary to other eye disorders, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.52X0	Glaucoma secondary to other eye disorders, left eye, mild stage	Diagnosis	ICD-10-CM
H40.52X1	Glaucoma secondary to other eye disorders, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.52X2	Glaucoma secondary to other eye disorders, left eye, severe stage	Diagnosis	ICD-10-CM
H40.52X3	Glaucoma secondary to other eye disorders, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.52X4	Glaucoma secondary to other eye disorders, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.53X0	Glaucoma secondary to other eye disorders, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.53X1	Glaucoma secondary to other eye disorders, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.53X2	Glaucoma secondary to other eye disorders, drugs, stage unspecified	Diagnosis	ICD-10-CM
H40.53X3	Glaucoma secondary to other eye disorders, drugs, mild stage	Diagnosis	ICD-10-CM
H40.53X4	Glaucoma secondary to other eye disorders, drugs, moderate stage	Diagnosis	ICD-10-CM
H40.60X0	Glaucoma secondary to other eye disorders, drugs, severe stage	Diagnosis	ICD-10-CM
H40.60X1	Glaucoma secondary to drugs, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.60X2	Glaucoma secondary to drugs, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.60X3	Glaucoma secondary to drugs, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.60X4	Glaucoma secondary to drugs, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.61X0	Glaucoma secondary to drugs, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.61X1	Glaucoma secondary to drugs, right eye, mild stage	Diagnosis	ICD-10-CM
H40.61X2	Glaucoma secondary to drugs, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.61X3	Glaucoma secondary to drugs, right eye, severe stage	Diagnosis	ICD-10-CM
H40.61X4	Glaucoma secondary to drugs, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.62X0	Glaucoma secondary to drugs, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.62X1	Glaucoma secondary to drugs, left eye, mild stage	Diagnosis	ICD-10-CM
H40.62X2	Glaucoma secondary to drugs, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.62X3	Glaucoma secondary to drugs, left eye, severe stage	Diagnosis	ICD-10-CM
H40.62X4	Glaucoma secondary to drugs, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.63X0	Glaucoma secondary to drugs, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.63X1	Glaucoma secondary to drugs, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.63X2	Glaucoma secondary to drugs, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.63X3	Glaucoma secondary to drugs, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.63X4	Glaucoma secondary to drugs, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.811	Glaucoma with increased episcleral venous pressure, right eye	Diagnosis	ICD-10-CM
H40.812	Glaucoma with increased episcleral venous pressure, left eye	Diagnosis	ICD-10-CM
H40.813	Glaucoma with increased episcleral venous pressure, bilateral	Diagnosis	ICD-10-CM
H40.819	Glaucoma with increased episcleral venous pressure, unspecified eye	Diagnosis	ICD-10-CM
H40.821	Hypersecretion glaucoma, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
H40.822	Hypersecretion glaucoma, left eye	Diagnosis	ICD-10-CM
H40.823	Hypersecretion glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.829	Hypersecretion glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.831	Aqueous misdirection, right eye	Diagnosis	ICD-10-CM
H40.832	Aqueous misdirection, left eye	Diagnosis	ICD-10-CM
H40.833	Aqueous misdirection, bilateral	Diagnosis	ICD-10-CM
H40.839	Aqueous misdirection, unspecified eye	Diagnosis	ICD-10-CM
H40.89	Other specified glaucoma	Diagnosis	ICD-10-CM
H40.9	Unspecified glaucoma	Diagnosis	ICD-10-CM
H42	Glaucoma in diseases classified elsewhere	Diagnosis	ICD-10-CM
H44.511	Absolute glaucoma, right eye	Diagnosis	ICD-10-CM
H44.512	Absolute glaucoma, left eye	Diagnosis	ICD-10-CM
H44.513	Absolute glaucoma, bilateral	Diagnosis	ICD-10-CM
H44.519	Absolute glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H47.231	Glaucomatous optic atrophy, right eye	Diagnosis	ICD-10-CM
H47.232	Glaucomatous optic atrophy, left eye	Diagnosis	ICD-10-CM
H47.233	Glaucomatous optic atrophy, bilateral	Diagnosis	ICD-10-CM
H47.239	Glaucomatous optic atrophy, unspecified eye	Diagnosis	ICD-10-CM
Q15.0	Congenital glaucoma	Diagnosis	ICD-10-CM

Heart Failure

I09.81	Rheumatic heart failure	Diagnosis	ICD-10-CM
I11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney		
I13.0	disease	Diagnosis	ICD-10-CM
	Hypertensive heart and chronic kidney disease with heart failure and with		
I13.2	stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I42.0	Dilated cardiomyopathy	Diagnosis	ICD-10-CM
I42.5	Other restrictive cardiomyopathy	Diagnosis	ICD-10-CM
I42.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
I42.7	Cardiomyopathy due to drug and external agent	Diagnosis	ICD-10-CM
I42.8	Other cardiomyopathies	Diagnosis	ICD-10-CM
I43	Cardiomyopathy in diseases classified elsewhere	Diagnosis	ICD-10-CM
I50.1	Left ventricular failure, unspecified	Diagnosis	ICD-10-CM
I50.20	Unspecified systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.21	Acute systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.22	Chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.23	Acute on chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.30	Unspecified diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.31	Acute diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.32	Chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.33	Acute on chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
	Unspecified combined systolic (congestive) and diastolic (congestive) heart		
I50.40	failure	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I50.41	Acute combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.42	Chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.43	Acute on chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.810	Right heart failure, unspecified	Diagnosis	ICD-10-CM
I50.811	Acute right heart failure	Diagnosis	ICD-10-CM
I50.812	Chronic right heart failure	Diagnosis	ICD-10-CM
I50.813	Acute on chronic right heart failure	Diagnosis	ICD-10-CM
I50.814	Right heart failure due to left heart failure	Diagnosis	ICD-10-CM
I50.82	Biventricular heart failure	Diagnosis	ICD-10-CM
I50.83	High output heart failure	Diagnosis	ICD-10-CM
I50.84	End stage heart failure	Diagnosis	ICD-10-CM
I50.89	Other heart failure	Diagnosis	ICD-10-CM
I50.9	Heart failure, unspecified	Diagnosis	ICD-10-CM
P29.0	Neonatal cardiac failure	Diagnosis	ICD-10-CM
Hyperlipidemia			
E78.0	Pure hypercholesterolemia	Diagnosis	ICD-10-CM
E78.00	Pure hypercholesterolemia, unspecified	Diagnosis	ICD-10-CM
E78.01	Familial hypercholesterolemia	Diagnosis	ICD-10-CM
E78.1	Pure hyperglyceridemia	Diagnosis	ICD-10-CM
E78.2	Mixed hyperlipidemia	Diagnosis	ICD-10-CM
E78.3	Hyperchylomiconemia	Diagnosis	ICD-10-CM
E78.4	Other hyperlipidemia	Diagnosis	ICD-10-CM
E78.41	Elevated Lipoprotein(a)	Diagnosis	ICD-10-CM
E78.49	Other hyperlipidemia	Diagnosis	ICD-10-CM
E78.5	Hyperlipidemia, unspecified	Diagnosis	ICD-10-CM
Hypertension			
H35.031	Hypertensive retinopathy, right eye	Diagnosis	ICD-10-CM
H35.032	Hypertensive retinopathy, left eye	Diagnosis	ICD-10-CM
H35.033	Hypertensive retinopathy, bilateral	Diagnosis	ICD-10-CM
H35.039	Hypertensive retinopathy, unspecified eye	Diagnosis	ICD-10-CM
I10	Essential (primary) hypertension	Diagnosis	ICD-10-CM
I11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
I11.9	Hypertensive heart disease without heart failure	Diagnosis	ICD-10-CM
I12.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease	Diagnosis	ICD-10-CM
I12.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPGS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I15.0	Renovascular hypertension	Diagnosis	ICD-10-CM
I15.1	Hypertension secondary to other renal disorders	Diagnosis	ICD-10-CM
I15.2	Hypertension secondary to endocrine disorders	Diagnosis	ICD-10-CM
I15.8	Other secondary hypertension	Diagnosis	ICD-10-CM
I15.9	Secondary hypertension, unspecified	Diagnosis	ICD-10-CM
I1A.0	Resistant hypertension	Diagnosis	ICD-10-CM
I67.4	Hypertensive encephalopathy	Diagnosis	ICD-10-CM
N26.2	Page kidney	Diagnosis	ICD-10-CM

Ischemic Heart Disease

I20.0	Unstable angina	Diagnosis	ICD-10-CM
I20.1	Angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I20.2	Refractory angina pectoris	Diagnosis	ICD-10-CM
I20.8	Other forms of angina pectoris	Diagnosis	ICD-10-CM
I20.81	Angina pectoris with coronary microvascular dysfunction	Diagnosis	ICD-10-CM
I20.89	Other forms of angina pectoris	Diagnosis	ICD-10-CM
I24.0	Acute coronary thrombosis not resulting in myocardial infarction	Diagnosis	ICD-10-CM
I24.1	Dressler's syndrome	Diagnosis	ICD-10-CM
I24.8	Other forms of acute ischemic heart disease	Diagnosis	ICD-10-CM
I24.81	Acute coronary microvascular dysfunction	Diagnosis	ICD-10-CM
I24.89	Other forms of acute ischemic heart disease	Diagnosis	ICD-10-CM
I25.10	Atherosclerotic heart disease of native coronary artery without angina pectoris	Diagnosis	ICD-10-CM
I25.110	Atherosclerotic heart disease of native coronary artery with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.111	Atherosclerotic heart disease of native coronary artery with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.112	Atherosclerotic heart disease of native coronary artery with refractory angina pectoris	Diagnosis	ICD-10-CM
I25.118	Atherosclerotic heart disease of native coronary artery with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.119	Atherosclerotic heart disease of native coronary artery with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.3	Aneurysm of heart	Diagnosis	ICD-10-CM
I25.41	Coronary artery aneurysm	Diagnosis	ICD-10-CM
I25.42	Coronary artery dissection	Diagnosis	ICD-10-CM
I25.5	Ischemic cardiomyopathy	Diagnosis	ICD-10-CM
I25.6	Silent myocardial ischemia	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPGS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I25.700	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.701	Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.702	Atherosclerosis of coronary artery bypass graft(s), unspecified, with refractory angina pectoris	Diagnosis	ICD-10-CM
I25.708	Atherosclerosis of coronary artery bypass graft(s), unspecified, with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.710	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.711	Atherosclerosis of autologous vein coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.712	Atherosclerosis of autologous vein coronary artery bypass graft(s) with refractory angina pectoris	Diagnosis	ICD-10-CM
I25.718	Atherosclerosis of autologous vein coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.719	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.720	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.721	Atherosclerosis of autologous artery coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.722	Atherosclerosis of autologous artery coronary artery bypass graft(s) with refractory angina pectoris	Diagnosis	ICD-10-CM
I25.728	Atherosclerosis of autologous artery coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.729	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.730	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.731	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.732	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with refractory angina pectoris	Diagnosis	ICD-10-CM
I25.738	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.739	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.750	Atherosclerosis of native coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
I25.751	Atherosclerosis of native coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.752	Atherosclerosis of native coronary artery of transplanted heart with refractory angina pectoris	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPGS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I25.758	Atherosclerosis of native coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.759	Atherosclerosis of native coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.760	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
I25.761	Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.762	Atherosclerosis of bypass graft of coronary artery of transplanted heart with refractory angina pectoris	Diagnosis	ICD-10-CM
I25.768	Atherosclerosis of bypass graft of coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.769	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.790	Atherosclerosis of other coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.791	Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.792	Atherosclerosis of other coronary artery bypass graft(s) with refractory angina pectoris	Diagnosis	ICD-10-CM
I25.798	Atherosclerosis of other coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.799	Atherosclerosis of other coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.810	Atherosclerosis of coronary artery bypass graft(s) without angina pectoris	Diagnosis	ICD-10-CM
I25.811	Atherosclerosis of native coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
I25.812	Atherosclerosis of bypass graft of coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
I25.82	Chronic total occlusion of coronary artery	Diagnosis	ICD-10-CM
I25.83	Coronary atherosclerosis due to lipid rich plaque	Diagnosis	ICD-10-CM
I25.84	Coronary atherosclerosis due to calcified coronary lesion	Diagnosis	ICD-10-CM
I25.85	Chronic coronary microvascular dysfunction	Diagnosis	ICD-10-CM
I25.89	Other forms of chronic ischemic heart disease	Diagnosis	ICD-10-CM
I25.9	Chronic ischemic heart disease, unspecified	Diagnosis	ICD-10-CM

Liver Disease CCW

K70	Alcoholic liver disease	Diagnosis	ICD-10-CM
K70.0	Alcoholic fatty liver	Diagnosis	ICD-10-CM
K70.1	Alcoholic hepatitis	Diagnosis	ICD-10-CM
K70.10	Alcoholic hepatitis without ascites	Diagnosis	ICD-10-CM
K70.11	Alcoholic hepatitis with ascites	Diagnosis	ICD-10-CM
K70.2	Alcoholic fibrosis and sclerosis of liver	Diagnosis	ICD-10-CM
K70.3	Alcoholic cirrhosis of liver	Diagnosis	ICD-10-CM
K70.30	Alcoholic cirrhosis of liver without ascites	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
K70.31	Alcoholic cirrhosis of liver with ascites	Diagnosis	ICD-10-CM
K70.4	Alcoholic hepatic failure	Diagnosis	ICD-10-CM
K70.40	Alcoholic hepatic failure without coma	Diagnosis	ICD-10-CM
K70.41	Alcoholic hepatic failure with coma	Diagnosis	ICD-10-CM
K70.9	Alcoholic liver disease, unspecified	Diagnosis	ICD-10-CM
K71.0	Toxic liver disease with cholestasis	Diagnosis	ICD-10-CM
K71.11	Toxic liver disease with hepatic necrosis, with coma	Diagnosis	ICD-10-CM
K71.7	Toxic liver disease with fibrosis and cirrhosis of liver	Diagnosis	ICD-10-CM
K71.8	Toxic liver disease with other disorders of liver	Diagnosis	ICD-10-CM
K71.9	Toxic liver disease, unspecified	Diagnosis	ICD-10-CM
K72	Hepatic failure, not elsewhere classified	Diagnosis	ICD-10-CM
K72.0	Acute and subacute hepatic failure	Diagnosis	ICD-10-CM
K72.00	Acute and subacute hepatic failure without coma	Diagnosis	ICD-10-CM
K72.01	Acute and subacute hepatic failure with coma	Diagnosis	ICD-10-CM
K72.1	Chronic hepatic failure	Diagnosis	ICD-10-CM
K72.10	Chronic hepatic failure without coma	Diagnosis	ICD-10-CM
K72.11	Chronic hepatic failure with coma	Diagnosis	ICD-10-CM
K72.9	Hepatic failure, unspecified	Diagnosis	ICD-10-CM
K72.90	Hepatic failure, unspecified without coma	Diagnosis	ICD-10-CM
K72.91	Hepatic failure, unspecified with coma	Diagnosis	ICD-10-CM
K74	Fibrosis and cirrhosis of liver	Diagnosis	ICD-10-CM
K74.0	Hepatic fibrosis	Diagnosis	ICD-10-CM
K74.00	Hepatic fibrosis, unspecified	Diagnosis	ICD-10-CM
K74.01	Hepatic fibrosis, early fibrosis	Diagnosis	ICD-10-CM
K74.02	Hepatic fibrosis, advanced fibrosis	Diagnosis	ICD-10-CM
K74.1	Hepatic sclerosis	Diagnosis	ICD-10-CM
K74.2	Hepatic fibrosis with hepatic sclerosis	Diagnosis	ICD-10-CM
K74.3	Primary biliary cirrhosis	Diagnosis	ICD-10-CM
K74.4	Secondary biliary cirrhosis	Diagnosis	ICD-10-CM
K74.5	Biliary cirrhosis, unspecified	Diagnosis	ICD-10-CM
K74.6	Other and unspecified cirrhosis of liver	Diagnosis	ICD-10-CM
K74.60	Unspecified cirrhosis of liver	Diagnosis	ICD-10-CM
K74.69	Other cirrhosis of liver	Diagnosis	ICD-10-CM
K75.0	Abscess of liver	Diagnosis	ICD-10-CM
K75.1	Phlebitis of portal vein	Diagnosis	ICD-10-CM
K75.8	Other specified inflammatory liver diseases	Diagnosis	ICD-10-CM
K75.81	Nonalcoholic steatohepatitis (NASH)	Diagnosis	ICD-10-CM
K75.89	Other specified inflammatory liver diseases	Diagnosis	ICD-10-CM
K75.9	Inflammatory liver disease, unspecified	Diagnosis	ICD-10-CM
K76.0	Fatty (change of) liver, not elsewhere classified	Diagnosis	ICD-10-CM
K76.1	Chronic passive congestion of liver	Diagnosis	ICD-10-CM
K76.2	Central hemorrhagic necrosis of liver	Diagnosis	ICD-10-CM
K76.3	Infarction of liver	Diagnosis	ICD-10-CM
K76.5	Hepatic veno-occlusive disease	Diagnosis	ICD-10-CM
K76.6	Portal hypertension	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
K76.7	Hepatorenal syndrome	Diagnosis	ICD-10-CM
K76.8	Other specified diseases of liver	Diagnosis	ICD-10-CM
K76.81	Hepatopulmonary syndrome	Diagnosis	ICD-10-CM
K76.82	Hepatic encephalopathy	Diagnosis	ICD-10-CM
K76.89	Other specified diseases of liver	Diagnosis	ICD-10-CM
K76.9	Liver disease, unspecified	Diagnosis	ICD-10-CM
K77	Liver disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
K80.30	Calculus of bile duct with cholangitis, unspecified, without obstruction	Diagnosis	ICD-10-CM
K80.31	Calculus of bile duct with cholangitis, unspecified, with obstruction	Diagnosis	ICD-10-CM
K80.32	Calculus of bile duct with acute cholangitis without obstruction	Diagnosis	ICD-10-CM
K80.33	Calculus of bile duct with acute cholangitis with obstruction	Diagnosis	ICD-10-CM
K80.34	Calculus of bile duct with chronic cholangitis without obstruction	Diagnosis	ICD-10-CM
K80.35	Calculus of bile duct with chronic cholangitis with obstruction	Diagnosis	ICD-10-CM
K80.36	Calculus of bile duct with acute and chronic cholangitis without obstruction	Diagnosis	ICD-10-CM
K80.37	Calculus of bile duct with acute and chronic cholangitis with obstruction	Diagnosis	ICD-10-CM
K83.0	Cholangitis	Diagnosis	ICD-10-CM
R16.0	Hepatomegaly, not elsewhere classified	Diagnosis	ICD-10-CM
R16.2	Hepatomegaly with splenomegaly, not elsewhere classified	Diagnosis	ICD-10-CM
Z48.23	Encounter for aftercare following liver transplant	Diagnosis	ICD-10-CM
Z94.4	Liver transplant status	Diagnosis	ICD-10-CM

Liver Disease Extended DX List

K70	Alcoholic liver disease	Diagnosis	ICD-10-CM
K70.0	Alcoholic fatty liver	Diagnosis	ICD-10-CM
K70.1	Alcoholic hepatitis	Diagnosis	ICD-10-CM
K70.10	Alcoholic hepatitis without ascites	Diagnosis	ICD-10-CM
K70.11	Alcoholic hepatitis with ascites	Diagnosis	ICD-10-CM
K70.2	Alcoholic fibrosis and sclerosis of liver	Diagnosis	ICD-10-CM
K70.3	Alcoholic cirrhosis of liver	Diagnosis	ICD-10-CM
K70.30	Alcoholic cirrhosis of liver without ascites	Diagnosis	ICD-10-CM
K70.31	Alcoholic cirrhosis of liver with ascites	Diagnosis	ICD-10-CM
K70.4	Alcoholic hepatic failure	Diagnosis	ICD-10-CM
K70.40	Alcoholic hepatic failure without coma	Diagnosis	ICD-10-CM
K70.41	Alcoholic hepatic failure with coma	Diagnosis	ICD-10-CM
K70.9	Alcoholic liver disease, unspecified	Diagnosis	ICD-10-CM
K71	Toxic liver disease	Diagnosis	ICD-10-CM
K71.0	Toxic liver disease with cholestasis	Diagnosis	ICD-10-CM
K71.1	Toxic liver disease with hepatic necrosis	Diagnosis	ICD-10-CM
K71.10	Toxic liver disease with hepatic necrosis, without coma	Diagnosis	ICD-10-CM
K71.11	Toxic liver disease with hepatic necrosis, with coma	Diagnosis	ICD-10-CM
K71.2	Toxic liver disease with acute hepatitis	Diagnosis	ICD-10-CM
K71.3	Toxic liver disease with chronic persistent hepatitis	Diagnosis	ICD-10-CM
K71.4	Toxic liver disease with chronic lobular hepatitis	Diagnosis	ICD-10-CM
K71.5	Toxic liver disease with chronic active hepatitis	Diagnosis	ICD-10-CM
K71.50	Toxic liver disease with chronic active hepatitis without ascites	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
K71.51	Toxic liver disease with chronic active hepatitis with ascites	Diagnosis	ICD-10-CM
K71.6	Toxic liver disease with hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K71.7	Toxic liver disease with fibrosis and cirrhosis of liver	Diagnosis	ICD-10-CM
K71.8	Toxic liver disease with other disorders of liver	Diagnosis	ICD-10-CM
K71.9	Toxic liver disease, unspecified	Diagnosis	ICD-10-CM
K72	Hepatic failure, not elsewhere classified	Diagnosis	ICD-10-CM
K72.0	Acute and subacute hepatic failure	Diagnosis	ICD-10-CM
K72.00	Acute and subacute hepatic failure without coma	Diagnosis	ICD-10-CM
K72.01	Acute and subacute hepatic failure with coma	Diagnosis	ICD-10-CM
K72.1	Chronic hepatic failure	Diagnosis	ICD-10-CM
K72.10	Chronic hepatic failure without coma	Diagnosis	ICD-10-CM
K72.11	Chronic hepatic failure with coma	Diagnosis	ICD-10-CM
K72.9	Hepatic failure, unspecified	Diagnosis	ICD-10-CM
K72.90	Hepatic failure, unspecified without coma	Diagnosis	ICD-10-CM
K72.91	Hepatic failure, unspecified with coma	Diagnosis	ICD-10-CM
K73	Chronic hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K73.0	Chronic persistent hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K73.1	Chronic lobular hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K73.2	Chronic active hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K73.8	Other chronic hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K73.9	Chronic hepatitis, unspecified	Diagnosis	ICD-10-CM
K74	Fibrosis and cirrhosis of liver	Diagnosis	ICD-10-CM
K74.0	Hepatic fibrosis	Diagnosis	ICD-10-CM
K74.00	Hepatic fibrosis, unspecified	Diagnosis	ICD-10-CM
K74.01	Hepatic fibrosis, early fibrosis	Diagnosis	ICD-10-CM
K74.02	Hepatic fibrosis, advanced fibrosis	Diagnosis	ICD-10-CM
K74.1	Hepatic sclerosis	Diagnosis	ICD-10-CM
K74.2	Hepatic fibrosis with hepatic sclerosis	Diagnosis	ICD-10-CM
K74.3	Primary biliary cirrhosis	Diagnosis	ICD-10-CM
K74.4	Secondary biliary cirrhosis	Diagnosis	ICD-10-CM
K74.5	Biliary cirrhosis, unspecified	Diagnosis	ICD-10-CM
K74.6	Other and unspecified cirrhosis of liver	Diagnosis	ICD-10-CM
K74.60	Unspecified cirrhosis of liver	Diagnosis	ICD-10-CM
K74.69	Other cirrhosis of liver	Diagnosis	ICD-10-CM
K75	Other inflammatory liver diseases	Diagnosis	ICD-10-CM
K75.0	Abscess of liver	Diagnosis	ICD-10-CM
K75.1	Phlebitis of portal vein	Diagnosis	ICD-10-CM
K75.2	Nonspecific reactive hepatitis	Diagnosis	ICD-10-CM
K75.3	Granulomatous hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K75.4	Autoimmune hepatitis	Diagnosis	ICD-10-CM
K75.8	Other specified inflammatory liver diseases	Diagnosis	ICD-10-CM
K75.81	Nonalcoholic steatohepatitis (NASH)	Diagnosis	ICD-10-CM
K75.89	Other specified inflammatory liver diseases	Diagnosis	ICD-10-CM
K75.9	Inflammatory liver disease, unspecified	Diagnosis	ICD-10-CM
K76	Other diseases of liver	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
K76.0	Fatty (change of) liver, not elsewhere classified	Diagnosis	ICD-10-CM
K76.1	Chronic passive congestion of liver	Diagnosis	ICD-10-CM
K76.2	Central hemorrhagic necrosis of liver	Diagnosis	ICD-10-CM
K76.3	Infarction of liver	Diagnosis	ICD-10-CM
K76.4	Peliosis hepatitis	Diagnosis	ICD-10-CM
K76.5	Hepatic veno-occlusive disease	Diagnosis	ICD-10-CM
K76.6	Portal hypertension	Diagnosis	ICD-10-CM
K76.7	Hepatorenal syndrome	Diagnosis	ICD-10-CM
K76.8	Other specified diseases of liver	Diagnosis	ICD-10-CM
K76.81	Hepatopulmonary syndrome	Diagnosis	ICD-10-CM
K76.82	Hepatic encephalopathy	Diagnosis	ICD-10-CM
K76.89	Other specified diseases of liver	Diagnosis	ICD-10-CM
K76.9	Liver disease, unspecified	Diagnosis	ICD-10-CM
K77	Liver disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
K80.30	Calculus of bile duct with cholangitis, unspecified, without obstruction	Diagnosis	ICD-10-CM
K80.31	Calculus of bile duct with cholangitis, unspecified, with obstruction	Diagnosis	ICD-10-CM
K80.32	Calculus of bile duct with acute cholangitis without obstruction	Diagnosis	ICD-10-CM
K80.33	Calculus of bile duct with acute cholangitis with obstruction	Diagnosis	ICD-10-CM
K80.34	Calculus of bile duct with chronic cholangitis without obstruction	Diagnosis	ICD-10-CM
K80.35	Calculus of bile duct with chronic cholangitis with obstruction	Diagnosis	ICD-10-CM
K80.36	Calculus of bile duct with acute and chronic cholangitis without obstruction	Diagnosis	ICD-10-CM
K80.37	Calculus of bile duct with acute and chronic cholangitis with obstruction	Diagnosis	ICD-10-CM
K83.0	Cholangitis	Diagnosis	ICD-10-CM
R16.0	Hepatomegaly, not elsewhere classified	Diagnosis	ICD-10-CM
R16.2	Hepatomegaly with splenomegaly, not elsewhere classified	Diagnosis	ICD-10-CM
Z48.23	Encounter for aftercare following liver transplant	Diagnosis	ICD-10-CM
Z94.4	Liver transplant status	Diagnosis	ICD-10-CM

Liver Disease Procedures

06L20ZZ	Occlusion of Gastric Vein, Open Approach	Procedure	ICD-10-PCS
06L23ZZ	Occlusion of Gastric Vein, Percutaneous Approach	Procedure	ICD-10-PCS
06L24ZZ	Occlusion of Gastric Vein, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
06L30ZZ	Occlusion of Esophageal Vein, Open Approach	Procedure	ICD-10-PCS
06L33ZZ	Occlusion of Esophageal Vein, Percutaneous Approach	Procedure	ICD-10-PCS
06L34ZZ	Occlusion of Esophageal Vein, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
	Drainage of Greater Omentum with Drainage Device, Percutaneous Approach	Procedure	ICD-10-PCS
0D9S30Z	Drainage of Greater Omentum, Percutaneous Approach	Procedure	ICD-10-PCS
0D9S3ZZ	Drainage of Greater Omentum with Drainage Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D9S40Z	Drainage of Lesser Omentum with Drainage Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D9S4ZZ	Drainage of Lesser Omentum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D9T30Z	Drainage of Lesser Omentum with Drainage Device, Percutaneous Approach	Procedure	ICD-10-PCS
0D9T3ZZ	Drainage of Lesser Omentum, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
OD9T40Z	Drainage of Lesser Omentum with Drainage Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
OD9T4ZZ	Drainage of Lesser Omentum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
OD9V30Z	Drainage of Mesentery with Drainage Device, Percutaneous Approach	Procedure	ICD-10-PCS
OD9V3ZZ	Drainage of Mesentery, Percutaneous Approach	Procedure	ICD-10-PCS
OD9V40Z	Drainage of Mesentery with Drainage Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
OD9V4ZZ	Drainage of Mesentery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
OD9W30Z	Drainage of Peritoneum with Drainage Device, Percutaneous Approach	Procedure	ICD-10-PCS
OD9W3ZZ	Drainage of Peritoneum, Percutaneous Approach	Procedure	ICD-10-PCS
OD9W40Z	Drainage of Peritoneum with Drainage Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
OD9W4ZZ	Drainage of Peritoneum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
ODL57DZ	Occlusion of Esophagus with Intraluminal Device, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
ODL58DZ	Occlusion of Esophagus with Intraluminal Device, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0W9F30Z	Drainage of Abdominal Wall with Drainage Device, Percutaneous Approach	Procedure	ICD-10-PCS
0W9F3ZZ	Drainage of Abdominal Wall, Percutaneous Approach	Procedure	ICD-10-PCS
0W9F40Z	Drainage of Abdominal Wall with Drainage Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0W9F4ZZ	Drainage of Abdominal Wall, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0W9G30Z	Drainage of Peritoneal Cavity with Drainage Device, Percutaneous Approach	Procedure	ICD-10-PCS
0W9G3ZZ	Drainage of Peritoneal Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
0W9G40Z	Drainage of Peritoneal Cavity with Drainage Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0W9G4ZZ	Drainage of Peritoneal Cavity, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0W9J30Z	Drainage of Pelvic Cavity with Drainage Device, Percutaneous Approach	Procedure	ICD-10-PCS
0W9J3ZZ	Drainage of Pelvic Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
Lung Cancer			
C34.00	Malignant neoplasm of unspecified main bronchus	Diagnosis	ICD-10-CM
C34.01	Malignant neoplasm of right main bronchus	Diagnosis	ICD-10-CM
C34.02	Malignant neoplasm of left main bronchus	Diagnosis	ICD-10-CM
C34.10	Malignant neoplasm of upper lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.11	Malignant neoplasm of upper lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.12	Malignant neoplasm of upper lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.2	Malignant neoplasm of middle lobe, bronchus or lung	Diagnosis	ICD-10-CM
C34.30	Malignant neoplasm of lower lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.31	Malignant neoplasm of lower lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.32	Malignant neoplasm of lower lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.80	Malignant neoplasm of overlapping sites of unspecified bronchus and lung	Diagnosis	ICD-10-CM
C34.81	Malignant neoplasm of overlapping sites of right bronchus and lung	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
C34.82	Malignant neoplasm of overlapping sites of left bronchus and lung	Diagnosis	ICD-10-CM
C34.90	Malignant neoplasm of unspecified part of unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.91	Malignant neoplasm of unspecified part of right bronchus or lung	Diagnosis	ICD-10-CM
C34.92	Malignant neoplasm of unspecified part of left bronchus or lung	Diagnosis	ICD-10-CM
D02.20	Carcinoma in situ of unspecified bronchus and lung	Diagnosis	ICD-10-CM
D02.21	Carcinoma in situ of right bronchus and lung	Diagnosis	ICD-10-CM
D02.22	Carcinoma in situ of left bronchus and lung	Diagnosis	ICD-10-CM
Z85.110	Personal history of malignant carcinoid tumor of bronchus and lung	Diagnosis	ICD-10-CM
Z85.118	Personal history of other malignant neoplasm of bronchus and lung	Diagnosis	ICD-10-CM
Obesity			
OD16079	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
OD1607A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
OD1607B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
OD1607L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
OD160J9	Bypass Stomach to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
OD160JA	Bypass Stomach to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
OD160JB	Bypass Stomach to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
OD160JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
OD160K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
OD160KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
OD160KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
OD160KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
OD160Z9	Bypass Stomach to Duodenum, Open Approach	Procedure	ICD-10-PCS
OD160ZA	Bypass Stomach to Jejunum, Open Approach	Procedure	ICD-10-PCS
OD160ZB	Bypass Stomach to Ileum, Open Approach	Procedure	ICD-10-PCS
OD160ZL	Bypass Stomach to Transverse Colon, Open Approach	Procedure	ICD-10-PCS
OD16479	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
OD1647A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
OD1647B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
OD1647L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
0D164J9	Bypass Stomach to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JA	Bypass Stomach to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JB	Bypass Stomach to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164Z9	Bypass Stomach to Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZA	Bypass Stomach to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZB	Bypass Stomach to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZL	Bypass Stomach to Transverse Colon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D16879	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168J9	Bypass Stomach to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JA	Bypass Stomach to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JB	Bypass Stomach to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
0D168Z9	Bypass Stomach to Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZA	Bypass Stomach to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZB	Bypass Stomach to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZL	Bypass Stomach to Transverse Colon, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D19079	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1907A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1907B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190JB	Bypass Duodenum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190Z9	Bypass Duodenum to Duodenum, Open Approach	Procedure	ICD-10-PCS
0D190ZA	Bypass Duodenum to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D190ZB	Bypass Duodenum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D19479	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1947A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1947B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194JB	Bypass Duodenum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
0D194Z9	Bypass Duodenum to Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194ZA	Bypass Duodenum to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194ZB	Bypass Duodenum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Via		
0D19879	Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Via		
0D1987A	Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Via Natural		
0D1987B	or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
	Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or		
0D198J9	Artificial Opening Endoscopic	Procedure	ICD-10-PCS
	Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or		
0D198JA	Artificial Opening Endoscopic	Procedure	ICD-10-PCS
	Bypass Duodenum to Ileum with Synthetic Substitute, Via Natural or		
0D198JB	Artificial Opening Endoscopic	Procedure	ICD-10-PCS
	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Via		
0D198K9	Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Via		
0D198KA	Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Via		
0D198KB	Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
	Bypass Duodenum to Duodenum, Via Natural or Artificial Opening		
0D198Z9	Endoscopic	Procedure	ICD-10-PCS
	Bypass Duodenum to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198ZB	Bypass Duodenum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Open		
0D1A07A	Approach	Procedure	ICD-10-PCS
	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0JB	Bypass Jejunum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Open		
0D1A0KA	Approach	Procedure	ICD-10-PCS
	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Open		
0D1A0KB	Approach	Procedure	ICD-10-PCS
0D1A0ZA	Bypass Jejunum to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D1A0ZB	Bypass Jejunum to Ileum, Open Approach	Procedure	ICD-10-PCS
	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Percutaneous		
0D1A47A	Endoscopic Approach	Procedure	ICD-10-PCS
	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Percutaneous		
0D1A47B	Endoscopic Approach	Procedure	ICD-10-PCS
	Bypass Jejunum to Jejunum with Synthetic Substitute, Percutaneous		
0D1A4JA	Endoscopic Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
0D1A4JB	Bypass Jejunum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4ZA	Bypass Jejunum to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4ZB	Bypass Jejunum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A87A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A87B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8JB	Bypass Jejunum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZA	Bypass Jejunum to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZB	Bypass Jejunum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZH	Bypass Jejunum to Cecum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B07B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0JB	Bypass Ileum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0ZB	Bypass Ileum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D1B47B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4JB	Bypass Ileum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4ZB	Bypass Ileum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B87B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8JB	Bypass Ileum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8ZB	Bypass Ileum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8ZH	Bypass Ileum to Cecum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
0DB60Z3	Excision of Stomach, Open Approach, Vertical	Procedure	ICD-10-PCS
0DB60ZZ	Excision of Stomach, Open Approach	Procedure	ICD-10-PCS
0DB63Z3	Excision of Stomach, Percutaneous Approach, Vertical	Procedure	ICD-10-PCS
0DB63ZZ	Excision of Stomach, Percutaneous Approach	Procedure	ICD-10-PCS
0DB67Z3	Excision of Stomach, Via Natural or Artificial Opening, Vertical	Procedure	ICD-10-PCS
0DB67ZZ	Excision of Stomach, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DB68Z3	Excision of Stomach, Via Natural or Artificial Opening Endoscopic, Vertical	Procedure	ICD-10-PCS
0DB80ZZ	Excision of Small Intestine, Open Approach	Procedure	ICD-10-PCS
0DB90ZZ	Excision of Duodenum, Open Approach	Procedure	ICD-10-PCS
0DBB0ZZ	Excision of Ileum, Open Approach	Procedure	ICD-10-PCS
0DQ64ZZ	Repair Stomach, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
	Restriction of Stomach with Extraluminal Device, Percutaneous Endoscopic Approach		
0DV64CZ	Approach	Procedure	ICD-10-PCS
0F190Z3	Bypass Common Bile Duct to Duodenum, Open Approach	Procedure	ICD-10-PCS
OTRB07Z	Replacement of Bladder with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
43644	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and Roux-en-Y gastroenterostomy (roux limb 150 cm or less)	Procedure	CPT-4
43645	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and small intestine reconstruction to limit absorption	Procedure	CPT-4
43770	Laparoscopy, surgical, gastric restrictive procedure; placement of adjustable gastric restrictive device (eg, gastric band and subcutaneous port components)	Procedure	CPT-4
43842	Gastric restrictive procedure, without gastric bypass, for morbid obesity; vertical-banded gastroplasty	Procedure	CPT-4
43843	Gastric restrictive procedure, without gastric bypass, for morbid obesity; other than vertical-banded gastroplasty	Procedure	CPT-4
43845	Gastric restrictive procedure with partial gastrectomy, pylorus-preserving duodenoileostomy and ileoileostomy (50 to 100 cm common channel) to limit absorption (biliopancreatic diversion with duodenal switch)	Procedure	CPT-4
43846	Gastric restrictive procedure, with gastric bypass for morbid obesity; with short limb (150 cm or less) Roux-en-Y gastroenterostomy	Procedure	CPT-4
43847	Gastric restrictive procedure, with gastric bypass for morbid obesity; with small intestine reconstruction to limit absorption	Procedure	CPT-4
E66.01	Morbid (severe) obesity due to excess calories	Diagnosis	ICD-10-CM
E66.09	Other obesity due to excess calories	Diagnosis	ICD-10-CM
E66.1	Drug-induced obesity	Diagnosis	ICD-10-CM
E66.2	Morbid (severe) obesity with alveolar hypoventilation	Diagnosis	ICD-10-CM
E66.8	Other obesity	Diagnosis	ICD-10-CM
E66.9	Obesity, unspecified	Diagnosis	ICD-10-CM
K95.01	Infection due to gastric band procedure	Diagnosis	ICD-10-CM
K95.09	Other complications of gastric band procedure	Diagnosis	ICD-10-CM
K95.81	Infection due to other bariatric procedure	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPGS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
K95.89	Other complications of other bariatric procedure	Diagnosis	ICD-10-CM
O99.210	Obesity complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.211	Obesity complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.212	Obesity complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.213	Obesity complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.214	Obesity complicating childbirth	Diagnosis	ICD-10-CM
O99.215	Obesity complicating the puerperium	Diagnosis	ICD-10-CM
O99.840	Bariatric surgery status complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.841	Bariatric surgery status complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.842	Bariatric surgery status complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.843	Bariatric surgery status complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.844	Bariatric surgery status complicating childbirth	Diagnosis	ICD-10-CM
O99.845	Bariatric surgery status complicating the puerperium	Diagnosis	ICD-10-CM
Z68.30	Body mass index (BMI) 30.0-30.9, adult	Diagnosis	ICD-10-CM
Z68.31	Body mass index (BMI) 31.0-31.9, adult	Diagnosis	ICD-10-CM
Z68.32	Body mass index (BMI) 32.0-32.9, adult	Diagnosis	ICD-10-CM
Z68.33	Body mass index (BMI) 33.0-33.9, adult	Diagnosis	ICD-10-CM
Z68.34	Body mass index (BMI) 34.0-34.9, adult	Diagnosis	ICD-10-CM
Z68.35	Body mass index (BMI) 35.0-35.9, adult	Diagnosis	ICD-10-CM
Z68.36	Body mass index (BMI) 36.0-36.9, adult	Diagnosis	ICD-10-CM
Z68.37	Body mass index (BMI) 37.0-37.9, adult	Diagnosis	ICD-10-CM
Z68.38	Body mass index (BMI) 38.0-38.9, adult	Diagnosis	ICD-10-CM
Z68.39	Body mass index (BMI) 39.0-39.9, adult	Diagnosis	ICD-10-CM
Z68.41	Body mass index (BMI) 40.0-44.9, adult	Diagnosis	ICD-10-CM
Z68.42	Body mass index (BMI) 45.0-49.9, adult	Diagnosis	ICD-10-CM
Z68.43	Body mass index (BMI) 50-59.9, adult	Diagnosis	ICD-10-CM
Z68.44	Body mass index (BMI) 60.0-69.9, adult	Diagnosis	ICD-10-CM
Z68.45	Body mass index (BMI) 70 or greater, adult	Diagnosis	ICD-10-CM

Osteoporosis

M80.00XA	Age-related osteoporosis with current pathological fracture, unspecified site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.011A	Age-related osteoporosis with current pathological fracture, right shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.012A	Age-related osteoporosis with current pathological fracture, left shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.019A	Age-related osteoporosis with current pathological fracture, unspecified shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.021A	Age-related osteoporosis with current pathological fracture, right humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.022A	Age-related osteoporosis with current pathological fracture, left humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.029A	Age-related osteoporosis with current pathological fracture, unspecified humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.031A	Age-related osteoporosis with current pathological fracture, right forearm, initial encounter for fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPGS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M80.032A	Age-related osteoporosis with current pathological fracture, left forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.039A	Age-related osteoporosis with current pathological fracture, unspecified forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.041A	Age-related osteoporosis with current pathological fracture, right hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.042A	Age-related osteoporosis with current pathological fracture, left hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.049A	Age-related osteoporosis with current pathological fracture, unspecified hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.051A	Age-related osteoporosis with current pathological fracture, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.052A	Age-related osteoporosis with current pathological fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.059A	Age-related osteoporosis with current pathological fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.061A	Age-related osteoporosis with current pathological fracture, right lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.062A	Age-related osteoporosis with current pathological fracture, left lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.069A	Age-related osteoporosis with current pathological fracture, unspecified lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.071A	Age-related osteoporosis with current pathological fracture, right ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.072A	Age-related osteoporosis with current pathological fracture, left ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.079A	Age-related osteoporosis with current pathological fracture, unspecified ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.08XA	Age-related osteoporosis with current pathological fracture, vertebra(e), initial encounter for fracture	Diagnosis	ICD-10-CM
M80.0AXA	Age-related osteoporosis with current pathological fracture, other site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.0B1A	Age-related osteoporosis with current pathological fracture, right pelvis, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.0B2A	Age-related osteoporosis with current pathological fracture, left pelvis, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.0B9A	Age-related osteoporosis with current pathological fracture, unspecified pelvis, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.80XA	Other osteoporosis with current pathological fracture, unspecified site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.811A	Other osteoporosis with current pathological fracture, right shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.812A	Other osteoporosis with current pathological fracture, left shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPGS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M80.819A	Other osteoporosis with current pathological fracture, unspecified shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.821A	Other osteoporosis with current pathological fracture, right humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.822A	Other osteoporosis with current pathological fracture, left humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.829A	Other osteoporosis with current pathological fracture, unspecified humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.831A	Other osteoporosis with current pathological fracture, right forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.832A	Other osteoporosis with current pathological fracture, left forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.839A	Other osteoporosis with current pathological fracture, unspecified forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.841A	Other osteoporosis with current pathological fracture, right hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.842A	Other osteoporosis with current pathological fracture, left hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.849A	Other osteoporosis with current pathological fracture, unspecified hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.851A	Other osteoporosis with current pathological fracture, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.852A	Other osteoporosis with current pathological fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.859A	Other osteoporosis with current pathological fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.861A	Other osteoporosis with current pathological fracture, right lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.862A	Other osteoporosis with current pathological fracture, left lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.869A	Other osteoporosis with current pathological fracture, unspecified lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.871A	Other osteoporosis with current pathological fracture, right ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.872A	Other osteoporosis with current pathological fracture, left ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.879A	Other osteoporosis with current pathological fracture, unspecified ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.88XA	Other osteoporosis with current pathological fracture, vertebra(e), initial encounter for fracture	Diagnosis	ICD-10-CM
M80.8AXA	Other osteoporosis with current pathological fracture, other site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.8B1A	Other osteoporosis with current pathological fracture, right pelvis, initial encounter for fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M80.8B2A	Other osteoporosis with current pathological fracture, left pelvis, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.8B9A	Other osteoporosis with current pathological fracture, unspecified pelvis, initial encounter for fracture	Diagnosis	ICD-10-CM
M81.0	Age-related osteoporosis without current pathological fracture	Diagnosis	ICD-10-CM
M81.6	Localized osteoporosis [Lequesne]	Diagnosis	ICD-10-CM
M81.8	Other osteoporosis without current pathological fracture	Diagnosis	ICD-10-CM
Overweight			
E66.3	Overweight	Diagnosis	ICD-10-CM
Z68.25	Body mass index (BMI) 25.0-25.9, adult	Diagnosis	ICD-10-CM
Z68.26	Body mass index (BMI) 26.0-26.9, adult	Diagnosis	ICD-10-CM
Z68.27	Body mass index (BMI) 27.0-27.9, adult	Diagnosis	ICD-10-CM
Z68.28	Body mass index (BMI) 28.0-28.9, adult	Diagnosis	ICD-10-CM
Z68.29	Body mass index (BMI) 29.0-29.9, adult	Diagnosis	ICD-10-CM
Prostate			
C61	Malignant neoplasm of prostate	Diagnosis	ICD-10-CM
D07.5	Carcinoma in situ of prostate	Diagnosis	ICD-10-CM
Z85.46	Personal history of malignant neoplasm of prostate	Diagnosis	ICD-10-CM
Rheumatoid Arthritis			
L40.50	Arthropathic psoriasis, unspecified	Diagnosis	ICD-10-CM
L40.51	Distal interphalangeal psoriatic arthropathy	Diagnosis	ICD-10-CM
L40.54	Psoriatic juvenile arthropathy	Diagnosis	ICD-10-CM
L40.59	Other psoriatic arthropathy	Diagnosis	ICD-10-CM
M05.00	Felty's syndrome, unspecified site	Diagnosis	ICD-10-CM
M05.011	Felty's syndrome, right shoulder	Diagnosis	ICD-10-CM
M05.012	Felty's syndrome, left shoulder	Diagnosis	ICD-10-CM
M05.019	Felty's syndrome, unspecified shoulder	Diagnosis	ICD-10-CM
M05.021	Felty's syndrome, right elbow	Diagnosis	ICD-10-CM
M05.022	Felty's syndrome, left elbow	Diagnosis	ICD-10-CM
M05.029	Felty's syndrome, unspecified elbow	Diagnosis	ICD-10-CM
M05.031	Felty's syndrome, right wrist	Diagnosis	ICD-10-CM
M05.032	Felty's syndrome, left wrist	Diagnosis	ICD-10-CM
M05.039	Felty's syndrome, unspecified wrist	Diagnosis	ICD-10-CM
M05.041	Felty's syndrome, right hand	Diagnosis	ICD-10-CM
M05.042	Felty's syndrome, left hand	Diagnosis	ICD-10-CM
M05.049	Felty's syndrome, unspecified hand	Diagnosis	ICD-10-CM
M05.051	Felty's syndrome, right hip	Diagnosis	ICD-10-CM
M05.052	Felty's syndrome, left hip	Diagnosis	ICD-10-CM
M05.059	Felty's syndrome, unspecified hip	Diagnosis	ICD-10-CM
M05.061	Felty's syndrome, right knee	Diagnosis	ICD-10-CM
M05.062	Felty's syndrome, left knee	Diagnosis	ICD-10-CM
M05.069	Felty's syndrome, unspecified knee	Diagnosis	ICD-10-CM
M05.071	Felty's syndrome, right ankle and foot	Diagnosis	ICD-10-CM
M05.072	Felty's syndrome, left ankle and foot	Diagnosis	ICD-10-CM
M05.079	Felty's syndrome, unspecified ankle and foot	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M05.09	Felty's syndrome, multiple sites	Diagnosis	ICD-10-CM
M05.10	Rheumatoid lung disease with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.111	Rheumatoid lung disease with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.112	Rheumatoid lung disease with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.119	Rheumatoid lung disease with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.121	Rheumatoid lung disease with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.122	Rheumatoid lung disease with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.129	Rheumatoid lung disease with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.131	Rheumatoid lung disease with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.132	Rheumatoid lung disease with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.139	Rheumatoid lung disease with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.141	Rheumatoid lung disease with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.142	Rheumatoid lung disease with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.149	Rheumatoid lung disease with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.151	Rheumatoid lung disease with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.152	Rheumatoid lung disease with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.159	Rheumatoid lung disease with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.161	Rheumatoid lung disease with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.162	Rheumatoid lung disease with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.169	Rheumatoid lung disease with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.171	Rheumatoid lung disease with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.172	Rheumatoid lung disease with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
	Rheumatoid lung disease with rheumatoid arthritis of unspecified ankle and foot		
M05.179		Diagnosis	ICD-10-CM
M05.19	Rheumatoid lung disease with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.20	Rheumatoid vasculitis with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.211	Rheumatoid vasculitis with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.212	Rheumatoid vasculitis with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.219	Rheumatoid vasculitis with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.221	Rheumatoid vasculitis with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.222	Rheumatoid vasculitis with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.229	Rheumatoid vasculitis with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.231	Rheumatoid vasculitis with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.232	Rheumatoid vasculitis with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.239	Rheumatoid vasculitis with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.241	Rheumatoid vasculitis with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.242	Rheumatoid vasculitis with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.249	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.251	Rheumatoid vasculitis with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.252	Rheumatoid vasculitis with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.259	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M05.261	Rheumatoid vasculitis with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.262	Rheumatoid vasculitis with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.269	Rheumatoid vasculitis with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.271	Rheumatoid vasculitis with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.272	Rheumatoid vasculitis with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.279	Rheumatoid vasculitis with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.29	Rheumatoid vasculitis with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.30	Rheumatoid heart disease with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.311	Rheumatoid heart disease with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.312	Rheumatoid heart disease with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.319	Rheumatoid heart disease with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.321	Rheumatoid heart disease with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.322	Rheumatoid heart disease with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.329	Rheumatoid heart disease with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.331	Rheumatoid heart disease with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.332	Rheumatoid heart disease with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.339	Rheumatoid heart disease with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.341	Rheumatoid heart disease with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.342	Rheumatoid heart disease with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.349	Rheumatoid heart disease with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.351	Rheumatoid heart disease with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.352	Rheumatoid heart disease with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.359	Rheumatoid heart disease with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.361	Rheumatoid heart disease with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.362	Rheumatoid heart disease with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.369	Rheumatoid heart disease with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.371	Rheumatoid heart disease with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.372	Rheumatoid heart disease with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.379	Rheumatoid heart disease with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.39	Rheumatoid heart disease with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.40	Rheumatoid myopathy with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.411	Rheumatoid myopathy with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.412	Rheumatoid myopathy with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.419	Rheumatoid myopathy with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.421	Rheumatoid myopathy with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M05.422	Rheumatoid myopathy with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.429	Rheumatoid myopathy with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.431	Rheumatoid myopathy with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.432	Rheumatoid myopathy with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.439	Rheumatoid myopathy with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.441	Rheumatoid myopathy with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.442	Rheumatoid myopathy with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.449	Rheumatoid myopathy with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.451	Rheumatoid myopathy with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.452	Rheumatoid myopathy with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.459	Rheumatoid myopathy with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.461	Rheumatoid myopathy with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.462	Rheumatoid myopathy with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.469	Rheumatoid myopathy with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.471	Rheumatoid myopathy with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.472	Rheumatoid myopathy with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.479	Rheumatoid myopathy with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.49	Rheumatoid myopathy with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.50	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.511	Rheumatoid polyneuropathy with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.512	Rheumatoid polyneuropathy with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.519	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.521	Rheumatoid polyneuropathy with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.522	Rheumatoid polyneuropathy with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.529	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.531	Rheumatoid polyneuropathy with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.532	Rheumatoid polyneuropathy with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.539	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.541	Rheumatoid polyneuropathy with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.542	Rheumatoid polyneuropathy with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.549	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.551	Rheumatoid polyneuropathy with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.552	Rheumatoid polyneuropathy with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.559	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.561	Rheumatoid polyneuropathy with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.562	Rheumatoid polyneuropathy with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M05.569	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.571	Rheumatoid polyneuropathy with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.572	Rheumatoid polyneuropathy with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.579	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.59	Rheumatoid polyneuropathy with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.60	Rheumatoid arthritis of unspecified site with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.611	Rheumatoid arthritis of right shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.612	Rheumatoid arthritis of left shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.619	Rheumatoid arthritis of unspecified shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.621	Rheumatoid arthritis of right elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.622	Rheumatoid arthritis of left elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.629	Rheumatoid arthritis of unspecified elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.631	Rheumatoid arthritis of right wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.632	Rheumatoid arthritis of left wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.639	Rheumatoid arthritis of unspecified wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.641	Rheumatoid arthritis of right hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.642	Rheumatoid arthritis of left hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.649	Rheumatoid arthritis of unspecified hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.651	Rheumatoid arthritis of right hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.652	Rheumatoid arthritis of left hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.659	Rheumatoid arthritis of unspecified hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.661	Rheumatoid arthritis of right knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.662	Rheumatoid arthritis of left knee with involvement of other organs and systems	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M05.669	Rheumatoid arthritis of unspecified knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.671	Rheumatoid arthritis of right ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.672	Rheumatoid arthritis of left ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.679	Rheumatoid arthritis of unspecified ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.69	Rheumatoid arthritis of multiple sites with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.70	Rheumatoid arthritis with rheumatoid factor of unspecified site without organ or systems involvement	Diagnosis	ICD-10-CM
M05.711	Rheumatoid arthritis with rheumatoid factor of right shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.712	Rheumatoid arthritis with rheumatoid factor of left shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.719	Rheumatoid arthritis with rheumatoid factor of unspecified shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.721	Rheumatoid arthritis with rheumatoid factor of right elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.722	Rheumatoid arthritis with rheumatoid factor of left elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.729	Rheumatoid arthritis with rheumatoid factor of unspecified elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.731	Rheumatoid arthritis with rheumatoid factor of right wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.732	Rheumatoid arthritis with rheumatoid factor of left wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.739	Rheumatoid arthritis with rheumatoid factor of unspecified wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.741	Rheumatoid arthritis with rheumatoid factor of right hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.742	Rheumatoid arthritis with rheumatoid factor of left hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.749	Rheumatoid arthritis with rheumatoid factor of unspecified hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.751	Rheumatoid arthritis with rheumatoid factor of right hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.752	Rheumatoid arthritis with rheumatoid factor of left hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.759	Rheumatoid arthritis with rheumatoid factor of unspecified hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.761	Rheumatoid arthritis with rheumatoid factor of right knee without organ or systems involvement	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M05.762	Rheumatoid arthritis with rheumatoid factor of left knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.769	Rheumatoid arthritis with rheumatoid factor of unspecified knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.771	Rheumatoid arthritis with rheumatoid factor of right ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.772	Rheumatoid arthritis with rheumatoid factor of left ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.779	Rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.79	Rheumatoid arthritis with rheumatoid factor of multiple sites without organ or systems involvement	Diagnosis	ICD-10-CM
M05.7A	Rheumatoid arthritis with rheumatoid factor of other specified site without organ or systems involvement	Diagnosis	ICD-10-CM
M05.80	Other rheumatoid arthritis with rheumatoid factor of unspecified site	Diagnosis	ICD-10-CM
M05.811	Other rheumatoid arthritis with rheumatoid factor of right shoulder	Diagnosis	ICD-10-CM
M05.812	Other rheumatoid arthritis with rheumatoid factor of left shoulder	Diagnosis	ICD-10-CM
M05.819	Other rheumatoid arthritis with rheumatoid factor of unspecified shoulder	Diagnosis	ICD-10-CM
M05.821	Other rheumatoid arthritis with rheumatoid factor of right elbow	Diagnosis	ICD-10-CM
M05.822	Other rheumatoid arthritis with rheumatoid factor of left elbow	Diagnosis	ICD-10-CM
M05.829	Other rheumatoid arthritis with rheumatoid factor of unspecified elbow	Diagnosis	ICD-10-CM
M05.831	Other rheumatoid arthritis with rheumatoid factor of right wrist	Diagnosis	ICD-10-CM
M05.832	Other rheumatoid arthritis with rheumatoid factor of left wrist	Diagnosis	ICD-10-CM
M05.839	Other rheumatoid arthritis with rheumatoid factor of unspecified wrist	Diagnosis	ICD-10-CM
M05.841	Other rheumatoid arthritis with rheumatoid factor of right hand	Diagnosis	ICD-10-CM
M05.842	Other rheumatoid arthritis with rheumatoid factor of left hand	Diagnosis	ICD-10-CM
M05.849	Other rheumatoid arthritis with rheumatoid factor of unspecified hand	Diagnosis	ICD-10-CM
M05.851	Other rheumatoid arthritis with rheumatoid factor of right hip	Diagnosis	ICD-10-CM
M05.852	Other rheumatoid arthritis with rheumatoid factor of left hip	Diagnosis	ICD-10-CM
M05.859	Other rheumatoid arthritis with rheumatoid factor of unspecified hip	Diagnosis	ICD-10-CM
M05.861	Other rheumatoid arthritis with rheumatoid factor of right knee	Diagnosis	ICD-10-CM
M05.862	Other rheumatoid arthritis with rheumatoid factor of left knee	Diagnosis	ICD-10-CM
M05.869	Other rheumatoid arthritis with rheumatoid factor of unspecified knee	Diagnosis	ICD-10-CM
M05.871	Other rheumatoid arthritis with rheumatoid factor of right ankle and foot	Diagnosis	ICD-10-CM
M05.872	Other rheumatoid arthritis with rheumatoid factor of left ankle and foot	Diagnosis	ICD-10-CM
M05.879	Other rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.89	Other rheumatoid arthritis with rheumatoid factor of multiple sites	Diagnosis	ICD-10-CM
M05.8A	Other rheumatoid arthritis with rheumatoid factor of other specified site	Diagnosis	ICD-10-CM
M05.9	Rheumatoid arthritis with rheumatoid factor, unspecified	Diagnosis	ICD-10-CM
M06.00	Rheumatoid arthritis without rheumatoid factor, unspecified site	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPGS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M06.011	Rheumatoid arthritis without rheumatoid factor, right shoulder	Diagnosis	ICD-10-CM
M06.012	Rheumatoid arthritis without rheumatoid factor, left shoulder	Diagnosis	ICD-10-CM
M06.019	Rheumatoid arthritis without rheumatoid factor, unspecified shoulder	Diagnosis	ICD-10-CM
M06.021	Rheumatoid arthritis without rheumatoid factor, right elbow	Diagnosis	ICD-10-CM
M06.022	Rheumatoid arthritis without rheumatoid factor, left elbow	Diagnosis	ICD-10-CM
M06.029	Rheumatoid arthritis without rheumatoid factor, unspecified elbow	Diagnosis	ICD-10-CM
M06.031	Rheumatoid arthritis without rheumatoid factor, right wrist	Diagnosis	ICD-10-CM
M06.032	Rheumatoid arthritis without rheumatoid factor, left wrist	Diagnosis	ICD-10-CM
M06.039	Rheumatoid arthritis without rheumatoid factor, unspecified wrist	Diagnosis	ICD-10-CM
M06.041	Rheumatoid arthritis without rheumatoid factor, right hand	Diagnosis	ICD-10-CM
M06.042	Rheumatoid arthritis without rheumatoid factor, left hand	Diagnosis	ICD-10-CM
M06.049	Rheumatoid arthritis without rheumatoid factor, unspecified hand	Diagnosis	ICD-10-CM
M06.051	Rheumatoid arthritis without rheumatoid factor, right hip	Diagnosis	ICD-10-CM
M06.052	Rheumatoid arthritis without rheumatoid factor, left hip	Diagnosis	ICD-10-CM
M06.059	Rheumatoid arthritis without rheumatoid factor, unspecified hip	Diagnosis	ICD-10-CM
M06.061	Rheumatoid arthritis without rheumatoid factor, right knee	Diagnosis	ICD-10-CM
M06.062	Rheumatoid arthritis without rheumatoid factor, left knee	Diagnosis	ICD-10-CM
M06.069	Rheumatoid arthritis without rheumatoid factor, unspecified knee	Diagnosis	ICD-10-CM
M06.071	Rheumatoid arthritis without rheumatoid factor, right ankle and foot	Diagnosis	ICD-10-CM
M06.072	Rheumatoid arthritis without rheumatoid factor, left ankle and foot	Diagnosis	ICD-10-CM
M06.079	Rheumatoid arthritis without rheumatoid factor, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.08	Rheumatoid arthritis without rheumatoid factor, vertebrae	Diagnosis	ICD-10-CM
M06.09	Rheumatoid arthritis without rheumatoid factor, multiple sites	Diagnosis	ICD-10-CM
M06.0A	Rheumatoid arthritis without rheumatoid factor, other specified site	Diagnosis	ICD-10-CM
M06.1	Adult-onset Still's disease	Diagnosis	ICD-10-CM
M06.20	Rheumatoid bursitis, unspecified site	Diagnosis	ICD-10-CM
M06.211	Rheumatoid bursitis, right shoulder	Diagnosis	ICD-10-CM
M06.212	Rheumatoid bursitis, left shoulder	Diagnosis	ICD-10-CM
M06.219	Rheumatoid bursitis, unspecified shoulder	Diagnosis	ICD-10-CM
M06.221	Rheumatoid bursitis, right elbow	Diagnosis	ICD-10-CM
M06.222	Rheumatoid bursitis, left elbow	Diagnosis	ICD-10-CM
M06.229	Rheumatoid bursitis, unspecified elbow	Diagnosis	ICD-10-CM
M06.231	Rheumatoid bursitis, right wrist	Diagnosis	ICD-10-CM
M06.232	Rheumatoid bursitis, left wrist	Diagnosis	ICD-10-CM
M06.239	Rheumatoid bursitis, unspecified wrist	Diagnosis	ICD-10-CM
M06.241	Rheumatoid bursitis, right hand	Diagnosis	ICD-10-CM
M06.242	Rheumatoid bursitis, left hand	Diagnosis	ICD-10-CM
M06.249	Rheumatoid bursitis, unspecified hand	Diagnosis	ICD-10-CM
M06.251	Rheumatoid bursitis, right hip	Diagnosis	ICD-10-CM
M06.252	Rheumatoid bursitis, left hip	Diagnosis	ICD-10-CM
M06.259	Rheumatoid bursitis, unspecified hip	Diagnosis	ICD-10-CM
M06.261	Rheumatoid bursitis, right knee	Diagnosis	ICD-10-CM
M06.262	Rheumatoid bursitis, left knee	Diagnosis	ICD-10-CM
M06.269	Rheumatoid bursitis, unspecified knee	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M06.271	Rheumatoid bursitis, right ankle and foot	Diagnosis	ICD-10-CM
M06.272	Rheumatoid bursitis, left ankle and foot	Diagnosis	ICD-10-CM
M06.279	Rheumatoid bursitis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.28	Rheumatoid bursitis, vertebrae	Diagnosis	ICD-10-CM
M06.29	Rheumatoid bursitis, multiple sites	Diagnosis	ICD-10-CM
M06.30	Rheumatoid nodule, unspecified site	Diagnosis	ICD-10-CM
M06.311	Rheumatoid nodule, right shoulder	Diagnosis	ICD-10-CM
M06.312	Rheumatoid nodule, left shoulder	Diagnosis	ICD-10-CM
M06.319	Rheumatoid nodule, unspecified shoulder	Diagnosis	ICD-10-CM
M06.321	Rheumatoid nodule, right elbow	Diagnosis	ICD-10-CM
M06.322	Rheumatoid nodule, left elbow	Diagnosis	ICD-10-CM
M06.329	Rheumatoid nodule, unspecified elbow	Diagnosis	ICD-10-CM
M06.331	Rheumatoid nodule, right wrist	Diagnosis	ICD-10-CM
M06.332	Rheumatoid nodule, left wrist	Diagnosis	ICD-10-CM
M06.339	Rheumatoid nodule, unspecified wrist	Diagnosis	ICD-10-CM
M06.341	Rheumatoid nodule, right hand	Diagnosis	ICD-10-CM
M06.342	Rheumatoid nodule, left hand	Diagnosis	ICD-10-CM
M06.349	Rheumatoid nodule, unspecified hand	Diagnosis	ICD-10-CM
M06.351	Rheumatoid nodule, right hip	Diagnosis	ICD-10-CM
M06.352	Rheumatoid nodule, left hip	Diagnosis	ICD-10-CM
M06.359	Rheumatoid nodule, unspecified hip	Diagnosis	ICD-10-CM
M06.361	Rheumatoid nodule, right knee	Diagnosis	ICD-10-CM
M06.362	Rheumatoid nodule, left knee	Diagnosis	ICD-10-CM
M06.369	Rheumatoid nodule, unspecified knee	Diagnosis	ICD-10-CM
M06.371	Rheumatoid nodule, right ankle and foot	Diagnosis	ICD-10-CM
M06.372	Rheumatoid nodule, left ankle and foot	Diagnosis	ICD-10-CM
M06.379	Rheumatoid nodule, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.38	Rheumatoid nodule, vertebrae	Diagnosis	ICD-10-CM
M06.39	Rheumatoid nodule, multiple sites	Diagnosis	ICD-10-CM
M06.80	Other specified rheumatoid arthritis, unspecified site	Diagnosis	ICD-10-CM
M06.811	Other specified rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M06.812	Other specified rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M06.819	Other specified rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M06.821	Other specified rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M06.822	Other specified rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M06.829	Other specified rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M06.831	Other specified rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M06.832	Other specified rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M06.839	Other specified rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M06.841	Other specified rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M06.842	Other specified rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M06.849	Other specified rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M06.851	Other specified rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M06.852	Other specified rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M06.859	Other specified rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M06.861	Other specified rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M06.862	Other specified rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M06.869	Other specified rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M06.871	Other specified rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M06.872	Other specified rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M06.879	Other specified rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.88	Other specified rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M06.89	Other specified rheumatoid arthritis, multiple sites	Diagnosis	ICD-10-CM
M06.8A	Other specified rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M06.9	Rheumatoid arthritis, unspecified	Diagnosis	ICD-10-CM
M08.00	Unspecified juvenile rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M08.011	Unspecified juvenile rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.012	Unspecified juvenile rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.019	Unspecified juvenile rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.021	Unspecified juvenile rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M08.022	Unspecified juvenile rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M08.029	Unspecified juvenile rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.031	Unspecified juvenile rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M08.032	Unspecified juvenile rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M08.039	Unspecified juvenile rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.041	Unspecified juvenile rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M08.042	Unspecified juvenile rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M08.049	Unspecified juvenile rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.051	Unspecified juvenile rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M08.052	Unspecified juvenile rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M08.059	Unspecified juvenile rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.061	Unspecified juvenile rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M08.062	Unspecified juvenile rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M08.069	Unspecified juvenile rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.071	Unspecified juvenile rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.072	Unspecified juvenile rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.079	Unspecified juvenile rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.08	Unspecified juvenile rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M08.09	Unspecified juvenile rheumatoid arthritis, multiple sites	Diagnosis	ICD-10-CM
M08.0A	Unspecified juvenile rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M08.1	Juvenile ankylosing spondylitis	Diagnosis	ICD-10-CM
M08.20	Juvenile rheumatoid arthritis with systemic onset, unspecified site	Diagnosis	ICD-10-CM
M08.211	Juvenile rheumatoid arthritis with systemic onset, right shoulder	Diagnosis	ICD-10-CM
M08.212	Juvenile rheumatoid arthritis with systemic onset, left shoulder	Diagnosis	ICD-10-CM
M08.219	Juvenile rheumatoid arthritis with systemic onset, unspecified shoulder	Diagnosis	ICD-10-CM
M08.221	Juvenile rheumatoid arthritis with systemic onset, right elbow	Diagnosis	ICD-10-CM
M08.222	Juvenile rheumatoid arthritis with systemic onset, left elbow	Diagnosis	ICD-10-CM
M08.229	Juvenile rheumatoid arthritis with systemic onset, unspecified elbow	Diagnosis	ICD-10-CM
M08.231	Juvenile rheumatoid arthritis with systemic onset, right wrist	Diagnosis	ICD-10-CM
M08.232	Juvenile rheumatoid arthritis with systemic onset, left wrist	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M08.239	Juvenile rheumatoid arthritis with systemic onset, unspecified wrist	Diagnosis	ICD-10-CM
M08.241	Juvenile rheumatoid arthritis with systemic onset, right hand	Diagnosis	ICD-10-CM
M08.242	Juvenile rheumatoid arthritis with systemic onset, left hand	Diagnosis	ICD-10-CM
M08.249	Juvenile rheumatoid arthritis with systemic onset, unspecified hand	Diagnosis	ICD-10-CM
M08.251	Juvenile rheumatoid arthritis with systemic onset, right hip	Diagnosis	ICD-10-CM
M08.252	Juvenile rheumatoid arthritis with systemic onset, left hip	Diagnosis	ICD-10-CM
M08.259	Juvenile rheumatoid arthritis with systemic onset, unspecified hip	Diagnosis	ICD-10-CM
M08.261	Juvenile rheumatoid arthritis with systemic onset, right knee	Diagnosis	ICD-10-CM
M08.262	Juvenile rheumatoid arthritis with systemic onset, left knee	Diagnosis	ICD-10-CM
M08.269	Juvenile rheumatoid arthritis with systemic onset, unspecified knee	Diagnosis	ICD-10-CM
M08.271	Juvenile rheumatoid arthritis with systemic onset, right ankle and foot	Diagnosis	ICD-10-CM
M08.272	Juvenile rheumatoid arthritis with systemic onset, left ankle and foot	Diagnosis	ICD-10-CM
M08.279	Juvenile rheumatoid arthritis with systemic onset, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.28	Juvenile rheumatoid arthritis with systemic onset, vertebrae	Diagnosis	ICD-10-CM
M08.29	Juvenile rheumatoid arthritis with systemic onset, multiple sites	Diagnosis	ICD-10-CM
M08.2A	Juvenile rheumatoid arthritis with systemic onset, other specified site	Diagnosis	ICD-10-CM
M08.3	Juvenile rheumatoid polyarthritis (seronegative)	Diagnosis	ICD-10-CM
M08.40	Pauciarticular juvenile rheumatoid arthritis, unspecified site	Diagnosis	ICD-10-CM
M08.411	Pauciarticular juvenile rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.412	Pauciarticular juvenile rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.419	Pauciarticular juvenile rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.421	Pauciarticular juvenile rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M08.422	Pauciarticular juvenile rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M08.429	Pauciarticular juvenile rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.431	Pauciarticular juvenile rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M08.432	Pauciarticular juvenile rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M08.439	Pauciarticular juvenile rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.441	Pauciarticular juvenile rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M08.442	Pauciarticular juvenile rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M08.449	Pauciarticular juvenile rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.451	Pauciarticular juvenile rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M08.452	Pauciarticular juvenile rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M08.459	Pauciarticular juvenile rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.461	Pauciarticular juvenile rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M08.462	Pauciarticular juvenile rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M08.469	Pauciarticular juvenile rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.471	Pauciarticular juvenile rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.472	Pauciarticular juvenile rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.479	Pauciarticular juvenile rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.48	Pauciarticular juvenile rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M08.4A	Pauciarticular juvenile rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M08.80	Other juvenile arthritis, unspecified site	Diagnosis	ICD-10-CM
M08.811	Other juvenile arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.812	Other juvenile arthritis, left shoulder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M08.819	Other juvenile arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.821	Other juvenile arthritis, right elbow	Diagnosis	ICD-10-CM
M08.822	Other juvenile arthritis, left elbow	Diagnosis	ICD-10-CM
M08.829	Other juvenile arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.831	Other juvenile arthritis, right wrist	Diagnosis	ICD-10-CM
M08.832	Other juvenile arthritis, left wrist	Diagnosis	ICD-10-CM
M08.839	Other juvenile arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.841	Other juvenile arthritis, right hand	Diagnosis	ICD-10-CM
M08.842	Other juvenile arthritis, left hand	Diagnosis	ICD-10-CM
M08.849	Other juvenile arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.851	Other juvenile arthritis, right hip	Diagnosis	ICD-10-CM
M08.852	Other juvenile arthritis, left hip	Diagnosis	ICD-10-CM
M08.859	Other juvenile arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.861	Other juvenile arthritis, right knee	Diagnosis	ICD-10-CM
M08.862	Other juvenile arthritis, left knee	Diagnosis	ICD-10-CM
M08.869	Other juvenile arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.871	Other juvenile arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.872	Other juvenile arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.879	Other juvenile arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.88	Other juvenile arthritis, other specified site	Diagnosis	ICD-10-CM
M08.89	Other juvenile arthritis, multiple sites	Diagnosis	ICD-10-CM
M08.90	Juvenile arthritis, unspecified, unspecified site	Diagnosis	ICD-10-CM
M08.911	Juvenile arthritis, unspecified, right shoulder	Diagnosis	ICD-10-CM
M08.912	Juvenile arthritis, unspecified, left shoulder	Diagnosis	ICD-10-CM
M08.919	Juvenile arthritis, unspecified, unspecified shoulder	Diagnosis	ICD-10-CM
M08.921	Juvenile arthritis, unspecified, right elbow	Diagnosis	ICD-10-CM
M08.922	Juvenile arthritis, unspecified, left elbow	Diagnosis	ICD-10-CM
M08.929	Juvenile arthritis, unspecified, unspecified elbow	Diagnosis	ICD-10-CM
M08.931	Juvenile arthritis, unspecified, right wrist	Diagnosis	ICD-10-CM
M08.932	Juvenile arthritis, unspecified, left wrist	Diagnosis	ICD-10-CM
M08.939	Juvenile arthritis, unspecified, unspecified wrist	Diagnosis	ICD-10-CM
M08.941	Juvenile arthritis, unspecified, right hand	Diagnosis	ICD-10-CM
M08.942	Juvenile arthritis, unspecified, left hand	Diagnosis	ICD-10-CM
M08.949	Juvenile arthritis, unspecified, unspecified hand	Diagnosis	ICD-10-CM
M08.951	Juvenile arthritis, unspecified, right hip	Diagnosis	ICD-10-CM
M08.952	Juvenile arthritis, unspecified, left hip	Diagnosis	ICD-10-CM
M08.959	Juvenile arthritis, unspecified, unspecified hip	Diagnosis	ICD-10-CM
M08.961	Juvenile arthritis, unspecified, right knee	Diagnosis	ICD-10-CM
M08.962	Juvenile arthritis, unspecified, left knee	Diagnosis	ICD-10-CM
M08.969	Juvenile arthritis, unspecified, unspecified knee	Diagnosis	ICD-10-CM
M08.971	Juvenile arthritis, unspecified, right ankle and foot	Diagnosis	ICD-10-CM
M08.972	Juvenile arthritis, unspecified, left ankle and foot	Diagnosis	ICD-10-CM
M08.979	Juvenile arthritis, unspecified, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.98	Juvenile arthritis, unspecified, vertebrae	Diagnosis	ICD-10-CM
M08.99	Juvenile arthritis, unspecified, multiple sites	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M08.9A	Juvenile arthritis, unspecified, other specified site	Diagnosis	ICD-10-CM
M15.0	Primary generalized (osteo)arthritis	Diagnosis	ICD-10-CM
M15.1	Heberden's nodes (with arthropathy)	Diagnosis	ICD-10-CM
M15.2	Bouchard's nodes (with arthropathy)	Diagnosis	ICD-10-CM
M15.3	Secondary multiple arthritis	Diagnosis	ICD-10-CM
M15.4	Erosive (osteo)arthritis	Diagnosis	ICD-10-CM
M15.8	Other polyosteoarthritis	Diagnosis	ICD-10-CM
M15.9	Polyosteoarthritis, unspecified	Diagnosis	ICD-10-CM
M16.0	Bilateral primary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.10	Unilateral primary osteoarthritis, unspecified hip	Diagnosis	ICD-10-CM
M16.11	Unilateral primary osteoarthritis, right hip	Diagnosis	ICD-10-CM
M16.12	Unilateral primary osteoarthritis, left hip	Diagnosis	ICD-10-CM
M16.2	Bilateral osteoarthritis resulting from hip dysplasia	Diagnosis	ICD-10-CM
M16.30	Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip	Diagnosis	ICD-10-CM
M16.31	Unilateral osteoarthritis resulting from hip dysplasia, right hip	Diagnosis	ICD-10-CM
M16.32	Unilateral osteoarthritis resulting from hip dysplasia, left hip	Diagnosis	ICD-10-CM
M16.4	Bilateral post-traumatic osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.50	Unilateral post-traumatic osteoarthritis, unspecified hip	Diagnosis	ICD-10-CM
M16.51	Unilateral post-traumatic osteoarthritis, right hip	Diagnosis	ICD-10-CM
M16.52	Unilateral post-traumatic osteoarthritis, left hip	Diagnosis	ICD-10-CM
M16.6	Other bilateral secondary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.7	Other unilateral secondary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.9	Osteoarthritis of hip, unspecified	Diagnosis	ICD-10-CM
M17.0	Bilateral primary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.10	Unilateral primary osteoarthritis, unspecified knee	Diagnosis	ICD-10-CM
M17.11	Unilateral primary osteoarthritis, right knee	Diagnosis	ICD-10-CM
M17.12	Unilateral primary osteoarthritis, left knee	Diagnosis	ICD-10-CM
M17.2	Bilateral post-traumatic osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.30	Unilateral post-traumatic osteoarthritis, unspecified knee	Diagnosis	ICD-10-CM
M17.31	Unilateral post-traumatic osteoarthritis, right knee	Diagnosis	ICD-10-CM
M17.32	Unilateral post-traumatic osteoarthritis, left knee	Diagnosis	ICD-10-CM
M17.4	Other bilateral secondary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.5	Other unilateral secondary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.9	Osteoarthritis of knee, unspecified	Diagnosis	ICD-10-CM
M18.0	Bilateral primary osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
	Unilateral primary osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.10		Diagnosis	ICD-10-CM
M18.11	Unilateral primary osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.12	Unilateral primary osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.2	Bilateral post-traumatic osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.30		Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPGS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M18.31	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.32	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.4	Other bilateral secondary osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.50	Other unilateral secondary osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.51	Other unilateral secondary osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.52	Other unilateral secondary osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.9	Osteoarthritis of first carpometacarpal joint, unspecified	Diagnosis	ICD-10-CM
M19.011	Primary osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.012	Primary osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.019	Primary osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.021	Primary osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.022	Primary osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.029	Primary osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.031	Primary osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.032	Primary osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.039	Primary osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.041	Primary osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.042	Primary osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.049	Primary osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.071	Primary osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.072	Primary osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.079	Primary osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.09	Primary osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.111	Post-traumatic osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.112	Post-traumatic osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.119	Post-traumatic osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.121	Post-traumatic osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.122	Post-traumatic osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.129	Post-traumatic osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.131	Post-traumatic osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.132	Post-traumatic osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.139	Post-traumatic osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.141	Post-traumatic osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.142	Post-traumatic osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.149	Post-traumatic osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.171	Post-traumatic osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.172	Post-traumatic osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.179	Post-traumatic osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.19	Post-traumatic osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.211	Secondary osteoarthritis, right shoulder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M19.212	Secondary osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.219	Secondary osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.221	Secondary osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.222	Secondary osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.229	Secondary osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.231	Secondary osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.232	Secondary osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.239	Secondary osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.241	Secondary osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.242	Secondary osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.249	Secondary osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.271	Secondary osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.272	Secondary osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.279	Secondary osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.29	Secondary osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.90	Unspecified osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.91	Primary osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.92	Post-traumatic osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.93	Secondary osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M45.0	Ankylosing spondylitis of multiple sites in spine	Diagnosis	ICD-10-CM
M45.1	Ankylosing spondylitis of occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M45.2	Ankylosing spondylitis of cervical region	Diagnosis	ICD-10-CM
M45.3	Ankylosing spondylitis of cervicothoracic region	Diagnosis	ICD-10-CM
M45.4	Ankylosing spondylitis of thoracic region	Diagnosis	ICD-10-CM
M45.5	Ankylosing spondylitis of thoracolumbar region	Diagnosis	ICD-10-CM
M45.6	Ankylosing spondylitis lumbar region	Diagnosis	ICD-10-CM
M45.7	Ankylosing spondylitis of lumbosacral region	Diagnosis	ICD-10-CM
M45.8	Ankylosing spondylitis sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M45.9	Ankylosing spondylitis of unspecified sites in spine	Diagnosis	ICD-10-CM
M45.A0	Non-radiographic axial spondyloarthritis of unspecified sites in spine	Diagnosis	ICD-10-CM
M45.A1	Non-radiographic axial spondyloarthritis of occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M45.A2	Non-radiographic axial spondyloarthritis of cervical region	Diagnosis	ICD-10-CM
M45.A3	Non-radiographic axial spondyloarthritis of cervicothoracic region	Diagnosis	ICD-10-CM
M45.A4	Non-radiographic axial spondyloarthritis of thoracic region	Diagnosis	ICD-10-CM
M45.A5	Non-radiographic axial spondyloarthritis of thoracolumbar region	Diagnosis	ICD-10-CM
M45.A6	Non-radiographic axial spondyloarthritis of lumbar region	Diagnosis	ICD-10-CM
M45.A7	Non-radiographic axial spondyloarthritis of lumbosacral region	Diagnosis	ICD-10-CM
M45.A8	Non-radiographic axial spondyloarthritis of sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M45.AB	Non-radiographic axial spondyloarthritis of multiple sites in spine	Diagnosis	ICD-10-CM
M46.80	Other specified inflammatory spondylopathies, site unspecified	Diagnosis	ICD-10-CM
M46.81	Other specified inflammatory spondylopathies, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M46.82	Other specified inflammatory spondylopathies, cervical region	Diagnosis	ICD-10-CM
M46.83	Other specified inflammatory spondylopathies, cervicothoracic region	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M46.84	Other specified inflammatory spondylopathies, thoracic region	Diagnosis	ICD-10-CM
M46.85	Other specified inflammatory spondylopathies, thoracolumbar region	Diagnosis	ICD-10-CM
M46.86	Other specified inflammatory spondylopathies, lumbar region	Diagnosis	ICD-10-CM
M46.87	Other specified inflammatory spondylopathies, lumbosacral region	Diagnosis	ICD-10-CM
	Other specified inflammatory spondylopathies, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M46.88	Other specified inflammatory spondylopathies, multiple sites in spine	Diagnosis	ICD-10-CM
M46.90	Unspecified inflammatory spondylopathy, site unspecified	Diagnosis	ICD-10-CM
M46.91	Unspecified inflammatory spondylopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M46.92	Unspecified inflammatory spondylopathy, cervical region	Diagnosis	ICD-10-CM
M46.93	Unspecified inflammatory spondylopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M46.94	Unspecified inflammatory spondylopathy, thoracic region	Diagnosis	ICD-10-CM
M46.95	Unspecified inflammatory spondylopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M46.96	Unspecified inflammatory spondylopathy, lumbar region	Diagnosis	ICD-10-CM
M46.97	Unspecified inflammatory spondylopathy, lumbosacral region	Diagnosis	ICD-10-CM
M46.98	Unspecified inflammatory spondylopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M46.99	Unspecified inflammatory spondylopathy, multiple sites in spine	Diagnosis	ICD-10-CM
M47.011	Anterior spinal artery compression syndromes, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.012	Anterior spinal artery compression syndromes, cervical region	Diagnosis	ICD-10-CM
M47.013	Anterior spinal artery compression syndromes, cervicothoracic region	Diagnosis	ICD-10-CM
M47.014	Anterior spinal artery compression syndromes, thoracic region	Diagnosis	ICD-10-CM
M47.015	Anterior spinal artery compression syndromes, thoracolumbar region	Diagnosis	ICD-10-CM
M47.016	Anterior spinal artery compression syndromes, lumbar region	Diagnosis	ICD-10-CM
M47.019	Anterior spinal artery compression syndromes, site unspecified	Diagnosis	ICD-10-CM
M47.021	Vertebral artery compression syndromes, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.022	Vertebral artery compression syndromes, cervical region	Diagnosis	ICD-10-CM
M47.029	Vertebral artery compression syndromes, site unspecified	Diagnosis	ICD-10-CM
M47.10	Other spondylosis with myelopathy, site unspecified	Diagnosis	ICD-10-CM
M47.11	Other spondylosis with myelopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.12	Other spondylosis with myelopathy, cervical region	Diagnosis	ICD-10-CM
M47.13	Other spondylosis with myelopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.14	Other spondylosis with myelopathy, thoracic region	Diagnosis	ICD-10-CM
M47.15	Other spondylosis with myelopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.16	Other spondylosis with myelopathy, lumbar region	Diagnosis	ICD-10-CM
M47.20	Other spondylosis with radiculopathy, site unspecified	Diagnosis	ICD-10-CM
M47.21	Other spondylosis with radiculopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.22	Other spondylosis with radiculopathy, cervical region	Diagnosis	ICD-10-CM
M47.23	Other spondylosis with radiculopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.24	Other spondylosis with radiculopathy, thoracic region	Diagnosis	ICD-10-CM
M47.25	Other spondylosis with radiculopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.26	Other spondylosis with radiculopathy, lumbar region	Diagnosis	ICD-10-CM
M47.27	Other spondylosis with radiculopathy, lumbosacral region	Diagnosis	ICD-10-CM
M47.28	Other spondylosis with radiculopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
M47.811	Spondylosis without myelopathy or radiculopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.812	Spondylosis without myelopathy or radiculopathy, cervical region	Diagnosis	ICD-10-CM
M47.813	Spondylosis without myelopathy or radiculopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.814	Spondylosis without myelopathy or radiculopathy, thoracic region	Diagnosis	ICD-10-CM
M47.815	Spondylosis without myelopathy or radiculopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.816	Spondylosis without myelopathy or radiculopathy, lumbar region	Diagnosis	ICD-10-CM
M47.817	Spondylosis without myelopathy or radiculopathy, lumbosacral region	Diagnosis	ICD-10-CM
M47.818	Spondylosis without myelopathy or radiculopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.819	Spondylosis without myelopathy or radiculopathy, site unspecified	Diagnosis	ICD-10-CM
M47.891	Other spondylosis, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.892	Other spondylosis, cervical region	Diagnosis	ICD-10-CM
M47.893	Other spondylosis, cervicothoracic region	Diagnosis	ICD-10-CM
M47.894	Other spondylosis, thoracic region	Diagnosis	ICD-10-CM
M47.895	Other spondylosis, thoracolumbar region	Diagnosis	ICD-10-CM
M47.896	Other spondylosis, lumbar region	Diagnosis	ICD-10-CM
M47.897	Other spondylosis, lumbosacral region	Diagnosis	ICD-10-CM
M47.898	Other spondylosis, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.899	Other spondylosis, site unspecified	Diagnosis	ICD-10-CM
M47.9	Spondylosis, unspecified	Diagnosis	ICD-10-CM
M48.8X1	Other specified spondylopathies, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M48.8X2	Other specified spondylopathies, cervical region	Diagnosis	ICD-10-CM
M48.8X3	Other specified spondylopathies, cervicothoracic region	Diagnosis	ICD-10-CM
M48.8X4	Other specified spondylopathies, thoracic region	Diagnosis	ICD-10-CM
M48.8X5	Other specified spondylopathies, thoracolumbar region	Diagnosis	ICD-10-CM
M48.8X6	Other specified spondylopathies, lumbar region	Diagnosis	ICD-10-CM
M48.8X7	Other specified spondylopathies, lumbosacral region	Diagnosis	ICD-10-CM
M48.8X8	Other specified spondylopathies, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M48.8X9	Other specified spondylopathies, site unspecified	Diagnosis	ICD-10-CM
Smoking			
1034F	Current tobacco smoker (CAD, CAP, COPD, PV) (DM) Tobacco use cessation intervention, pharmacologic therapy (COPD, CAD, CAP, PV, Asthma) (DM) (PV)	Procedure	CPT-2
4001F	Patient screened for tobacco use and received tobacco cessation intervention (counseling, pharmacotherapy, or both), if identified as a tobacco user (PV, CAD)	Procedure	CPT-2
4004F	Smoking and tobacco use cessation counseling visit; intermediate, greater than 3 minutes up to 10 minutes	Procedure	CPT-2
99406	Smoking and tobacco use cessation counseling visit; intensive, greater than 10 minutes	Procedure	CPT-4
F17.200	Nicotine dependence, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F17.201	Nicotine dependence, unspecified, in remission	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
F17.203	Nicotine dependence unspecified, with withdrawal	Diagnosis	ICD-10-CM
F17.208	Nicotine dependence, unspecified, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
	Nicotine dependence, unspecified, with unspecified nicotine-induced disorders		
F17.209		Diagnosis	ICD-10-CM
F17.210	Nicotine dependence, cigarettes, uncomplicated	Diagnosis	ICD-10-CM
F17.211	Nicotine dependence, cigarettes, in remission	Diagnosis	ICD-10-CM
F17.213	Nicotine dependence, cigarettes, with withdrawal	Diagnosis	ICD-10-CM
F17.218	Nicotine dependence, cigarettes, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
	Nicotine dependence, cigarettes, with unspecified nicotine-induced disorders		
F17.219		Diagnosis	ICD-10-CM
F17.223	Nicotine dependence, chewing tobacco, with withdrawal	Diagnosis	ICD-10-CM
	Nicotine dependence, chewing tobacco, with other nicotine-induced disorders		
F17.228		Diagnosis	ICD-10-CM
	Nicotine dependence, chewing tobacco, with unspecified nicotine-induced disorders		
F17.229		Diagnosis	ICD-10-CM
F17.290	Nicotine dependence, other tobacco product, uncomplicated	Diagnosis	ICD-10-CM
F17.291	Nicotine dependence, other tobacco product, in remission	Diagnosis	ICD-10-CM
F17.293	Nicotine dependence, other tobacco product, with withdrawal	Diagnosis	ICD-10-CM
	Nicotine dependence, other tobacco product, with other nicotine-induced disorders		
F17.298		Diagnosis	ICD-10-CM
	Nicotine dependence, other tobacco product, with unspecified nicotine-induced disorders		
F17.299		Diagnosis	ICD-10-CM
	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intermediate, greater than 3 minutes, up to 10 minutes		
G0436		Procedure	HCPCS
	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intensive, greater than 10 minutes		
G0437		Procedure	HCPCS
	Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes)		
G9016	[demo project code only]	Procedure	HCPCS
G9276	Documentation that patient is a current tobacco user	Procedure	HCPCS
	Patient documented as tobacco user and received tobacco cessation intervention (must include at least one of the following: advice given to quit smoking or tobacco use, counseling on the benefits of quitting smoking or tobacco use, assistance with or		
G9458		Procedure	HCPCS
O99.330	Smoking (tobacco) complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.331	Smoking (tobacco) complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.332	Smoking (tobacco) complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.333	Smoking (tobacco) complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.334	Smoking (tobacco) complicating childbirth	Diagnosis	ICD-10-CM
O99.335	Smoking (tobacco) complicating the puerperium	Diagnosis	ICD-10-CM
S4995	Smoking cessation gum	Procedure	HCPCS
S9075	Smoking cessation treatment	Procedure	HCPCS
S9453	Smoking cessation classes, nonphysician provider, per session	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
T65.221A	Toxic effect of tobacco cigarettes, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.222A	Toxic effect of tobacco cigarettes, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.223A	Toxic effect of tobacco cigarettes, assault, initial encounter	Diagnosis	ICD-10-CM
T65.224A	Toxic effect of tobacco cigarettes, undetermined, initial encounter	Diagnosis	ICD-10-CM
Z71.6	Tobacco abuse counseling	Diagnosis	ICD-10-CM
Z87.891	Personal history of nicotine dependence	Diagnosis	ICD-10-CM
Transient Ischemic Attack			
G45.0	Vertebo-basilar artery syndrome	Diagnosis	ICD-10-CM
G45.1	Carotid artery syndrome (hemispheric)	Diagnosis	ICD-10-CM
G45.2	Multiple and bilateral precerebral artery syndromes	Diagnosis	ICD-10-CM
G45.3	Amaurosis fugax	Diagnosis	ICD-10-CM
G45.8	Other transient cerebral ischemic attacks and related syndromes	Diagnosis	ICD-10-CM
G45.9	Transient cerebral ischemic attack, unspecified	Diagnosis	ICD-10-CM
G46.0	Middle cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.1	Anterior cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.2	Posterior cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.3	Brain stem stroke syndrome	Diagnosis	ICD-10-CM
G46.4	Cerebellar stroke syndrome	Diagnosis	ICD-10-CM
G46.5	Pure motor lacunar syndrome	Diagnosis	ICD-10-CM
G46.6	Pure sensory lacunar syndrome	Diagnosis	ICD-10-CM
G46.7	Other lacunar syndromes	Diagnosis	ICD-10-CM
G46.8	Other vascular syndromes of brain in cerebrovascular diseases	Diagnosis	ICD-10-CM
G97.31	Intraoperative hemorrhage and hematoma of a nervous system organ or structure complicating a nervous system procedure	Diagnosis	ICD-10-CM
G97.32	Intraoperative hemorrhage and hematoma of a nervous system organ or structure complicating other procedure	Diagnosis	ICD-10-CM
I60.00	Nontraumatic subarachnoid hemorrhage from unspecified carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.01	Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.02	Nontraumatic subarachnoid hemorrhage from left carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.10	Nontraumatic subarachnoid hemorrhage from unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I60.11	Nontraumatic subarachnoid hemorrhage from right middle cerebral artery	Diagnosis	ICD-10-CM
I60.12	Nontraumatic subarachnoid hemorrhage from left middle cerebral artery	Diagnosis	ICD-10-CM
I60.2	Nontraumatic subarachnoid hemorrhage from anterior communicating artery	Diagnosis	ICD-10-CM
I60.20	Nontraumatic subarachnoid hemorrhage from unspecified anterior communicating artery	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I60.21	Nontraumatic subarachnoid hemorrhage from right anterior communicating artery	Diagnosis	ICD-10-CM
I60.22	Nontraumatic subarachnoid hemorrhage from left anterior communicating artery	Diagnosis	ICD-10-CM
I60.30	Nontraumatic subarachnoid hemorrhage from unspecified posterior communicating artery	Diagnosis	ICD-10-CM
I60.31	Nontraumatic subarachnoid hemorrhage from right posterior communicating artery	Diagnosis	ICD-10-CM
I60.32	Nontraumatic subarachnoid hemorrhage from left posterior communicating artery	Diagnosis	ICD-10-CM
I60.4	Nontraumatic subarachnoid hemorrhage from basilar artery	Diagnosis	ICD-10-CM
I60.50	Nontraumatic subarachnoid hemorrhage from unspecified vertebral artery	Diagnosis	ICD-10-CM
I60.51	Nontraumatic subarachnoid hemorrhage from right vertebral artery	Diagnosis	ICD-10-CM
I60.52	Nontraumatic subarachnoid hemorrhage from left vertebral artery	Diagnosis	ICD-10-CM
I60.6	Nontraumatic subarachnoid hemorrhage from other intracranial arteries	Diagnosis	ICD-10-CM
I60.7	Nontraumatic subarachnoid hemorrhage from unspecified intracranial artery	Diagnosis	ICD-10-CM
I60.8	Other nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I60.9	Nontraumatic subarachnoid hemorrhage, unspecified	Diagnosis	ICD-10-CM
I61.0	Nontraumatic intracerebral hemorrhage in hemisphere, subcortical	Diagnosis	ICD-10-CM
I61.1	Nontraumatic intracerebral hemorrhage in hemisphere, cortical	Diagnosis	ICD-10-CM
I61.2	Nontraumatic intracerebral hemorrhage in hemisphere, unspecified	Diagnosis	ICD-10-CM
I61.3	Nontraumatic intracerebral hemorrhage in brain stem	Diagnosis	ICD-10-CM
I61.4	Nontraumatic intracerebral hemorrhage in cerebellum	Diagnosis	ICD-10-CM
I61.5	Nontraumatic intracerebral hemorrhage, intraventricular	Diagnosis	ICD-10-CM
I61.6	Nontraumatic intracerebral hemorrhage, multiple localized	Diagnosis	ICD-10-CM
I61.8	Other nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I61.9	Nontraumatic intracerebral hemorrhage, unspecified	Diagnosis	ICD-10-CM
I62.00	Nontraumatic subdural hemorrhage, unspecified	Diagnosis	ICD-10-CM
I62.01	Nontraumatic acute subdural hemorrhage	Diagnosis	ICD-10-CM
I62.02	Nontraumatic subacute subdural hemorrhage	Diagnosis	ICD-10-CM
I62.9	Nontraumatic intracranial hemorrhage, unspecified	Diagnosis	ICD-10-CM
I63.00	Cerebral infarction due to thrombosis of unspecified precerebral artery	Diagnosis	ICD-10-CM
I63.011	Cerebral infarction due to thrombosis of right vertebral artery	Diagnosis	ICD-10-CM
I63.012	Cerebral infarction due to thrombosis of left vertebral artery	Diagnosis	ICD-10-CM
I63.013	Cerebral infarction due to thrombosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.019	Cerebral infarction due to thrombosis of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.02	Cerebral infarction due to thrombosis of basilar artery	Diagnosis	ICD-10-CM
I63.031	Cerebral infarction due to thrombosis of right carotid artery	Diagnosis	ICD-10-CM
I63.032	Cerebral infarction due to thrombosis of left carotid artery	Diagnosis	ICD-10-CM
I63.033	Cerebral infarction due to thrombosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.039	Cerebral infarction due to thrombosis of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.09	Cerebral infarction due to thrombosis of other precerebral artery	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPGS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I63.10	Cerebral infarction due to embolism of unspecified precerebral artery	Diagnosis	ICD-10-CM
I63.111	Cerebral infarction due to embolism of right vertebral artery	Diagnosis	ICD-10-CM
I63.112	Cerebral infarction due to embolism of left vertebral artery	Diagnosis	ICD-10-CM
I63.113	Cerebral infarction due to embolism of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.119	Cerebral infarction due to embolism of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.12	Cerebral infarction due to embolism of basilar artery	Diagnosis	ICD-10-CM
I63.131	Cerebral infarction due to embolism of right carotid artery	Diagnosis	ICD-10-CM
I63.132	Cerebral infarction due to embolism of left carotid artery	Diagnosis	ICD-10-CM
I63.133	Cerebral infarction due to embolism of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.139	Cerebral infarction due to embolism of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.19	Cerebral infarction due to embolism of other precerebral artery	Diagnosis	ICD-10-CM
I63.20	Cerebral infarction due to unspecified occlusion or stenosis of unspecified precerebral arteries	Diagnosis	ICD-10-CM
	Cerebral infarction due to unspecified occlusion or stenosis of right vertebral artery		
I63.211	Cerebral infarction due to unspecified occlusion or stenosis of left vertebral artery	Diagnosis	ICD-10-CM
I63.212	Cerebral infarction due to unspecified occlusion or stenosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.213	Cerebral infarction due to unspecified occlusion or stenosis of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.219	Cerebral infarction due to unspecified occlusion or stenosis of right carotid arteries	Diagnosis	ICD-10-CM
I63.22	Cerebral infarction due to unspecified occlusion or stenosis of left carotid arteries	Diagnosis	ICD-10-CM
I63.231	Cerebral infarction due to unspecified occlusion or stenosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.232	Cerebral infarction due to unspecified occlusion or stenosis of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.233	Cerebral infarction due to unspecified occlusion or stenosis of other precerebral arteries	Diagnosis	ICD-10-CM
I63.239	Cerebral infarction due to unspecified occlusion or stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.29	Cerebral infarction due to unspecified occlusion or stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.30	Cerebral infarction due to thrombosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.311	Cerebral infarction due to thrombosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.312	Cerebral infarction due to thrombosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.313	Cerebral infarction due to thrombosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.319	Cerebral infarction due to thrombosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.321	Cerebral infarction due to thrombosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.322	Cerebral infarction due to thrombosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.323	Cerebral infarction due to thrombosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I63.329	Cerebral infarction due to thrombosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.331	Cerebral infarction due to thrombosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.332	Cerebral infarction due to thrombosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.333	Cerebral infarction due to thrombosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
	Cerebral infarction due to thrombosis of unspecified posterior cerebral artery		
I63.339	Cerebral infarction due to thrombosis of right cerebellar artery	Diagnosis	ICD-10-CM
I63.341	Cerebral infarction due to thrombosis of left cerebellar artery	Diagnosis	ICD-10-CM
I63.342	Cerebral infarction due to thrombosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.343	Cerebral infarction due to thrombosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.349	Cerebral infarction due to thrombosis of other cerebral artery	Diagnosis	ICD-10-CM
I63.39	Cerebral infarction due to embolism of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.40	Cerebral infarction due to embolism of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.411	Cerebral infarction due to embolism of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.412	Cerebral infarction due to embolism of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.413	Cerebral infarction due to embolism of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.419	Cerebral infarction due to embolism of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.421	Cerebral infarction due to embolism of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.422	Cerebral infarction due to embolism of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.423	Cerebral infarction due to embolism of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.429	Cerebral infarction due to embolism of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.431	Cerebral infarction due to embolism of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.432	Cerebral infarction due to embolism of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.433	Cerebral infarction due to embolism of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.439	Cerebral infarction due to embolism of right cerebellar artery	Diagnosis	ICD-10-CM
I63.441	Cerebral infarction due to embolism of left cerebellar artery	Diagnosis	ICD-10-CM
I63.442	Cerebral infarction due to embolism of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.443	Cerebral infarction due to embolism of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.449	Cerebral infarction due to embolism of other cerebral artery	Diagnosis	ICD-10-CM
I63.49	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.50	Cerebral infarction due to unspecified occlusion or stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.511	Cerebral infarction due to unspecified occlusion or stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.512	Cerebral infarction due to unspecified occlusion or stenosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.513	Cerebral infarction due to unspecified occlusion or stenosis of unspecified middle cerebral arteries	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Characteristics in this Request

Code	Description	Code Category	Code Type
I63.519	Cerebral infarction due to unspecified occlusion or stenosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.521	Cerebral infarction due to unspecified occlusion or stenosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.522	Cerebral infarction due to unspecified occlusion or stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.523	Cerebral infarction due to unspecified occlusion or stenosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.529	Cerebral infarction due to unspecified occlusion or stenosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.531	Cerebral infarction due to unspecified occlusion or stenosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.532	Cerebral infarction due to unspecified occlusion or stenosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.533	Cerebral infarction due to unspecified occlusion or stenosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.539	Cerebral infarction due to unspecified occlusion or stenosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.541	Cerebral infarction due to unspecified occlusion or stenosis of right cerebellar artery	Diagnosis	ICD-10-CM
I63.542	Cerebral infarction due to unspecified occlusion or stenosis of left cerebellar artery	Diagnosis	ICD-10-CM
I63.543	Cerebral infarction due to unspecified occlusion or stenosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.549	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.59	Cerebral infarction due to unspecified occlusion or stenosis of other cerebral artery	Diagnosis	ICD-10-CM
I63.6	Cerebral infarction due to cerebral venous thrombosis, nonpyogenic	Diagnosis	ICD-10-CM
I63.8	Other cerebral infarction	Diagnosis	ICD-10-CM
I63.81	Other cerebral infarction due to occlusion or stenosis of small artery	Diagnosis	ICD-10-CM
I63.89	Other cerebral infarction	Diagnosis	ICD-10-CM
I63.9	Cerebral infarction, unspecified	Diagnosis	ICD-10-CM
I67.841	Reversible cerebrovascular vasoconstriction syndrome	Diagnosis	ICD-10-CM
I67.848	Other cerebrovascular vasospasm and vasoconstriction	Diagnosis	ICD-10-CM
I67.89	Other cerebrovascular disease	Diagnosis	ICD-10-CM
I97.810	Intraoperative cerebrovascular infarction during cardiac surgery	Diagnosis	ICD-10-CM
I97.811	Intraoperative cerebrovascular infarction during other surgery	Diagnosis	ICD-10-CM
I97.820	Postprocedural cerebrovascular infarction following cardiac surgery	Diagnosis	ICD-10-CM
I97.821	Postprocedural cerebrovascular infarction following other surgery	Diagnosis	ICD-10-CM

Appendix E. List of Non- Proprietary and Proprietary Names of Medical Products Used to Define Characteristics in this Request

Non-Proprietary	Proprietary Name
Obesity	
benzphetamine HCl	Regimex
benzphetamine HCl	benzphetamine
diethylpropion HCl	diethylpropion
liraglutide	Saxenda
liraglutide	Victoza 2-Pak
liraglutide	Victoza 3-Pak
liraglutide	liraglutide
lorcaserin HCl	Belviq
lorcaserin HCl	Belviq XR
naltrexone HCl/bupropion HCl	Contrave
orlistat	Alli
orlistat	Xenical
phendimetrazine tartrate	phendimetrazine tartrate
phentermine HCl	Adipex-P
phentermine HCl	Lomaira
phentermine HCl	phentermine
phentermine HCl/topiramate	Qsymia
semaglutide	Ozempic
semaglutide	Wegovy
tirzepatide	Mounjaro
tirzepatide	Zepbound
Smoking	
nicotine	Nicoderm CQ
nicotine	Nicotrol
nicotine	Nicotrol NS
nicotine	nicotine
nicotine bitartrate	Nicotine Tartrate
nicotine polacrilex	Nicorelief
nicotine polacrilex	Nicorette
nicotine polacrilex	Quit 2
nicotine polacrilex	Quit 4
nicotine polacrilex	Stop Smoking Aid
nicotine polacrilex	nicotine (polacrilex)
nicotine polacrilex	nicotine polacrilex (bulk)
varenicline tartrate	Chantix
varenicline tartrate	Chantix Continuing Month Box
varenicline tartrate	Chantix Starting Month Box
varenicline tartrate	Tyrvaya
varenicline tartrate	varenicline tartrate

Appendix F. Specifications for Type 5 Request: cder_mpl1r_wp314_nsdp_v01

This request executed the Cohort Identification and Descriptive Analysis (CIDA) tool, version 14.2.0, to assess utilization and uptake of the 2021, part 2 (Approved July 2021-December 2021) New Molecular Entities (NMEs) in the Sentinel Distributed Database (SDD).

Query period: 01/01/2021 - 04/30/2025

Coverage requirement: Medical and Drug Coverage

Minimum Pre-Index Enrollment Days: 183 days

Minimum Post-Index Required Days: 0 days

Enrollment Gap: 45 days

Age Groups: 0-17, 18-24, 25-40, 41-64, 65+ years

Sex: M, F

Other Demographic Restrictions: n/a

Stratifications: Age group, Sex, Calendar Month (for Figures only)

Data Restrictions: None

Chart Availability Restriction Indicator: No

Envelope macro: Reclassify encounters during inpatient stay as inpatient

Freeze data: No

Yes (Indicates if counts of episodes censored by death)

Drop Censor Output Indicator: and query end should be excluded from output to prevent death small cells from being sent to SOC.)

Exposure

Scenario	Index Exposure/ Event	Cohort definition	Type 5 Exposure	Exclude evidence of days supply if exposure washout	Care Setting and Diagnosis Position		Treatment Episode	Exposure Episode	Exposure Episode Extension	Create Baseline	End At-Risk Period at Table?
			Washout Period	includes dispensing	Requirements	Gap Type					
1	finerenone	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	Any care setting, any diagnosis position		Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications for Type 5 Request: cder_mpl1r_wp314_nsdp_v01

Exposure											
Scenario	Index Exposure/ Event	Cohort definition	Type 5 Exposure Washout Period	Exclude evidence of days supply if exposure washout includes dispensing	Care Setting and Diagnosis Position Requirements	Treatment Episode Gap Type	Exposure Episode Gap	Exposure Episode Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of	
2	fexinidazole	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date	
3	belumosudil	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date	
4	odevixibat	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date	
5	anifrolumab-fnia	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date	

Appendix F. Specifications for Type 5 Request: cder_mpl1r_wp314_nsdp_v01

Exposure												
Scenario	Index Exposure/ Event	Cohort definition	Type 5 Exposure Washout Period	Exclude evidence of days supply if exposure washout includes dispensing	Care Setting and Diagnosis Position Requirements			Treatment Episode Gap Type	Exposure Episode Gap	Exposure Episode Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of
6	avalglucosidase alfa- ngpt	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	Any care setting, any diagnosis position		Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date	
7	beluzifan	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	Any care setting, any diagnosis position		Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date	
8	difelikefalin	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	Any care setting, any diagnosis position		Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date	
9	lonapegsomatropin- tcgd	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	Any care setting, any diagnosis position		Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date	

Appendix F. Specifications for Type 5 Request: cder_mpl1r_wp314_nsdp_v01

Exposure											
Scenario	Index Exposure/ Event	Cohort definition	Type 5 Exposure Washout Period	Exclude evidence of days supply if exposure washout includes dispensing	Care Setting and Diagnosis Position Requirements	Treatment Episode Gap Type	Exposure Episode Gap	Exposure Episode Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of	
10	mobocertinib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date	
11	tisotumab vedotin-tfv	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date	
12	atogepant	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date	
13	maralixibat	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date	

Appendix F. Specifications for Type 5 Request: cder_mpl1r_wp314_nsdp_v01

Exposure											
Scenario	Index Exposure/ Event	Cohort definition	Type 5 Exposure Washout Period	Exclude evidence of days supply if exposure washout includes dispensing	Care Setting and Diagnosis Position Requirements	Treatment Episode Gap Type	Exposure Episode Gap	Exposure Episode Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of	
14	avacopan	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date	
15	asciminib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date	
16	ropeginterferon alfa-2b-njft	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date	
17	vosoritide	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date	

Appendix F. Specifications for Type 5 Request: cder_mpl1r_wp314_nsdp_v01

Scenario	Index Exposure/ Event	Cohort definition	Exposure								
			Type 5 Exposure Washout Period	Exclude evidence of days supply if exposure washout includes dispensing	Care Setting and Diagnosis Position Requirements	Treatment Episode Gap Type	Exposure Episode Gap	Exposure Episode Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of	
18	maribavir	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date	
19	pafolacianine	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date	
20	tezepelumab-ekko	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date	
21	efgartigimod alfa-fcab	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date	

Appendix F. Specifications for Type 5 Request: cder_mpl1r_wp314_nsdp_v01

Exposure											
Scenario	Index Exposure/ Event	Cohort definition	Type 5 Exposure Washout Period	Exclude evidence of days supply if exposure washout includes dispensing	Care Setting and Diagnosis Position Requirements	Treatment Episode Gap Type	Exposure Episode Gap	Exposure Episode Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of	
22	incisiran	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date	
23	tralokinumab-ldrm	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date	

ICD-9, ICD-10, HCPCS, and CPT codes are provided by Optum360.
 NDC codes are checked against First Data Bank's FDB MedKnowledge®.
 N/A: Not applicable

Appendix G. Baseline Characteristics Used in this Request
Baseline Characteristics

Covariate Name	Covariate Number	Code Category	Complex Covariate Components	Care Setting and Diagnosis Position Requirements	Number of Instances the Covariate Should be Found in Evaluation Period	Covariate Evaluation Period Start	Covariate Evaluation Period End	Forced Supply to Attach to a Code (only applies to RX codes)	Lookback Period Date Only
<i>Chronic Conditions Data Warehouse</i>									
Acute Myocardial Infarction	1	DX		IPP, IPS	1	-183	-1	N/A	Y
Alzheimer's Disease	2	DX		Any	1	-183	-1	N/A	Y
Non-Alzheimer's Dementia	3	DX		Any	1	-183	-1	N/A	Y
	4	DX		IPP, IPS	1	-183	-1	N/A	Y
Atrial Fibrillation	5	DX		AV*, ED*, OA*	2	-183	-1	N/A	Y
	6	CC	4 or 5		1			N/A	Y
	7	DX		IP*, IS*	1	-183	-1	N/A	Y
Diabetes	8	DX		AV*, ED*, OA*	2	-183	-1	N/A	Y
	9	CC	7 or 8		1			N/A	Y
Heart Failure	10	DX		IP*, AV*, ED*, OA*	1	-183	-1	N/A	Y
	11	DX		IP*, IS*	1	-183	-1	N/A	Y
Hyperlipidemia	12	DX		AV*, ED*, OA*	2	-183	-1	N/A	Y
	13	CC	11 or 12		1			N/A	Y
	14	DX		IP*, IS*	1	-183	-1	N/A	Y
Hypertension	15	DX		AV*, ED*, OA*	2	-183	-1	N/A	Y
	16	CC	14 or 15		1			N/A	Y
Depression	17	DX		Any	1	-183	-1	N/A	Y
Ischemic Heart Disease	18	DX		Any	1	-183	-1	N/A	Y
Rheumatoid Arthritis/Osteoarthritis	19	DX		Any	2	-183	-1	N/A	Y
	20	DX		IP*	1	-183	-1	N/A	Y
Stroke/Transient Ischemic Attack (TIA)	21	DX		AV*, ED*, OA*	2	-183	-1	N/A	Y
	22	CC	20 or 21		1			N/A	Y
	23	DX		IP*, IS*	1	-183	-1	N/A	Y
Breast Cancer	24	DX		AV*, ED*, OA*	2	-183	-1	N/A	Y
	25	CC	23 or 24		1			N/A	Y

Appendix G. Baseline Characteristics Used in this Request
Baseline Characteristics

Covariate Name	Covariate Number	Code Category	Complex Covariate Components	Care Setting and Diagnosis Position Requirements	Found in Evaluation Period	Number of Instances the Covariate Should be	Covariate Evaluation Period Start	Covariate Evaluation Period End	Forced Supply to Attach to a Code	Lookback Period Date Only
									(only applies to RX codes)	
Colorectal Cancer	26	DX		IP*, IS*	1	-183	-1	N/A		Y
	27	DX		AV*, ED* OA*	2	-183	-1	N/A		Y
	28	CC	26 or 27		1			N/A		Y
Prostate Cancer	29	DX		IP*, IS*	1	-183	-1	N/A		Y
	30	DX		AV*, ED* OA*	2	-183	-1	N/A		Y
	31	CC	29 or 30		1			N/A		Y
Lung Cancer	32	DX		IP*, IS*	1	-183	-1	N/A		Y
	33	DX		AV*, ED* OA*	2	-183	-1	N/A		Y
	34	CC	32 or 33		1			N/A		Y
Endometrial Cancer	35	DX		IP*, IS*	1	-183	-1	N/A		Y
	36	DX		AV*, ED* OA*	2	-183	-1	N/A		Y
	37	CC	35 or 36		1			N/A		Y
Acquired Hypothyroidism	38	DX		IP*, IS*,	1	-183	-1	N/A		Y
	39	DX		AV*, ED* OA*	2	-183	-1	N/A		Y
	40	CC	38 or 39		1			N/A		Y
Anemia	41	DX		Any	1	-183	-1	N/A		Y
	42	DX		IP*, IS*,	1	-183	-1	N/A		Y
Asthma	43	DX		AV*, ED* OA*	2	-183	-1	N/A		Y
	44	CC	42 or 43		1			N/A		Y
	45	DX		IP*, IS*,	1	-183	-1	N/A		Y
Benign Prostatic Hyperplasia	46	DX		AV*, ED* OA*	2	-183	-1	N/A		Y
	47	CC	45 or 46		1			N/A		Y
	48	DX		IP*, IS*,	1	-183	-1	N/A		Y
Chronic Kidney Disease	49	DX		AV*, ED* OA*	2	-183	-1	N/A		Y
	50	CC	48 or 49		1			N/A		Y
	51	DX		IP*, IS*,	1	-183	-1	N/A		Y
Chronic Obstructive Pulmonary Disease (COPD) and Bronchiectasis	52	DX		AV*, ED* OA*	2	-183	-1	N/A		Y
	53	CC	51 or 52		1			N/A		Y
Glaucoma	54	DX		AV*, ED*, OA*	1	-183	-1	N/A		Y

Appendix G. Baseline Characteristics Used in this Request
Baseline Characteristics

Covariate Name	Covariate Number	Code Category	Complex Covariate Components	Care Setting and Diagnosis Position Requirements	Found in Evaluation Period	Number of Instances the Covariate Should be	Forced Supply to Attach to a Code (only applies to RX codes)		Lookback Period Date Only
							Covariate Evaluation Period Start	Covariate Evaluation Period End	
Osteoporosis	55	DX		IP*, IS*,	1	-183	-1	N/A	Y
	56	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	57	CC	55 or 56		1			N/A	Y
<i>Other</i>									
Obesity (Diagnosis or Procedure Codes)	58	DX, PX		Any	1	-183	-1	N/A	Y
Obesity (Dispensing Codes)	59	RX		Any	1	-183	-1	N/A	Y
Overweight	60	DX		Any	1	-183	-1	N/A	Y
Smoking (Diagnosis or Procedure Codes)	61	DX, PX		Any	1	-183	-1	N/A	Y
Smoking (Dispensing Codes)	62	RX		Any	1	-183	-1	N/A	Y
Alcohol Abuse or Dependence	63	DX, PX		Any	1	-183	-1	N/A	Y
Drug Abuse or Dependence	64	DX, PX		Any	1	-183	-1	N/A	Y
History of Cardiac Arrest	65	DX		Any	1	-183	-1	N/A	Y
History of Coronary Angioplasty or Bypass	66	DX		Any	1	-183	-1	N/A	Y

Appendix G. Baseline Characteristics Used in this Request
Baseline Characteristics

Covariate Name	Covariate Number	Code Category	Complex Covariate Components	Care Setting and Diagnosis Position Requirements	Number of Instances the Covariate Should be Found in Evaluation Period	Covariate Evaluation		Forced Supply to Attach to a Code (only applies to RX codes)	Lookback Period Date Only
						Period Start	Period End		
Liver Disease CCW	67	DX		IP*, IS*	1	-183	-1	N/A	Y
	68	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	69	CC	67 or 68		1			N/A	Y
	70	PX		AV*	1	-183	-1	N/A	Y
	71	DX		AV*	1	-183	-1	N/A	Y
	72	CC	70 and 71		1			N/A	Y
	73	PX		ED*	1	-183	-1	N/A	Y
	74	DX		ED*	1	-183	-1	N/A	Y
	75	CC	73 and 74		1			N/A	Y
	76	PX		OA*	1	-183	-1	N/A	Y
	77	DX		OA*	1	-183	-1	N/A	Y
	78	CC	76 and 77		1			N/A	Y
	79	PX		IS*	1	-183	-1	N/A	Y
	80	DX		IS*	1	-183	-1	N/A	Y
	81	CC	79 and 80		1			N/A	Y
	82	CC	69 or 72 or 75 or 78 or 81		1			N/A	Y

Appendix G. Baseline Characteristics Used in this Request
Baseline Characteristics

Covariate Name	Covariate Number	Code Category	Complex Covariate Components	Care Setting and Diagnosis Position Requirements	Number of Instances the Covariate Should be Found in Evaluation Period	Covariate Evaluation		Forced Supply to Attach to a Code (only applies to RX codes)	Lookback Period Date Only
						Period Start	Period End		
Liver Disease Extended	83	DX		IP*, IS*,	1	-183	-1	N/A	Y
	84	DX		AV*, ED* OA*	2	-183	-1	N/A	Y
	85	CC	83 or 84		1			N/A	Y
	86	PX		AV*	1	-183	-1	N/A	Y
	87	DX		AV*	1	-183	-1	N/A	Y
	88	CC	86 and 87		1			N/A	Y
	89	PX		ED*	1	-183	-1	N/A	Y
	90	DX		ED*	1	-183	-1	N/A	Y
	91	CC	89 and 90		1			N/A	Y
	92	PX		OA*	1	-183	-1	N/A	Y
	93	DX		OA*	1	-183	-1	N/A	Y
	94	CC	92 and 93		1			N/A	Y
	95	PX		IS*	1	-183	-1	N/A	Y
	96	DX		IS*	1	-183	-1	N/A	Y
	97	CC	95 and 96		1			N/A	Y
	98	CC	85 or 88 or 91 or 94 or 97		1			N/A	Y

Appendix G. Baseline Characteristics Used in this Request

Baseline Characteristics

Covariate Name	Covariate Number	Code Category	Complex Covariate Components	Care Setting and Diagnosis Position Requirements	Number of Instances the Covariate Should be Found in Evaluation Period	Covariate Evaluation Period Start	Covariate Evaluation Period End	Forced Supply to Attach to a Code (only applies to RX codes)	Lookback Period Date Only
			RX: Drug code DX: Diagnosis code PX: Procedure code CC: Complex covariates (multiple COVARNU M values are used to define a covariate)	IP*: inpatient hospital stays, any diagnoses IS*: non-acute institutional stays, any diagnoses ED*: emergency department encounters AV*: ambulatory visits OA*: other ambulatory visits					N: Lookback period should search for evidence of a date or an interval Y: Lookback period should search for evidence of a date only

The wildcard symbol () can be used to represent 'any' values of either the care setting or principal discharge diagnosis flag. Wildcard does not restrict a specific principal diagnosis position. The principal discharge diagnosis flag is only relevant for diagnosis codes.

The (P) at the end of the care setting refers to the primary diagnosis position, while the (S) refers to the secondary diagnosis position. This indicates that only the first or second diagnosis on the claims should be used for specified codes. For example, IPP (Inpatient Primary) uses the first diagnosis position, and IPS (Inpatient Secondary) uses the second diagnosis position.

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Appendix G. Baseline Characteristics Used in this Request

Baseline Characteristics											
Covariate Name	Covariate Number	Code Category	Complex Covariate Components	Care Setting and Requirements	Diagnosis Position	Found in Evaluation Period	Covariate	Covariate	Forced Supply to Attach to a Code (only applies to RX codes)	Lookback Period Date	
							Evaluation Period Start	Evaluation Period End	Only		

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.


Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Care setting/PDX parameter.

N/A: Not applicable

Appendix H. Design Diagram Used in this Request



¹ Includes all valid exposure during the query period; only the first valid episode's incidence is assessed using the washout period.

² 23 scenarios defined on initiation of NMEs approved in 2021 part 2 (one scenario per NME); Cohort entry date = first dispensing date for qualifying NME.

³ Baseline characteristics:

Window I: Age, Sex, Year

Window II: Chronic conditions warehouse (CCW), alcohol abuse or dependence, drug abuse or dependence, history of cardiac arrest, history of coronary angioplasty or bypass, obesity, overweight, and smoking

⁴ Censoring: earliest of death, disenrollment, data partner data end date, query end date